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Abstract 
Background:  Myocardial infarction (MI) and stroke are the predominant endpoints of 
large-scale epidemiological research on cardiovascular disease (CVD) in healthy 
populations.  This thesis capitalised on opportunities presented by linked electronic 
health records (EHR) to investigate the association of risk factors with the initial 
presentation of a wide range of pathologically diverse CVDs, with a focus on gender 
differences. 
Objective: To determine whether gender, smoking and blood pressure have 
homogeneous associations with the initial presentation of a range of CVDs.  
Design: Cohort studies using data from the CALIBER research platform linking four data 
sources (primary care, disease registry, hospitalisation and mortality records) for 
1,758,584 patients free from symptomatic CVD registered with 225 UK general practices 
between 2001 and 2010.  
Main outcome measures:  Initial presentation of CVD with stable angina, unstable 
angina, MI, heart failure, ventricular arrhythmias, coronary death, stroke, abdominal 
aortic aneurysm (AAA) and peripheral arterial disease (PAD).  
Results:  69% of initial presentations of CVD (N=95,267) were neither MI nor stroke.   
Men had higher rates of all presentations, with age-adjusted gender rate ratios from 1.23 
(95% confidence interval 1.19-1.27)) for stroke to 4.27 (3.92-4.65) for AAA.  The 
association of current smoking (compared to non-smoking) varied from an age-adjusted 
hazard ratio (HR) of 1.01 (0.90-1.13) for arrhythmia to 4.71 (4.15-5.35) for AAA. Gender 
differences were found only for MI (women: 2.59 (2.37-2.83); men: 2.20 (2.05-2.37)) and 
AAA (women: 7.00 (5.64-8.70); men: 3.88 (3.33-4.53)).  The association of systolic blood 
pressure was similar across all CVD presentations, excepting AAA, ranging from age-
adjusted HR of 1.19 (1.16-1.22) per standard deviation (SD) for heart failure to 1.28 
(1.24-1.31) for PAD, with minimal gender differences.    
Conclusions:  Gender, smoking and blood pressure had heterogeneous associations 
across a wide range of initial CVD presentations.   The implications of these findings for 
public health, clinical practice and research are discussed. 
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Introduction 
This thesis is concerned with atherosclerotic disease, the underlying processes which 
manifests in different patients as the different atherosclerotic diseases, such as coronary 
artery disease, ischaemic stroke, and peripheral arterial disease. Historically, this group of 
diseases has been approached as if they have the same underlying causal processes and 
therefore should benefit from similar prevention and treatment strategies. While this 
commonality of cause may be assumed, the majority of epidemiological studies in this 
area have focussed on studying an individual disease at a time, with “first myocardial 
infarction” or “first stroke” being common endpoints. In contrast, the approach of this 
thesis has been to take this assumption of common underlying disease processes 
seriously by studying the onset of symptomatic atherosclerotic disease overall as 
indicated by the first manifestation of any symptomatic atherosclerotic disease. At the 
same time, I have also questioned whether the causal processes for this group of diseases 
are actually as unified as may be assumed. The overarching question for my thesis is 
therefore to question whether the association of common risk factors varies with the 
specific disease which marks the onset of symptomatic atherosclerotic disease. 
Homogeneity in association of risk factors would indicate commonality of causal 
processes and vindicate a one-size-fits-all approach to risk factor management. However, 
heterogeneity in association of risk factors with different diseases would indicate 
differences in causal processes and raise the question of more bespoke approaches to risk 
factor management.  
1. Terminology 
Before further discussion, a few comments about terminology are required. As one of the 
purposes of this thesis is to question whether the common atherosclerotic diseases share 
the same causal processes and therefore really are diseases subtypes, I wished to get 
away from using this term. Throughout this thesis, I have therefore used the phrase 
“onset of cardiovascular disease with … [e.g. stable angina]” to refer to the first 
manifestation of symptomatic atherosclerotic cardiovascular disease with a specific 
disease such as stable angina. However, this usage can be overly clunky.  I have therefore 
also used the terminology of “initial presentation” used by Murabito et al in an earlier 
Framingham paper on initial presentation of coronary heart disease”,(1) where onset of 
coronary heart disease with, say, stable angina, is referred to as patients “presenting with 
stable angina” or “initial presentation with stable angina”. While I risked confusion by 
using the term “presentation”, which can also be used in epidemiology to mean the cluster 
of symptoms with which an individual patient presents to healthcare services at a 
particular moment in time, I decided the term was apposite, given that I measured onset 
of cardiovascular disease (CVD) using records of consultation with health services. 
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Initial presentation of cardiovascular disease with, say, myocardial infarction (MI) should 
also be distinguished from first MI, a concept more commonly used epidemiology. First MI 
(or first other cardiovascular disease) usually refers to first presentation of a specific 
disease rather than first presentation of any cardiovascular disease. First MI could 
therefore be preceded by another cardiovascular disease such as stable angina and indeed 
it is not uncommon for studies to use history of CHD as a co-variable in studies of first MI. 
Initial presentation of CVD with MI,  could not, however, be preceded by other 
symptomatic cardiovascular diseases according to the definition used in this thesis.  
 
Definition of initial versus first presentation: 
The example of myocardial infarction  
Initial presentation of cardiovascular disease with myocardial infarction (MI) – First 
presentation of any symptomatic cardiovascular disease. Not preceded by any other 
symptomatic cardiovascular disease 
First presentation of myocardial infarction – First presentation of a specific 
cardiovascular disease i.e. first MI. Could be preceded by another symptomatic 
cardiovascular disease 
 
For the remainder of this chapter, I develop the rationale for my choice of cardiovascular 
diseases (endpoints) and risk factors.  Then, I briefly describe the way in which electronic 
health records provide a viable approach to answering my questions. I end the chapter by 
describing the structure of the remainder of my thesis. 
2. Choice of endpoints 
2.1. Onset of cardiovascular disease 
Much of cardiovascular disease epidemiology is dominated by a focus on the association 
of risk factors with mortality but this approach conflates the relationship between risk 
factors which may be associated with onset and subsequent progression of the disease, 
whether to more acute forms of CVD or mortality, obscuring important aspects of 
aetiology.  For example, the association of smoking(2)  or South Asian ethnicity(3) with 
coronary heart disease mortality is well-documented. However, for both these risk 
factors,  there is evidence  that while smokers and South Asians  are at increased risk of 
myocardial infarction (MI), they may be more likely to survive an MI than non-smokers / 
non-Asians.(4,5) Similarly, there is some evidence that in patients with stable angina the 
rate of myocardial infarction (MI) or death does not vary by gender,(6) in contrast to the 
usual male excess in rates of MI  or CHD mortality.(7) These examples show how a focus 
only on mortality can obscure a more complex relationship between disease and several 
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risk factors, indicating the need to look at the disease as it progresses from onset, through 
different stages and eventually to mortality. (8) A more detailed understanding of the 
changing nature of risk would allow an assessment of the relative advantage of 
interventions at different stages in progression of CVD. The first stage in understanding 
the aetiology is to understand onset, or as the King in Alice in Wonderland says “`Begin at 
the beginning, … and go on till you come to the end: then stop.”(9)  
2.2. Specific rather than composite endpoints 
The study of aetiology of CVD has been dominated by research focussing on composite 
endpoints, such as CHD mortality or cerebrovascular disease. Take the example of 
coronary heart disease. The use of composite endpoints has been partly driven by the 
concept of CHD as if it were a single disease entity, partly by the need to combine 
endpoints to generate sufficiently powered studies, and partly by the lack of clinical detail 
to allow more detailed phenotyping in epidemiological research. However, greater 
specificity in defining coronary diseases, at least with acute coronary syndrome, has 
clearly borne fruit. The evolution of the definition of myocardial infraction from a purely 
fatal disease to non-fatal acute myocardial infarction (MI) to the specific MI subtypes of 
ST-elevation and non-ST elevation MI(10) has led to an improved understanding of 
coronary heart diseases with differential risk profiles, (11,12) if not completely 
differential treatments.(13) Further comparisons between myocardial infarction and 
unstable angina, although less common, have also proven to be informative. (14,15)  
 
Recent evidence has also suggested a shift in the presentation of CHD over time, with a)a 
decline in case fatality leaving more people living with CHD as a chronic disease;(16–18)  
b) a decline in STEMI coupled with a rise in nSTEMI;(19,20) and c) a decline in myocardial 
infarction of whatever type coupled with a rise in angina pectoris.(21,22) These trends 
suggest a possible shift toward less acute and more chronic forms of coronary heart 
disease, which in turn argues for the importance of a more nuanced understanding of the 
onset of different subtypes of CHD and the progression of the disease through multiple 
stages as it develops over time. 
2.3. Broader than CHD or stroke 
Although studies comparing risk factors for myocardial infarction with those for stroke 
are not uncommon, a broader approach of studying the whole range of cardiovascular 
disease is still relatively rare,(23,24) despite the commonality of risk factors across the 
range of arterial beds. This approach was first used in a small number of Framingham 
studies over twenty years ago,(1,25) but has not been commonly used subsequently. This 
thesis therefore includes atherosclerotic disease in the cerebral, coronary, abdominal and 
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peripheral arterial beds, but also cardiac arrhythmias and heart failure as two cardiac 
diseases which may be significant competing risk to the atherosclerotic CVDs and share 
many of the same risk factors.  
3. Choice of risk factors 
For the thesis, I chose to focus on three risk factors: gender, smoking and blood pressure.  
These three are arguably the most important, most widely recorded, and most widely 
investigated measures of risk, covering demographic, behavioural and physiological 
domains.  
3.1. Gender 
The incidence of specific CVD presentations, when studied individually, varies by 
gender,(26–29) and there is some evidence that the extent of gender difference in 
atherosclerosis varies by arterial bed.(30) However, it is not known whether the onset of 
CVD with specific presentations varies by gender or the extent of such variation; these 
questions are the subject the first substantive set of analyses for this thesis.  
 
Throughout the thesis, gender-specific results have been reported and the effect 
modification of gender has been investigated where appropriate. The reasons for this are 
twofold. First there is some evidence that gender modifies the effect of some common risk 
factors for at least some cardiovascular diseases, especially smoking(2), and diabetes.(31) 
It is hoped that the detailed analysis on gender in this thesis will contribute to the debate 
about gender differences in the possible physiology in cardiovascular disease in women 
and men. (32) Second, the lack of gender-specific reporting hinders meta-analyses of the 
impact of gender on treatments and outcomes;(33) a review of gender-based analyses in 
Cochrane systematic reviews pertaining to CHD found limited studies reporting gender-
based results. Twenty per cent of those that did found significant gender differences, 
suggesting gender differences in treatments and outcomes are uncommon but not 
unknown.(34) Different areas of CVD research are better than others in reporting gender-
specific effects; studies of CHD more commonly report gender-based results than do 
studies in stroke research.(35) I have therefore considered it important to make a 
contribution to the better understanding of gender differences to report on gender-based 
results, even in chapters where the principle focus is on other risk factors.  
3.2. Smoking  
The second set of substantive analyses investigates the association of smoking with 
specific presentations which signal the onset of symptomatic CVD.  Smoking was chosen 
because it is one of the leading risk factor for the burden of disease in North America and 
Western Europe,(36) and remains a common modifiable risk factor in the United 
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Kingdom, with 23% of men and 19% of women estimated to be current smokers in 
2011.(37) There is some evidence that smoking may pose a greater risk for coronary 
heart disease than for stroke.(38,39)  There is also evidence which suggests gender may 
modify the effect of smoking on CVD.(2) 
3.3. Blood pressure 
Blood pressure was chosen for investigation because raised blood pressure is one of the  
larger modifiable risk factors for the burden of disease, particularly  cardiovascular 
disease(40,41) and remains a common modifiable risk factor in United Kingdom, with 
31% of men and 28% of women estimated to have hypertension.(37)   However, in 
contrast to smoking, raised blood pressure appears to pose broadly similar risks for 
mortality from most cardiovascular diseases.(42) There is conflicting evidence of effect 
modification by gender of the association of raised blood pressure with CVDs, at least for 
coronary heart disease mortality.(42,43)  
4. Linked electronic health records 
Linked electronic health records (EHRs) provide a unique opportunity to investigate the 
questions posed in this thesis because such resources provide the large number of 
patients required to study multiple disease presentations combined with the clinical 
detail and event capture needed to specify risk factors and endpoints. The CArdiovascular 
disease research using LIinked Bespoke studies and Electronic health Records (CALIBER) 
research platform has EHRs for over two million adult patients. CALIBER also links four 
data sources, including the acute coronary syndrome registry, Myocardial Ischaemia 
National Audit Project (MINAP), with the clinical details necessary to distinguish specific 
types of myocardial infarctions and unstable angina. Through incorporation of the 
primary care record, CALIBER can be used to investigate onset of disease by allowing 
exclusion of patients with history of disease recorded prospectively (rather than based on 
recollection).  CALIBER, which encompasses multiple sources, including mortality, is also 
more likely to capture all events, including those which occur out of hospital, then those 
which rely solely on primary and secondary care records.  
5. Aims and objectives 
The aim of this thesis is to investigate whether there is heterogeneity of association 
between specific cardiovascular risk factors and the onset of clinical cardiovascular 
disease across a wide range of initial disease presentations and whether any such 
heterogeneity is modified by gender.  There are four objectives to address this aim: 
1. Investigate whether there is heterogeneity in the association of gender (a non-
modifiable risk factor) with the onset of cardiovascular disease across twelve 
different clinical disease presentations.  
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2. Investigate whether there is heterogeneity in the association of smoking (a 
modifiable risk factor - health behaviour) with the onset of cardiovascular disease 
across twelve different clinical disease presentations. 
3. Investigate whether there is heterogeneity in the association of systolic and 
diastolic blood pressure (a modifiable risk factor – physiological) with the onset of 
cardiovascular disease across twelve different clinical disease presentations.  
4. Investigate whether the associations of smoking and blood pressure with the 
range of endpoints are modified by gender. 
6. Layout of thesis 
I begin my thesis by describing electronic health record research in general and the 
specific research platform used for my research, CALIBER, in detail (Chapter 2). I then 
describe my methods generally applicable to all of the substantive analyses in my thesis, 
including definition of risk factors and endpoints, as well as approaches to statistical 
analysis (Chapter 3). I then describe the derivation of the overall cohort and cohort 
patients (Chapter 4). In the next three chapters (5-7), I report on the specific methods and 
findings of my substantive analyses on the association of gender, smoking and blood 
pressure with initial presentations of cardiovascular disease.  Finally, I summarise the 
overall findings and describe the implications for research, clinical and public health 
practice (Chapter 8). The appendices include acronyms, codes lists, and variable 
definitions used, as well as other supporting material. 
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Source EHR datasets, linkage, creating research data, data quality 
and governance:  The CALIBER research platform 
1. Introduction 
This chapter describes the elements which were combined to create the CArdiovascular 
disease research using LIinked Bespoke studies and Electronic health Records (CALIBER) 
research platform through which the thesis cohort data was generated, as well as the 
research governance for the thesis.  
 
The use of electronic health records (EHR) in epidemiological research is a growing field, 
with considerable interest from academic funders, policy leaders and government in the 
research potential of these resources, in the United Kingdom(44–48) and internationally.(49–
52) The United Kingdom has the potential to lead the world in EHR research because of the 
internationally unique congruence of publically-funded universal healthcare covering 
primary, secondary and tertiary care; long-established computerisation of general practice; 
unique personal identifiers in health care; and a range of clinical registries providing depth of 
clinical detail.  
 
The science of using electronic health records for research, however, is still in its infancy, 
with on-going debates about different aspects of the methodology.  In the last ten years, much 
of the methodological debate has been about appropriate research and  information 
governance required to protect patient identity/privacy with linked records,(53–56) lack of 
individual patient consent to use of data,(57–59) and methods of linking data.(60–65) While 
the debate on these issues continues,(66) it is also now broadening out into how best to make 
EHR research more transparent, accurate and reproducible,(67–69) and how best to use 
EHRs for translational research and randomised controlled trials.(70–72) This has occurred 
at the same time as an explosion in the volume of linked EHR data available and studies using 
EHR.(73)  The fact that STROBE(74) and other reporting guidelines(75) are currently being 
developed to incorporate issues raised by  EHR research is a further indication of the on-
going discussion around methodological quality of such research. In this chapter I seek to 
describe the linked EHR data I use for my research in the context of some of the issues raised 
by these papers.  
 
First, I describe each of the constituent data sources which have been combined to create the 
CALIBER research platform, giving a brief description of the context in which the data 
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originate the type of information recorded, the coding system used, and any known 
information biases in the dataset. Second, I describe how the linkage was done, the quality of 
linkage between the datasets – to the extent that it is known -  and any information bias that 
may been introduced in the process of linkage. Third, I summarise the available evidence of 
the validity of EHR records in general for identifying specific risk factors and endpoints 
relevant to this thesis. Fourth, I describe the work I undertook, with colleagues, to make the 
process of creating research-ready data from these raw EHRs more transparent and 
reproducible.  Fifth and finally, I describe the research and information governance used for 
this study.  
2. Data Sources 
CALIBER consists of 4 constituent data sources, each of which is described below.  
2.1. General Practice Research Database (GPRD) 
The GPRD is a primary care database containing anonymised patient records for 
approximately eight per cent of the UK population (5.2 million patients), owned by the 
Department of Health from 1994 and curated by the Medicines and Healthcare Regulatory 
Authority (MHRA).(76)  Individual general practices which use the Vision computer system 
to record data on diagnoses, symptoms, referrals, test results, hospital admissions, 
prescriptions, procedures, treatments and health behaviours are paid to submit data to 
GPRD. Patients registered with these practice are informed about the data extraction and 
offered the opportunity to opt out of having their personal data extracted. GPRD have not 
published data on how many patients exercised this right. Forty per cent of the 636 general 
practices participating in GPRD permit additional data to be extracted to allow linkage of 
individual patient records with other data sources.(77) Data from these practices (n=225), all 
located in England, are used in the current study. In April 2012, GPRD was incorporated by 
the Clinical Practice Research Database (CPRD) which will expand data collected to other 
general practice computer systems and increase the size and coverage of primary care data 
substantially. 
 
Vision and the other UK general practice computer systems use Read codes, a hierarchical 
clinical coding system developed for general practice in the United Kingdom (UK). (78)  
Named after Dr James Read, who developed the codes in the 1980s to allow general 
practitioners to capture reliably and consistently the range of information required in general 
practice, such as symptoms and examinations, not just definitive diagnoses.(79) With over 
100,000 codes in the Read classification, compared to approximately 20,000 in ICD-10, there 
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are the potential for multiple codes for individual diseases and endpoints. The hierarchical 
nature of the coding system means the more specific terms can be related to their more 
general ‘parents’.  The Read Codes have now been cross-referenced to the Systematized 
Nomenclature of Medicine - Clinical Terms (SNOMED CT), an international hierarchical 
coding system for use with electronic health records.  
 
GPRD has two key methods of ensuring quality of the data it makes available to the research 
community. First, they include only patients whose data is of “acceptable research quality”, 
excluding those where gaps or inconsistencies in the patient’s record raises concern. The 
criteria GPRD uses to identify patients of research quality are listed in Table 1.  The second 
method is a data quality audit of all patient records in a practice: recording is assessed 
against ten practice-based standards, again listed in Table 1.(80) GPRD did not publish the 
levels or proportion required of a practice to meet their standards.  If a practice meets these 
standards, they are designated “up to standard” (UTS). The first practice designated UTS in 
CALIBER achieved this status on 19th April 1988. Eighty per cent of the practices in CALIBER 
achieved UTS status by 1st January 2000, with the other practices achieving UTS in 
subsequent years. None of the practices in CALIBER have had their UTS status revoked, 
although this is theoretically possible.  
 
Marked changes in the quality and completeness of data recording in general practices during 
the period of this study cohort came with radical re-working of the NHS contract with general 
practitioners. The new GP contract, which came into force in April 2004, introduced the 
Quality and Outcomes Framework (QoF), which stipulates specific information which must 
be recorded and levels of preventive treatment to be attained in order to attract 
payment.(81) Changes to the standards in the QoF have occurred at regular intervals since 
then.(82) Studies have investigated the effect of the QoF on patient care,(83) on recording of 
information,(84) and health inequalities, including one finding that recording of CHD quality 
indicators increased more for men than for women, after the introduction of the QoF.(85) 
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Table 1: Data quality standards used by GPRD 
Patient-level quality standards: 
Acceptable research quality (ARQ) 
 
Practice-level quality standards:  Up to 
standard (UTS) 
An empty or invalid 1st registration date1 Percentage of patients of ARQ 
Absence of a record for a year of birth Monthly prescription rate comparable to other  
practices 
A first registration date prior to birth year Percentage of prescriptions with a medical 
indication 
A transferred out2 reason with no transferred 
out date 
Death rates comparable to other  practices 
A transferred out date with no transferred 
out reason 
Cause of death recorded 
A transferred out date prior to their first 
registration date 
Outcome of pregnancy recorded 
A transferred out date prior to their current 
registration date 
Referral rate comparable to other practices 
A current registration date prior to their first 
registration date 
Percentage of referrals with recorded clinical 
speciality 
A current registration date prior to their 
birth year 
 
A gender other than 
Female/Male/Indeterminate 
 
An age > 115 at end of follow up  
Recorded health care episodes in years prior 
to birth year 
 
Registration status of temporary patients  
 
Patients included in dataset: The population registered with general practice is not 
synonymous with the general resident population, because not all residents register with a 
GP. Specific groups are more likely not to register, i.e. asylum seekers, members of the armed 
forces and their families, convicted prisoners, the homeless and sex workers(86,87) but the 
number of registered people is not routinely assessed. One recent government report 
suggests that the number of unregistered people is approximately 1% of the total 
population.(87) There may be some under-representation of men in a cohort based on GP 
registration, given that men will constitute a greater part of the unregistered population, but 
the size of this is small compared to size of the registered population.  
                                                             
1 Registration here means registration date means date when the first registered with the general practice. 
2 Transferred out refers to when patient leave practice.  
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GPRD extracts data from specific general practices using the Vision software, also raising the 
possibility of selection bias if Vision practices are systematically different from practices 
which use other GP computer systems. GPRD report that the population in their dataset is 
broadly representative of the population of England and Wales in terms of age and gender 
profile,(76) though GPRD tends to under-represent certain regions, particularly the north of 
England. The subset of linkable practices shares the demographic profile of the full GPRD 
dataset.(77) 
  
Gender differences in consultation rates in primary care: One concern about using primary 
care EHRs to study gender differences is the differing relationship between women and men 
with general practice and healthcare in general. Women have been found to consult their 
general practitioner more overall than men do;(88) however, a substantial portion of this 
difference can be explained by more consultations by women during the reproductive 
years,(89) possibly leading to greater completeness in health behaviours and risk factor 
recording but not necessarily endpoints. Men with symptoms of chest pain recorded on the 
Rose Angina scale have been found, in one study, to be more likely consult for their chest pain 
and to be diagnosed with coronary disease than were women.(90) However,  other studies 
have found that when consultations for specific diseases are compared between men and 
women, there are minimal differences in consultation rates between the two genders, 
including for established cardiovascular disease.(91,92)  
 
Quality of prescribed medication recording: Prescribing data from GPRD is highly complete 
and has been used extensively for drug safety research.(93) GPRD only records prescriptions 
issued and does not measure medications taken, although the requesting of repeat 
prescriptions does suggest that medication is being taken. A recent study comparing smoking 
cessation medication in The Health Improvement Network (THIN) (which takes data from 
the same GP computer system as GPRD) found high concordance between prescribing and 
dispensing data.(94) Mabotuwana found, albeit in a New Zealand population, a positive 
predictive value (PPV) of 81.4% (95%CI 78-85) for prescriptions for chronic conditions to be 
dispensed with seven days, though again this does not necessarily measure medications 
taken.(95) 
 
Quality of diagnostic  codes in GPRD in general: A recent systematic review of studies 
validating diagnoses in GPRD found those comparing the records in GPRD to non-EHR 
sources (principally requests to GPs for additional information and/or paper medical 
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records) had a median positive predictive value (PPV) of 88% across a range of 
diagnoses.(96) All studies which assessed cardiovascular diagnoses had a median PPV of 
85.30 (range: 48-100), while those validating endocrine, nutritional and metabolic diagnoses 
had a median PPV of 87.70 (range: 53-100). A second systematic review also found 
considerable variation in the positive predictive value (PPV) of diagnoses; acute conditions 
were in general less well recorded, although myocardial infarction appeared to be an 
exception to this finding.(97)  However, as both systematic reviews point out, these studies 
do not identify the negative predictive value of a diagnosis in GPRD, so we do not know the 
validity of a cardiovascular diagnosis being absent from the GPRD database.  More detail on 
studies of specific cardiovascular disease endpoints is given in Section 4: Accuracy of EHR 
data. 
 
Quality of risk factor recording: I identified a small number of studies, but no systematic 
review, investigating the completeness and accuracy of recording of health behaviours, such 
as smoking, and biomarkers, such as blood pressure or lipid measurement, further described 
in Section 4: Accuracy of EHR data.  Although recent studies are lacking, such studies as exist 
seem to indicate that risk factors are under-recorded in GPRD.  
 
Conclusions: Although GPRD covers a small proportion of the UK population, the dataset has 
been found to be representative of that population. Women appear to consult more 
frequently than men, but this difference may be limited to younger ages. There is some 
evidence that for the same diagnosis, the rate of consultations is similar between men and 
women, although one study found that men are more likely to consult for symptoms of 
coronary disease, i.e. chest pain, which may lead to more complete or earlier diagnosis in men 
than in women. Diagnostic codes used in GPRD have been found, across the risk factors and 
cardiovascular disease endpoints relevant to this thesis, to have PPVs over 85%. The 
recording of risk factors and health behaviours may under-estimate the level of such risk 
factors in the population.  
2.2. Myocardial Ischaemia National Audit Project (MINAP) 
As far as I am aware there are only two countries (UK and Sweden) in the world with a 
national, on-going registry of acute coronary syndrome in which participation is mandated in 
all hospitals.   MINAP is the national registry of patients attending hospitals in England and 
Wales with suspected acute coronary syndromes (ACS), curated by the National Institute for 
Cardiovascular Outcomes Research, hosted by University College London.  Details of MINAP 
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have been published elsewhere,(98) but are repeated briefly here. Information on the timing 
of symptom onset and admission, clinical features and investigations (including ECG results 
and biomarkers of myocardial necrosis ), past medical history, risk factors such as smoking, 
hospital treatment and discharge diagnosis are collected prospectively at participating 
hospitals, and submitted to the Central Cardiac Audit Database (CCAD).  These records are 
regularly linked by CCAD to mortality data from the Office of National Statistics and made 
available in anonymised form to researchers as well as fed back to individual hospitals for 
quality purposes. MINAP was started in 2000, with a limited number of hospitals submitting 
data. The Registry achieved near national coverage in 2003, reaching 242 hospitals in 2009, 
100% of NHS hospitals in England and Wales. The MINAP data used in the CALIBER research 
platform runs from January 2003 to August 2009, when the MINAP data was exported for 
linkage to the trusted third party. Plans for updating the linkage are being considered.   
 
Patients included in dataset: When compared to acute myocardial infarctions (AMI) recorded 
in hospital episode statistics (HES), ST elevation myocardial infarctions (STEMI) recorded in 
MINAP have been found in one study to be near complete, but only about half of non ST 
elevation myocardial infarctions (nSTEMI) were recorded.(98)  A consequence of this under-
recording is that the MIs of women may be less likely to be recorded, as they are more likely 
to suffer from an nSTEMI. In a comparison of MINAP with the Patient Episode Database for 
Wales (PEDW), Lyons and colleagues found that those whose MIs were not recorded were 
more likely to be older and female.(99,100)  Furthermore, they found that the more nSTEMIs 
a hospital reported, the greater the agreement between MINAP and PEDW.  In contrast, a 
more recent comparison of MINAP with English HES found similar number of women 
recorded in MINAP as recorded in HES.(101)  It is unclear whether using MINAP as a sole 
source of information on MI is likely to bias estimates of any gender differences.  
 
Quality of data included in dataset: As well as CCAD monitoring 20 fields continually for 
completeness as the data are submitted, MINAP also conducts an annual data quality 
exercise, by asking participating hospitals to submit data on 20 fields on a random sample of 
20 patients, from the original medical records. The median hospital score from the 2010 
audit was 94.8% (IQR 90.0-97.8). I could find no peer-reviewed publication on the agreement 
between MINAP data and clinical records, whether on the recording of acute coronary 
syndrome or other risk factor information recorded in MINAP.  
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Conclusions: MINAP is a useful source of information on MI, particularly as it provides 
information on MI phenotype, unlike HES.   MINAP should be used in conjunction with other 
sources of information on MI, as it is likely to under-estimate the number of MIs, particularly 
in women and older people.   Although information on risk factors, such as smoking and 
diabetes are available in MINAP, the recording is, of necessity, retrospective. I therefore made 
the decision to take risk factor information only from GPRD. 
2.3. Hospital Episode Statistics (HES) 
HES, owned by the NHS and provided by the NHS Information Centre, consists of data on 
admissions since the financial year 1989/90, outpatients since 2003/4 and accident and 
emergency attendance since 2007/8. The hospital admission data includes private patients 
treated on NHS premises, NHS patients treated by independent providers on behalf of the 
NHS and patients not resident in England, as well as NHS patients treated in NHS premises.  
The record for each episode  includes up to 20 diagnoses, coded using the International 
Classification of Disease, Version 10 (ICD-10),(102) and up to 24 procedures, coded using the 
Office of Population Censuses and Surveys (OPCS)  Version 4 codes.(103) HES data available 
in the CALIBER research platform runs from 1st April 1997 to 31st October 2009. 
 
The funding environment for hospitals changed in 2004 when the NHS switched from block 
contracts to payment by results (PbR), in which hospitals were paid a fee for each admission, 
grouped into broad reimbursement bands.(104) One of the impacts of this change in funding 
environment has been a substantial increase in the number of diagnoses recorded for each 
admission.   
 
Patients included in dataset: HES is put through a series of data quality checks, principally 
testing consistency, duplication and completeness.(105) Since 2007/8, HES has published an 
annual data quality report, which highlight known problems with the data for a given year; of 
particular relevance is the section on coverage which highlights where individual hospitals 
have a shortfall between the number of records submitted and the number of admissions 
reported.  The scale of these shortfalls (35,120  in 2009/10)(106) is dwarfed by the overall 
number of admissions records in HES (14,537,712 admissions in 2009/10),(107) and tends 
to affect a limited number of trusts in any given year.  Thus in any given year the 
completeness of HES in recording admissions to NHS hospitals is very high. 
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Admissions to or procedures done privately by independent providers are not included in 
HES and therefore not included in this study. Relatively little research has been published on 
the number of patients who might be missed if data from independent providers is not 
included.(108,109) One report found an increase of 12% in the number of revascularisation 
procedures in London in from April 2001 to December 2003 if such private procedures in 
independent facilities are included in the total number of procedures.(109)  
 
Quality of HES data (general): A recent systematic review assessed the quality of discharge 
coding in HES.(110) Over all the studies, the median diagnostic accuracy was 80.3% (IQR: 
63.3–94.1%) ¸while the accuracy of procedure coding was 84.2% (IQR: 68.7–88.7%). In those 
studies conducted since the introduction of Payment by Results, the accuracy of primary 
diagnosis alone improved to 96.0% (IQR: 89.3–96.2%).  The Audit Commission has also 
conducted an annual audit of discharge diagnoses since PbR was brought in. The 2010 
national audit on all hospitals found an average error rate of 11.3% (range 1 to 30%).(111) In 
the 2011 audit in 60 poorly performing hospitals, they found average error rate of 9%.(112)   
Details of the accuracy of EHR records for specific endpoints are addressed in Section 4: 
Accuracy of EHR data. 
 
Conclusions: HES discharge data has nearly complete coverage of admissions and procedures 
performed in NHS hospitals, though unmeasured private admissions and procedures may be 
as high as 10% of the overall number for some procedures, particularly in London. The 
accuracy is also good, and has improved since the introduction of Payment by Results. No 
evidence of any differences between men and women in accuracy of recording has been 
reported. 
2.4. Mortality data from the Office for National Statistics (ONS) 
Data on vital status and cause of death originate from ONS mortality records. By law, any 
death occurring within England and Wales must be registered with the Registrar of Births 
and Deaths, normally within 5 days of the death. Such registration must be accompanied by a 
medical certificate of the cause of death, except in the limited number of cases where death is 
referred to a coroner. The mortality data for England and Wales is therefore highly 
complete.(113)  UK mortality data do not, however, include people either normally or 
formerly resident in the UK who die abroad.   
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Of importance to this thesis is the accuracy of the underlying cause of death on death 
certificates. I used the example of coronary heart disease (CHD) to research what is known 
about the accuracy of death certificates.  I searched Medline between January 1990 to March 
2010 for articles on the accuracy of coding on death certificates for any type of CHD, 
excluding any articles which assessed deaths before 1985 only. The results are summarised 
in Appendix B. They fall broadly into four types, assessing:  
 coding on death certificates vs autopsy results; 
 coding on death certificates vs  the results of adjudication of a panel, based on a 
multiple sources of information;  
 agreement between doctors on cause of death; and 
 coding on death certificates to diagnoses from contemporaneous hospitalisations.  
Only four studies on a UK population could be found, (114–117) three of which were by 
Goldacre and colleagues who assessed the relationship between hospital discharge diagnosis 
and cause of death, the third type of death certificate studies.  None used ICD-10. The first, in 
1993, looked at the cause of death for all hospitalised patients who died with four months of 
their admission.  Of those hospitalised for IHD, 77.8% (8271) had IHD coded as the 
underlying cause of death, and 90.2% (9596) had circulatory disease mentioned. Overall 
85.9% (18,378) of people with admission for circulatory disease had circulatory disease 
listed as the underlying cause of death. The effect of age on accuracy was assessed and 
reported as minimal, although no results for IHD are given; gender was not mentioned.(114)  
The second study analysed any changes in the proportion of death certificates with MI 
mentioned as a cause of death compared to MI specified as the underlying cause of death 
between 1979 and 1998. Although the mortality rate for MI fell significantly over the 20 year 
period, the ratio of underlying to mentioned did not change materially during that time, 
suggesting that this ratio is a relatively stable measure. This ratio was similar across age 
groups and between men and women.(115)  The third study looked again at hospital 
discharge data linked to mortality data from 1979 to 1998 in people aged 35-74 following 
admissions for MI (and stroke). Amongst those who died within 30 days, 85.2% had MI on 
their death certificate, while 90.2% had CHD (410-414) as an underlying cause of death.  As 
the time period between admission and death lengthened, the proportion dying of the same 
cause reduced; however, there was little difference in proportion if the death took place in or 
out of hospital.(116)  These three studies, in broad terms, suggest that cause of death coding 
on UK death certificates is reasonably accurate and that there is little age or gender difference 
in their accuracy. Mant et al., who looked at overall accuracy of coding of coronary heart 
   
35 
 
disease deaths,(117) as well as specificity for chronic versus acute CHD, found lower PPV 
(70%) for codes on death certificates. However, this study included arrhythmias (ICD-9 426-
427) and atherosclerosis (440) as well as coronary heart disease (410-414), which may 
explain the difference with the Goldacre studies.  
 
Most death certificate studies identified looked at the accuracy of coding in ICD-9, no longer 
used in UK death certification. Only one, by Pajunen and colleagues,(118) looked at coding in 
ICD-10 using data collected between 1998-2002 for the FINMONICA/FINAMI registries, for 
both IHD and sudden death (I20-25, I46, R96, R98). They found that for men and women 
aged 35 to 74, the sensitivity of the death certificate was 92%; for men and women over 75, 
sensitivity diverges slightly (men 89% to women 90%) but the difference is minimal. Again 
death certificates appear highly accurate – at least in a Finnish context -- when assessed 
against a registry of acute coronary syndrome, with minimal gender differences. Of particular 
importance for this thesis is that FINMONICA/FINAMI is a community registry and therefore 
includes all of out-of-hospital deaths identified as due to coronary disease.  
 
Of particular concern is the accuracy of death certificate coding when deaths occur out of 
hospital or suddenly. Goraya et al., using multiple sources of information on cause of death, 
found that relying on death certificates alone in an American context would like 
underestimate deaths from IHD that occurred out of hospital by about 5%, with a sensitivity 
of 91% (85-95) and specificity of 86% (71-95%) for this sub-group of IHD deaths.(119)  
Several American studies found that death certificates for OOH coronary deaths, when 
compared to physician-adjudicated or multiple-source cause of death, are relatively poor 
method to identify sudden cardiac deaths (SCDs) in particular.(119–121) However, in the UK, 
where a death is sudden and unexpected, deaths are certified by a coroner, usually following 
a post-mortem. Approximately 40% of deaths from IHD receive a death certificate in this 
way,(122) while in at least one of the US studies, the post mortem rate was less than 20%, 
suggesting that the accuracy of death certificates for this sub-group would be higher in the 
UK than reported in these studies. 
 
Conclusions: The available evidence applicable to the UK suggests that the coding on death 
certificates for at least coronary heart disease is likely to be accurate, although possibly up to 
10% of cases may be missed. However, of greater importance for the current thesis is that 
there is no evidence to suggest systematic differences between the genders in accuracy of 
death certificates for these diagnoses.  
   
36 
 
2.5. Index of multiple deprivation 
ONS generated the index of multiple deprivation (IMD) 2007,(123) a combination of scores 
across seven domains, covering diverse aspects of deprivation such as crime, employment 
and access to health care, at the level of lower super output area, which covers a population 
of approximately 1500 people or 400 households.  Provided patients have a viable postcode, 
an IMD score and rank can be attributed to them. IMD score and rank are linked with 
individual patients, prior to pseudo-anonymisation.  IMD has been criticised as a measure of 
individual deprivation,(124) and it is undoubtedly cruder than individual measures of social 
class, such as those used in the Whitehall II.(125) However, IMD has been found to be 
strongly associated with CHD disease and mortality. (126,127) No individual measures of 
deprivation are currently available within GPRD, so although it would be preferable to have 
an individual measure of deprivation, IMD is an adequate measure for this PhD.  
3. Data Linkage 
Unlike the situation for many countries (e.g. US, Australia), the United Kingdom has a unique 
health identifier for everyone registered with the National Health Service (NHS). The NHS 
number was introduced with the inception of the NHS in 1948, based originally on the 
national registration number issued at the start of the Second World War.3 The computerised 
NHS Central Register (NHSCR), created in 1991 from local paper records, is responsible for 
maintaining the system of NHS numbers in England and Wales. A new-style 10-digit NHS 
number was introduced in 1996, nine digits to uniquely identify individuals with a 10th check 
digit to confirm the validity of the other nine.(128)NHS numbers are issued to babies born in 
England and Wales at birth, to anyone who registering with a GP, receiving treatment from a 
hospital able to issue NHS numbers or on request from the local Primary Care Trust. In the 
UK, the NHS number is used as the field common to multiple datasets which allows 
information on individuals in different datasets to be linked.  Additional fields such as name 
or date of birth (patient identifiers) which should remain constant across a range of datasets 
can also be used to link datasets.  
 
One approach to linking datasets while providing maximal protection for participant privacy, 
used in creating the CALIBER research platform, is to use a trusted third party (TPP) to make 
the linkage. Each organisation curating a dataset (the data holders) creates a file containing a 
dataset-specific pseudo-identifier (identifiers that are specific to patients in each file but 
                                                             
3 In Scotland, the equivalent number is the Community Health Index, maintained by the Central Register. In 
Northern Ireland, the equivalent number is the Health and Care Number. 
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which bear no relation to the real patient identifiable information) for each patient as well as 
variables with identifiable information which can be used to link data, but no other clinical or 
other sensitive information. All data holders then send these files the TPP, who then matches 
the information from all the datasets, either deterministically or probabilistically, and creates 
a key file with the patient pseudo-identifiers from each dataset. The data holder sends their 
dataset with clinical information and the patient pseudo-identifier to the researchers. The 
TTP send the key file, which allows the researcher to link multiple datasets using the linked 
pseudo-identifiers. Using this approach means that no research organisation or the TPP ever 
has both patient identifiers and clinical or other sensitive information and no data user has 
personal information from any dataset other than their own.  The process is represented in 
Figure 1 below. 
3.1. CALIBER data linkage process 
The CALIBER research platform was created by the linkage of five constituent datasets, which 
were linked in two stages. For the main linkage to MINAP, Northgate (the TTP used for this 
linkage) received a list of unique patient identifier fields and demographic characteristics 
(NHS number, date of birth, sex, and postcode of residence) and their associated source-
specific pseudo-identifiers. Records were linked using a pre-defined deterministic linkage 
algorithm (i.e.  records linked only if an exact match is found) and remaining records were 
linked using a probabilistic method (e.g. records matched with as similar sounding names or 
common misspellings). Once the linkage was completed, the patient-identifying variables 
were removed, leaving the key file which links GPRD patient pseudo-identifiers to MINAP 
hospital record number pseudo-identifiers. MINAP patient pseudo-identifiers are recorded 
using a one-way cryptographic hashing algorithm and GPRD patient pseudo-identifiers are 
recorded using an unrelated sequential serial number.  Northgate have not provided the 
CALIBER collaboration with any information on quality of the linkage, i.e. proportion of 
patients linked either deterministically or probabilistically.  
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Figure 1: Data linkage using trusted third party to create CALIBER research platform 
 
Figure courtesy of Dr Spiros Denaxas, Clinical Epidemiology Group, University College London 
 
Before linkage to MINAP, GPRD was also linked to HES admissions data, mortality data and 
deprivation data separately, in October 2010, using similar methods to MINAP. GPRD report 
that for a patient to be put forward for linkage, he or she had to be: 
a) Actively registered with a consenting practice at some point during the period for which 
data are available for the second data source; 
b) Been of acceptable research quality in the November 2010 version of GPRD GOLD  
c) Had a valid NHS number.(129) 
GPRD report that 5.8 million patients were eligible for linkage (but do not report how many 
were not). They do note that approximately 50% of those without a valid NHS number were 
not of acceptable research quality so would be excluded for studies using GPRD data in any 
case, but do not specify the number of patients affected. Of those eligible for linkage, 4.4 
million (77%) were matched with HES and 4.2 million were eligible for MINAP linkage.(129) 
About 99% of the patients eligible for linkage had a valid NHS number and could thus be 
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linked deterministically.(77) . GPRD do not report a per record linkage statistics which is 
generally considered the most appropriate measure of linkage performance.  
 
One potential bias with the linked mortality data is that GPRD provides clinical data on a 
registered population while ONS provides mortality data for resident population. Registered 
patients who die abroad will therefore not be identified as dead using ONS mortality data. 
The Foreign Office report that approximately 6,000 British nationals die abroad every year, of 
whom 55% die of natural causes,(130)  which represents approximately 0.5% of the deaths 
in a given year.  No further information could be found on the proportion of these deaths 
which occur in British residents travelling abroad (who may still be registered with English 
GP) and those which occur in British nationals resident abroad (who may no longer be 
registered with an English GP). The number provides the maximal estimation of the extent to 
which mortality may be underestimated in this cohort for this reason, although the actual 
number is likely to be much smaller. GPRD provide their own mortality variable derived from 
registration status, GP own recording of mortality, age and frequency of consultation.  This 
variable can provide another measure to assess the accuracy of ONS mortality status but have 
not been tested in this thesis.  
4. Accuracy of EHR data 
Underpinning the work of this thesis is the accuracy of electronic health records (EHRs) in 
identifying both risk factors and endpoints.  In collaboration with other members of the 
Clinical Epidemiology Group, particularly Marina Daskapolous, I searched for studies on the 
accuracy of EHRs from primary and secondary care and from death certificates, regardless of 
country.  While sensitivity and specificity are the gold standard measures of accuracy of tests 
or records because they do not depend on the population prevalence of the condition in a 
given study, these measures are much less commonly reported than positive predictive value 
in EHR validation studies.  Because our purpose was to undertake a highly sensitive search 
for studies of EHR accuracy and compare across a single measure of accuracy, we restricted 
the search to studies which published either positive or negative predictive values.  This 
work benefitted from a number of recent systematic reviews focussing on specific data 
sources such as GPRD(96,97) and HES(110), as well as reviews focussing on specific 
endpoints.(131–134)  Below, I summarise the findings on the key risk factors and 
presentations of cardiovascular disease used in this study.  
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4.1. Risk factors 
I identified a small number of studies, but no systematic review, investigating the 
completeness and accuracy of recording of health behaviours, such as smoking, and 
biomarkers, such as blood pressure or lipid measurement in GPRD.   
 
One study which compared recorded smoking status in general practice records against both 
GP questionnaire and levels reported in the General Household Survey found under-
recording of current smokers but particularly ex-smokers.(135) However, this study looked 
at recording prior to the introduction of the Quality and Outcomes Framework in 2004, 
which,  as mentioned above, has been found to increase the level of recording of both 
smoking status and cholesterol level, although to a lesser extent in women than in men.(85) 
 
Comparing the level of clinically recognised hypertension or dyslipidaemia (defined as 
recording of clinical diagnosis, biomarkers raised above cut-off or treatment), MacDonald et 
al. found significant under-recording of these conditions, when compared to the levels 
reported in the Health Survey for England, particularly in women.(136) Wilkins et al. found 
evidence in a comparison between GPRD and the Health Survey for England of  fewer men 
identified with hypertension in GPRD than would be expected, in comparison to the Health 
Survey for England.(88)   
 
Diabetes is the only co-morbid condition used in the analysis for this thesis. A recent 
systematic review of misclassification and miscoding of diabetes across primary, secondary 
and registry data concluded that the quantitative measurement of accuracy was poor.(137) 
The focus of this review, however, was the ability of codes to distinguish between types of 
diabetes and other related diagnoses such as glucose intolerance. The review did not include 
any studies in English which reported the positive predictive value (PPV) of EHR codes for 
diabetes.  In two studies of primary care data not included in the review, the PPV of diabetes 
codes is very high (99-100%).(138–140) 
4.2. Presentations of cardiovascular disease 
The accuracy of coding of cardiovascular disease endpoints has been assessed in a number of 
studies across a range of different settings. A total of 25 studies, including 3 systematic 
reviews, were found which assessed the PPV of codes from either primary or secondary care. 
None assessed the PPV of linked datasets and none reported the negative predictive value of 
these codes. A variety of methods were used to estimate the PPV, with the most common 
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being chart or expert review.  Most of the studies used data from the United States, but others 
were found using data from the UK, Canada, Finland and the Netherlands. Those studies 
which also published confidence intervals have been included in Figure 2 below. Where the 
studies specified further characteristics such as fatal or non-fatal presentations or probable 
or definite diagnoses, this information is also given.  A brief summary of the studies by the 
endpoints used in this thesis has been given below. 
 
Abdominal aortic aneurysm – A 1994  study comparing the Scottish Morbidity Record (the 
Scottish equivalent of HES) to medical records found a specificity of 98% for AAA but did not 
report PPV.(141) One recent UK study of coding in HES for abdominal aortic aneurysm (AAA) 
found a high level of accurate coding (94.9%), although the way in which accuracy was 
assessed was evaluation of congruence between diagnosis, treatment and method of 
admission.(142)  No studies on the accuracy of coding of AAA from primary care were 
identified.  
 
Angina pectoris – One US study comparing EHRs and physician-adjudicated cardiovascular 
endpoints in women only found a low PPV for angina pectoris in hospital EHRs (40%, 95% CI 
39-42%)(143), while a European study in men only comparing EHR to disease registry 
entries found a much higher PPV for unstable angina (78%; 74-83%).(144) A single Scottish 
study comparing primary care EHRs to paper medical records found a PPV of 100% for 
angina in primary care data.(138) Another study found the prescription of nitrate had a 
sensitivity of 73% and specificity of 96% for a GP diagnosis of angina (PPV could not be 
calculated from the data given.)(145)  
 
Acute myocardial infarction – The PPVs for acute myocardial infarction found in studies of 
data from secondary care compared to paper medical records have generally been over 
85%,(131,144,146)  with the exception of  a study in women only which found a PPV of 78% 
(75-80%).(143) A US study which explicitly investigated gender differences in accuracy 
found lower sensitivity for AMI codes in women compared to men.(147) Compared to the 
other endpoints, myocardial infarction has a large number of studies assessing the accuracy 
of coding within GPRD, most  of which identified specificity for MI codes of over 90%.(148–
153) The PPV in studies which report this measure varied from 85% to 100%.(138,139,148) 
 
Coronary heart disease - A single study from secondary care found a PPV of 91% (88-93%) for 
the more general codes for coronary or ischaemic heart disease compared to hospital 
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notes.(144) Studies in primary care found PPVs ranging from of 83% (70-96%) to 100%. 
(139,140,154) 
 
Heart failure – A systematic review of studies of data from secondary care in North America 
found the PPV for heart failure codes were generally very high, with most in excess of 90%.  
Many of the studies in the review included patients seen as outpatients. The one European 
study of coding accuracy in secondary care identified found a lower PPV of 80%.(144) 
Studies based on primary care data (GPRD) found PPVs of 82-83%.(155,156) 
 
Peripheral arterial disease (PAD) -  One study which compared hospital codes and physician 
adjudication in women only found a low PPV for PAD of 31% (26-36%).(143) One early study 
of GPRD found a PPV of 75% for PAD.(157) 
 
Stroke, including ischaemic stroke  - A systematic review of studies of data principally from 
secondary care in North America found a wide range of PPV for stroke codes, with the 
majority of studies finding PPV over 80%; studies of transient ischaemic attack had lower 
PPV and those of intracranial bleed and subarachnoid haemorrhage, higher.(133) Two older 
Scottish  studies on accuracy of coding in secondary care found PPVs of 75% and 
95%.(158,159) One study comparing GPRD stroke codes to paper records found a PPV of 
89%,(160) while another study found little agreement between different medical 
professionals on which codes indicated acute stroke.(67) 
 
Ventricular arrhythmia, cardiac arrest and sudden cardiac death – A systematic review of 
studies of data from secondary care in North America found PPV between 78-100% for 
studies using 427.x and 798.x, with the highest PPV (92%) when both were used.(134) 
Consistent results were found in a European study not included in this review.(161) Two 
studies of primary care data suggest poor accuracy  of ventricular arrhythmias codes in GPRD 
but did not report confidence intervals.(162,163) 
 
While the PPV varies between endpoints, the majority of studies have found PPV in excess of 
80% for all endpoints.  
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Figure 2: Positive predictive value and 95% confidence intervals for cardiovascular 
disease presentations recorded in EHR sources  
 
5. From raw data to research-ready data – the CALIBER research platform 
A key methodological challenge of epidemiological research using EHRs is to robustly convert 
raw data to research-ready data. An important aspect of this thesis was not only to create 
usable data to complete the specific analyses for this PhD thesis, but to do so in such a way 
that created resources which others could use to make the process of using CALIBER 
research platform for subsequent research more efficient, transparent and reproducible.  
This section of the thesis describes the steps to create research-ready data and the CALIBER 
approach.  
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In order to understand the process of generating research-ready data from this linked 
dataset, a basic understanding of the data structures is required. GPRD provides data in 
several files, which are described in Table 2.  All these files are essentially very long lists of 
unsorted records; for example, the clinical file has 356,446,923 records, at least one and often 
multiple records for each consultation by every patient registered with all the practices in 
GPRD over the entire time period of the dataset. The relevant records have to be selected 
from each relevant file and combined to provide understandable information about 
individual patients.   The same process is used for selecting data from HES and ONS, while 
MINAP provides data in specified variables.  In the CALIBER research platform, each entry 
specifies the dataset used in creating each variable.  
The key stages in creating research-ready data are: 
1) Development of code lists used to define exposures, co-variates and endpoints and 
select relevant data from each data file 
2) Definition of such variables, i.e. how the records extracted from data files will be used 
to specify the value of research variables 
3) Algorithms for dealing with duplication and contradiction in the variables created  
At each stage of the process, we sought to ensure all our decisions were explicit, documented, 
reproducible and consistent. Each stage is described in more detail below.  
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Table 2: Selected constituent data files used for PhD, † including description and number of rows in full CALIBER research platform 
Constituent 
Data files 
Description Records 
Used for  
GPRD files 
Patient 
Year of birth, gender, marital status,  registration details and other 
administrative information 
5,372,790 Demographic co-variates 
Practice 
Region of practice, date practice met data quality standards and last data 
collection date 
226 Modelling data clustered at general 
practice level 
Clinical 
Record of each consultation including practice, patient and consultation 
identifiers, date of data entry, date of consultation,  and medcode (GPRD 
synonym for Read codes)  
356,446,923 Specifying cohort, and defining 
ethnicity, clinical co-variates, and 
endpoints 
Additional 
Information, such as measurements (e.g. blood pressure measurement or BMI) 
or categories (e.g. smoking status – current, ex, non) which are not captured by 
Read code.  
97,244,627 Defining clinical co-variates 
Test 
Type of test performed, values, units of measure and normal range for 
laboratory. 
227,075,743 Defining clinical co-variates 
Therapy 
Prescriptions issued included British National Formula (BNF) code, GPRD 
product code, total quantity prescribed, pack type, number of packs, numeric 
daily dose, total quantity and number of repeats. 
400,859,645 Defining clinical co-variates and 
specifying endpoints (stable angina) 
HES files 
Patient 
Patient identifier, birthyear, gender, ethnicity, ethnicity, HES data collection 
start and end, and matching quality data 
2,026,520 Defining demographic co-variate 
(ethnicity only) 
Diagnosis 
(Admissions) 
Patient identifier, admission identifier, date of discharge, ICD10 code, primary 
diagnosis flag 
7,983,022  Specifying cohort, and defining 
clinical co-variates and endpoints 
ONS files 
Mortality 
Patient identifier, date of death, under-lying cause of death, cause of death (1-
10) 
278,088 Specifying cohort and defining 
endpoints 
†GPRD Staff, consultation, referral and immunisation files not used in this PhD. 
   
46 
 
5.1. Selecting relevant codes to defining risk factors and 
cardiovascular diseases 
In order to select the relevant records from the study population’s data, a code list for 
each variable is needed. At its simplest, a small number of ICD codes are required to select 
either mortality or hospital diagnosis data; much more extensive lists are required to 
select records from GPRD.  Exchange and discussion about code lists is an important 
aspect of making EHR research transparent and reproducible. To date, many EHR studies 
do not publish all the code lists they use, either in the paper or in supplementary material, 
although this situation is slowly changing. We therefore decided to create auditable 
STATA do-files used to select code lists for each variable, following the method 
recommended by Dave and Petersen,(68) as part of our aim to increase transparency and 
reproducibility in EHR research.  
 
To generate each code list, initial search terms were agreed by at least two clinicians, and 
the relevant code dictionary searched for matching codes. For ICD-10 codes, OPCS-4 
codes and entity codes (used by GPRD to specify the content of subsequent fields in the 
additional and test files – See Table 2 above), the search was done by hand with reference 
to any published studies found. For Read codes, STATA do-files were used to search the 
electronic code dictionary provided by GPRD. Additional codes were identified by hand-
searching the NHS Read code browser, asking for suggestions from colleagues who had 
produced lists for other studies or, in some cases, identifying code lists in published 
studies or government reports. A preliminary sifting of the identified codes for relevance 
was completed, and then two clinicians rated the resulting lists for relevance and 
assigned response categories. Any disagreements were resolved in face-to-face meetings. 
For the Read code lists, the STATA do-files were amended to include any additions or 
exclusions, providing an audit trail of the code-selection process and a resource which can 
be used by other researchers. The STATA do-files were spot checked for accuracy by a 
researcher who had not written the original do-file.  All variable definitions and coding 
lists used are available through the CALIBER web portal, described in Appendix C. 
 
In creating the variable and coding algorithms, we took an inclusive approach but 
identified codes which we thought were less definitive as “possible” in our assignment of 
response categories. We agreed principles on the ways in which we would assign codes to 
the different response categories, particularly the “history of” and “possible” categories, 
both to ensure consistency and increase openness about our coding decisions.  The 
principles we used have been given in Appendix C. 
 
   
47 
 
The CALIBER variable and coding algorithms were developed through a process of 
multiple clinical speciality review across two institutions (University College London and 
the London School of Hygiene and Tropical Medicine). Professor Harry Hemingway (HH) 
– Cardiovascular Epidemiology, Professor Liam Smeeth (LS) – General Practice, Professor 
Adam Timmis (AT) – Clinical Cardiology, Dr Anoop Shah (AS) – Clinical Pharmacology, Dr 
Kate Walters (KW) – General Practice, Dr David Osborne (DO) – Psychiatry, all provided 
clinical expertise in the development of the CALIBER code lists. Spiros Denaxas (SD) 
provided technical advice and wrote the programs to extract the relevant records. Emily 
Herrett (EH) and I wrote the STATA do-files for selecting the Read code lists, further do-
files of the mental health portion of the CALIBER manual were developed by Ruzan 
Udumyan (RU).  
5.2. CALIBER Variable definitions 
Once the relevant records can be selected using agreed code lists, the way in which the 
information in those records will be combined to create research-ready data must be 
defined. A format for CALIBER variable definitions was agreed which included the 
following elements: 
1) Variable label – plain language name 
2) Variable name – variable name used in data files 
3) Chapter – Section of CALIBER data portal 
4) Variable definition – plain language definition 
5) Variable type - continuous, binary, or categorical 
6) Data sources – specifies from which constituent CALIBER data source records will be 
selected 
7) Dictionaries – Data dictionary used 
8) Agreed: Date on which the variable definition was agreed 
9) Units – used for continuous variables only 
10) Range – extreme limits were set to exclude biologically implausible values 
11) Response categories – for binary and categorical variables only 
12) Implementation rule: Logical rule which specifies the way in which the raw data is 
used to create the variable.  
A sample definition for diagnosis of angina in primary care from the CALIBER data portal 
is shown in Figure 3.  Further details on accessing the data portal in 0 Appendix C: 
CALIBER Data Portal and Developmental Tools. 
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Figure 3: Diagnosis of stable angina (primary care) from CALIBER data portal 
 
 
The variable definitions were agreed by both clinical and non-clinical researchers. In 
general we have aimed to give due weight to existing structures in the data and code 
hierarchies. For example, within GPRD, clinical signs or test results can be recorded either 
as a Read code (e.g. “O/E blood pressure raised”) or as additional data linked to specific 
entity codes. We therefore created two blood pressure variables, a categorical variable 
with response categories based on the descriptions in the Read codes and a continuous 
variable, with the blood pressure data included in the additional file.   
 
As part of the process for defining variables using data from either the GPRD test or 
additional files (see Table 2 above for description of these files), we checked which codes 
in the additional file were associated with our Read codes of interest. If the codes 
appeared to be completely unrelated to the Read code - for example, the Read Code 
“44PF.00: Total: HDL ratio” was linked to code “265: Sinus x-ray” - we excluded any data 
linked to those codes. We were surprised by some of these anomalies but as they affected 
few patients we did not investigate the reasons for this any further. We also excluded 
records linked to specific entity codes which described laboratory tests for conditions in 
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which we were not interested, e.g. entity code “363: Lipoprotein electrophoresis” linked 
to Read codes for low density lipoprotein (LDL).  Finally, if there was a contradiction 
between the Read code used and the name of the linked entity code, we generally did not 
use any data linked to those records because we had no way of knowing whether the 
Read code or the entity code was the correct designation, although the two were clearly 
related. In one exception to this principle, we identified a systematic mismatch between 
Read Code “44PF.00 - Total: HDL ratio” and entity code “338 - HDL/LDL ratio”, which 
affected >1,900,000 test records. We allowed this mismatched pair in our definition but 
flagged the problem in the manual. GPRD could not provide an explanation of this 
apparent systematic mismatch, though informed us that entity codes are allocated by the 
GP software, not GPRD.4  For a sample entity code report, see Appendix C.  To clarify how 
some entity codes are used within GPRD, we also ran reports which identified the 
associated Read codes and number of records. See Appendix C for an example of a reverse 
entity code report.  
 
Values for observations of clinical signs or test results are only used in the CALIBER 
variable definitions if they are specific (i.e. equal to a given value) and if the units 
recorded are those stipulated in our variable definition or were missing. Where they were 
missing, mean values for those with values and those without were compared in this 
thesis and those with missing values excluded if they were substantially and significantly 
different.  
 
For some categorical variables, the response categories from the Read list and the 
response categories from the associated entity code could theoretically contradict each 
other. Where there are potential code conflicts between two sources of data, we have 
identified this in the response categories, so that researchers can determine themselves 
how they wish to handle these conflicts.  
 
We concentrated on developing definitions for variables which could act as building 
blocks for more complex variable definitions, which we called base variables (the building 
blocks) and composite variables (more complex definitions). For example, the specific 
composite definition of stable angina is: 
Stable angina pectoris identified by diagnosis or prescription of nitrates, 
Nicorandil, Ivabradine or Ranolazine, and confirmed by test abnormality, or by 
CABG or PCI without acute myocardial infarction or unstable angina in previous 
30 days  
 
                                                             
4 Personal communication, A. Gallagher, 26.1.2012. 
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To implement this definition requires data from eight variables (diagnosis of stable 
angina, nitrate prescription, atheroma test, ischaemia test, CABG, PCI, MI and UA), six of 
which are themselves composite variables (e.g. atheroma test composed of invasive 
angiogram, CT angiogram, MRI angiogram, angiogram modality not specified and 
angiogram anatomy not otherwise specified combined). While some composite 
definitions of particular interest to current CALIBER researchers are provided on the 
CALIBER data portal, we recognized that many projects will wish to develop their own 
definitions using the base variables as building blocks. As mentioned above, all variable 
definitions used for this thesis are available on the CALIBER data portal (See Appendix C: 
CALIBER Data Portal and Developmental Tools for further information).  
 
JG led the development of the first set of CALIBER variable definitions, with draft 
definitions provided by JG, EH, and RU. The definitions for the initial variables were 
agreed between HH, LS, EH and JG. SD provided technical advice, checked the association 
between Read and entity codes, and wrote the implementation rules for the CALIBER 
research platform, as well as all the computer programs to implement them. AS provided 
editorial support, additional variable definitions and clinical advice. 
5.3. Algorithms for resolving duplicates or conflicts in the data 
Steps taken to resolve duplicate entries or conflicts in the data for particular variables 
were recorded in do-files, which are available on request.  However, further work could 
be undertaken to develop easily understandable algorithms for what steps have been 
used to resolve inconsistencies in the data.  
5.4. The added value of the CALIBER research platform 
CALIBER contains over 300 base and composite variables on medical history, diagnosis, 
investigations, procedures and prescriptions, with the associated code lists created in a 
transparent and reproducible manner. The variables are recorded in an online data 
manual, curated by CALIBER staff using established metadata standards(164). Version 
control is achieved by using a source control repository system. The approach taken is 
sufficiently flexible that additional variables can be added using the same rigorous 
approach; this has now been done for base variables required for deriving the Charlton 
Index for co-morbidities,(165,166) adapted for CALIBER.  
6. Information & research governance 
Ethics approval was sought by the CALIBER collaboration for linking the constituent 
datasets to create the CALIBER research platform.  In order to use all of the datasets from 
the research platform, individual researchers have to seek approval from the relevant 
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authorities to use each constituent dataset. Details of each approval obtained are given 
below.  
6.1. Ethics approval 
Ethics approval is not specifically required for the cohort studies undertaken for this PhD 
because only anonymised data is used in the research. However, ethics approval was 
obtained for the development of the CALIBER research platform as a whole. The 
Lewisham Local Research Ethics Committee gave approval for a period of five years for 
the project entitled “CALIBER dataset”, reference number 09/H0810/16, on 8th April 
2009. 
6.2. Independent Scientific Approval Committee (ISAC) approval 
The ISAC of the Medicines and Healthcare products Regulatory Agency (MHRA) requires 
submission of study protocol as well information on key investigators and sample code 
lists. Approval of Protocol 10_052R was approved on 8th June 2010. The protocol was 
revised to include use of HES and ONS datasets, and Protocol 10_052RA was approved on 
8th February 2011.  
6.3. MINAP Academic Group (MAG) approval 
The MAG require for a project protocol and evidence of peer-review, for which they 
accept ISAC approval. The MAG approval for “Gender differences in the development and 
prognosis of coronary disease where initial disease manifestation is stable angina, 
myocardial infarction or unheralded coronary death” was approved on 29.6.2010.  
6.4. Study registration 
In order to receive CALIBER Scientific Oversight Committee (SOC) approval, all protocols 
had to be registered with clinicaltrials.gov and the analytic protocol for the study date 
specified and dated. The clinicaltrials.gov registration for initial presentation of 
unheralded coronary death (CALIBER-09-05) was obtained on 2.7.210 and revised on 
19.12.2011.  
6.5. CALIBER SOC approval 
CALIBER SOC approval for initial presentation of unheralded coronary death (used for 
upgrade) was obtained on 8th June 2010 and for initial presentation of multiple endpoints 
was obtained on 25.11.2011.  
6.6. Patient and Public Involvement 
On 31.5.2011, I presented the summary of my research proposal to the Clinical 
Epidemiology Group’s Patient and User Involvement Group, which includes carers and 
patients with coronary disease. The focus of the project on analysing gender differences 
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across a range of presentations was supported. The conclusions of the research will be fed 
back to the group in September 2013.  
7. Conclusions 
In this chapter,  I described in detail the constituent datasets of CALIBER, including how 
the data is recorded, health services factors which may affect the quality and 
completeness of that EHR data, as well as what evidence is available on the accuracy for 
my co-variates and endpoints. I further discussed what steps were taken as part of the 
CALIBER collaboration to make the datasets available in CALIBER more transparent and 
research using them more reproducible.  Further information on the creation of and early 
studies using the CALIBER collaboration can be found in the protocol paper published in 
December 2012.(167) Finally, I summarised the information and research governance 
processes followed,  approvals received for this thesis and patient and public involvement 
in the research project. 
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Specific methods: Definitions of cohort, risk factors and 
endpoints and statistical considerations 
1. Introduction 
In the previous chapter, I described the constituent datasets used in the CALIBER 
research platform, as well as the methods used by the CALIBER collaboration to develop 
research-ready data. In this chapter, I have described the study design, population, risk 
factor and cardiovascular (CVD) endpoint definitions used in my three related studies on 
the association of gender, smoking and blood pressure with initial presentations of CVD. A 
key feature of my PhD is the focus on the initial presentation of CVD with any of 12 CVD 
types (which may have been fatal or non-fatal).  Here, I have outlined key issues in 
modelling these multiple endpoints using competing risks and described the shared 
statistical methods used for my analyses, as well as treatment of missing data. More 
details on the statistical methods used for each study are given in the relevant chapters.  
  
2. Study Design 
The study design for all three studies (gender, smoking and blood pressure) was a 
prospective cohort study using patients registered with General Practice Research 
Database (GPRD) practices and data derived from electronic health records (EHRs). While 
EHR cohorts are similar to cohorts with bespoke data collection, such as Whitehall II or 
UK Biobank, it is worthwhile to draw out some differences. Bespoke longitudinal cohort 
studies record a variety of measurements when the patient enters the study (called 
baseline measurements), usually completed in the space of a few hours or days.  
Participants are all enrolled within a relatively short time, such as six months, not least to 
minimise the cost of employing staff to record the baseline measurements.  Participants 
are then followed up at regular intervals, to update baseline measurements and record 
events of interest that have happened since the last assessment. In Framingham or 
Whitehall II, for example, phases of data collection are carried out approximately every 
two years. With some studies, linkages are made to electronic health records or mortality 
data, particularly for long term follow-up.(168) EHR cohort studies do not have such 
control over when or which measurements are recorded, because such measurements are 
done as part of routine care in general practice or hospital. However, the specification of a 
baseline time period prior to study entry from which recorded measurements will be 
used could be considered the equivalent of collection of baseline data at enrolment in 
bespoke cohorts.  
   
The beginning of the study is 1st January 2001, the date on which the Office for National 
Statistics (ONS) cause-specific mortality was reliably available in the CALIBER linked 
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dataset. It would be possible to emulate the brief enrolment period used by bespoke 
longitudinal cohorts by restricting patients to those who were registered on this date, but 
one of the strengths of EHR data is that it is possible to include patients as and when they 
meet the study criteria, as there are no cost implications to doing so. I therefore employed 
an open or dynamic cohort design, also used in the QRISK EHR cohort studies,(127,169–
173) with patients entering the study when they registered with a GPRD practice and met 
the minimum observation time, age and medical history criteria.  The inclusion and 
exclusion criteria are formally defined below. 
3. Cohort population 
3.1. Inclusion criteria 
GPRD was the only constituent dataset used to define the inclusion criteria for the cohort 
population, drawn from all patients registered with GPRD practices. I restricted the 
population to patients who met GPRD’s individual data quality standards (called 
“acceptable research quality”, described in greater detail in Chapter 2) and restricted the 
data I used to define endpoints in GPRD to data collected when the practice met GPRD’s 
practice data quality standards (called “up to standard” (UTS), also described in Chapter 
2).  I imposed a minimum period of one year of up-to-standard observation prior to study 
entry to improve the quality of baseline data and increase that likelihood that relevant 
prior medical history was captured. I included patients aged 30 and above, in line with the 
Framingham cohort, one of the few existing studies to investigate multiple initial 
presentation of cardiovascular disease phenotypes.(1) I imposed the high age limit of 100 
because of concerns about accuracy of age information at greater ages.5 The formal 
inclusion criteria are listed below in the order in which they were implemented by the 
data manager, over which I had limited control. Patients were included if: 
1) They were of acceptable research quality; 
2) Their gender was recorded as either male or female; 
3) They were registered with the GPRD practice on or after 1st January 2000; 
4) They were aged between 30 and 100 the year before study entry; 
5) Their current registration period contained at least one year of up-to-standard 
(UTS) observation time before 1st of January 2001, the beginning of the study.  
3.2. Exclusion criteria 
A combination of all the constituent datasets were used to define the exclusion criteria for 
the cohort population.  Because patients remain registered with a practice until they are 
                                                             
5 It should be noted that with increases in longevity documented in the latest census, the number 
of patients over 100 to be expected in an 8% sample of the English population (i.e. patients in 
GPRD) is not small. 
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formally removed, it is possible to be registered with a practice and also to be dead. There 
were a number of patients who met our inclusion criteria but had a date of death prior to 
study entry (n= 1,678), who were excluded from the study. I also identified a small 
number of patients (n=222) with two ONS mortality records, presumably indicating a 
problem with the data linkage for these patients; these patients were similarly excluded.  
The purpose of these studies was to investigate initial presentation of onset of CVD with 
different initial presentations, so I excluded any patient with a prior history of CVD in any 
dataset. I also excluded patients whose first record of a cardiovascular event after study 
entry indicated a historical event, e.g. history of MI or stroke rehabilitation, suggesting I 
may have missed a prior event. To summarise, patients were excluded from the cohort if: 
1) They had an ONS date of death prior to study entry; 
2) They had more than one ONS date of death; 
3) They had a record in any of CALIBER constituent data sources of symptomatic 
atherosclerotic disease prior to study entry, i.e. a record of coronary disease, 
ischaemic cerebrovascular disease, peripheral arterial disease or unspecified 
atherosclerotic disease. Patients with a record of ventricular arrhythmias, cardiac 
arrest or heart failure were also excluded from the cohort.  Details on the 
definitions of atherosclerotic and cardiac disease is given below in the description 
of endpoint variables; 
4) They had a code indicating history of disease as the first record after study entry 
and it was the only code on the day, suggesting that prior history of disease had 
been missed.  
Figure 1 in Chapter 4 – Description of Cohort Population shows the derivation of the cohort 
sample. Table 1 in the same chapter describes the number of people excluded for each 
specific disease presentation.  
3.3. Study entry dates, study exit dates and observation time 
With an open cohort, each patient has their own study entry time, although the majority 
in fact enter the study at the study beginning, i.e. 1st January 2001. Otherwise, patients 
entered 1 year after a) they registered with an UTS practice, b) their practice achieved 
UTS status, or c) they reached their 30th birthday.  The study end date was 25th March 
2010, the last date on which data from any practice was available.  Patients were right-
censored when they left the practice or their practice provided the last GPRD download, 
whichever came first. 
 
In  Section 1of this chapter, I described some of the differences between EHR cohort 
studies and bespoke longitudinal cohort studies, in particular the range of time during 
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which data used for defining risk factors and co-variates is taken. As specified in the 
variable definitions below (Section 56), data used to define some of the co-variates and 
history of CVD was taken from any point in the participant’s record during their current 
registration period, a portion of which time could be before their practice had achieved 
UTS status, GPRD’s data recording quality standard. The observation time reported for 
this thesis in Chapter 4 has therefore been divided into overall observation time (from 
current registration date to cardiovascular endpoint or censoring date), UTS observation 
time (from current registration or UTS date whichever came later) and time to event 
(from study entry to cardiovascular endpoint or censoring date).  The last equates to the 
standard observation time reported in cohort studies, but the other two are presented to 
give some sense of the observation time from which medical history was taken and the 
observation time during which the practice met data quality standards.  
4. Variable Definitions 
The variables used to specify risk factors, co-variates and cardiovascular endpoints are 
defined below.  Data from the four constituent datasets was used to create the cohort of 
patients free from cardiovascular disease and to define the endpoints, while principally 
GPRD is used to define the risk factors and co-variates.  (See Figure 4.) 
Figure 4: CALIBER constituent datasets used to define study variables 
 
CVD indicates cardiovascular disease; HES, Hospital Episode Statistics; GPRD, General 
Practice Research Database; MINAP, Myocardial Ischaemia National Audit Project; ONS, 
Office for National Statistics. 
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4.1. Risk factors and co-variates 
Each of the risk factors and co-variates are defined below.  Age, sex and social deprivation 
were taken as static values from the GPRD patient file. The other variables have 
potentially multiple records per patient.  For clinical co-variates which change over time, 
such as smoking status, I searched GPRD for relevant records and used the one recorded 
on the date closest to the patient’s study entry or, in the case of blood pressure, a mean of 
all values in the two years prior to study entry. (See Figure 6 below for a graphical 
presentation). Information on which data files were used and how the data was selected 
are given in variable definitions accessible through the CALIBER web portal (access 
details provided in Appendix C). Further details on how I arrived at the values for each co-
variate are given below. 
4.1.1. Definitions 
4.1.1.1. Gender 
Gender was recorded in the patient file in GPRD. As mentioned above, patients with 
indeterminate gender were excluded from the study. My findings on the association of 
gender with the different initial presentations of CVD have been given in Chapter 5.  
4.1.1.2. Smoking  
Smoking status was recorded in routine general practice, with information obtained by 
general practitioners, practices nurse, healthcare assistants or administrative staff either 
in the context of new patient questionnaires or individual consultations. Since 2004, GPs 
have been incentivised to collect smoking data, under the Quality and Outcomes 
Framework.(174) This data is provided by GPRD, using a variety of Read codes. For the 
purposes of this thesis, smoking status was categorised as non-smoker, ex-smoker, or 
current smoker.  Codes which indicated patients were participating in smoking cessation 
programme were taken to indicate that they were current smokers, rather than ex-
smokers. Where a patient’s last smoking status prior to study entry was non-smoker, 
their status was changed to ex-smoker if there was any previous record of being a smoker 
at any point in the patient’s history.  See Figure 5  for a graphic representation of this 
variable definition. My findings on the association of smoking status with the different 
initial presentations of CVD have been given in Chapter 6. 
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Figure 5: Definition of smoking status at baseline 
 
Figure used courtesy of Marina Daskopoulos, Clinical Epidemiology Group, University College London 
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4.1.1.3. Blood pressure 
The blood pressure measurements used in this study were recorded as part of routine 
care in general practice. The measurements were made by a wide variety of staff, 
including GPs and practice nurses, using different machines under a variety of conditions, 
ranging from GP consultations for potentially unrelated illnesses to new patient checks to 
hypertension clinics.  The data was provided by GPRD. No information on the 
circumstances under which the measurements were taken was available for this study. 
Systolic blood pressure (SBP) at baseline was defined as the mean SBP over the two years 
prior to study entry.  Diastolic blood pressure (DBP) at baseline was similarly defined. For 
all analyses which incorporated either measure, SBP and DBP were modelled using 
change in standard deviation in values. (See Figure 6.) My findings on the association 
between blood pressure and the initial presentation of CVD have been described in 
Chapter 7.  
4.1.1.4. Age 
Age at study entry was derived from the year of birth recorded in GPRD, assuming a date 
of birth of 1st January of that year. The actual date of birth is not available in pseudo-
anonymised data to protect patient identities.  
4.1.1.5. Social deprivation 
The index of multiple deprivation (IMD) 2007(123) is described in detail in Chapter 2. 
IMD was used to measure social deprivation. I divided IMD into quintiles with the lowest 
quintile indicating the greatest deprivation.    
4.1.1.6. Ethnic group 
Ethnic group is self-reported ethnic group, recorded in either GPRD or Hospital Episode 
Statistics (HES).  Where more than one ethnic group was recorded for a patient, I 
attempted to resolve any inconsistency within each constituent dataset and then between 
datasets. Conflicts between records were resolved by taking the lowest level ethnic 
category that was consistent with the conflicting codes, so, for example if patients were 
recorded as White and White British, they were categorised as White British. If they were 
recorded as White British and White European, they were coded as White.  Partly because 
of the code conflicts and partly to simplify analysis, the ethnic groups were then 
amalgamated into White, Black, South Asian, Other and Unknown categories.  
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4.1.1.7. Alcohol consumption 
Participant’s alcohol consumption was derived from GPRD using data in the clinical and 
the additional files which indicated: 
 Weekly alcohol consumption 
 Daily alcohol consumption 
 Categorical identification of drinking habits by the GP 
Patients were categorised as non-drinker, ex-drinker, occasional drinker, current drinker, 
and excess drinker, including binge drinker.  Where a weekly or daily unit amount was 
recorded, the patient was allocated to the relevant category based on their gender and the 
NHS recommended daily/weekly units.  
4.1.1.8. Use of anti-hypertension medication 
Use of anti-hypertensive medication was derived from at least two successive 
prescriptions for commonly used agents [beta-blockers, angiotensin-converting-enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARBs), thiazides] as well as other less 
common preparations. The specific medications included in this variable are listed in 
Appendix D – Medications.  
4.1.1.9. Lipids 
Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, and triglycerides in mmol/L were recorded in the GPRD test file.  
Records with unit in mmol/L or those with none were extracted, but there were 
significant differences in the distribution of those with units recorded and those with 
none, so only those with mmol/L specified were used.  
4.1.1.10. Use of statins 
Use of statins was derived from a minimum of a single prescription of a statin recorded in 
GPRD during the two years before study entry.  See Appendix D– Medications for specific 
agents. 
4.1.1.11. Body mass index 
Patients’ body mass index (BMI) in kg/m2 recorded in the GPRD additional file was used 
for this variable.  
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Figure 6: Mean blood pressure measurements during baseline period 
   
62 
 
4.1.1.12. Diabetes mellitus 
Patients with diabetes mellitus were identified by any record in GPRD prior to study entry 
of: 
 a diagnosis of Type I, Type II or not further specified; 
 monitoring or treatment which specifically identified diabetes; 
 complications of diabetes; or  
 one or more prescriptions for insulin or oral anti-diabetic medication. 
This approach to defining diabetes did not take into account any measurements of blood 
glucose (although these are available in limited patients in GPRD) and may have under-
estimated diabetes. Although the date of onset of diabetes is generally difficult to 
determine, the approach to analysis used in this thesis did not treat diabetes as a time-
varying co-variate, so the timing of onset of diabetes did not pose a problem for these 
particular set of analyses.  
4.1.2. Statistical description of baseline characteristics of cohort 
For all these variables, the extent of missingness and the number of available 
observations for each variable within the dataset is given in Chapter 4. For continuous 
variables, the mean and standard deviation have been presented, while for categorical 
variables, the number in each response category and proportion have been presented. 
Where appropriate, comparisons to the Office for National Statistics 2001 Census or 
Health Survey for England have been made. 
4.2. Initial clinical presentations of cardiovascular disease phenotypes 
4.2.1. Overall approach 
I defined the onset of CVD with specific initial presentations as the recording of a specific 
diagnosis on first recorded date.  This somewhat simplistic approach does not allow for 
an evolving or developing history of a particular presentation, where a patient may 
initially be thought to have one presentation (say angina pectoris) which is later clarified 
to be another presentation (say NSTEMI). However, given that the data used from both 
HES and the Myocardial Ischaemia National Audit Project (MINAP) are based on 
discharge rather than admission diagnosis, the extent of this misclassification was likely 
to be relatively small. A fellow member of the Clinical Epidemiology Group investigated 
this question, calculating the time elapsed between the first recorded diagnosis and the 
subsequent one for a sample of patients from CALIBER; she found that the mean number 
of days between different types of events was over 60 days for all presentations, 
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suggesting that using the first recorded diagnosis is a robust approach to studying onset 
of CVD.6  
 
Where more than one diagnosis was recorded on one day, I used the most specific and 
serious presentation. For example, on a given day, a patient admitted with a myocardial 
infarction might have a record in HES indicating myocardial infarction not otherwise 
specified, one from GPRD indicating coronary heart disease not otherwise specified and 
one from MINAP indicating STEMI; the last would be used in the endpoint definition. The 
ordering of diagnoses, agreed with two clinicians (HH & LS) has been shown in Appendix 
E.  
 
I used all four constituent data sources (GPRD, MINAP, HES, ONS) to define the following 
cardiovascular phenotypes.   Where codes allowed a distinction to be made between a 
historical diagnosis and an incident diagnosis, both historical and incident codes were 
used to exclude patients from the cohort, but only incident codes were used to identify 
initial presentation of CVD.  All presentations were defined to include both fatal and non-
fatal presentations, with the exception of stable angina, which does not include fatal 
presentations, and unheralded coronary death which does not include non-fatal 
presentations. The definitions have been given below, but are also summarised in Table 3, 
with the key codes used from each data source. All ICD-10 and Read codes lists used to 
define variables are available on the CALIBER web portal.  
 
                                                             
6 Personal communication, Eleni Rapsomaniki, 21.10.2012 
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Table 3: Overview of datasets and codes used to define the initial presentation of cardiovascular disease 
Endpoint 
Primary Care 
 
Disease 
Registry  
 
Hospital Procedures 
 
Hospital 
Diagnoses† 
 
Causes of death‡ 
 
 
 GPRD MINAP HES HES ONS 
 Read codes Registry specific OPCS-4 ICD-10 ICD-10 
Acute Myocardial 
Infarction  
 
G30X000 Acute ST 
segment elevation 
myocardial infarction 
 
G307100 Acute non-ST 
segment elevation 
myocardial infarction 
 
G30..14 Heart attack, 
G30..15 MI Acute 
myocardial infarction + 60 
other codes as Acute 
Myocardial Infarction Not 
Otherwise Specified 
 
MI with or without ST 
elevation based on 
initial ECG findings, 
raised troponins and 
clinical diagnosis 
Not used (there is no 
code that is specific to 
primary coronary 
intervention) 
Acute myocardial 
infarction I21, 
 
Current complications 
of acute myocardial 
infarction I23 
Acute myocardial 
infarction I21, 
 
Current complications 
of acute myocardial 
infarction I23  
Unstable angina 
G311.13/G311100 
Unstable angina, G233200 
Angina at rest, G311400 
Worsening angina + 13 
other codes 
 
Discharge diagnosis of 
unstable angina, no 
raised ST elevation 
No raised troponin 
levels 
not used Unstable or worsening 
angina I20.0 
Acute ischaemic heart 
disease I24,  
Coronary thrombosis 
not resulting in 
myocardial infarction 
I24.0,  
Other forms of 
ischaemic heart 
disease I24.8, 
Acute ischaemic heart 
disease, unspecified 
not used 
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Endpoint 
Primary Care 
 
Disease 
Registry  
 
Hospital Procedures 
 
Hospital 
Diagnoses† 
 
Causes of death‡ 
 
 
 GPRD MINAP HES HES ONS 
 Read codes Registry specific OPCS-4 ICD-10 ICD-10 
I24.9 
 
Stable angina 
G33..00 Stable Angina, 
G33z.00 Angina pectoris 
NOS + 25 other codes for 
diagnosis of stable angina 
pectoris 
 
30 codes for evidence of 
coronary artery disease at 
angiography (CT,MR, 
invasive or not specified) 
 
151 Read codes for 
evidence of myocardial 
ischaemia (Resting ECG, 
exercise ECG, stress echo, 
radioisotope scan) 
 
Two or more successive 
prescriptions for anti-
anginals 
not used Coronary Artery 
Bypass Graft (CABG) 
K40-K46 or 
Percutaneous 
Coronary Intervention 
(PCI) K49,K50,K75 
 
not within 30 days of 
an acute coronary 
syndrome 
Stable angina pectoris 
I20 excluding unstable 
angina I20.0 
not used 
Coronary heart 
disease not 
otherwise 
specified 
G3…00 Ischaemic Heart 
Disease + 90 other codes  
including CHD NOS, 
chronic ischaemic  heart 
disease, silent myocardial 
infarction 
not used not used CHD NOS, chronic 
ischaemic  heart 
disease, silent 
myocardial infarction 
I25 excluding I25.2, 
old myocardial 
infarction 
not used 
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Endpoint 
Primary Care 
 
Disease 
Registry  
 
Hospital Procedures 
 
Hospital 
Diagnoses† 
 
Causes of death‡ 
 
 
 GPRD MINAP HES HES ONS 
 Read codes Registry specific OPCS-4 ICD-10 ICD-10 
Heart failure * 
G58..00 Heart Failure + 92 
other Read codes for heart 
failure diagnosis 
not used not used I50 Heart 
failure(including all 
sub,   
I11.0 Hypertensive 
heart disease with 
(congestive) heart 
failure, I13.0 
Hypertensive heart 
and renal disease with 
(congestive) heart 
failure, I13.2 
Hypertensive heart 
and renal disease with 
both (congestive) 
heart failure and renal 
disease 
I50 Heart failure  
I11.0 Hypertensive 
heart disease with 
(congestive) heart 
failure, I13.0 
Hypertensive heart 
and renal disease with 
(congestive) heart 
failure, I13.2 
Hypertensive heart 
and renal disease with 
both (congestive) 
heart failure and renal 
disease 
Ventricular 
arrhythmias, 
cardiac arrest and 
sudden cardiac 
death 
G574.00 Ventricular 
fibrillation and flutter, 
G757.00 Cardiac arrest +  
35 other Read codes  for 
ventricular fibrillation , 
asystole, cardiac arrest, 
cardiac resuscitation, 
electro-mechanical 
dissociation,  
 
G575100 Sudden cardiac 
death, so described 
not used Implanted cardiac 
defibrillation device 
X50, Implantation, 
revision and renewal 
of cardiac defibrillator 
K59 
I46 (cardiac arrest) 
I47.0 (re-entry 
ventricular 
arrhythmia) 
I47.2 (ventricular 
tachycardia) 
 
 
 
I46 (cardiac arrest, 
includes I46.1 sudden 
cardiac death) 
I47.0 (re-entry 
ventricular 
arrhythmia) 
I47.2 (ventricular 
tachycardia) 
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Endpoint 
Primary Care 
 
Disease 
Registry  
 
Hospital Procedures 
 
Hospital 
Diagnoses† 
 
Causes of death‡ 
 
 
 GPRD MINAP HES HES ONS 
 Read codes Registry specific OPCS-4 ICD-10 ICD-10 
Unheralded 
coronary death 
Any CVD excluded Any CVD excluded Any CVD excluded Any CVD excluded I20 Angina Pectoris, 
I21 Acute myocardial 
infarction, I22 
Subsequent 
myocardial infarction, 
I23 Certain current 
complications 
following acute 
myocardial infarction, 
I24 Other acute 
ischaemic heart 
diseases and I25 
Chronic ischaemic 
heart disease 
 
not preceded by any 
other CVD 
presentation 
Ischaemic stroke 
G64..11 CVA – cerebral 
artery occlusion, G64..13 
Stroke due to cerebral 
arterial occlusion, G6W..00 
Cereb infarct due 
unspecified 
occlusion/stenosis of 
precerebral arteries, 
G6X..00 Cerebral infarction 
due  to unspecified 
occlusion or stenosis of 
cerebral arteries plus 8 
not used not used I63 Cerebral infarction    
 
 
 
 
I63 Cerebral infarction 
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Endpoint 
Primary Care 
 
Disease 
Registry  
 
Hospital Procedures 
 
Hospital 
Diagnoses† 
 
Causes of death‡ 
 
 
 GPRD MINAP HES HES ONS 
 Read codes Registry specific OPCS-4 ICD-10 ICD-10 
other codes 
Peripheral arterial 
disease (PAD) 
72 codes for Lower limb 
peripheral arterial disease 
diagnosis (including 
diabetic PAD, gangrene 
and intermittent 
claudication 
Evidence of 
atherosclerosis of iliac and 
lower limb arteries based 
on angiography or  
Dopplers 
not used L50-L54 Bypass, 
reconstruction and 
other open operations 
on iliac artery 
 L58-L60, L62 Bypass, 
reconstruction, 
transluminal 
operations or other 
open operations of 
femoral artery, 
 L65 Revision of 
reconstruction of 
artery 
 
I70.2 atherosclerosis 
of arteries of 
extremities, 
I73.9 peripheral 
vascular disease 
intermittent 
claudication  
 
Peripheral 
complications of 
diabetes including 
gangrene 0.5 suffix of 
E10 Insulting 
dependent diabetes 
mellitus, E11 Non-
insulin-dependent 
diabetes mellitus, E12 
Malnutrition-related 
diabetes mellitus, E13 
Other specified 
diabetes mellitus,  E14 
Unspecified diabetes 
mellitus 
 
I70.2 atherosclerosis 
of arteries of 
extremities, 
 
I73.9 peripheral 
vascular disease 
intermittent 
claudication,  
 
Peripheral 
complications of 
diabetes including 
gangrene 0.5 suffix of 
E10 Insulting 
dependent diabetes 
mellitus, E11 Non-
insulin-dependent 
diabetes mellitus, E12 
Malnutrition-related 
diabetes mellitus, E13 
Other specified 
diabetes mellitus,  E14 
Unspecified diabetes 
mellitus 
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Endpoint 
Primary Care 
 
Disease 
Registry  
 
Hospital Procedures 
 
Hospital 
Diagnoses† 
 
Causes of death‡ 
 
 
 GPRD MINAP HES HES ONS 
 Read codes Registry specific OPCS-4 ICD-10 ICD-10 
Abdominal aortic 
aneurysm (AAA) 
G714.00 Abdominal aortic 
aneurysm without 
mention of rupture + 11 
more codes for AAA 
diagnosis 
 
13 codes for evidence of 
AAA on ultrasound or CT 
scan 
not used L16 Extra anatomic 
bypass of aorta, 
L18-L23 Replacement 
of aneurysmal 
segment of aorta, 
bypass of segment of 
aorta, plastic repair of 
aorta, 
 L25-L28 
Transluminal or 
endovascular 
insertion of stent on 
aneurysmal segment 
of aorta 
I71.3 Abdominal 
aortic aneurysm, 
ruptured. 
 
171.4 AAA, without 
rupture 
 
  
I71.3 Abdominal 
aortic aneurysm, 
ruptured. 
 
171.4 AAA, without 
rupture 
 
† Primary cause of admission. ‡ Underlying cause of death 
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4.2.2. Definitions of CVD presentations 
4.2.2.1. Stable angina  
Stable angina (SA) was defined using three of the four data sources: GPRD, HES and 
MINAP. Patients with stable angina were identified by a record of: 
 a diagnosis of stable angina or angina pectoris not further specified (ICD-10  I20, 
excluding I20.0); 
 a coronary artery bypass graft (CABG) or percutaneous coronary intervention 
(PCI) not within 30 days of an admission for myocardial infarction or unstable 
angina; 
 two or more subsequent prescriptions for nitrates(145,175,176) or other specific 
anti-anginal medication (See Appendix D for specific medications); or 
 an abnormal result following an exercise ECG, stress echocardiogram, 
radioisotope scan, or an invasive, computed tomography (CT), magnetic 
resonance imaging (MRI) or unspecified angiogram. 
Patients were also excluded from the cohort if they had a record in MINAP of history of 
angina.  
4.2.2.2. Acute myocardial infarction 
Acute myocardial infarction (AMI) includes three subtypes: ST elevation myocardial 
infarction (STEMI), non-ST elevation myocardial infarction (nSTEMI) and myocardial 
infarction not otherwise specified (MI NOS). These presentations were defined using 
three data sources: GPRD, HES & MINAP.  Patients with STEMI were identified by a 
combination of ST-elevation on ECG, raised troponins and clinical findings indicative of MI 
in MINAP data, as defined by the internationally agreed definition of STEMI.(177)  A 
record of diagnosis of STEMI in GPRD was also included, on the basis that this would 
reflect information from a discharge letter from an acute admission. Similarly, patients 
with nSTEMI were identified by no ST-elevation on ECG, raised troponins and clinical 
findings indicative of MI in MINAP data and diagnosis code alone from GPRD. All other 
records which did not specify type of myocardial infarction (MI), including AMI codes 
from HES (ICD-10 I21, I22, & I23), were included in MI not otherwise specified (NOS).   
Additionally, patients were excluded from the cohort if they had a history of MI in MINAP 
or a record of old myocardial infarction (I25.2) in HES.  Patients with unheralded fatal MI 
were included in the unheralded coronary death category.  
4.2.2.3. Unstable angina 
Unstable angina (UA) was defined using 3 data sources: GPRD, HES and MINAP. Patients 
with unstable angina were identified in MINAP by clinical findings of acute coronary 
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syndrome but no raised ST elevation on ECG and no raised troponin levels. UA was 
further identified by diagnosis of unstable angina (ICD10 I20.0) or acute ischaemic heart 
disease (I24, I 24.0, I24.8 & I24.9) in HES or unstable/worsening angina or acute coronary 
syndrome in GPRD.  
4.2.2.4. Coronary heart disease not otherwise specified (CHD NOS) 
Patients with coronary heart disease not otherwise specified (CHD NOS)  were those with 
a variety of non-specific diagnoses such as CHD NOS, chronic ischaemic heart disease and 
silent myocardial ischaemia (I25 excluding I25.2, old myocardial infarction) in either 
GPRD or HES.  
4.2.2.5. Heart failure 
Heart failure (HF) was defined using all four data sources. Patients with heart failure were 
identified by a record of: 
 a diagnosis of heart failure in HES (I50, I26.0, I11.0, I13.0 & I13.2) or GPRD; or 
 a result of left ventricular hypertrophy on a resting ECG in GPRD; or  
 an underlying cause of death (UCOD) of HF in mortality data as the first 
presentation of atherosclerotic disease after study entry. 
Furthermore, patients were excluded if they had a history of heart failure recorded in 
MINAP or GPRD.  
4.2.2.6. Unheralded coronary death 
Unheralded coronary death (UCD) was defined using one data source: ONS.  Patients with 
unheralded coronary death were identified by an UCOD from coronary heart disease 
(ICD-10 I20-I25) which was not preceded by any other atherosclerotic code. 
4.2.2.7. Ventricular arrhythmias, cardiac arrest and sudden cardiac 
death 
Patients with ventricular arrhythmias, cardiac arrest or sudden cardiac death were 
identified by: 
 a diagnosis of ventricular tachycardia (I47.2) or fibrillation (I47.0); or  
 asystole, cardiac arrest (I46, I46.0 & I46.9), cardiac resuscitation, electro-
mechanical dissociation; or 
 implanted cardiac defibrillation device; or 
 a diagnosis of sudden cardiac death in HES or GPRD; or 
 mortality from cardiac arrest, sudden cardiac death or ventricular arrhythmia.    
Patients were also excluded from the cohort if they had a record of history of ventricular 
tachycardia or fibrillation in GPRD.  
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4.2.2.8. Ischaemic stroke 
Ischaemic stroke was defined using all four data sources: GPRD, HES, MINAP and ONS. 
Patients with stroke were identified by: 
 a record of ischaemic stroke (I63); or 
 a record of stroke not otherwise specified (I64, G46.3-G46.7); or 
 mortality from any of the above as the first presentation of CVD. 
Patients with stroke NOS were included in this category on the basis that the large 
majority of such unspecified strokes would be ischaemic; however, this category will 
include some patients with haemorrhagic stroke.  
 
In addition, patients were excluded from the cohort if they had a record for sequelae of 
stroke (I69) or other cerebrovascular events such as transient ischaemic attack (TIA) 
(G45.8 & G45.9), a record of  other ischaemic cerebrovascular diseases including 
occlusion and stenosis of cerebral arteries (I65 & I66), other cerebrovascular diseases 
(I67) and other vascular syndromes of brain in cerebrovascular disease not used 
elsewhere (G46), abnormal result on a carotid ultrasound or angiogram, abnormal result 
on cerebral CT;  or a procedure on cerebral arteries indicative of atherosclerotic disease. 
4.2.2.9. Abdominal aortic aneurysm event 
Abdominal aortic aneurysm (AAA) was defined using all four data sources: GPRD, HES, 
MINAP and ONS. Patients with AAA were identified by: 
 a diagnosis of AAA (I71), other than thoracic AAA ; or 
 an abnormal results on abdominal ultrasound or CT indicating AAA; or  
 a procedure for AAA; or 
 mortality from AAA as the first presentation of CVD. 
4.2.2.10. Peripheral arterial disease  
Peripheral arterial disease (PAD) was defined using all four data sources: GPRD, HES, 
MINAP and ONS. Patients with PAD were identified by: 
 a diagnosis of  PAD (I73, I73.1, I73.8, I73.9) including peripheral complications of 
diabetes, peripheral ischaemia, peripheral vascular disease, gangrene and 
intermittent claudication; or 
 an abnormal results on abdominal ultrasound or CT indicating PAD; or  
 a procedure for PAD; or 
 Mortality from PAD as the first presentation of CVD. 
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4.2.3. Statistical description of endpoints 
With EHR data, it is possible to compare the number of initial presentations of CVD 
overall with a specific endpoint to the number of first presentations of that specific 
endpoint (ignoring any prior presentations with other disease presentations). Such a 
comparison gives a sense of the importance of distinguishing between initial presentation 
of CVD overall and first presentation of specific disease presentations and how this might 
vary between types of CVD. This comparison is presented, separately for men and women, 
by broad age groups, in Chapter 4.  
 
I have also described the number and proportion of each specific initial presentation of 
CVD, separately for men and women. I have included in Chapter 4 the number of patients 
censored and have given the specific reason for censoring. I have given the number of 
endpoints which were fatal on the same or next calendar day as the endpoint. More 
detailed timing of endpoints is not available so deaths within 24 hours cannot be 
calculated. To give a sense of distribution of events by age, I have presented the rate for 
each initial presentation in 10 year age bands. Finally, I have presented the number of 
events that are contributed by each constituent data source in CALIBER for each endpoint.  
5. Statistical modelling 
5.1. Approaches to handling missing data 
With any longitudinal cohort study, whether bespoke or EHR, missing data can be an 
issue both in its potential to create bias and/or the loss of power and precision in effect 
estimates with complete case analysis. Both types of cohort study have problems with 
loss to follow up, and missing data among those who are followed up, but the effect of 
missing data is likely to be different. With the relatively small sample sizes in bespoke 
cohorts, the loss of precision and power from missing data can become an important 
issue; with the large (indeed huge) sample sizes available in EHR cohorts, the greater 
issue is potential information bias, making it important to understand why data may not 
be recorded in EHR.  Rubin first identified the importance of the mechanism that lead to 
missing data when determining appropriate approaches to dealing with such 
missingness.(178) He identified the following categories of missingness: 
1. Missing completely at random – the missing values are not systematically 
different from the observed values and the reason for missingness is unrelated to 
the factor being measured. So, for example, a smoking record is not recorded for a 
patient because the practice nurse missed work because of a transport strike.  
2. Missing at random – missing values are systematically different from the observed 
values but the difference can be explained by differences in other variables.  So, 
for example, young men are more likely to have a missing smoking record in 
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GPRD than young women because they do not attend their GP for contraceptive 
advice and therefore have a smoking history taken prior to prescription of the 
birth control pill. 
3. Missing not at random – missing values are systematically different from the 
observed values and the reason for missingness is directly related to the factor 
being observed. So, for example, smokers may be less likely to have their smoking 
status recorded in GPRD because some smokers may avoid going to the GP in case 
they are challenged about their smoking.   
There are a number of approaches to dealing with missingness, whether it be to use 
complete case analysis, or to replace the missing values with imputed values. Each 
approach has specific drawbacks, some of which are outlined in Sterne et al.(179) and 
which may or may not be appropriate depending on the reason for missingness.7 Multiple 
imputation of missing data is becoming the approach of choice for dealing with 
missingness, but I decided to carry out complete case analysis, for a number of reasons. 
First, for a limited number of co-variates that capture some of the key risk factors for 
cardiovascular disease, missingness is low in my covariates. Second, multiple imputation 
is computationally very intense(179); given that I have to take a pragmatic approach to 
my modelling to take account of computational capacity, without imputation, dealing with 
missingness using multiple imputation was not practical. Third, and not least, it is not 
clear that it was appropriate to use multiple imputation with these EHR in my dataset. A 
general research programme is currently under way at University College London on the 
appropriateness of multiple imputation to deal with missingness in health indicators in 
primary care EHR research. The initial findings, using data from the Health Improvement 
Network (THIN) database the data from which is sourced from most of the same practices 
as GPRD, suggest that some data, such as blood pressure and height and weight, are 
missing at random, while others, particularly reported smoking and drinking habits, are 
missing not at random, rendering multiple imputation inappropriate for at least these 
latter variables.(180) In fact, the reasons for missingness across the whole GPRD dataset 
may be different – Marston et al. was limited to health indicator information recorded 
within one year of registration, when data are more likely to be recorded as part of 
general health check rather than because of some indication such as subjective 
                                                             
7 One approach which is usually given short shrift is replacing missing values with a missing category; 
however, it is worth noting that this approach could lead to useful information when combined with EHR 
research. Where patients do not have certain risk factor information recorded, patients who lack this 
information may have specific risks. In a preliminary analysis for this thesis, I found that no recording of 
smoking status had a similar association with unheralded coronary death as did smoking. Although this raises 
intriguing questions, the issue of non-recorded risk factor information was not further pursued in this thesis.  
   
75 
 
assessment by the GP of excess weight. The data used in this PhD have not been limited to 
such a narrow time window, adding weight to the arguments against using multiple 
imputation. Although these potential information biases are also problematic for 
complete case analysis, I considered it better not to compound the missing data problem 
with multiple imputation wrongly applied.  
5.1.1. Description of missing data and patients excluded for missing 
data 
In Chapter 4, I have identified the extent of missing data for each of my risk factors and 
co-variates, to the extent it can be identified. So, for example, it is possible to state how 
many patients do not have a smoking status recorded in their GPRD record, but it is not 
possible to state how many people who have diabetes do not have a diagnosis of diabetes 
recorded.  I have also described differences between patients in the overall cohort with 
missing and complete data for IMD, smoking and blood pressure. 
5.2. Approaches to modelling competing risks 
The main focus of this PhD is to understand the effect of gender, smoking and blood 
pressure on initial presentation of specific cardiovascular disease phenotypes.   As I have 
shown in Chapters 5-7, very few previous studies have attempted this intuitively 
important analysis because of small statistical size, lack of assessment of a wide range of 
phenotypes in a single study, or lack of the temporal resolution necessary to identify 
phenotypes as initial presentation. In studies potentially large enough to assess multiple 
endpoints, most studies use composite endpoints which, for example in coronary disease, 
conflate CHD death with non-fatal MI. Such composite endpoints conflate both multiple 
phenotypes (fatal MI combined with other fatal coronary disease) and confuse onset and 
progression.   Such approaches also privilege the study of mortality over onset, although 
this is not always stated. While such an approach might be justified during time periods 
with high rates of cardiovascular mortality, as mortality declines and morbidity from 
cardiovascular disease increases,(181,182) such a focus becomes harder to justify. A 
refocusing on initial presentation of cardiovascular phenotypes and possible approaches 
to primary prevention across all arterial beds becomes more important.   
 
Different initial presentations can be seen as risks which compete with each other. Only 
one cardiovascular phenotype can be the initial presentation and the others compete to 
be an alternate initial presentation. This approach to modelling associations between risk 
factors and phenotypes is relatively unusual in cardiovascular disease epidemiology – see 
Chapters 5, 6, and 7 for exemplar studies on association of gender, smoking and blood 
pressure for specific phenotypes - but is much more common in epidemiological studies 
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of cancer, where such approaches have been used to identified competing risks of disease 
reoccurrence, onset of secondary cancers or risks associated with treatment.(183)    
 
So what are the appropriate statistical methods to evaluate whether one specific risk 
factor has similar or heterogeneous effects on the first of many different endpoints? 
Consider the following simplified example: We are interested in determining whether 
women are more likely than men to present with stable angina as the first clinical 
manifestation of coronary disease.  We know that some women may in fact have a 
myocardial infarction without ever being diagnosed with stable angina. If a woman first 
develops an MI as her initial coronary disease presentation, she cannot develop stable 
angina as the first presentation; the MI prevents stable angina from occurring as an initial 
presentation.   Below I describe approaches to describing and modelling this situation.  
5.2.1. Descriptive methods 
The naïve approach to describing time to competing events, called by some the ‘naïve’ 
Kaplan Meier approach, would be to treat the MI as a censoring event, as we would, more 
conventionally, treat withdrawal from the study or the end of study. However, these other 
administrative reasons for censoring differ in one important regard to another 
cardiovascular event: theoretically, the patient could still experience stable angina after 
administrative censoring. We are simply not able to observe this because this other 
unrelated event stopped our observation of the patient; his or her hazard of stable angina 
is the same as those patients remaining in the study.  However, with the occurrence of a 
different initial presentation such as MI, the presentation of stable angina as an initial 
presentation could never occur.  His or her hazard of experiencing an initial presentation 
of angina is not the same as those patients in the study because it is now zero. If we treat a 
different presentation simply as another reason for censoring, a key assumption of time-
to-event analysis is violated:  the independence of time to event and time to censoring 
distributions.  Putter et al., amongst others, have shown that treating competing events as 
censoring events leads to an overestimation of probability of an event at any one point in 
time (of both the event of interest and the competing risk) such that the probability of 
either event occurring can be greater than 1, clearly an impossibility.(184,185)   
 
A different approach, called the latent failure time approach, assumes that each person 
has a hypothetical failure time for each type of competing risk. In our simple example, one 
woman might have a hypothetical failure time for stable angina of 1.5 years and of 2.3 
years for myocardial infarction.  We never observe the failure time for myocardial 
infarction because the failure time for stable angina comes first. The difficulty with this 
approach is that we, by definition, cannot observe the latent failure times for events 
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which do not occur; we simply do not know what those times might be.  More formally, 
without making strong additional assumptions, we cannot choose between different joint 
survival functions which can all fit the observed cause-specific hazards equally well.(184)  
 
A more appropriate approach to describing multiple endpoints is the crude cumulative 
incidence function, or sub-distribution function, which takes account of other competing 
risks in calculating the probability of a specific endpoint at a given point in time.  To 
return to our example, we can calculate the probability of an initial presentation of stable 
angina at a given point in time, say at 5 years, given that an MI has not occurred.  The 
cumulative incidence for a specific endpoint at time t is calculated by summing the 
proportion of individuals at risk who experience that endpoint at every point in time up 
to time t.  Individuals are removed from the risk pool whenever a competing event occurs.  
This approach allows researchers to look at the probability of occurrence of specific 
events, taking into account other competing events, but does not in itself allow any 
analysis of the cause-specific effect of co-variates. 
5.2.2. Modelling methods 
An approach to modelling competing risks which does allow comparison of cause-specific 
co-variates is to model co-variates and endpoints jointly in a Cox proportional hazard 
model. This can be done with record duplication or augmentation, creating a record for 
each possible failure for every patient in the study, with only one of the duplicate records 
recording a failure for the failure type that is actually observed.  So, in our example, a 
woman could have a failure from stable angina or she could have a failure from MI; it so 
happens that she had a failure from stable angina but not MI, but in the data to be 
analysed she will have two records, one for failure type stable angina and one for failure 
type MI.  This approach, proposed by Lunn and McNeil(186) and recommended by Putter 
et al. (184) has the virtue that standard approaches and commands for time-to-event 
analysis, such as Cox proportional hazard, can be used once the dataset has been 
augmented. This approach allows simultaneous estimation of the cause-specific hazards 
of different failure types, and the ability to test the equality of the effect of specific 
covariates.  They are more accurate than any hazard calculated in separate individual Cox 
proportional hazards because they have been estimated jointly. (186) 
 
These are interpreted essentially as any interaction term might be – the effect of the 
covariate, say smoking, on specific failure types, say angina as compared to MI, with the 
added caveat that the effect has been estimated in the context of the other potential 
hazards.(187)  Incidentally, this approach can be extended to do multi-state analysis, 
investigating multiple sequential failure types.  Essentially what the cause-specific hazard 
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is estimating is the “probability of failure specifically resulting from cause k in a small 
interval of time, given that no failure of any kind has occurred thus far.”(183) 
Consequently, the overall hazard for any kind of failure can be derived by adding all the 
cause-specific hazards. The virtue in this approach to modelling cause-specific risks is 
that the effect of covariates can be compared in a straight forward way; “the drawback is 
that the everyday interpretation of these hazards is not intuitive.”(184)  
 
It is also possible to estimate the cumulative incidence function for specific endpoints, 
taking into account the cause-specific hazards of a set of co-variates, essentially 
combining the hazard ratios from the Cox modelling with the incidence function.  
Although this approach could provide the most interpretable model while taking account 
of both competing risks and cause-specific hazards, it is computationally difficult. No 
STATA program exists to compute these models and is therefore beyond the scope of this 
PhD.   
5.2.3. Computational considerations and specific approach used to 
model cause-specific hazards  
 I developed a common Cox proportional hazard model(188)  for competing risks, using 
data augmentation, to estimate the hazard ratios for the co-variates for each presentation 
in the context of competing risks.(184,186) Data augmentation requires creating a dataset 
with a stratum for each endpoint which includes all patients, so, for example, with 10 
endpoints and 1,000,000 patients, the dataset to be analysed would be 10,000,000 
records.    Within each endpoint stratum, occurrence of the relevant endpoint is counted 
as a failure and patients are censored at the point at which a competing event occurs.  
With datasets of this size, computational capacity and time are serious concerns.  
Although Lunn and McNeil advocate running the competing risk as a single overall model 
with interaction terms for all co-variates and strata,(186) I followed an alternative 
approach suggested by Putter et al.(184) and ran each stratum in sequence, following 
creation of the appropriate dataset.  Even with this approach, the more complex frailty 
models for a single endpoint took up to 10 hours to converge on a powerful personal 
computer (Dell computer with core 2, quad 3 GHZ processors, and 8 Gb RAM, local copy of 
STATA MP4).  Using other computing resources, such as the University College London 
super-computer, Legion, was not an option because of the data permission requirements 
of the GPRD constituent dataset.  Through experimentation with running multiple copies 
of STATA and increase in computer power (Dell personal computer I7, 8 processor with 
3.4 gigahertz (GHZ) and 16 Gb RAM), run times were improved but still remain a 
substantial issue with survival analysis and datasets of this size.  
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One drawback to this pragmatic approach to competing risks analysis is that I could not 
model the random effect of key risk factors between endpoints because each endpoint is 
modelled separately. In order to confirm the existence and extent of heterogeneity 
between endpoints, I therefore used techniques from meta-analysis and calculated the I2 
and tau-squared (τ2).(189)  
 
To further specify the Cox models,  I used the Efron method to deal with tied failure 
times.(190)  Patients are clustered at general practice level, so a frailty term was included 
to take account of this clustering.(191) Where events occurred on the same day as study 
entry, a factor of 0.5 was added to the event date, so these events were not excluded from 
the model estimations. I tested the proportional hazards assumption visually using log-log 
rank graphs. All analyses were performed using STATA version 12 (StataCorp, 4905 
Lakeway Drive, College Station, TX 77845, United States). 
 
The cause-specific hazard ratios, with 95% confidence intervals, are presented in the 
chapters on the association of gender, smoking and blood pressure on specific 
cardiovascular fatal and non-fatal endpoints. In all chapters, I have first shown the broad 
cardiovascular endpoints of ischaemic stroke, coronary disease (defined as acute MI and 
unheralded coronary death), abdominal aortic aneurysm and peripheral arterial disease 
and then the cardiac presentations of  stable angina, unstable angina, acute myocardial 
infarction, ventricular arrhythmias/ cardiac arrest/sudden cardiac death, heart failure, 
and unheralded coronary death. I have further presented the cause-specific hazards for 
ST-elevation myocardial infarction (STEMI), non-STEMI and myocardial infarction not 
further specified in additional analyses.  
6. Summary of descriptive analyses completed 
Throughout this chapter, I have noted the descriptive analyses I have presented in 
Chapter 4 where relevant. Here, for convenience, I summarise those analyses. The results 
of the modelling of the association of gender, smoking and blood pressure have been 
presented in Chapters 5, 6 and 7. I describe the following information on my cohort: 
1. Derivation of the cohort:  The number (percentage) excluded for each 
inclusion/exclusion criteria. Exclusions for previous CVD are further broken down by 
specific CVD presentation.  
2. Observation time: Mean and standard deviation of observation time in years, 
separately for women and men in ten year age bands; further separated into overall, 
UTS observation time and observation time after study entry.  
3. Number of observations for co-variates with potentially multiple records: For those co-
variates where the number of measurements can vary between patients, i.e. excluding 
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age and sex, I have presented the number of patients, for men and women separately, 
who had no observations and, amongst those who had at least one observation, the 
median number of observations and interquartile range.  
4. Baseline characteristics of cohort: Mean (standard deviation) of all continuous co-
variates and number (proportion) of all categorical co-variates, as well as number of 
patients with no measurements at any point.  
5. Comparison of initial and first presentation for all endpoints: The number and 
percentage of endpoints, for initial presentation of CVD overall and for first 
presentation within a specific CVD, separately for men and women, over all ages and 
for 3 broad age groups.  
6. Number of endpoint and case fatality: The number and percentage of endpoints, 
including number and percentage of patients censored at practice leaving or last 
practice download. The number of endpoints fatal within 1 calendar day.  
7. Rate of specific initial presentations: The rate of each specific initial presentation in 10 
year age bands.  
8. Data source for endpoints:  The number and percentage of each endpoint to which 
each constituent dataset contributed. 
9.  Patients with missing data for specific co-variates: Comparison of characteristics of 
patients with missing data for IMD, smoking and blood pressure compared to those 
with complete data on these variables.  
7. Conclusions 
In this chapter, I have described the derivation of the cohort used in my three related 
studies of the association gender, smoking and blood pressure with the initial 
presentation of different cardiovascular disease phenotypes. I defined the risk factors, co-
variates and endpoints used in my studies. I then justified the need for competing risk 
analysis for these studies and my decision to use complete case analysis, rather than other 
approaches to missing data. Finally, I described the statistical methods I used to describe 
the cohort and endpoints and model the associations between my risk factors and the 
multiple endpoints, including the concessions I made in my modelling approach on 
grounds of computational intensity.  
   
81 
 
Description of Cohort Population 
1. Introduction 
In the previous two chapters, I described the creation of the CALIBER research platform, 
the study design, the derivation of the cohort population, the definition of co-variates and 
the 12 cardiovascular disease (CVD) endpoints used in my three related studies. I also 
described my statistical approach to describing the cohort and analysing the association 
between my key risk factors and the endpoints within a competing risk framework. Here I 
have described the characteristics of the cohort in detail, presenting results of the 
descriptive analyses common to all three studies.  
2. Derivation of the cohort population  
The derivation of the overall cohort population, from CALIBER research platform, is 
shown in Figure 7. The total General Practice Research Database (GRPD) population 
available within CALIBER was 5,372,790. As described in Chapter 3, I included patients 
who: 
1) were of acceptable research quality,  
2) had a definite gender,  
3) were registered with their practice on or after 1st January 2000,  
4) were aged between 30 and 100 the year before study entry, and 
5) had at least 1 year of up-to-standard (UTS) observation after 1st January 2000 in 
GPRD. 
Patients were excluded if they:  
6)  had an Office of National Statistics (ONS) date of death prior to study entry; 
7)  had more than one ONS date of death; 
8) had a record in any of CALIBER constituent data sources of symptomatic 
atherosclerotic disease prior to study entry, i.e. a record of coronary disease, 
ischaemic cerebrovascular disease, peripheral arterial disease, unspecified 
atherosclerotic disease, ventricular arrhythmias, cardiac arrest or heart failure; or  
9) had a first record after study entry of code indicating history of disease.  
With electronic health record (EHR) data, unlike with some bespoke cohorts, it is possible 
to look at all the patients who did not meet the inclusion criteria. I have therefore given 
the number and proportion of patients in the overall CALIBER research platform who did 
not met the inclusion criteria as well as showing the number of patients who were 
excluded by each of the exclusion criteria. (See Figure 1.) After exclusions, 1,758,584 
patients aged 30 to 100 with no history of clinically manifest cardiovascular disease 
(CVD) remained.  For each set of analyses in Chapters 5 to 7, patients with relevant risk 
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factor data were selected to form the cohorts specific to those set of analyses. Further 
details are given in each of the relevant chapters.  
 
Table 4 shows the number of patients excluded for each prior disease presentation, 
including those whose first record after study entry indicated history of relevant disease. 
The majority of the exclusions were for previous cardiac disease, although a large number 
of patients were also excluded because of previous cerebrovascular disease. The greatest 
number of patients who were excluded because they had a history of CVD as their first 
record after study entry were excluded because of a history of stroke. The latter category 
could include patients with a history of haemorrhagic stroke, who were not explicitly 
excluded from the study.
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Figure 7: Derivation of cohort population, including number of endpoints in cohort 
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Table 4: Clinically manifest CVD at baseline: Number of patients excluded for 
specific cardiovascular disease categories   
Disease 
 
Prior to study 
entry 
“History of” as 
1st record 
Stroke, transient ischaemic attack or other ischaemic 
cerebral disease 
37,518 1,573 
Abdominal aortic aneurysm 3,765 23 
Peripheral arterial disease 11,953 1 
Other unspecified atherosclerotic disease 845 47 
All cardiac 125,606 99 
       Stable angina 85,809 -- 
       Unstable angina 548 -- 
      Coronary artery bypass graft and percutaneous  
       coronary intervention 
2,732  36 
      Coronary heart disease not otherwise specified 6,695 4 
      Acute myocardial infarction 15,533 46 
      Heart failure 12,261 1 
      Ventricular arrhythmias,  cardiac arrest & sudden 
       cardiac death 
2,028 12 
Total 179,687 1,743 
 
3. Observation time  
As discussed in Chapter 3, the period during which patients in these EHRs could be 
observed can be divided into three periods. The first is from the very first point at which 
they register with a practice until they have a specific endpoint or are censored. This is 
the maximal time during which information is available on these patients. However, many 
patients registered with a practice before the practice met GPRD-specified data quality 
standards and became up to standard (UTS). Thus a second possible period of 
observation is the time patients spent registered with a practice which was UTS. A third 
possible type of observation time is the more conventional time under observation after 
study entry which could be called the endpoint follow-up period.  
 
The 1,758,592 patients in the cohort had a total observation time from patient 
registration to diagnosis/censoring of 27,073,983 person years, with a median total 
observation time of 12.1 person years (IQR: 5.2-21.4).  The total UTS observation time 
was 16,277,652 person years with a median of 8.9 (4.3-13.0).  The total observation time 
during endpoint follow-up was 9,397,209 person years, median 5.5 (2.1-9.1).  Each type of 
observation time has been shown separately for women and men in 10 year age bands. 
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Older patients tended to have longer periods of observation time, both before and after 
study entry, with the longest median endpoint follow-time in the 50-59 age band. 
Table 5: Person years of observation time, in years, from patient registration, 
practice up to standard date and endpoint follow-up 
  Patient registration to end of follow-up time 
Age Observation time 
from 
Women Men 
Person yrs Median (IQR) Person yrs Median (IQR) 
30-39 Patient registration 3,699,762 8.4 (4.1,15.5) 4,081,184 8.6 (4.1,16.4) 
 Practice UTS time 2,718,088 7.5 (3.7,11.4) 2,834,450 7.6 (3.7,11.4) 
 Endpoint follow-up 1,495,058 4.0 (1.4,8.2) 1,523,289 3.9 (1.5,8.0) 
40-49 Patient registration 2,828,389 13.5 (5.5,22.2) 2,891,166 12.1 (5.,20.9) 
 Practice UTS time 1,820,152 9.7 (4.4,13.7) 1,863,302 9.0 (4.1,13.2) 
 Endpoint follow-up 1,130,215 7.4 (2.7,9.1) 1,160,918 6.7 (2.5,9.1) 
50-59 Patient registration 2,911,600 16.4 (7.5,27.0) 2,831,390 16.2 (7.5,26.0) 
 Practice UTS time 1,644,367 10.3 (5.6,14.4) 1,594,646 10.3 (5.4,14.1) 
 Endpoint follow-up 993,756 8.3 (3.3,9.1) 954,902 7.6 (3.1,9.1) 
60-69 Patient registration 2,081,170 16.5 (7.7,28.9) 1,792,371 16.3 (7.5,28.5) 
 Practice UTS time 1,081,902 10.3 (5.4,14.4) 918,960 10.1 (5.,14.1) 
 Endpoint follow-up 643,040 7.7 (3.,9.1) 530,827 6.6 (2.7,9.1) 
70-79 Patient registration 1,560,571 17.3 (9.1,29.3) 1,062,665 17.1 (9.,30.2) 
 Practice UTS time 744,825 10.3 (5.6,14.1) 489,202 10.0 (5.1,13.7) 
 Endpoint follow-up 420,442 6.6 (2.7,9.1) 266,247 5.5 (2.3,9.1) 
80+ Patient registration 913,550 13.4 (4.9,24.3) 420,165 15.3 (6.7,27.5) 
 Practice UTS time 396,110 7.1 (3.4,11.6) 171,646 7.5 (3.6,12.1) 
 Endpoint follow-up 197,009 3.2 (1.4,6.2) 81,507 3.2 (1.3,6.1) 
Overall Patient registration 13,995,042 12.3 (5.3,21.5) 13,078,941 11.9 (5.2,21.2) 
 Practice UTS time 8,405,444 9.0 (4.3,13.1) 7,872,207 8.7 (4.2,12.9) 
 Endpoint follow-up 4,879,520 5.7 (2.1,9.1) 4,517,689 5.2 (2.1,9.1) 
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4. Number of observations for co-variates 
The number of patients with no data recorded for each potential co-variate and the mean 
number of observations and interquartile range for those with data recorded are 
presented in Table 4. For the modelling in this thesis, only baseline data was used, but this 
table indicates that amongst those with any data recorded, there are multiple records for 
most potential co-variates, particularly the medications reflecting the use of repeat 
prescriptions. Both the index of multiple deprivation and ethnic group in hospital episode 
statistics are recorded once for each patient.  
Table 6:  Number of patients with missing data for baseline characteristics, and the 
median and interquartile range of observations for patients with data 
 No observations Total Observations 
 Women Men Women Men 
Index of Multiple Deprivation 3,878 3,533   
Ethnic Group (HES) 337,531 466,850   
Ethnic Group (GPRD) 621,291 619,428 1 (1-1) 1 (1-1) 
Ethnic group (overall) 383,168 471,362   
Smoking status 118,767 186,182 3 (2-6) 3 (1-5) 
Systolic & diastolic blood pressure  318,688 478,277 10 (4-20) 8 (3-19) 
Total cholesterol  798,875 756,337 3 (1-6) 3 (1-6) 
HDL cholesterol  838,259 795,382 2 (1-5) 3 (1-5) 
LDL cholesterol  850,272 808,489 2 (1-4) 2 (1-4) 
Triglycerides  829,244 785,841 2 (1-5) 3 (1-5) 
Diabetes diagnosis 882,721 837,431 2 (1-3) 2 (1-3) 
Diabetic medication scripts - Any 882,929 839,975 37 (13-86) 41 (16-88) 
                                                      - Insulin 897,241 854,494 22 (6-50) 27 (10-56) 
                                                      - Oral  885,338 843,051 36 (12-85) 39 (15-87) 
Body mass index  510,132 567,699 4 (2-8) 3 (1-6) 
Alcohol consumption status  571,786 572,134 2 (1-3) 2 (1-3) 
Statin scripts 878,899 836,887 23 (10-45) 21 (9-40) 
BP lowering scripts - Any 777,792 781,352 30 (5-78) 26 (5-67) 
                                       - Diuretics  844,088 832,393 23 (4-55) 21 (5-47) 
                                       - β-blockers  843,730 825,012 8 (2-34) 10 (2-33) 
                                       - ACEIs & ARBs  859,395 823,298 25 (6-56) 21 (5-51) 
                                       - CA-channel blocker 867,730 832,799 16 (4-38) 18 (6-38) 
HES indicates Hospital Episode Statistics; GPRD, General Practice Research Database; ACEI, 
Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood 
pressure; CA, calcium.  
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5. Baseline characteristics of cohort 
The baseline characteristics of the cohort have been presented, separately for men and 
women, in Table 7 below.  Where comparisons were made with external data sources, 
data from 2005 were chosen because this year reflects the mid-point of the follow-up 
time.  
Age: The population of the cohort was younger than the English population, with a higher 
proportion of patients in the younger age bands than the equivalent age bands in the mid-
year population estimates for 2005 for England. This information has been included in 
Table 7 for comparison.(192) The younger age of the research cohort was partly because 
patients were excluded if they had a history of symptomatic cardiovascular disease, which 
would exclude more older than younger patients. The cohort was also younger because 
patients were added to the open cohort when they reached their 30th birthday. If patients 
who were added to the cohort on attaining their 30th birthday were ignored, the 
population structure was broadly similar to that of England as a whole.  
Ethnic group: Amongst patients with ethnic group recorded, the majority of the patients 
reported belonging to White ethnic group; however, 42.6% of women and 54.9% of men 
did not have their ethnicity recorded.  
Smoking: Substantially more women than men reported being non-smokers (women: 
54.0% (95% CI 53.9-54.1%); men: 39.8% (39.7-39.9%); however, men were also much 
more likely than women not to have their smoking status recorded (men: 21.7% (21.6-
21.8); women: 13.2% (13.1-13.3).  The proportion of cohort patients who reported being 
current smokers was slightly lower than the proportion reported in the 2005 Health 
Survey for England – 27% in men and 24% in women. (193) While the lower rate may 
reflect missing information, a lower rate of smoking would be expected in a cohort free 
from symptomatic cardiovascular disease, given the association between smoking and 
cardiovascular disease.  
Blood pressure: Men had higher mean blood pressure and less variability than women 
(men: 134.4 mmHg (134.4-134.5; women:  128.8 mmHg (128.8-128.9)). However, a 
substantially higher proportion of men did not have blood pressure recorded (men: 
55.7% (55.6-55.8); women: 35.4% (35.3-35.5). Amongst patients with a blood pressure 
recording, the proportion of patients with raised blood pressure (>140/90) was 
essentially the same in both genders (women: 20.4% (20.3-20.5); men: 19.1% (19.0-
19.2)), but a higher proportion of women than men were on blood pressure-lowering 
medication (women:  16.0 % (15.9-16.1); men: 10.6% (10.5-10.7)).  The higher recording 
of blood pressure amongst women may be due to younger women having blood pressure 
measured as part of contraception risk assessment. The proportion of patients with high 
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blood pressure was substantially lower than that recorded in the Health Survey for 
England for 2005, which found 34.6% of men and 28.3% of women had high blood 
pressure.(193) Again, this could be due to the healthy cohort effect or possibly 
undiagnosed high blood pressure amongst the cohort.  
 Diabetes:  Patients were recorded as having diabetes if they had a diagnosis of diabetes 
(Type I or II or unspecified) or were prescribed either insulin or oral anti-diabetic 
medication. There was therefore, by definition, no missing data, although patients who 
are diabetic may not have been diagnosed by their general practitioner. The proportion of 
patients who were diabetic, using all diagnostic and prescribing information, was similar 
in women and men (women: 2.4 (2.4-2.4); men: 2.8 (2.8-2.8)). Again this was somewhat 
lower than the proportion of people with diabetes reported in the Health Survey for 
England, which found 4.3% of men and 3.4% of women reported having diabetes.(193) 
Lipids: The level of missing data for recording level of the different lipids was 
exceptionally high, with 88.7% (88.6-88.8) of women and 88.1% (88.0-88.2%) of men 
having no record at baseline.  
Obesity: The mean body mass index (BMI) for women was 26.3 kg/m2 (26.3-26.3) 
essentially the same as that for men whose mean BMI was 26.8 kg/m2 (26.8-26.8). These 
means were also similar to that in the Health Survey for England which found a mean BMI 
of 26.9 for both men and women.(193) However, there is again a high proportion of 
missing data amongst the cohort patients, with a higher proportion of data missing in 
men (women: 56.7% (56.6-56.8); men: 66.2% (66.1-66.3)).  
Alcohol consumption:  Unusually for this cohort, the proportion of men with no alcohol 
consumption information recorded (66.9% (66.8-67.0)) was similar to the proportion in 
women (63.6% (63.5-63.7). Amongst those with this information recorded, about one 
fifth of both men and women with alcohol consumption recorded were current drinkers, 
which is higher than the proportion in women in the Health Survey for England but lower 
than the proportion in men.(193)  
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Table 7: Baseline characteristics of the cohort, in women and men 
 Women Men 
Socio-demographic factors 
Age in years, n (%) n %  % 
Cohort England 
mid-2005* 
Cohort England 
mid-2005* 
   30-39 332,390 36.9 22.7 342,067 39.9 24.6 
   40-49 187,562 20.8 22.1 201,264 23.5 24.6 
   50-59 155,990 17.3 19.4 153,875 17.9 20.6 
   60-69 103,675 11.5 15.1 91,221 10.6 15.5 
   70-79 71,816 8.0 11.9 49,166 5.7 10.6 
   80+ 48,968 5.5 8.9 20,590 2.4 5.1 
   Total 900,401 -- -- 858,183 -- -- 
Age in years, mean (sd)  48.0 (16) 45.6 (14) 
Ethnic group, n (%)   
  White 466,852 51.8 348,007 40.6 
  Black  15,770 1.8 11,434 1.3 
  South Asian 14,697 1.6 12,453 1.5 
  Other and mixed 19,914 2.2 14,927 1.7 
  Not recorded 383,168 42.6 471,362 54.9 
Deprivation Quintile, n (%)*   
  1st quintile (most deprived) 174,208 19.3 174,207 20.3 
  2nd quintile  178,099 19.8 171,647 20.0 
  3rd quintile 181,055 20.1 169,005 19.7 
  4th quintile 181,475 20.2 169,488 19.7 
  5th quintile (least deprived) 181,686 20.2 170,303 19.8 
  Not recorded 3,878 0.4 3,533 0.4 
Clinical risk factors 
Smoking Status, n (%)   
  Non smoker 486,059 54.0 341,600 39.8 
  Ex-smoker 113,172 12.6 115,375 13.4 
  Current Smoker 182,403 20.3 215,026 25.1 
  Not recorded 118,767 13.2 186,182 21.7 
Blood Pressure   
  SBP in mmHg, mean (sd)  128.8 19.6 134.4 17.2 
  DBP in mmHg, mean (sd) 77.7 9.8 81.2 9.8 
  Raised blood pressure, n (%) 184,120 20.4 164273 19.1 
  On BP lowering medication, n 
(%) 
143,970 16.0 90,846 10.6 
  Treated SBP in mmHG, mean (sd) 148.1 18.6 148.6 16.4 
  Not recorded, n (%) 318,821 35.4 478,413 55.7 
Diabetes, n (%)       
  Diagnosed with diabetes 17,680 2.0 20,752 2.4 
  On insulin  3,160 0.4 3,689 0.4 
  On oral medication 15,063 1.7 15,132 1.8 
  On any medication 18,223 2.0 18,821 2.2 
  Diagnosed or on medication 21,957 2.4 23,668 2.8 
Lipids in mmol/l, mean (sd)     
   Total cholesterol (TC) 5.5 1.1 5.4 1.1 
   High density lipoprotein 1.5 0.5 1.3 0.4 
   Low density lipoprotein 3.3 1.0 3.3 1.0 
   Triglycerides  1.5 1.0 1.9 1.5 
   On statins at baseline, n (%)  21,502  2.4  21,296  2.5 
   Total cholesterol on statins  5.4 1.3 5.1 1.3 
   Not recorded (TC), n (%) 798,875   88.7   
756,337  
 88.1  
Obesity     
  BMI in kg/m2, mean (sd) 26.3 5.8 26.8 4.6 
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 Women Men 
  Not recorded, n (%) 510,132   56.7   
567,699  
 66.2  
Alcohol consumption, n (%)     
  Non-drinker 68,397 7.6 34,208 4.0 
  Ex-drinker 5,784 0.6 5,879 0.7 
  Occasional drinker (<1x a week) 42,916 4.8 23,440 2.7 
  Current drinker 192,111 21.3 186,400 21.7 
  Excess drinker, incl. binging  18,540 2.1 34,913 4.1 
  Not recorded 572,653 63.6 573,343 66.9 
*Mid-year population estimates from Office for National Statistics. sd indicates standard 
deviation; TC, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
BP, blood pressure; BMI, body mass index.  
 
6. Data source for all endpoints 
The constituent data source for each endpoint was identified. GPRD contributes the 
greatest number of CVD endpoints, followed by HES, ONS and then MINAP, although the 
relative contribution of each data source varies depending on the specific initial 
presentation. The number and proportion of patients with each endpoint, from each data 
source, have been given separately for men and women in Table 8. 
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Table 8: The proportion of specific endpoint provided by GPRD, HES, MINAP and ONS  
 Data Source 
n (% of category) 
Disease GPRD HES MINAP ONS 
Stroke 7,380 (46.3) 7,216 (45.2)  0 1,357 ( 8.5) 
Abdominal aortic aneurysm 1,749 (65.5)   557 (20.9)    0   365 (13.7) 
Peripheral arterial disease 8,488 (86.2) 1,281 (13.0) 0    78 ( 0.8) 
Cardiac disease 40,027 (59.9) 19,798 (29.6) 1,136 ( 1.7) 5,835 ( 8.7) 
     
Stable angina 20,210 (98.7)   251 ( 1.2)    24 ( 0.1) 0 
Unstable angina   563 (17.8) 2,542 (80.2)    63 ( 2.0) 0 
Coronary heart disease not otherwise specified 5,660 (71.1) 2,297 (28.9) 0 0 
Myocardial infarction 4,314 (32.7) 7,822 (59.3) 1,049 ( 8.0) 0 
   ST elevation myocardial infarction   384 (41.5) 0   542 (58.5) 0 
   Non ST elevation myocardial infarction   847 (62.6) 0   507 (37.4) 0 
  Myocardial infarction not otherwise specified 3,083 (28.3) 7,822 (71.7) 0 0 
Heart failure 8,484 (67.8) 3,455 (27.6) 0   571 ( 4.6) 
Ventricular arrhythmias, cardiac arrest & sudden cardiac death 1,438 (34.0) 2,789 (65.9) 0     7 ( 0.2) 
Unheralded coronary death 0 0 0 5,527(100.0) 
Total 57,644 (60.5) 28,852 (30.3) 1,136 ( 1.2) 7,635 ( 8.0) 
 GPRD indicates General Practice Research Database; HES, Hospital Episode Statistics; MINAP, Myocardial Ischaemia National Audit Project; ONS, Office for 
National Statistics. 
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7. Comparison of initial presentation of CVD with specific endpoints to 
first presentation of specific endpoints 
Initial presentation of CVD overall with a specific endpoint is defined as the first 
presentation across any of the possible endpoints; first presentation of a specific endpoint 
is the first presentation of particular endpoint which may or may not be preceded by 
another presentation of different CVD endpoint. In Table 9 and Table 10, the number of 
first and initial presentations has been shown for women and for men in each of three 
broad age groups, as well as the proportion of first presentations which were initial 
presentation of CVD. The number of first and initial presentations was highest in the 60-
79 age band; however, the increase in women was greater because men had high number 
of initial and first presentations in the youngest age group as well as in the middle age 
group. For both men and women, the proportion of first presentations which are also 
initial presentations were lower in cardiac disease phenotypes than in the other CVD 
phenotypes.  In both men and women, the proportion of first presentations which were 
also initial presentations for each phenotype varies by age. The most common pattern for 
both men and women was a decline in the proportion of first presentations which were 
also initial presentations in middle age bands, increasing again in the oldest age group, 
although with the total presentations the proportion of initial which were also first 
presentations increased with increasing age in men but not women.   
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Table 9:  Number of initial presentations of any cardiovascular disease endpoints, number of first presentations of cardiovascular disease 
endpoints, and proportion of initial presentations that also first presentations in women 
 Age <60 years Age 60-79 years Age 80+ years All ages 
Women 
First Initial % 
 
First Initial % 
 
First Initial % 
 
First Initial % 
 
Stroke  1,356   1,269  93.6  4,668   4,110  88.0  4,166   3,682  88.4  10,190   9,061  88.9 
Abdominal aortic aneurysm  69   54  78.3  602   481  79.9  247   212  85.8  918   747  81.4 
Peripheral arterial disease  1,267   1,151  90.8  2,926   2,510  85.8  1,053   869  82.5  5,246   4,530  86.4 
Acute MI & CHD death  1,607   1,311  81.6  4,689   3,463  73.9  2,967   2,159  72.8  9,263   6,933  74.8 
Cardiac              
  Stable angina  4,917   3,604  73.3  7,965   5,331  66.9  1,695   1,017  60.0  14,577   9,952  68.3 
  Unstable angina  1,019   559  54.9  1,419   660  46.5  377   184  48.8  2,815   1,403  49.8 
  Coronary heart disease NOS  2,747   990  36.0  5,414   1,891  34.9  1,018   466  45.8  9,179   3,347  36.5 
  Acute myocardial infarction  1,341   1,091  81.4  3,249   2,423  74.6  1,536   1,159  75.5  6,126   4,673  76.3 
  Vent. arrhyth, c arrest & sudden c arrest  682   573  84.0  1,212   873  72.0  265   181  68.3  2,159   1,627  75.4 
  Heart Failure  768   580  75.5  4,362   3,323  76.2  3,680   3,079  83.7  8,810   6,982  79.3 
  Coronary death  295   220  74.6  1,742   1,040  59.7  1,732   1,000  57.7  3,769   2,260  60.0 
Total 14,461   10,091  69.8  33,559   22,642  67.5  15,769  11,849 75.1  63,789   44,582  69.9 
MI indicates myocardial infarction; CHD, coronary heart disease; NOS -not otherwise specified; vent. Arrhyth – ventricular arrhythmia; c. arrest, cardiac 
arrest. 
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Table 10:  Number of initial presentations of any cardiovascular disease endpoints, number of first presentations of cardiovascular disease 
endpoints, and proportion of initial presentations that also first presentations in men 
 Age <60 years Age 60-79 years Age 80+ years All ages 
Men First Initial % First Initial % First Initial % First Initial % 
Stroke  1,989   1,793  90.1  4,388   3,762  85.7  1,532   1,337  87.3  7,909   6,892  87.1 
Abdominal aortic aneurysm  359   289  80.5  1,697   1,326  78.1  359   309  86.1  2,415   1,924  79.7 
Peripheral arterial disease  2,417   2,087  86.3  3,464   2,773  80.1  554   457  82.5  6,435   5,317  82.6 
Acute MI & CHD death  6,184   5,252  84.9  6,770   5,052  74.6  1,720   1,205  70.1  14,674   11,509  78.4 
Cardiac              
  Stable angina  9,378   4,983  53.1  8,957   4,995  55.8  967   555  57.4  19,302   10,533  54.6 
  Unstable angina  2,055   1,046  50.9  1,571   628  40.0  199   91  45.7  3,825   1,765  46.1 
  Coronary heart disease NOS  7,448   2,100  28.2  7,528   2,241  29.8  659   269  40.8  15,635   4,610  29.5 
  Acute myocardial infarction  5,090   4,307  84.6  4,700   3,569  75.9  888   636  71.6  10,678   8,512  79.7 
  Vent. arrhyth, c arrest & sudden c arrest   1,626   1,209  74.4  1,934   1,284  66.4  167   114  68.3  3,727   2,607  69.9 
  Heart Failure  1,679   1,146  68.3  4,254   2,947  69.3  1,804   1,435  79.5  7,737   5,528  71.4 
  Coronary death  1,228   945  77.0  2,439   1,483  60.8  1,014   569  56.1  4,681   2,997  64.0 
Total 33,269   19,905  59.8  40,932   25,008  61.1  8,143   5,772  70.9  82,344   50,685  61.6 
MI indicates myocardial infarction; CHD, coronary heart disease; NOS - not otherwise specified; vent. Arrhyth – ventricular arrhythmia; c. arrest, cardiac 
arrest. 
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8. Number of endpoints and case fatality 
Out of the 1,758,584 cohort patients, after a median of 5.7 years follow up in women and 
5.2 in men, 95,267 (5.4%) patients experienced an initial presentation of interest while a 
further 55,620 died from another cause (3.2%). The remaining 1,663,317 (94.6%) left the 
practice (26.2%) or were censored at the last practice download (65.3%).  Figure 8 shows 
the number of patients with each specific initial presentation of CVD, while Figure 9 
shows the proportion each initial presentation made of all the presentations, in all 
patients and in women and men separately. Stroke and MI constituted 31% of all initial 
presentations, with other presentations constituting the majority (69%). While the 
proportion of presentations which were cardiac were similar between men and women,  
acute myocardial infarction formed a greater proportion of initial presentation in men, 
while heart failure was more common initial presentation in women. Women were also 
more likely to have stroke as an initial presentation compared to men.   
 
Twelve per cent of the cardiovascular events were fatal within 1 calendar day of the event 
date (n=11,403), with a considerable range in the proportion of fatal events, depending 
on the diagnosis. As expected, unheralded coronary death is 100% fatal within 1 day, 
while stable angina is virtually 0%. Fatalities in the other presentations range from 0.6% 
for unstable angina to 23.1% for abdominal aortic aneurysm. Table 11 below shows the 
number and proportion of endpoints, as well as the number which were fatal within 1 
calendar day.  Of note is the higher case fatality in women from almost all initial 
presentations, with stroke and abdominal aortic aneurysm showing the greatest 
differences between genders.  
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Figure 8: Number of initial presentations in patients with no clinically manifest CVD at baseline  
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Figure 9: Proportion of initial presentation of CVD for each presentation, overall 
and in men and women 
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PAD indicates peripheral arterial disease; AAA, abdominal aortic aneurysm; AMI, acute 
myocardial infarction; CHD NOS, coronary heart disease not otherwise specified; LVA, CA & 
SCD, ventricular arrhythmias, cardiac arrest and sudden cardiac death; UA, unstable angina. 
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Table 11: Number of women and men with each endpoint and proportion fatal within one calendar day  
 Endpoints 
n (% CVD endpoints) 
Fatal within 1 calendar day 
n (% of category) 
Disease Women Men Women Men 
Stroke 9,061 (20.3) 6,892 (13.6) 1,293 (14.3)   583 (8.5) 
Abdominal aortic aneurysm   747 (1.7) 1,924 (3.8)   209 (28.0)   409 (21.3) 
Peripheral arterial disease 4,530 (10.2) 5,317 (10.5)    85 (1.9)    39 (0.7) 
Cardiac disease 30,244 (67.8) 36,552 (72.1) 4,101 (13.6) 4,684 (12.8) 
Stable angina 9,952 (22.3) 10,533 (20.8)     6 (0.1)    11 (0.1) 
Unstable angina 1,403 (3.1) 1,765 (3.5)     5 (0.4)    13 (0.7) 
Coronary heart disease not otherwise specified 3,347 (7.5) 4,610 (9.1)   278 (8.3)   313 (6.8) 
Myocardial infarction 4,673 (10.5) 8,512 (16.8)   436 (9.3)   481 (5.7) 
   ST elevation myocardial infarction   282 (0.6)   644 (1.3)    12 (4.3)     8 (1.2) 
   Non ST elevation myocardial infarction   505 (1.1)   849 (1.7)     3 (0.6)     3 (0.4) 
  Myocardial infarction not otherwise specified 3,886 (8.7) 7,019 (13.8)   421 (10.8)   470 (6.7) 
Heart failure 6,982 (15.7) 5,528 (10.9)   815 (11.7)   517 (9.4) 
Ventricular arrhythmias, cardiac arrest & sudden cardiac death 1,627 (3.6) 2,607 (5.1)   301 (18.5)   352 (13.5) 
Unheralded coronary death 2,260 (5.1) 2,997 (5.9) 2,260 (100.0) 2,997 (100.0) 
Total 44,582 (100)  50,685 (100) 5,688 (12.8) 5,715 (11.3) 
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9. Rate of initial presentation of CVD with specific endpoints 
The rate of initial presentation per 100,000 person years in 10 year age bands was 
calculated. The rates for most presentations increased up to age 70-79 years and declined 
thereafter. Stable angina has the greatest increase amongst these presentations up to this 
age, but both heart failure and stroke as initial presentations continued to rise, indeed rise 
steeply, by age 80 and did not decline. The rates per 100,000 person years in ten year age 
bands and overall, are shown in Table 12 below.  
10. Patients with missing data 
One of the concerns with electronic health record data is the extent of data, particularly 
risk factor data, which is unrecorded for patients. Although unrecorded data is not 
missing in the sense that a survey response might be missing – patients have either not 
attended general practice or not had their risk factors assessed – this data will be referred 
to as missing henceforth. Below I have compared in greater detail the characteristics of 
patients with missing data for four key risk factors which have been incorporated in later 
analyses.  
10.1. Index of multiple deprivation not recorded 
Very few patients (n= 7,411, 0.4%) had the index of multiple deprivation (IMD) missing, 
because IMD is missing only in those patients who did not have a valid postcode recorded 
when the data was linked. Lacking a valid postcode could be due to clerical error, but 
could also be due to patients being homeless with no fixed address. The mean age of those 
with IMD missing (46.1 years (45.8-46.4) was marginally younger than those with IMD 
recorded (47.8 years (47.8- 47.9).  Both men and women were just as likely to have their 
IMD status recorded (women: 52.3% (51.2-53.5%); men:  48.8% (48.7-48.9%)) as not 
(women: 51.2% (51.1-51.3%); men: 47.8% (46.5-48.8%)).  Other differences in terms of 
smoking status or smoking status recorded, diabetic or not, blood pressure recorded or 
not, were also negligible. 
10.2. Smoking status not recorded 
Overall 304,949 (17.3%) patients in the overall cohort had no smoking status recorded in 
GPRD. They were slightly older than those with smoking status recorded; mean age for 
those with no smoking status was 49.3 years (95%CI 49.2- 49.3) compared to 47.6 (47.5 -
47.6) in those with data on this risk factor. The greatest difference was in patients aged 80 
and over where 29.3% (29.0-29.6) of patients had no smoking status recorded compared 
to 16.3% (16.2-16.4%) in the 30-39 year olds.  Men were much less likely to have their 
smoking status recorded (61.1% (60.9-61.2) than women (38.9% (38.8-39.1). The 
proportion of patients with missing smoking status increased somewhat with increasing 
social deprivation, so 18.4% (18.2-18.5) in the least deprived quintile were missing data 
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compared to 22.1% (21.9-22.2) in the most deprived quintile.  Patients who were diabetic 
were much more likely to have their smoking status recorded 92.3% (92.1-92.5) than not 
7.7% (7.5-7.9).  There was also wide variation between practices in the proportion of 
patients with smoking status missing, ranging from 2.96% to 58.36%. 
10.3. Blood pressure not recorded 
Of patients with no recorded smoking status, 245,228 (80.4%) also had blood pressure 
(BP) missing. However, considerably more patients had no recent BP measurement than 
were missing smoking status; in total 797,234 patients, 45.3% of the overall cohort.  
Unlike smoking, those with BP missing were younger than those with BP recorded: 46.6 
(46.6- 46.7) compared to 48.9 years (48.8-48.9).   The proportion of patients with missing 
BP data was greatest in patients under 50. BP was missing in 60.0% (59.9-60.1) of men 
compared to 40.0% (39.9-40.1) of women.  The proportion of patients in each IMD 
category was similar in patients with and without missing BP measurements. Ten per 
cent of patients with diabetes had no BP measurement at baseline.  There was variation 
between practices in the proportion of patients with a BP measurements but this did not 
vary as widely as the recording of smoking status. 
10.4. IMD, smoking and blood pressure not recorded 
Overall, 860,692 (49.9%) patients in the overall cohort did not have IMD, smoking and 
blood pressure recorded at baseline. The mean age of those with missing data was 47.1 
years (47.1- 47.2), slightly younger than those with these data recorded (48.5 years (48.5-
48.6). The age group with the highest proportion of missing data was 40-49 with 53.2% 
(53.1-53.4%) missing compared to 48.9% (48.8- 49.1) overall.  The greatest difference 
was in the proportion of men with missing data (58.6% (58.4-58.6) compared to women 
with missing data (41.5% (41.1-41.6). Those with diabetes were much more likely to have 
data recorded than not (85.1% (85.1- 85.1) vs 14.9% (14.9- 14.9)), though it is worth 
noting that over 10% of diabetic patients had no smoking status and no recent blood 
pressure recorded.  
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Table 12: Rate of different initial presentations per 100,000 person years of observations in 10 year age bands 
Endpoints 30-39 40-49 50-59 60-69 70-79 80-89 90+ All ages 
Stroke 12.1  
(10.9-13.4) 
35.7 
 (33.3-38.2) 
96.2 
 (91.9-100.7) 
262.2  
(253.1-271.6) 
695.5  
(676.0-715.4) 
1653.2  
(1603.1-1704.9) 
2869.1 
 (2693.4-3056.4) 
169.5  
(166.9-172.2) 
Abdominal aortic aneurysm  0.8  
(0.6-1.2) 
 2.2  
(1.7-2.9) 
13.7 
 (12.1-15.4) 
62.8  
(58.4-67.5) 
155.2  
(146.1-164.8) 
193.1 
 (176.5-211.3) 
140.3  
(105.4-186.8) 
28.4  
(27.3-29.5) 
Peripheral arterial disease  9.5  
(8.5-10.7) 
36.7 
 (34.3-39.3) 
108.0 
 (103.5-112.7) 
226.8  
(218.3-235.5) 
379.9 
 (365.6-394.8) 
477.1  
(450.5-505.2) 
462.8 
 (395.4-541.7) 
104.6  
(102.6-106.7) 
Cardiac disease 61.4 
 (58.7-64.3) 
267.0 
 (260.4-273.8) 
607.7 
 (596.8-618.7) 
1101.7 
(1082.9-1120.9) 
1641.4 
 (1611.4-1671.9) 
2094.8 
 (2038.3-2152.9) 
2400.4  
(2240.1-2572.2) 
531.8 
(527.2-536.5) 
Stable angina 24.7  
(23.0-26.5) 
113.2  
(109.0-117.7) 
268.6  
(261.4-275.9) 
494.7  
(482.1-507.5) 
654.6 
 (635.8-674.0) 
574.4  
(545.2-605.2) 
483.7 
 (414.6-564.2) 
217.7 
 (214.7-220.7) 
Unstable angina  7.5 
 (6.6-8.5) 
25.2 
 (23.2-27.3) 
41.0  
(38.3-44.0) 
64.5 
 (60.1-69.3) 
76.9  
(70.6-83.7) 
97.8  
(86.2-111.0) 
104.5  
(75.0-145.5) 
33.7  
(32.5-34.9) 
Coronary heart disease not 
otherwise specified 
 6.9 
 (6.0-7.9) 
35.8 
 (33.4-38.3) 
105.6 
 (101.1-110.2) 
201.6  
(193.7-209.9) 
255.7 
 (244.0-267.9) 
266.0 
 (246.4-287.2) 
244.8  
(197.2-304.0) 
84.6 
 (82.7-86.4) 
Myocardial infarction 18.5 
 (17.0-20.1) 
77.8  
(74.3-81.5) 
156.4  
(150.9-162.0) 
258.4 
 (249.4-267.7) 
428.9 
 (413.7-444.6) 
633.9 
 (603.2-666.2) 
713.6 
 (628.6-810.0) 
140.1 
 (137.7-142.5) 
ST elevation myocardial infarction  2.4  
(1.9-3.0) 
 8.0 
 (6.9-9.3) 
12.8 
 (11.3-14.4) 
16.7 
 (14.6-19.3) 
22.2 
 (19.0-26.0) 
25.3  
(19.7-32.4) 
29.9 
 (16.1-55.5) 
 9.8 
 (9.2-10.5) 
Non ST elevation myocardial 
infarction 
 2.0  
(1.5-2.6) 
 8.8  
(7.6-10.1) 
15.8  
(14.1-17.6) 
27.7 
 (24.9-30.9) 
41.6  
(37.0-46.7) 
64.0  
(54.7-74.8) 
47.8 
 (29.3-78.0) 
14.4  
(13.6-15.2) 
Myocardial infarction not 
otherwise specified 
14.2  
(12.9-15.6) 
61.1 
 (58.0-64.3) 
127.9 
 (122.9-133.0) 
213.9  
(205.7-222.5) 
365.1 
 (351.1-379.7) 
544.7 
 (516.3-574.7) 
635.9  
(556.0-727.3) 
115.9 
 (113.7-118.1) 
Heart failure  5.7 
 (4.9-6.7) 
19.6 
(17.9-21.5) 
56.5  
(53.3-59.9) 
181.1 
 (173.6-189.0) 
601.3  
(583.3-619.9) 
1503.7  
(1456.0-1553.0) 
2457.1 
 (2294.9-2630.9) 
132.9  
(130.6-135.3) 
V. arrhythmias, cardiac arrest & 
sudden cardiac death 
10.1  
(9.0-11.3) 
20.4  
(18.6-22.3) 
51.7 
 (48.6-55.0) 
106.1  
(100.3-112.1) 
132.1 
 (123.8-140.9) 
108.0 
 (95.7-121.8) 
89.6 
 (62.6-128.1) 
45.0  
(43.7-46.4) 
Unheralded coronary death  3.9 
 (3.2-4.6) 
15.0 
 (13.5-16.6) 
36.1  
(33.5-38.9) 
82.6  
(77.6-88.0) 
225.3 
 (214.4-236.8) 
522.7  
(494.9-552.1) 
853.9 
(760.4-958.8) 
55.9 
 (54.4-57.4) 
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11. Conclusions 
A total of 1,758,584 met the basic inclusion and exclusion criteria for the overall cohort 
without reference to the completeness of co-variate data. As a whole the cohort was 
relatively young, as would be expected in a healthy cohort, and included a slightly higher 
proportion of women than men. Differences in the measured values of smoking and blood 
pressure between the current cohort and national averages recorded in the Health Survey 
for England could be due to missing data but could also be due to the healthy population 
in the cohort.  The level of lipid, alcohol consumption and BMI was disappointly low, so 
the decision was taken not to include these variables in the main modelling in subsequent 
chapters. Further work within the Clinical Epidemiology Team to develop robust 
approaches to multiple imputation to allow the association of these risk factors with 
initial presentation, as well as make suitable adjustments in modelling, are currently 
underway.  
 
The comparison between the onset of CVD with specific diseases and the first 
presentation of a specific disease revealed both gender and age differences. This 
distinction is important for understanding gender differences in the disease pathways:  
the initial presentation forms a lower proportion in men compared to women of first 
presentations across several diseases.  This difference is particularly notable with stable 
angina, where 54.6% of first presentations in men of all ages were also the initial 
presentation of CVD, while in women the proportion is 68.3%, with more extreme 
differences in the youngest age group. These differences point to the need to study the 
patient pathway from onset with any presentation through to subsequent events with 
greater precision than has been the case in previous research. The importance of a 
broader approach is reinforced by the proportion of initial presentations which are 
neither stroke nor acute MI – 69% overall (70% in women and 69% in men).  These 
findings show the importance of including the range of diseases with which CVD can 
initially present and indicates potentially wider opportunities for secondary prevention 
than currently exploited.  
 
Given the higher case fatality from stroke and AAA in women than in men, those 
secondary prevention opportunities may be more limited in women. Further research to 
determine whether women are receiving similar levels of primary prevention compared 
to men and whether any such differences might explain these differences in case fatality 
should be undertaken.  
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Although the rate of initial presentations increases with age across most CVD subtypes up 
to age 70-79, the relatively shallow increase below age 70 is perhaps surprising, but may 
be a reflection of the rate of increase in initial presentation. Patients who have a second or 
third event in later middle age will not be included in these rates.  The rapid increase in 
rate of both heart failure and stroke, starting at 70 and above, is likely a reflection of 
increasing blood pressure, and the long-term damage caused by that increase, with age. 
The association of blood pressure with initial presentation as modified by age is 
investigated in greater detail in Chapter 7.  
 
The examination of patients with data missing on key variables (IMD, smoking status and 
blood pressure) which are generally well recorded in the dataset showed some patterning 
by age, but principally by gender. Men were significantly more likely to have smoking and 
blood pressure data missing than women so that 39.5% of patients with complete data on 
these variables were male compared to 60.5% female.  Further discussion of the specific 
cohort used in Chapters 5-7 can be found in those chapters.  
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Gender and the initial presentation of a wide range of 
cardiovascular diseases: Influence of age, smoking and 
diabetes  
1. Abstract 
Background: Women are known to have lower rates of some cardiovascular diseases 
(CVD), e.g. myocardial infarction (MI) and abdominal aortic aneurysm (AAA), compared 
to men.  However, it is unknown the extent to which gender is differentially associated 
with the onset of CVD across a wide range of presentations. Based in part on previous 
research,(2,31) I hypothesised that there would be heterogeneity in the gender ratios 
between different initial presentations, and that these gender ratios would be stronger at 
younger ages, and weaker among smokers and people with diabetes. 
Objectives: To determine the heterogeneity of association of gender with the onset of 
CVD across a wide range of cardiovascular disease presentations and to determine 
whether those associations were modified by age, smoking or diabetes.  
Design: Cohort study using data from the CALIBER research platform linking four data 
sources (primary care, disease registry, hospitalisation and mortality records) for 
1,758,584 patients free from symptomatic CVD.  
Main outcome measures: Initial presentation of CVD with stable angina, unstable 
angina, MI, heart failure, ventricular arrhythmias, unheralded coronary death (UCD), 
stroke, AAA and peripheral arterial disease (PAD). 
Results:   In both men and women, CVD most commonly presented with stable angina, 
followed in women by stroke and in men by MI.   There was marked heterogeneity in 
gender effect, with an almost fourfold difference in gender rate ratios.  The most extreme 
were for AAA (4.27 (95%CI 3.92-4.65) and MI (2.51 (2.42-2.60)) with only modest effects 
for stroke, angina, and heart failure.  These rate ratios for MI and UCD were 4 and 6 times 
greater in the under-40s compared to those 80 and over.  Other presentations showed 
quite different effect modifications with age.  Amongst diabetics, the male excess for onset 
of CVD with all presentations except AAA was reduced, most substantially for the acute 
coronary presentations. The only clear effect modification for smoking was a reduction in 
the male excess amongst smokers for initial presentation with AAA.   
Conclusion: Onset of symptomatic CVD with the most common presentations (heart 
failure, stroke, stable angina) show only a modest male preponderance, while other 
presentations showed either a high (PAD, MI, UCD) or extremely high male 
preponderance (AAA). The extent of modification of the gender rate ratios by age, 
smoking status and diabetes varied considerably by initial CVD presentation.   
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2. Introduction 
The previous chapters described the creation of the CALIBER research platform, the 
general methods used for the thesis and general results applicable to the whole thesis. In 
this chapter, I examine the association of gender with the initial presentation of 
cardiovascular disease.  
 
Women are known to have much lower rates of some cardiovascular diseases (CVD), such 
as  myocardial infarction (MI) and abdominal aortic aneurysm (AAA), compared to men.  
For other CVDs, the incidence ratios are not clear. (194) There are a lack of large scale, 
prospective studies which examine the way in which gender patterns the initial 
presentation (non-fatal and fatal) of a wide range of cardiovascular diseases. In studies of 
first presentation of individual CVD presentations, men have been found to have higher 
incidence rates than women across a range of individual cardiovascular disease 
presentations, including stable angina,(195) unstable angina,(144) myocardial 
infarction,(144,196) ischaemic stroke(26,197), abdominal aortic aneurysm (198,199), 
heart failure(200,201), sudden cardiac death(202,203) and peripheral arterial 
disease.(204) However, these studies only investigate the onset or first presentation 
within a single disease presentation and disregard the possibly earlier onset of other CVD 
presentations. This approach does not give due regard to more generalised nature of 
atherosclerotic disease, with common risk factors potentially affecting the cerebral, 
coronary, abdominal and peripheral arterial beds.  The principal aim of this chapter’s 
analyses is to investigate the association of gender with the onset of CVD, looking at the 
first presentation of any disease across the entire range of CVD presentations. 
 
Although the majority of cardiovascular risk factors have been found to have similar risks 
for men and women, age, smoking and diabetes appear to modify the effect of gender on 
at least some cardiovascular disease presentations. Large-scale cohort studies or meta-
analyses support these being robust effects. I briefly summarise the evidence for the 
interaction between these risk factors and gender and the implications for my analyses 
below.  
 
The interaction between gender and age in the association with specific cardiovascular 
disease presentations has been documented in a number of studies mainly focussing on 
single disease presentations (fatal and non-fatal). Taking coronary heart disease (CHD) as 
an example, women develop coronary heart disease about 10 years later than men, (205) 
with an up to five-fold greater risk of CHD mortality in men compared to women, at least 
in middle-age. (206)  The difference in risk declines with age, reaching near parity in 
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people in their 70s or 80s.(207) Although some have attributed the closing of the gap in 
risk to increase in women’s risk after the menopause, women appear to have a steady 
increase in risk with age, while men have an excess risk at a younger age; it is the decline 
in risk in men which leads to the reduction in risk ratio at older ages.(208) Stroke appears 
to follow a similar pattern of male excess declining with age.(26) While other CVD 
presentations may not have similar interactions between age and gender, there is 
evidence that they all have gender differences in the mean age of onset. The extent of that 
difference varies from as little as two years for heart failure,(209) three for peripheral 
arterial disease,(28) four for stroke,(26) five for stable angina(210) and ruptured 
abdominal aortic aneurysm,(211) six for sudden cardiac death,(212) to ten years for 
acute myocardial infarction (205) and CHD mortality.(213) Given these differences, age is 
likely to modify the association of gender with the range of specific initial presentations of 
cardiovascular disease. The hypothesis that there is no effect modification by age will be 
tested in the analysis.  
 
Diabetes has also been shown, in large robust meta-analyses, to modify the effect of 
gender on coronary heart disease mortality, with a greater increase in the risk of CHD 
mortality in women with diabetes compared to the increase men,(31,214,215) to the 
extent that some authors have suggested that the male excess in risk of CHD is negated by 
diabetes.(216)  Although meta-analyses are lacking, diabetes has been shown to have  a 
greater effect on women’s risk of ischaemic stroke compared to men’s,(217) but no effect 
on the relative risk of sudden cardiac death.(218) Similarly, smoking has been found to 
pose a greater risk for women than for men for CHD(2),  stroke,(39) and possibly 
PAD.(204)  However, it is not clear whether the effect modification of gender by diabetes 
and smoking extends to a) initial presentation of cardiovascular disease rather than CVD 
mortality, and b) across the range of different possible CVD presentations. The hypothesis 
that there is no effect modification of gender by either risk factor will be tested in the 
analyses.  
 
My cohort study (2001-2010) takes place at a time of continuing reductions in the rate of  
cardiovascular mortality in both men and women,(219)  but there is some evidence that 
the rate of decline in women, particularly younger women, has been reversed.(220) To 
take an extreme example, if the rate of a specific initial presentation declined in men but 
remained constant in women over a given time period, the rate ratio would reduce over 
this time period. I have therefore also investigated whether the rate ratios did indeed 
decreased between three equal time periods, 2001-03, 2004-06 and 2007-09.  
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This chapter therefore has four key objectives: 
1. To summarise the existing literature on the association of gender with the onset of 
CVD across a wide range of disease presentations.  
2. To determine whether the risks comparing men to women for the onset of CVD 
vary across a wide range of cardiovascular disease presentations. 
3. To test whether any gender differences found are modified by age, diabetes and 
smoking of patients.  
4. To determine whether there is a declining trend in any gender differences for the 
range of disease presentations over the time period of the cohort.   
3. Literature review 
3.1. Search strategy 
The aim of my literature search for this chapter was to find studies which a) reported the 
gender-specific rate of onset of CVD with specific cardiovascular presentations in 
populations without clinically manifest cardiovascular disease and b) which included at 
least two endpoints.  I used a specific search strategy focussing on the rate of initial CVD 
presentation. The search terms I used are reproduced in Table 22 below. I limited both 
searches to papers in English with the full text available, published since 1992 in PubMed. 
I supplemented the studies found through the formal search strategy by searching 
reference lists of relevant papers, using forward citation searches of earlier relevant 
papers and asking other researchers for the details of any papers of which they were 
aware.  Relevant studies published before 1992 which were identified have also been 
included. 
Table 13: Search strategy used to identify studies on gender specific rate of onset of 
CVD with specific cardiovascular presentations 
Concepts Boolean 
operator 
Terms used 
Specific search 
Rate  (Incidence OR incident) rate 
Endpoints AND "myocardial infarction" OR STEMI OR nSTEMI OR "acute coronary 
syndrome"  OR “angina” OR “coronary insufficiency” or “acute 
coronary syndrome” OR “heart attack” 
  “abdominal aortic aneurysm” OR “peripheral arterial disease” OR 
“peripheral vascular disease” OR PAD OR “intermittent 
claudication” OR “peripheral ischaemia”  
  Stroke OR “cerebrovascular disease” OR “cerebrovascular accident” 
  (ventricu* AND arrhythm*) OR “cardiac arrest” OR “sudden cardiac 
death”  
  “heart failure” 
Gender AND “sex factors”[MESH] OR (sex OR gender) OR (women AND men) OR 
(male AND female) 
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3.2. Findings of literature search 
Five studies which described the rate of onset of CVD across several endpoints were 
found. Only one small study,  limited by cohort size (n=931) but not the number of 
endpoints investigated (n=6), could be found which reported rates of onset of CVD with 
different cardiovascular diseases in both men and women,(221) although Murabito et al. 
also reported the proportion of different presentations amongst participants who 
developed CHD in the Framingham cohort.(1)  Another four studies reported rates in men 
only.(222–225) The five studies of the overall onset of CVD are all bespoke cohort studies. 
 
I also identified a number of other studies which estimated gender-specific incidence 
rates for several cardiovascular diseases measured concomitantly, where prior 
manifestations with other cardiovascular disease types were ignored.(84,144,195–
197,226,227)  These studies provide comparative rates, within the same population, of 
the cardiovascular diseases of interest to this thesis, even if they do not report the onset 
of CVD with specific presentations. These additional studies of onset of specific 
cardiovascular diseases include bespoke cohort studies,(144,195–197,227) electronic 
health record studies,(84) and combinations of the two.(226)  I summarised the findings 
of these studies in Table 14. 
 
From this review, it is clear that the evidence of gender differences in the rate of onset of 
CVD overall with different specific diseases is limited.  The single study found which 
included both men and women found a higher rate of acute myocardial infarction (AMI) in 
men than in women, with similar rates of stable angina, heart failure, stroke and 
peripheral arterial disease. However, because of the small cohort size, the confidence 
intervals are wide, so differences may have been missed.  The studies of first 
presentations of specific cardiovascular diseases (regardless of previous differing CVD 
disease presentations) appear to show differing rate ratios (women compared to men) 
across a limited range of first presentations, with greatest male excess in rates of 
AMI.(84,144,195,227–229) Single studies also found a male excess in rates of unstable 
angina(144) and heart failure.(196) 
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Table 14 : Age-adjusted rate per 1,000 person years for a range of specific cardiovascular diseases in men and women  
Study Details   Cardiovascular Disease Presentations 
 Age-adjusted rate per 1,000 person years (95% confidence intervals) 
First Author 
& publ. year 
Cohort 
size 
Sex Age at 
entry 
CVD 
Events 
Stable 
Angina 
Unstable 
Angina 
Acute MI Unher’d 
Coronary 
Death 
Vent 
Arrhyth
. 
Heart 
Failure 
Stroke AAA PAD 
Studies of overall onset of  cardiovascular disease with specific presentations 
Baena-Diez 
 2010(221)a 
931 W 35-84 71 2.2 (1.0-3.8)  1.2 (0.3-2.0)   2.7 (1.4-4.0) 3.3 (1.9-4.6)  1.8 (0.7-2.9) 
  M  63 2.4 (0.9-3.9)  6.1 (3.6-8.5)   2.2 (0.9-3.5) 2.0 (0.6-3.4)  1.4 (0.4-2.4) 
Canoui-
Poitrine 
2009(222) 
9,758 M 50-59 292 2.4 (2.0-2.8) 5.0 (4.2-5.7)       
Glynn 
2005 (223) 
18,662 M 40-84 2,250   4.1   2.7   
Ducimetiere  
2001(224) 
7,359 Mb 50-59 200 2.6 (2.1-3.1) 2.9 (2.4-3.5)      
 2,399 Mc  121 5.4 (4.1-6.7) 5.2 (3.9-6.6)      
Dagenais 
 1990(225) 
4,576 M 35-64 603 6.7 4.7 2.2      
Internally age-standardised rate per 1,000 person years unless otherwise specified. A merged cell indicates composite endpoint. CVD indicates cardiovascular 
disease; MI, myocardial infarction; unher’d, unheralded, vent arrhyth, ventricular arrhythmias, cardiac arrest and sudden cardiac death; AAA, Abdominal 
aortic aneurysm; PAD, peripheral arterial disease; M, Men; W, Women; confidence intervals omitted where confidence intervals not specified in paper. a 
standardised to European population   b France  c Ireland. Where no confidence intervals are given, none were reported in the study.  
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Study Details Cardiovascular Disease Presentations 
 Age-adjusted rate per 1,000 person years (95% confidence intervals) 
First Author & publ. 
year 
Cohort 
size 
Sex Age 
at 
entry 
CVD 
Events 
Stable 
Angina 
Unstab
Angina 
Acute MI Unher’d 
Coronary 
Death 
Vent 
Arrhyth. 
Heart Failure Stroke AAA PAD 
Studies of first presentation of specific cardiovascular disease presentations 
Bhattarai 2012(84) 300,020 W 30+ 12,495 0.6d  0.6       
  M   1.0d  1.5       
Merry 2009(144) 21,148 W 20-69 277  1.0 0.9   0.5    
  M  692  2.6 3.5   0.9    
Ishikawa  2008(197)e 12,388 W 20-69 153   0.3    1.4   
  M  229   0.8    2.3   
Silventoinen 
2008(226) 
1,145,758 M 16-25 65,611 
  0.2 
  
 
0.3 
 
 
Arnold  2005(196)f 5,888 W 65+ 1,136   9.4  (8.2-10.6)   18.4 (16.8-20.0) 13.7 (12.3-15.1)   
  M  1,094   19.3 (17.2-21.4)   29.2 (26.7-31.7) 14.7 (12.9-16.5)   
Rothwell  2005(227)g 91,106 W 35-85 348  0.3 0.3  0.3  1.5 0.1 0.2 
  M  437  0.3 0.7  0.3  1.4 0.2 0.2 
Haan 1996(195)h 3032 W 65+ 446 7.1  4.8   10.6 10.1   
  M  447 13.4  6.3   9.1 10.0   
Internally age-standardised rate per 1,000 person years unless otherwise specified. A merged cell indicates composite endpoint. CVD indicates cardiovascular 
disease; MI, myocardial infarction; unher’d, unheralded, vent arrhyth, ventricular arrhythmias, cardiac arrest and sudden cardiac death; AAA, abdominal 
aortic aneurysm; PAD, peripheral arterial disease; M, Men; W, Women; confidence intervals omitted where confidence intervals not specified in paper. d 
incudes unstable angina and acute coronary syndrome; e rate in 2009 standardised to Japanese population of 1985;  f overall crude rates after 10 years of 
follow-up;  g crude rates, AMI = rate for STEMI; PAD = critical limb ischaemia; Vent arrhyth = sudden cardiac death only;   h Age-standardised rate calculated 
from age-specific rates published in paper. Where no confidence intervals are given, none were reported in the study. 
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4. Methods 
The data sources, population, risk factor and endpoint definitions are described in detail 
in Chapters 2 and 3, but are briefly summarised here for ease of reference. Any 
methodological details specific to the set of analyses in this chapter are also noted here.  
4.1. Data sources 
The data sources are described more fully in Chapter 2. In brief, the Cardiovascular 
disease research using Linked Bespoke studies and Electronic Records (CALIBER) e-
health research platform links NHS primary care data from the General Practice Research 
Database (GPRD),(76) to data for acute coronary syndrome (ACS) admissions from the 
Myocardial Ischaemia National Audit Project registry (MINAP),(98) NHS hospital 
admissions data from Hospital Episodes Statistics (HES),(230) and mortality and social 
deprivation data from the Office of National Statistics (ONS).(113,123) Records were 
primarily linked using a pre-defined deterministic linkage algorithm based on NHS 
number, with a small minority linked using a probabilistic method using DOB and 
postcode.(77) A web-based portal documenting the creation of all CALIBER data items, 
from these multiple data sources, is available at www.caliberresearch.org and further 
details on the creation of the CALIBER platform have been published elsewhere.(231) 
4.2.  Population 
The identification of the general cohort is described in detail in Chapter 3. All patients in 
the overall cohort had a valid age and gender recorded. For the main analysis in this 
chapter, I used the overall thesis cohort (overall n=1,758,584; women=900,401; 
men=858,183). For the analysis of effect modification by smoking status, the cohort was 
restricted to those with smoking status recorded at baseline, 82.7% of the overall cohort 
(women=781,634, men=672,001). More detail on patients excluded because of missing 
smoking data is given in Chapter 4.  Because patients were defined as diabetic if there was 
a positive record in GPRD indicating diabetes and defined as non-diabetic if there was no 
such record, there were, by definition, no patients with missing diabetic status. Therefore 
the overall cohort was used for the analysis of effect modification by diabetes.  
4.3. Risk Factors: 
Gender  
Gender was defined as the gender recorded in the GPRD patient data file.  
 
Other risk factors 
Age at entry was defined as the age in years in January of the first year of endpoint follow-
up; more precise estimates of age were not possible as only year of birth is supplied with 
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the data to protect patient identities. Smoking status was defined as the GPRD record of 
smoking status with the last possible date before endpoint follow-up and categorised as 
non-smoker, ex-smoker, or current smoker. If non-smokers had a previous record 
indicating smoking in their entire GPRD history, they were counted as an ex-smoker. 
Diabetes mellitus was defined as a diagnosis of Type 1, Type 2 or unspecified diabetes or 
at least one prescription for insulin or oral hypoglycaemic agent in the two years before 
the start of endpoint follow-up. 
 
Other risk factors were not used in the analyses in this chapter, but baseline values are 
presented to aid with interpretation and understanding of the analyses in this chapter. 
Except for ethnic group, all these risk factors were taken from GPRD data. Social 
deprivation was measured by the index of multiple deprivation (IMD) 2007,(123) 
dividing IMD into quintiles.  Ethnic group was categorised as White, Black, South Asian or 
Other, using self-reported ethnic group recorded in GPRD and HES, with unresolvable 
code conflicts between the two data sources recorded as missing. Systolic blood pressure 
(SBP) was defined as the mean SBP recorded in the two years prior to the start of 
endpoint follow-up. For all remaining risk factors, I used the most recent record from 
GPRD in the two years before the start of endpoint follow-up. Total cholesterol level was 
taken from laboratory results from plasma or serum samples, recorded mmol/L units. 
Lipid-lowering medication at baseline was derived from one or more prescriptions for a 
statin.  Body mass index (BMI) was defined as weight in kilograms over height in metres 
squared. The number of different blood-pressure-lowering medication classes prescribed 
was based on prescriptions categorised into thiazides, potassium-sparing diuretics, beta-
blockers, ace inhibitors and other less common medications. A complete list of drug 
classes and specific preparations is available in Appendix D.  
4.4. Endpoints:  Initial symptomatic presentations of cardiovascular 
disease 
The definition of my primary endpoints are described in more detail in Chapter 3, with 
additional information on the contribution of the different data sources to each endpoint 
described in Chapter 4.  To summarise briefly, my primary endpoints were fatal and non-
fatal presentations of a range of cardiovascular diseases encompassing coronary heart 
disease (stable angina, unstable angina, ST-elevation myocardial infarction (STEMI), non-
ST-elevation myocardial infarction (NSTEMI), myocardial infarction not otherwise 
specified (MI NOS), and coronary death unheralded by prior symptomatic disease), 
stroke, peripheral arterial disease (PAD), abdominal aortic aneurysm (AAA), heart failure, 
and ventricular arrhythmias including cardiac arrest and sudden cardiac death (SCD).  
Given the limited number of myocardial infarctions specified as STEMI or NSTEMI, the 
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main analyses used a composite endpoint of all acute myocardial infarctions (AMI) as an 
endpoint. Secondary analyses with specific myocardial infarction types have also been 
presented. For ease of comparison with previous studies, a composite endpoint of AMI 
and unheralded coronary death has also been included. Diagnoses were identified using 
codes from the International Classification of Diseases 10th Revision (ICD 10)(232) for the 
hospital data (HES) and mortality data (ONS), from Read Codes(78) for primary care data 
(GPRD) and bespoke variables in the ACS registry (MINAP).   
4.5. Statistical analysis 
My primary focus in this chapter was to investigate the heterogeneity of the association of 
gender with a range of initial presentations of CVD.   I first described the gender-specific 
rates, using person-time at risk as the denominator, standardised to the internal age 
structure for the whole cohort, using single years of age at entry, for all initial 
presentations. For each presentation, person years were defined as the time from each 
patient’s study entry until the onset of CVD with one of the initial presentations or until 
the patient left the practice or the date of the last practice data download. Confidence 
intervals for the rates were calculated using the method described by Breslow and 
Day.(233) 
 
I then estimated the rate ratios per 1,000 person years for each presentation, comparing 
men to women, using Poisson regression. I adjusted for age at entry only. To investigate 
whether any of these associations were modified by age, I estimated the gender rate 
ratios for each presentation stratified by 10 year age bands (30-39, 40-49, 50-59, 60-69, 
70-79, 80-89, 90+). The same stratified approach was used to investigate effect 
modification by smoking status (non-smoker, ex-smoker and current smoker) and 
diabetes (non-diabetic, diabetic).  
 
To investigate whether the gender rate ratios declined over time, I divided the cohort into 
three time periods (2001-03, 2004-06, 2007-09) and calculated the rate ratios for each 
time period.  Patient-time was allocated to the relevant decade, so patients could 
contribute time to all three periods, if they entered the study in the first and did not have 
a presentation or leave the cohort until the last.  
 
Continuous variables are shown as the mean (standard deviation) and categorical 
variables shown as frequencies (percentage). All analyses were performed using STATA 
version 12 (StataCorp, 4905 Lakeway Drive, College Station, TX 77845, United States). 
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5. Results 
For the main analyses in this study, there was a cohort of 1,758,584 people, with a total of   
9,397,192 person years of observation time (women: 4,879,503 person years; men: 
4,517,689 person years) and a median of 5.46 person years (Interquartile range (IQR) 
2.08-9.09). 
5.1.  Baseline characteristics 
The mean age in women was 49.0 years (standard deviation (sd) 16.0 years) and 46.6 (sd 
14.0) in men. Further baseline characteristics in five age categories and overall are given 
in Table 15 below. The proportions/means were calculated for patients with complete 
data for each co-variate; where this was less than the complete cohort used in this 
chapter, the number of patients with data for a given co-variate is shown at the base of the 
Table.   
 
The cohort was young, as would be expected in a healthy cohort, with women on average 
five years older than men.  At all ages, men were more likely to be either smokers or ex-
smokers and diabetic. Below the age of 60, men had higher blood pressure than women, 
with blood pressure increasing in women until they had higher mean blood pressure at 
aged 70 and over.  Even at higher ages, women were less likely to be on blood pressure 
medication. Otherwise, women and men had broadly similar characteristics, including 
mean BMI and mean total cholesterol.  
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Table 15- Baseline characteristics of patient cohort, in different age groups at baseline and overall 
 <50 years 50-59 years 60-69 years 70-79 years 80+ years All ages 
 Women Men Women Men Women Men Women Men Women Men Women Men 
Number 519,952 543,331 155,990 153,875 103,675 91,221 49,166 71,816 48,968 20,590 900,401 858,183 
Person-time in years, 
median (IQR) 
4.9 
(1.8-9.1) 
4.6 
(1.8-9.1) 
8.3 
(3.3-9.1) 
7.6 
(3.1-9.1) 
7.7 
(3.0-9.1) 
6.6 
(2.7-9.1) 
6.6 
(2.7-9.1) 
5.5 
(2.3-9.1) 
3.2 
(1.4-6.6) 
3.2 
(1.3-6.4) 
5.7 
(2.1-9.1) 
5.2 
(2.1-9.1) 
Ethnic Group, n (%) 
White 256,576 
(86.7) 
186,488 
(86.0) 
76,690 
(93.4) 
68,100 
(94.0) 
58,249 
(94.4) 
50,007 
(95.0) 
45,174 
(96.6) 
30,747 
(96.1) 
30,163 
(98.3) 
12,665 
(97.8) 
466,852 
(90.3) 
348,007 
(90.0) 
Black 12,778 
(4.3) 
9,077 
(4.2) 
1,403 
(1.7) 
1,098 
(1.5) 
1,069 
(1.7) 
797 
 (1.5) 
437 
 (0.9) 
391 
 (1.2) 
83 
 (0.3) 
71 
 (0.5) 
15,770 
(3.0) 
11,434 
(3.0) 
S. Asian 11,188 
(3.8) 
9,506 
(4.4) 
1,728 
(2.1) 
1,462  
(2.0) 
1,109 
(1.8) 
939  
(1.8) 
537 
(1.1) 
456  
(1.4) 
135  
(0.4) 
90 
 (0.7) 
14,697 
(2.8) 
12,453 
(3.2) 
Deprivation quintile, n (%) 
Least 105,181 
(20.3) 
105,636 
(19.5) 
33,332 
(21.4) 
32,784 
(21.4) 
20,907 
(20.2) 
18,494 
(20.3) 
13,456 
(18.8) 
9,614 
(19.6) 
8,810 
(18.1) 
3,775 
(18.4) 
181,686 
(20.3) 
170,303 
(19.9) 
Most  108,269 
(20.9) 
118,994 
(22) 
25,526 
(16.4) 
26,646 
(17.4) 
17,549 
(17.0) 
15,599 
(17.2) 
13,498 
(18.9) 
9,005 
(18.4) 
9,366 
(19.2) 
3,963 
(19.3) 
174,208 
(19.4) 
174,207 
(20.4) 
Smoking status, n (%) 
Non-smoker 277,628 
(60.1) 
217,280 
(51.5) 
83,425 
(61.1) 
59,223 
(48.9) 
58,442 
(64.7) 
36,466 
(48.9) 
40,272 
(68.6) 
20,511 
(51.8) 
26,292 
(76.7) 
8,120 
(54.5) 
486,059 
(62.2) 
341,600 
(50.8) 
Ex-smoker 62,358 
(13.5) 
55,081 
(13.1) 
20,562 
(15.1) 
24,235 
(20.0) 
15,139 
(16.8) 
19,681 
(26.4) 
10,022 
(17.1) 
11,780 
(29.8) 
5,091 
(14.8) 
4,598 
(30.9) 
113,172 
(14.5) 
115,375 
(17.2) 
Current smoker 121,697 
(26.4) 
149,524 
(35.4) 
32,614 
(23.9) 
37,555 
(31.0) 
16,786 
(18.6) 
18,470 
(24.8) 
8,395 
(14.3) 
7,304 
(18.4) 
2,911 
(8.5) 
2,173 
(14.6) 
182,403 
(23.3) 
215,026 
(32.0) 
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 <50 years 50-59 years 60-69 years 70-79 years 80+ years All ages 
 Women Men Women Men Women Men Women Men Women Men Women Men 
Blood pressure, mean (sd) 
SBP in mmHg 119.3 
(13.7) 
128.5 
(14.4) 
134.0 
(17.2) 
137.4 
(16.7) 
142.3 
(17.3) 
143.0 
(16.8) 
149.8 
(17.4) 
147.7 
(17) 
151.2 
(19.6) 
148.3 
(18.6) 
128.4 
(19.4) 
134.2 
(17.1) 
BP medication classes, n (%) 
None 501,646 
(96.5) 
527,896 
(97.2) 
132,263 
(84.8) 
134,837 
(87.6) 
76,469 
(73.8) 
70,484 
(77.3) 
45,568 
(63.5) 
33,833 
(68.8) 
29,748 
(60.7) 
14,121 
(68.6) 
785,694 
(87.3) 
781,171 
(91.0) 
  1 15,807 
(3.0) 
12,553 
(2.3) 
17,805 
(11.4) 
13,922 
(9) 
18,599 
(17.9) 
14,461 
(15.9) 
17,173 
(23.9) 
10,579 
(21.5) 
13,222 
(27.0) 
4,653 
(22.6) 
82,606 
(9.2) 
56,168 
(6.5) 
  2 2,089 
(0.4) 
2,204 
(0.4) 
4,925 
(3.2) 
3,948 
(2.6) 
6,830 
(6.6) 
4,691 
(5.1) 
7,015 
(9.8) 
3,674 
(7.5) 
4,688 
(9.6) 
1,393 
(6.8) 
25,547 
(2.8) 
15,910 
(1.9) 
  3 410 (0.1) 678 
 (0.1) 
997 
 (0.6) 
1,168 
(0.8) 
1,777 
(1.7) 
1,585 
(1.7) 
2,060 
(2.9) 
1,080 
(2.2) 
1,310 
(2.7) 
423 
(2.1) 
6,554 
(0.7) 
4,934 
(0.6) 
Other risk factors 
Total cholesterol in 
mmol/L, mean (sd) 
5.1  
(1.0) 
5.4 
 (1.2) 
5.7 
 (1.1) 
5.5 
 (1.1) 
5.8 
 (1.2) 
5.4  
(1.1) 
5.8  
(1.2) 
5.2  
(1) 
5.6 
 (1.2) 
5.0 
 (1.0) 
5.5 
 (1.1) 
5.4 
 (1.1) 
On statins, n (%)  2,307 
(0.5) 
5,323 
 (1.0) 
4,616 
(3.4) 
6,207 
(4.0) 
7,132 
(7.9) 
6,185 
(6.8) 
4,803 
(8.2) 
3,045 
(6.2) 
1,454 
(4.2) 
536 
 (2.6) 
20,312 
(2.6) 
21,296 
(2.5) 
Diabetes mellitus, n (%) 6,373 
(1.2) 
7,125 
(1.3) 
3,803 
(2.4) 
5,509 
(3.6) 
4,770 
(4.6) 
5,683 
(6.2) 
4,294 
(6.0) 
3,924 
(8.0) 
2,717 
(5.5) 
1,427 
(6.9) 
21,957 
(2.4) 
23,668 
(2.8) 
BMI in kg/m2, mean 
(sd) 
25.9 
(5.9) 
26.6 
 (4.7) 
27.2  
(5.8) 
27.6  
(4.7) 
27.4  
(5.6) 
27.3  
(4.4) 
26.7  
(5.3) 
26.5  
(4.1) 
24.7  
(4.8) 
25.1  
(3.9) 
26.3 
 (5.8) 
26.8  
(4.6) 
Overall N= 1,758,584.  N for variables with missing data: Ethnic group n= 904,054; IMD n= 1,751,173; smoking n=1,453,635; SBP n= 961,350; total cholesterol 
n= 203,372; BMI n= 680,753.  IQR indicates inter-quartile range; SBP, systolic blood pressure; BP, blood pressure; BMI, body mass index. 
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5.2. Rates of initial presentations of cardiovascular disease  
There were a total of 77,957 diagnoses, 41,401 in men and 36,556 in women. The number 
of each presentation is shown in Table 16 below. The age-standardised rates of initial 
presentation across the range of endpoints are shown in Table 16 below. Across all 
presentations, men had higher age-standardised rates than women.  Amongst the 
cardiovascular presentations in the head, heart, abdomen and peripheral arterial beds, 
stroke was the most common presentation in women, followed by AMI combined with 
unheralded coronary death, while in men the rate of AMI was higher than that of stroke.   
Amongst the cardiac presentations, stable angina was the most common presentation in 
both men and women, while the second most common presentation in women was heart 
failure and AMI in men. Unstable angina was the least common initial cardiac 
presentation for both men and women.  The greatest gender differences were in the rate 
of presentation with AMI (and consequently AMI with unheralded coronary death), with 
men having more than double the rate of women.  There is almost no difference in women 
between the rates of initial presentation with stroke and with stable angina, while in men 
the rate of presentation with AMI and stable angina are both significantly higher than 
initial presentation with stroke. The least common presentation in women was AAA, at 
approximately 10% of the rate of stable angina, the most common presentation. In men, 
the least common presentation was unstable angina, approximately 15% of the rate of 
stable angina. 
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Table 16: Age-standardised rates per 1,000 person years with 99% confidence 
intervals across wide range of initial presentations of cardiovascular disease 
Initial Presentation Women  Men 
 n Rate (99% CI) n Rate (99% CI) 
CVD presentations     
Stroke 6,988 1.71 (1.69-1.73) 5,489 1.93 (1.90-1.96) 
Acute myocardial infarct. & 
unheralded coronary death  
5,458 1.27 (1.25-1.29) 9,102 2.80 (2.77-2.84) 
Peripheral arterial disease 3,855 0.81 (0.79-0.83) 4,455 1.25 (1.23-1.28) 
Abdominal aortic aneurysm 606 0.13 (0.13-0.14) 1,592 0.52 (0.50-0.53) 
Cardiac presentations     
Stable angina 8,695 1.77 (1.74-1.79) 8,846 2.35 (2.31-2.38) 
Heart failure 5,485 1.31 (1.29-1.33) 4,460 1.69 (1.66-1.72) 
Acute myocardial infarct. (all) 3,853 0.85 (0.83-0.86) 6,835 1.96 (1.93-1.99) 
  ST-elevation myocardial infarct. 219 0.05 (0.05-0.05) 503 0.14 (0.13-0.15) 
  Non ST-elevation myocardial infarct. 428 0.09 (0.09-0.10) 684 0.19 (0.18-0.20) 
  Myocardial infarction NOS 3,206 0.70 (0.69-0.72) 5,648 1.63 (1.60-1.66) 
Coronary heart disease NOS 2,888 0.59 (0.58-0.61) 3,832 1.03 (1.01-1.05) 
Unheralded coronary death 1,605 0.42 (0.41-0.44) 2,267 0.84 (0.82-0.86) 
Ventricular arrhythmias, cardiac 
arrest   & sudden cardiac death 
1,357 0.30 (0.28-0.31) 2,146 0.58 (0.57-0.60) 
Unstable angina 1,224 0.25 (0.24-0.26) 1,479 0.39 (0.38-0.40) 
Gender-specific rates per 1,000 person years at risk, standardised to internal age structure 
for men and women combined, using single years of age at entry. Rates ordered from highest 
to lowest in within CVD presentations and within specific cardiac presentations using the 
rates in women. CVD indicates cardiovascular disease; NOS, not otherwise specified. 
 
5.3. Rate ratios of initial presentations of cardiovascular disease 
The gender rate ratios (RR) for each CVD presentation, comparing women to men, are 
presented in Figure 10 below.  All RRs show a significant male excess across the range of 
CVD presentations. The highest RR was for AAA, while the lowest was for stroke, with 
considerably heterogeneity in effect of gender, with a rate ratio for AAA almost 4 times 
the rate ratio for stroke.  Within the cardiac presentations, acute MI had almost twice the 
RR as the chronic presentations of heart failure and stable angina. 
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Figure 10: Age-adjusted gender rate ratios (men compared to women) for initial presentation of a range of cardiovascular disease 
presentations 
 
N=1,758,584.  CI indicates confidence interval; MI, myocardial infarction; NOS, not otherwise specified; CVD, cardiovascular disease; RR, gender rate ratios; 
Vent arrhyth, ventricular arrhythmias. 
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5.4. Effect modification of gender rate ratios by age 
The age-stratified gender rate ratios for CVD presentations are shown in Figure 11 below, 
while those for the cardiac presentations are shown in Figure 12. Additional results for 
the myocardial infarction types are shown in Appendix F.  The extent of effect 
modification by age varied by initial presentation. There was no effect modification by age 
for stable angina. There was a U-shaped relationship between age and gender for stroke, 
PAD, the ventricular arrhythmias and possibly for CHD NOS, with minimal gender 
differences in the rate of initial presentation in the youngest age group, increasing male 
excess through middle age and declining gender differences in the older age groups. For 
the remainder of the cardiac presentations (heart failure, AMI including all subtypes, 
unheralded coronary death and to a lesser extent unstable angina), the male excess was 
greatest in the youngest age groups and declined from 60 and over, if not at younger ages. 
The relationship between age, gender and initial presentation with AAA did not fit clearly 
into any of these patterns but bore similarities to the U-shaped pattern, with minimal 
gender differences in the youngest age groups and the male excess increasing with 
increasing age; however, AAA showed no decline in the male excess in the oldest age 
groups. However, the number of AAA presentations, especially at the younger ages, was 
very small.  
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Figure 11: Gender rate ratios (men compared to women) for initial presentation of 
cardiovascular disease, stratified by age group 
 
N=1,758,584; CI indicates confidence interval; MI, myocardial infarction.
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Figure 12: Gender rate ratios (men compared to women) for initial presentation of 
specific cardiac presentations, stratified by age group 
 
CI indicates confidence interval; NOS, not otherwise specified; Vent arrhyth, ventricular 
arrhythmias. 
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5.5. Effect modification of gender rate ratios by smoking 
In a subgroup of patients with smoking status recorded (n=1,453,635, 53.8% women), the 
effect modification of smoking on age-adjusted gender rate ratios for initial CVD 
presentations was calculated.  These rate ratios, stratified by smoking status, are shown 
in Figure 13 and Figure 14 below. The association between gender and initial 
presentation of CVDs did not show a consistent pattern across the range of cardiovascular 
diseases. Amongst current smokers, the male excess was considerably reduced for AAA, 
and, to a lesser extent, for the ventricular arrhythmias including cardiac arrest and 
sudden cardiac death. Amongst ex-smokers, there was a reduction in the male excess in 
heart failure, and the ventricular arrhythmias, although these effects are weak.  Amongst 
non-smokers, the male excess was reduced in peripheral arterial disease, again a 
relatively weak effect. Amongst the MI subtypes, the only presentation where an effect 
modification was evident was for nSTEMI, with a reduction in the male excess for both 
current and ex-smokers. (See Appendix F for results for the myocardial infarction types.) 
For the remainder of the presentations, there appeared to be minimal effect modification 
of the effect of gender by smoking.  
 
 
   
125 
 
Figure 13: Gender rate ratios (men compared to women) for initial presentation of cardiovascular disease, stratified by smoking status 
 
N=1,453,635.  CI indicates confidence interval; MI, myocardial infarction. 
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Figure 14: Gender rate ratios (men compared to women) for initial presentation of specific cardiac presentations, stratified by smoking status 
 
N=1,453,635.  CI indicates confidence interval; NOS, not otherwise specified; Vent arrhyth, ventricular arrhythmias. 
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5.6. Effect modification of gender rate ratios by diabetes 
The effect modification of diabetic status on age-adjusted gender rate ratios for initial 
CVD presentations was calculated.  Except for AAA, the male excess was reduced for all 
presentations. The strongest effect modification was for AMI and the composite AMI and 
unheralded coronary death, with diabetic patients having a two thirds reduction in the 
male excess compared to non-diabetic patients. The other acute coronary presentations 
(unstable angina and unheralded coronary death) also showed similar sizeable reductions 
in gender differences. For stroke and heart failure, although the effect modification was 
smaller, the gender difference was eliminated amongst diabetics.  (See Figure 15 and 
Figure 16 below. Additional results for MI subtypes in Appendix F.) 
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Figure 15: Gender rate ratios (men compared to women) for initial presentation of cardiovascular disease, stratified by diabetic status 
 
 
 
N=1,758,584.  CI indicates confidence interval; MI, myocardial infarction. 
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Figure 16: Gender rate ratios (men compared to women) for initial presentation of cardiac presentations, stratified by diabetic status 
 
N=1,758,584. CI indicates confidence interval; NOS, not otherwise specified; Vent arrhyth, ventricular arrhythmias. 
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5.7. Time trends 
For AMI plus unheralded coronary death, stroke, AAA and PAD, there were no significant 
trends in the rate ratios (men compared to women) over the three time periods between 
2001 and 2009. (See Table 17 below.) However, amongst the cardiac presentations, the 
RR for stable angina and CHD NOS increased over the time period, with non-overlapping 
99% confidence intervals. There was a smaller increase in CVD onset with heart failure, 
while there was a slight decrease in presentation of CVD with AMI, although with 
overlapping 99% confidence intervals. To investigate the possible reasons for this, the 
gender-specific age-adjusted rates for all presentations were calculated for each of the 
three time periods and presented in Figure 17 below.  
 
For AMI and unheralded coronary death, men showed a clear decrease in incident rates 
between 2001-03 and 2007-09 while the rates for women remained largely unchanged.  
For both stroke and heart failure, both men and women showed a reduction between 
2001-03 and 2004-06 which then continued in men but halted or reversed in women. 
Men appeared to have a greater reduction in the rate of stable angina than women 
(though the difference is small). Both men and women showed similar small increases in 
the rates of unstable angina and the ventricular arrhythmias. The rates of CHD NOS did 
not exhibit any clear trend, while the rates for AAA remained unchanged in both men and 
women throughout this period. 
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Table 17: Age-adjusted rate ratio (men compared to women) for range of initial 
presentations of cardiovascular disease for 2001-3, 2004-6, and 2007-9 
 Rate ratio of men compared to women 
 (99% confidence interval) 
Presentation 2001-3 2004-6 2007-9 
CVD presentations    
Acute MI & unheralded coronary death 2.57 (2.42, 2.73) 2.55 (2.41, 2.71) 2.41 (2.27, 2.55) 
Stroke 1.31 (1.23, 1.39) 1.33 (1.25, 1.42) 1.27 (1.19, 1.35) 
Abdominal aortic aneurysm 5.09 (4.25, 6.11) 4.29 (3.65, 5.05) 4.38 (3.75, 5.12) 
Peripheral arterial disease 1.74 (1.61, 1.87) 1.73 (1.60, 1.87) 1.69 (1.56, 1.82) 
Other deaths 1.36 (1.31, 1.41) 1.34 (1.29, 1.38) 1.28 (1.24, 1.32) 
Specific cardiac presentations    
Stable angina 1.35 (1.29, 1.41) 1.46 (1.39, 1.54) 1.55 (1.46, 1.64) 
Unstable angina 1.76 (1.53, 2.03) 1.68 (1.47, 1.92) 1.56 (1.38, 1.77) 
Coronary heart disease NOS 1.68 (1.54, 1.84) 1.96 (1.79, 2.14) 2.04 (1.88, 2.21) 
Acute myocardial infarction 2.73 (2.54, 2.93) 2.62 (2.45, 2.81) 2.43 (2.27, 2.60) 
Heart failure 1.39 (1.30, 1.49) 1.42 (1.32, 1.52) 1.48 (1.37, 1.59) 
Vent arrhyth, cardiac arrest & sudden 
cardiac death 
2.39 (2.09, 2.73) 2.20 (1.95, 2.48) 2.15 (1.93, 2.40) 
Unheralded coronary death 2.25 (2.01, 2.51) 2.40 (2.15, 2.69) 2.40 (2.14, 2.69) 
CVD indicates cardiovascular disease; MI, myocardial infarction; NOS, not otherwise 
specified; Vent arrhyth, ventricular arrhythmia.  
 
   
132 
 
 
Figure 17: Age-standardised rates per 1,000 person years for initial CVD presentations in men and women for three time periods 
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NOS indicates not otherwise specified; MI, myocardial infarctionvent, ventricular.
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6. Conclusions 
The incidence rate of atherosclerotic cardiovascular disease in men exceeded that of 
women for every initial presentation. However, the extent of the male excess varied 
considerably.  In each section below, I summarise my findings for each objective. I then 
describe the strengths and limitations of this set of analyses. The implications for clinical 
care, public health practice, and research of my findings from these and my other analyses 
are discussed in Chapter 8 – Conclusions and Recommendations.  
6.1. Summary of existing literature (Objective 1) 
Five studies which described the gender-specific rate of onset of CVD across several 
disease presentations were found in the literature search, only one of these included both 
men and women. This study identified a clear male excess for AMI but other no significant 
gender differences in the rate of initial presentation with other presentations;(221) 
however, given the small numbers and wide confidence intervals, the accuracy of the 
effect estimates and hence any gender ratio must be questioned.  Studies describing the 
rate of first presentation of specific diseases, which ignored any earlier presentation with 
other cardiovascular diseases presentations, found a clear male excess in rates of AMI, 
heart failure and unstable angina.  
6.2. Differences between men and women in rates of initial 
presentations of cardiovascular disease (Objective 2) 
6.2.1. Gender-specific rates of initial presentations 
Women had consistently lower age-standardised incidence rates per 1,000 person years 
of all the specific CVD presentations, but there was considerable heterogeneity in the 
rates across presentations both within and between genders.  The greatest gender 
difference was in the rate of AMI where men had almost double the rate in women; stable 
angina was the most common cardiac presentation in men followed by AMI while stable 
angina and stroke the most common presentations in women. In both men and women, 
the rate of the most common presentation was approximately 10 times the rate in the 
least common.  
 
It is not clear how meaningful it is to compare these results to the effect sizes found to the 
existing literature because existing studies have investigated older patients, collected data 
in earlier time periods than the current study, used different definitions of endpoints, or, 
in the limited initial presentation studies, employed fewer endpoints, all of which would 
affect the size of the rates.  The male-only studies of initial presentation of specific CVD 
presentations found consistently higher rates than the present analyses but used no more 
than three endpoints.(222–225) If additional presentations had been included, the rates 
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of initial presentation would have been reduced. The one study of initial presentation 
which included both men and women, as well as covering a similar time period, number 
of presentations and age range as the present analyses, found a substantially higher rate 
of acute MI in men than the current analyses; all other rates were potentially consistent 
with the current analyses given the wide confidence intervals.(221)  Out of all the first 
presentation studies which include multiple endpoints, the OXVASC study by Rothwell et 
al.(227) is the most similar to the current analyses, covering a similar age group, time 
period and wide range of specific CVD presentations. They found substantially lower rates 
of AMI in both genders and lower rate of stroke and AAA in men.  The reasons for these 
discrepancies are not clear, although may be related to different cohort populations – at 
least amongst the patients with an ethnic group recorded, there was a higher proportion 
of South Asian and Black patients in the current analyses compared to the OXVASC cohort.  
 
6.2.2. Gender rate ratios for initial presentation of cardiovascular 
disease 
The gender rate ratios (RRs) varied considerably between the different CVD initial 
presentations. Onset of symptomatic CVD with the most common presentations (heart 
failure, stroke, stable angina) show only a modest male preponderance, while other 
presentations showed either a high (PAD, MI, UCD) or extremely high male 
preponderance (AAA). The highest RR was for abdominal aortic aneurysm, while the 
lowest RR was for stroke.  The RR for the coronary disease presentations increased in a 
linear fashion from the chronic (stable angina) to the most acute (AMI & UCD), with the 
RR for heart failure similar to that of stable angina and the RR of the arrhythmias similar 
to that of AMI.  
 
No other study has published gender rate ratios with confidence intervals for the onset of 
CVD with the current wide range of initial presentations. These results show in a single 
study the considerable variation in the association of gender with the different 
presentations which signal the onset of symptomatic CVD.  
 
6.3. Modification by gender rate ratios by age, smoking or diabetic 
status (Objective 3) 
I found clear evidence of modification of the effect of gender by age, diabetic status, and to 
a lesser extent smoking. The effect of age varied by presentation with the most common 
pattern being one of lower gender differences at younger ages, increasing in middle age 
and then declining in older age. However, for the more acute coronary presentations, 
particularly AMI, gender differences were high at the youngest age and then declined 
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thereafter. Studies of gender differences in incidence of AMI or composite CHD have 
found age-related patterns similar to the current analyses,(207) but lack information on 
the age-related patterns of onset of CVD across the wide range of presentations used here. 
These findings are needed to combat the conventional wisdom, perpetuated even in a 
paper calling for improved research on gender differences in cardiovascular disease, that 
women develop CVD between 7 and 10 years later than men.(234) General practitioners 
may discount symptoms and signs of the onset of CVD if women are perceived to be too 
young to be developing the disease.  
 
Diabetes reduced substantially the male excess for most initial presentations of CVD, with 
the exception of AAA. Diabetes appears to have either no effect(235) or possibly a 
protective effect on AAA(236), so it is perhaps not surprising that there is no effect 
modification on the association of gender with AAA. The strongest effect modification was 
on presentation with AMI, which is in keeping with findings from studies including AMI as 
an endpoint.(14,207,237) The current analyses extend that finding to other acute 
coronary presentations (unstable angina, unheralded coronary death and possibly the 
ventricular arrhythmias).  Additionally, the current analyses indicate that diabetes 
essentially eliminates the already small gender differences in presentation with stroke 
and heart failure, in keeping with previous studies on heart failure(238) and 
stroke(239,240). 
 
Smoking status modified the effect of gender in relatively few presentations compared to 
age and diabetes. The strongest effect modification was for AAA, where the male excess 
was considerably reduced amongst current smokers and to a lesser extent amongst ex-
smokers.  A similar, but weaker, pattern was seen in initial presentation with ventricular 
arrhythmias.  The gender difference in PAD was reduced amongst non-smokers.  The links 
with AAA of both smoking and male gender are well-established(235), but no studies 
which identified an effect modification of smoking on the effect of gender have been 
identified. This paucity of research on women and AAA has been commented on 
previously.(241) This observed reduction in the gender risk ratio amongst both current 
smokers and ex-smokers supports the idea of risk stratification being a useful adjunct to 
any screening programmes for AAA(242) which is currently restricted in men in the 
UK.(243)  The reduction in male risk for PAD for non-smokers seems at odds with the 
limited studies which suggest either a greater sensitivity to smoking in women compared 
to men or no gender difference,(15,59) but this may be because previous studies have 
included asymptomatic PAD, unlike the current set of analyses. These differences to 
existing literature may be a consequence of focussing on onset of cardiovascular disease 
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rather than any disease presentation, but could also be due to the lack of large sufficiently 
powered studies incorporating both men and women.  
 
6.4. Trends in gender rate ratios (Objective 4) 
I found clear evidence of a reduction over time in gender rate ratios for the majority of the 
cardiac presentations, but not for the other CVD presentations. In a post-hoc analysis of 
age-standardised rates for three time periods, the rate ratio of AMI and UCD decreased in 
men but remained unchanged in women. HF rates also declined across all three time 
periods in men but plateaued in women from 2004-2006. The rate of arrhythmias 
appears to be increasing for both men and women, while the rate of stable angina 
declined in both men and women, with a possible slowing of reduction in women in 2007-
09.  These findings suggest that the recent gains made in reducing coronary heart disease 
are not shared equally between men and women, particularly for the more acute 
presentations.  
 
These findings are consistent with at least one other study on trends with multiple 
presentations in a single study. An Australian study of trends in hospitalisations between 
2000 to 2007 found a reduction in the rate of incident coronary heart disease 
hospitalisations in men but not in women and similar decline in both women and men in 
peripheral arterial disease. Unlike my findings, a greater reduction in the rates of 
admissions for cerebrovascular presentations was found in women.(24)  A study using 
primary care data between 2000 to 2009 found an increase in the rate ratio (women to 
men) for stable angina and no change for AMI, but these differences could be due to single 
source of data and different case definitions.(84) Studies of trends with single endpoints 
found similar patterns as those in the current study for AMI(245–247) , possibly for heart 
failure(248), stroke(249) and AAA (250,251) and different trends for peripheral arterial 
disease.(252) No studies on trends of stable angina or the arrhythmias covering the same 
or similar period could be found.  
6.5. Strengths 
One of the main strengths of this study, in common with other analyses, is the size of the 
cohort which is sufficiently large to allow the detailed examination of effect modification 
of the association of gender by age, smoking status and diabetes. In addition to replicating 
findings from studies which focus exclusively on individual endpoints like AMI, this study 
is able to extend findings on effect modification to less frequently studies presentation 
such as unstable angina and heart failure. The size of the cohort also allows detailed study 
of gender differences in relatively rare presentations such as AAA, leading to potentially 
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new insights on the effect modification of smoking on the association of gender with this 
presentation.  
6.6. Limitations 
One of the limitations of the current analyses is that no account was taken of other 
possible co-variates, which could affect the strength of the association of gender with the 
range of initial presentations. In addition to the common other risk factors such as lipids 
or BMI, no adjustment was made for prescription of either oral contraceptives or 
hormone replacement therapy (HRT) in women, both of which can increase the risk of at 
least some of these cardiovascular disease presentations.(253,254) This omission is 
potentially less serious for oral contraceptives: While HRT has been shown to have a 
significant impact on cardiovascular events, given the relatively low increase in risk and 
the relatively low rate of events in young women taking oral contraceptives, the effect of 
not adjusting for oral contraceptive use is likely to be minimal.  Another limitation is the 
use of diagnoses to identify onset of symptomatic CVD, where cardiovascular disease can 
be under-diagnosed in women.  For example, angina has been found to be under-
diagnosed in women who have chest pain similar to men,(255,256) as well as in women 
with differing angiographic results but similar prognosis as men.(257,258)  
 
As mentioned above, the implications of these findings for clinical practice, public health 
and research are further explored in Chapter 8 - Conclusions and Recommendations.  
 
7. Summary of Findings 
 Evidence of gender differences in the rates of initial presentation of CVD across a wide 
range of presentations has been lacking. 
 Common CVDs (heart failure, stroke, stable angina) show only a modest male 
preponderance. 
 There was marked heterogeneity in gender effect, with an almost fourfold difference in the 
male excess in the gender rate ratios, highest for AAA and lowest for stroke. 
 There is clear effect modification with age and diabetes across a wide range of 
presentations but the modification of effect of gender by smoking status was limited 
mainly to AAA.  
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Association of smoking with initial presentation of 
cardiovascular disease phenotypes 
1. Abstract 
Background: It is unknown whether smoking status is differentially associated with the 
onset of cardiovascular disease (CVD) across a wide range of presentations, covering the 
cerebral, coronary, abdominal and peripheral arterial circulations. 
Objectives: To determine whether current smokers and ex-smokers differ in their 
associations with a wide range of initial CVD presentations compared to non-smokers, 
and whether those associations are modified by gender. 
Design: Cohort study using data from the CALIBER research platform linking four data 
sources (primary care, disease registry, hospitalisation and mortality records) for 
1,453,635 patients free from symptomatic CVD with smoking status recorded. 
Main outcome measures: Initial presentation of CVD with stable angina, unstable 
angina, myocardial infarction (MI), heart failure, ventricular arrhythmias, coronary death, 
stroke, abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). 
Results: The association of being a current smoker compared to being a non-smoker  
varied considerably across all CVD presentations, ranging from no association with 
arrhythmia (age-adjusted hazard ratio (HR) 1.01 (0.90-1.13) to a strong association with 
AAA (HR 4.63 (4.08-5.25)). For all presentations, the association with being an ex-smoker 
was considerably smaller and the heterogeneity of effect was considerably reduced, but 
particularly amongst the cardiac presentations. For most presentations, women who were 
current smokers had similar risks to men, with the exception of modestly increased 
association with acute MI (women:  HR 2.59 (2.37-2.83); men:  2.20 (2.05-2.37)) and 
markedly increased association with AAA (women:  HR 7.12 (5.74-8.81); men: 3.77 (3.24-
4.39)).  Similar effect estimates were found with multivariable models, and for models 
with an extended cohort of patients with missing co-variate data.  
Conclusions:  Strongly heterogeneous effects of current smoking on initial CVD 
presentations were found. However, the heterogeneity of effect was much less 
pronounced in ex-smokers. Gender differences were limited to AAA and acute MI 
presentations in current smokers compared to non-smokers.  
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2. Introduction 
The previous chapter described the first substantive set of analyses for this thesis 
examining the association of gender with the range of initial presentations of 
cardiovascular disease. In this chapter, I investigate the association of smoking with these 
presentations.  
 
The effect of smoking on individual cardiovascular diseases is well-documented. Current 
smokers have up to a threefold risk for acute myocardial infarction (AMI) compared to 
non-smokers, with substantial attenuation of the risk in ex-smokers particularly in 
women.(205,259) Being a current smoker increases the risk of a stroke by 50%, with ex-
smokers having an attenuated but still increased risk, compared to non-smokers.(39)  The 
link between smoking and peripheral arterial disease (PAD), including abdominal aortic 
aneurysm (AAA), is similarly well-established, with levels of risk similar to AMI.(242,260) 
Although smoking increases the risk for ventricular arrhythmias, cardiac arrest and 
sudden cardiac death, the level of risk is less clear.(261–264) While the link between 
smoking and these common cardiovascular diseases (CVD) studied largely in isolation 
from each other have been robustly demonstrated, existing research disregards the 
possibly earlier onset of CVD with other disease presentations. This approach does not 
give due regard to more generalised nature of atherosclerotic disease, with common risk 
factors potentially affecting the cerebral, coronary, abdominal and peripheral arterial 
beds. As with the previous chapter on gender, the principal aim of this chapter’s analyses is 
to investigate the association of smoking with the onset of CVD, looking at the first 
presentation of any disease across the entire range of CVD presentations.  
 
If the onset of  CVD with common cardiovascular diseases differ in their association with 
smoking, this might lead to important insights into aetiology, including the design and 
interpretation of studies which evaluate the interplay between cardiovascular diseases 
and genetic variants.(265) Smoking has been shown to have both acute effects such as 
increasing blood pressure, heart rate, levels of carboxyhaemoglobin, and pro-thrombotic 
states, as well as chronic effects such as increasing the level of low-density lipoprotein 
cholesterol, fibrinogen, and platelet aggregation, so differing effects on distinct 
cardiovascular presentations can be expected.(266,267) Chronic effects might be 
expected to persist, even after quitting smoking, so I will investigate the effect of being an 
ex-smoker both by comparing ex-smokers to non-smokers in the main analyses and by 
further analyses of the sub-group of patients for whom more detailed information on 
quitting is available.  Additionally, there is evidence to suggest that smoking may pose a 
higher risk of several cardiovascular diseases in women compared to men, at least for 
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composite endpoints,(2,39,268) raising the question of whether such gender differences 
exist with specific initial presentations of CVD.   
 
My objectives for the analyses in this chapter are to: 
1. Summarise the existing literature on the association of current and ex-smoking 
compared to non-smoking with initial presentation of CVD across a wide range of 
presentations;  
2. Investigate whether, compared to non-smokers, being a current smoker or an ex-
smoker differ in the associations with these presentations;  
3. Determine whether any such effects are modified by gender; and  
4. Determine the effect of smoking cessation compared to continued smoking on 
initial cardiovascular disease presentations.  
3. Literature Review 
3.1. Search Strategy 
The aim of my literature search was to find cohort studies on initial presentation of CVD 
with specific presentations in populations without clinically manifest cardiovascular 
disease with at least two endpoints which reported gender-specific associations with 
smoking on those endpoints. I used both a specific strategy focussing on the association of 
smoking with initial CVD presentation for different specific presentations and a sensitive 
search focussing on observational studies on the association of smoking with 
cardiovascular disease in general, when my specific search found few papers. The search 
terms I used are reproduced in Table 18. I limited both searches to papers in English with 
the full text available, published since 1992 cited in the Medline database. For the specific 
search, I searched on pairs of specific endpoint groups in turn to make the process of 
sifting through papers manageable. I supplemented the studies found through the formal 
search strategy by searching reference lists of relevant papers, using forward citation 
searches of earlier relevant papers and asking other researchers for the details of any 
papers of which they were aware. Given the paucity of studies found, relevant studies 
published before 1992 which were identified through searching references were also 
included. Studies which have focussed exclusively on mortality endpoints, such as the 
recent Million women Study, (269) or specific endpoints, such as the recent systematic 
review and meta-analysis on the risk of smoking for CHD,(2) have not been included. 
3.2.  Findings from literature review 
Five studies which investigated the association between smoking and initial presentation 
of CVD with at least two endpoints were found, only one of which included 
women.(25,222,223,225,264,270) These studies have been summarised in Table 19; 
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additional studies where the endpoints were first presentation of a specific 
cardiovascular disease CVD, rather than initial presentation of CVD across any disease 
type, and which reported multiple endpoints in the same patient population have also 
been included. (15,271,272)  
Table 18: Search strategy used to identify studies on association of smoking with 
initial presentation of CVD 
Concepts Boolean 
operator 
Terms used 
Specific search 
Smoking  smoking OR cigarettes OR tobacco OR "Smoking/adverse 
effects"[MeSH] 
Endpoints AND "myocardial infarction" OR STEMI OR nSTEMI OR "acute 
coronary syndrome"  OR “angina” OR “coronary insufficiency” 
or “acute coronary syndrome” OR “heart attack” 
 AND “abdominal aortic aneurysm” OR “peripheral arterial disease” 
OR “peripheral vascular disease” OR PAD OR “intermittent 
claudication” OR “peripheral ischaemia”  
 AND Stroke OR “cerebrovascular disease” OR “cerebrovascular 
accident” 
 AND (ventricu* AND arrhythm*) OR “cardiac arrest” OR “sudden 
cardiac death”  
 AND “heart failure” 
Gender AND “sex factor”[MESH] OR (gender OR sex) OR (women AND 
men) OR (male AND female) 
Initial presentation  ((first OR initial) AND (presentation OR manifestation) ) OR 
(onset) 
Sensitive search 
Smoking  smoking OR cigarettes OR tobacco OR "Smoking/adverse 
effects"[MeSH] 
Endpoints AND “coronary disease” OR “CHD” OR “IHD”  OR  ((“ischemic” OR 
“ischaemic”) AND “heart disease”) OR “cerebrovascular 
disease” OR “peripheral arterial disease” OR “cardiovascular 
disease” OR “CVD”  
Gender AND “sex factor”[MESH] OR (gender OR sex) OR (women OR men) 
OR (male OR female) 
Cohort  AND “observational study” OR “cohort studies”[MESH] 
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None of the studies were conducted solely with electronic health records (EHRs), like the 
current analyses, although two used EHRs for endpoint identification.(15,270) 
Constituent studies of the one systematic review and meta-analysis.(272) were not 
included in the table. No studies were found which included amongst multiple endpoints 
ventricular arrhythmias, cardiac arrest, sudden cardiac death, heart failure, AAA, or PAD. 
In general the studies found current smoking to be a greater hazard for coronary heart 
disease presentations than for stroke, with a dose-response found in those studies which 
measured the level of smoking.(25) The one study of first presentation with CHD or 
stroke which included both  genders found women to be at increased risk of CHD but not 
stroke compared to men only amongst participants smoking the highest number of 
cigarettes per day.(272) 
 
There were several limitations to the initial presentation studies. First, they included a 
narrow range (typically 2 or 3) of endpoints rather than examining a wide range of 
common cardiovascular disease presentations.  Second, most were too small (typically 
analysing between 500-1,000 events) to assess reliably differences amongst multiple 
endpoints. Third, only one included women.(25)  The ‘first presentation’ studies lacked 
temporal resolution, having limited ability to distinguish the association between 
smoking and initial or subsequent presentations, an important distinction in 
understanding how cardiovascular disease develops.  
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Table 19: Cohort studies comparing risk of smoking between difference cardiovascular disease presentations  
Study Details Exposure Cardiovascular Presentation:  
Hazard Ratio of smokers compared to non-smokers (95% CI) 
First Author 
& year of publication 
Data years 
& 
country C
o
h
o
rt
 
si
ze
 
E
v
e
n
ts
 
A
g
e
 
G
ro
u
p
 
G
e
n
d
e
r Smoking 
status 
Stable 
Angina 
Unstable 
Angina 
Acute MI Unheralded 
Coronary 
Death 
Stroke 
Studies of overall onset of  cardiovascular disease with specific presentations      
Canoui-Poitrine 2009(222) 1991-1998 France 9,758 292 50-59 M Current 1.3 (0.8-2.0) 2.1 (1.4-3.0)    
Lawlor 2008(270) 1992-2001 S. Korea 648,346  30-64 M Ex   1.3 (1.2-1.5)  1.0 (0.9-1.1) 
      <10   2.0 (1.7-2.3)  1.4 (1.3-1.6) 
      10-19   2.3 (2.0-2.6)  1.6 (1.5-1.8) 
      20+   2.9 (2.6-3.3)  1.7 (1.6-1.9) 
Glynn 2005(223) 1982-2003 USA  22,071 1,348 40-84 M Ex   1.1 (1.0-1.3)  1.1 (0.9-1.3) 
      Current    1.8 (1.6-2.2)  1.83 (1.5-2.2) 
Dagenais 1990(225)a 1973-1986 Canada 4,576 603 35-64 M Ex 1.4 (0.9-2.2  0.5 (0.3-1.0) 1.1 (04-3.3)  
      Cigars/pipes 1.2 (0.6-2.4)  1.2 (0.6-2.5) 2.4 (0.7-7.8) 
      1-20  1.3 (0.8-2.0)  1.4 (0.8-2.2) 2.3 (0.9-6.0)  
      >20 1.7 (1.1-2.6)  1.6 (1.0-2.5) 3.4 (1.3-8.5) 
Stokes 1987(25)b  1948-1978 USA 5,209 -- <65 W Current 1.09  1.04 1.44 
     M  0.86  1.57 1.36  
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Study Details Exposure Cardiovascular Presentation:  
Hazard Ratio of smokers compared to non-smokers (95% CI) 
First Author 
& year of publication 
Data years 
& 
country C
o
h
o
rt
 
si
ze
 
E
v
e
n
ts
 
A
g
e
 
G
ro
u
p
 
G
e
n
d
e
r Smoking 
status 
Stable 
Angina 
Unstable 
Angina 
Acute MI Unheralded 
Coronary 
Death 
Stroke 
Studies of first presentation of specific cardiovascular disease presentations 
Merry 2011(15) 1987-2003 
Netherlands 
19,096 694 
20-59 M Ex 
 1.4 (1.0-1.9) 1.3 (0.9-1.8)  
 
      Current  1.6 (1.2-2.3) 3.1 (2.3-4.1)   
Kondo 2011(271) 2001-2008 
Japan 
25,464 110 
20-61  M Ex-smoker 
  0.8 (0.2-4.5)  
1.0 (0.4-2.4) 
      Light   6.8 (1.7-33.3)  0.7 (0.1-2.6) 
      Moderate   3.9 (1.3-17.0  2.5 (1.3-5.3) 
      Heavy   5.8 (1.8-25.9)  2.2 (1.0-5.2) 
Woodward 2005(272) 1966-1999 
Asia Pacific Region 
562,338 12,462 
>=20 M Current  
  1.6 (1.4-1.7) 
1.3 (1.2-1.4) 
     W    1.7 (1.5-2.0) 1.4 (1.3-1.6) 
Hazard ratios in original study unless otherwise specified. MI indicates myocardial infarction; a Relative risk; bCochran Mantel Haenzel test to compare age-adjusted 
prevalences for smoking.  
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4. Methods  
The data sources, population, risk factor and endpoint definitions, as well as composition 
of the cohort, are described in detail in Chapters 3 and 4. These are, however, briefly 
summarised here for ease of reference. Any methodological details specific to the set of 
analyses in this chapter are also noted.  
4.1. Data sources 
The Cardiovascular disease research using Linked Bespoke studies and  Electronic 
Records (CALIBER) e-health  research platform links primary care data from General 
Practice Research Database (GPRD),(76) to admissions for acute coronary syndrome 
(ACS) from the Myocardial Ischaemia National Audit Project registry (MINAP),(98) 
hospital admissions data from Hospital Episodes Statistics (HES),(230) and mortality and 
deprivation data from the Office of National Statistics (ONS).(113,123) Records were 
primarily linked using a pre-defined deterministic linkage algorithm based on NHS 
number, with a small minority linked using a probabilistic method using DOB and 
postcode.(77) A web-based portal documenting the creation of all CALIBER data items, 
from these multiple data sources, is available at www.caliberresearch.org and further 
details on the creation of the CALIBER research platform have been published 
elsewhere.(231) 
4.2. Population 
The identification of the general cohort is described in detail in Chapter 3. All patients in 
the overall cohort had a valid age and gender recorded. For the analysis in this chapter, 
the cohort was restricted to those patients who had smoking status recorded prior to 
cohort entry (82.7% of the overall cohort for the PhD). In Chapter 4, I have described in 
greater detail the ways in which patients with missing data differed to those with more 
complete data.  
4.3. Smoking  
Smoking status was defined as the GPRD record of smoking status with the last possible 
date before endpoint follow-up and categorised as non-smoker, ex-smoker, or current 
smoker. If non-smokers had a previous record indicating smoking in their entire GPRD 
history, they were counted as an ex-smoker. The formal variable definition is given in the 
CALIBER research platform accessible through the web-portal. Access to the web portal is 
described in Appendix C. 
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4.4. Other risk factors 
More detailed information on the definition of these risk factors is given in Chapter 3, 
with a brief summary given here. Gender was defined as the gender recorded in the GPRD 
patient data file. Age at entry was defined as the age in years in January of the first year of 
endpoint follow-up; more precise estimates of age were not possible as only year of birth 
is supplied with the data to protect patient identities. Social deprivation was measured by 
the index of multiple deprivation (IMD) 2007,(123) dividing IMD into quintiles. Ethnic 
group was categorised as White, Black, South Asian or Other, using self-reported ethnic 
group recorded in GPRD and HES, with unresolvable code conflicts between the two data 
sources recorded as missing. Systolic blood pressure (SBP) was defined as the mean SBP 
recorded in the two years prior to the start of endpoint follow-up. Diabetes mellitus was 
defined as a diagnosis of Type 1, Type 2 or unspecified diabetes or at least one 
prescription for insulin or oral hypoglycaemic agent before endpoint follow-up. For all 
remaining risk factors, I used the most recent record from GPRD in the two years before 
the start of endpoint follow-up. Total cholesterol level was taken from laboratory results 
from plasma or serum samples, recorded mmol/L units. Body mass index (BMI) was 
defined as weight in kilograms over height in metres squared. Lipid-lowering medication 
at baseline was derived from one or more prescriptions for a statin.  The number of 
different blood-pressure-lowering medication classes prescribed was based on 
prescriptions for thiazides, potassium-sparing diuretics, beta-blockers, ace inhibitors and 
other less common medications. A complete list of drug classes and specific preparations 
is available in Appendix D.   
4.5. Endpoints: Initial clinical presentations of cardiovascular disease 
The definition of my primary endpoints has been described in more detail in Chapter 3, 
with additional information on the contribution of the different data sources to each 
endpoint described in Chapter 4.  To summarise briefly, my primary endpoints were fatal 
and non-fatal presentations of a range of cardiovascular diseases encompassing coronary 
heart disease [(CHD) including stable angina, unstable angina, ST-elevation myocardial 
infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), myocardial 
infarction not otherwise specified (MI NOS), and coronary death unheralded by prior 
symptomatic disease], stroke, peripheral arterial disease (PAD), abdominal aortic 
aneurysm (AAA), heart failure (HF) and ventricular arrhythmias including cardiac arrest 
and sudden cardiac death (SCD). Given the limited number of myocardial infarctions 
specified as STEMI or NSTEMI, the main analyses used a composite endpoint of all acute 
myocardial infarctions (AMI) as an endpoint. Secondary analyses with specific myocardial 
infarction types have also been presented.  For ease of comparison with previous studies, 
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a composite endpoint of AMI and unheralded coronary death has also been included.  
Diagnoses were identified using codes from the International Classification of Diseases 
10th Revision (ICD 10)(232) for the hospital data (HES) and mortality data (ONS), from 
Read Codes(78) for primary care data (GPRD) and bespoke variables in the ACS registry 
(MINAP).   
4.6. Statistical analysis 
To confirm the validity of smoking status as recorded in GPRD, I calculated the Cox 
proportional hazard for current and ex-smokers compared to non-smokers, adjusted for 
age and sex, for lung cancer diagnosis, admission or death (ICD-10 C34).  
 
I developed a stratified Cox proportional hazard model  for competing risks, using data 
augmentation, to estimate the hazard ratios for smoking for each presentation overall and 
separately for men and women.(184) More detail on this method of data analysis has 
been given in Chapter3.  I produced three models, the first adjusted for gender, age and 
age-squared, the second also adjusted for deprivation, blood pressure, use of blood-
pressure-lowering medication, use of statins, and diabetes, the third also including a 
shared frailty term to take account of patients clustered at general practice level.(191) I 
used the Efron method to deal with tied failure times.(190) I tested the proportional 
hazards assumption visually using log-log plots.   The heterogeneity of the HR was tested 
using the I-squared (I2) test for heterogeneity and size of the heterogeneity estimated 
using Tau-squared (Τ2).(189) 
 
Multiple imputation for missing data was not undertaken, as there is some evidence that, 
at least for some risk factors, data recorded in these kind of primary care data are not 
missing at random.(180,273) Given the level of missingness in ethnic group, lipids and 
BMI, these variables were not included in the analyses. Gender, age, social deprivation, 
systolic blood pressure, use of blood pressure lowering medication, use of statins, and 
diabetes, in addition to smoking status, were used. All analyses were conducted on 
complete cases, except where specified.  Continuous variables are shown as the mean 
(standard deviation) and categorical variables shown as frequencies (percentage), 
separately for men and women. 
 
I have first presented the association between being a current smoker or ex-smoker 
compared to non-smokers with presentations in the cerebral, coronary, abdominal and 
peripheral arterial circulations (stroke, AMI plus UCD presentations, AAA, and PAD) and 
then with the cardiac presentations (stable angina, unstable angina, CHD NOS, AMI, 
ventricular arrhythmias/cardiac arrest/sudden cardiac death combined, heart failure and 
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UCD). Finally, the association between smoking status and specific myocardial infarction 
endpoints (STEMI, NSTEMI, and MI NOS) have been shown in Appendix G. 
 
In a sub-group analysis, I repeated this modelling disaggregating AMI subtypes with 
participants still in the cohort from January 2003, when MINAP data became available, to 
check whether any association found in the main analysis was an artefact of specifying the 
AMI subtypes prior to the inclusion of MINAP data. In a second subgroup analysis to test 
the effect of quitting on my endpoints, I selected participants who had a) at least two 
further years of observation at baseline and b) a record of smoking status within those 
two years. I then modelled the association with my endpoints for participants who quit 
smoking against those who continued to smoke and against non-smokers. In a post hoc 
analysis, I also modelled the association of smoking, adjusting for age and sex only, for all 
participants who met the study entry criteria including those in whom other covariate 
information was missing. 
 
In a post hoc analysis, I modelled the association of smoking, adjusting for age and sex 
only, for all participants who had smoking status recorded but for whom other covariate 
information was missing. 
 
All analyses were performed using STATA version 12 (StataCorp, 4905 Lakeway Drive, 
College Station, TX 77845, United States). 
5. Results 
From the overall healthy cohort of 1,758,584, 304,949 (17.3%) patients did not have 
smoking recorded.  Out of the 1,453,635 remaining patients with smoking status 
recorded, a further 555,743 (38.2%) did not have deprivation or blood pressure at 
baseline recorded. Therefore a total of 897,892 patients (60.5% women) were included in 
the main set of analyses for this chapter. Those excluded from the cohort because of 
missing data were more likely to be male, younger and a current smoker than those 
included in the complete case analysis. More detailed information on difference between 
patients with missing data and those with complete data is given in Chapter 4. Women 
had a follow-up time from study entry of 2,735,785 person years and men, 1,652,664 
person years, with a median of 4.82 person years (interquartile range (IQR): 1.88-9.09) 
for women and 4.16 (IQR: 1.69-8.09) for men.   
 
Risk of lung cancer was much higher in current smokers at baseline compared to non-
smokers (Hazard Ratio (HR) = 9.50 (95% CI 8.83-10.22; p=0.000)) and weaker in ex-
smokers compared to non-smokers (HR=3.93 (CI 3.63-4.26; p=0.000). 
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5.1. Baseline characteristics 
As shown in Table 18, men are more likely than women to be current or ex-smokers and 
have a higher mean age than women, except amongst non-smokers. Men are also more 
likely to have a history of diabetes recorded and to be on statins, regardless of smoking 
status. Women had lower mean systolic blood pressure than men, but were not 
necessarily more likely to be on blood pressure lowering medication.  The proportion of 
current smokers increased with increasing deprivation, while the proportion of non-
smokers decreased; there was no significant difference in the proportion of ex-smokers 
between deprivation groups. 
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Table 20: Baseline characteristics of patients by smoking status and gender  
 
Values are n (%) unless otherwise specified. IMD -  index of multiple deprivation, sd – standard deviation, BMI – body mass index, BP – blood pressure. Data 
presented for subset of patients for ethnic group (n= 522,666 (58.2%)), total cholesterol (n= 176,662 (19.7%)), and BMI (n= 608,999 (67.8%)).  
 Non-smoker Ex-smoker Current smoker 
 Women Men Women Men Women Men 
Overall, n (%) 335,681 (61.8) 174,307 (49.1) 87,230 (16.1) 76,456 (21.5) 119,986 (22.1) 104,232 (29.4) 
Age in years, mean (sd) 49.3 (16.4) 48.7 (14.7) 49.5 (16.1) 53.5 (15.2) 44.9 (13.3) 45.6 (12.8) 
Ethnic group:    White 173,812 (85.4) 75,316 (84.8) 53,104 (95.7) 39,414 (92.3) 72,012 (95.3) 50,479 (89.3) 
                               Black 9,411 ( 4.6) 4,145 ( 4.7) 639 ( 1.2) 919 ( 2.2) 1,194 ( 1.6) 1,674 ( 3.0) 
                               South Asian 9,807 ( 4.8) 4,843 ( 5.5) 351 ( 0.6) 936 ( 2.2) 531 ( 0.7) 1,854 ( 3.3) 
Deprivation (IMD):    Least deprived quintile 76,422 (22.8) 40,009 (23.0) 18,598 (21.3) 15,943 (20.9) 16,091 (13.4) 14,282 (13.7) 
                                         Most deprived quintile 55,552 (16.5) 29,474 (16.9) 14,815 (17.0) 13,069 (17.1) 34,200 (28.5) 30,560 (29.3) 
Systolic BP in mmHG, mean (sd) 129 (19.7) 134 (16.9) 129 (19.3) 137 (17.3) 126 (18.3) 132 (17.0) 
Classes of BP lowering medication:   0 274,301 (81.7) 142,446 (81.7) 71,058 (81.5) 57,998 (75.9) 105,312 (87.8) 91,581 (87.9) 
                                                                      1  43,107 (12.8) 22,560 (12.9) 11,320 (13.0) 12,943 (16.9) 10,959 ( 9.1) 9,396 ( 9.0) 
                                                                      2    14,333 ( 4.3) 7,067 ( 4.1) 3,841 ( 4.4) 4,149 ( 5.4) 2,974 ( 2.5) 2,496 ( 2.4) 
                                                                      3+ 3,940 ( 1.2) 2,234 ( 1.3) 1,011 ( 1.2) 1,366 ( 1.8) 741 ( 0.6) 759 ( 0.7) 
Total cholesterol in mmol/L, mean (sd) 5.5 (1.1) 5.3 (1.1) 5.6 (1.1) 5.4 (1.1) 5.6 (1.2) 5.4 (1.2) 
Statin prescription 11,609 ( 3.5) 8,296 ( 4.8) 4,060 ( 4.7) 6,151 ( 8.0) 3,353 ( 2.8) 4,231 ( 4.1) 
Diabetes 11,982 ( 3.6) 9,407 ( 5.4) 3,393 ( 3.9) 6,182 ( 8.1) 3,254 ( 2.7) 4,608 ( 4.4) 
BMI in kg/m2, mean (sd) 26 ( 5.7) 27 ( 4.5) 27 ( 5.8) 28 ( 4.5) 26 ( 5.7) 26 ( 4.6) 
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5.2. Events 
Amongst patients with complete data for this chapter’s analyses, there were a total of 
52,581 CVD endpoints with a further 26,590 deaths from other causes. The number of 
specific CVD presentations for women and men are shown in Table 21 below. 
Table 21: Number of specific initial presentations for women and men 
 Women Men 
Presentation* n % CVD n % CVD 
Stable angina 6,495 24.4 5,686 21.3 
Stroke 5,039 18.9 3,448 12.9 
Heart Failure 4,026 15.1 2,933 11.0 
Peripheral arterial disease 2,810 10.5 2,828 10.6 
Acute myocardial infarction (all) 2,747 10.3 3,943 15.2 
Myocardial infarction not otherwise specified 2,258 8.5 3,160 11.9 
Coronary heart disease not otherwise specified 2,141 8.0 2,520 9.5 
Unheralded Coronary Death 1,114 4.2 2,933 11.0 
Vent arrhythmias, cardiac arrest & sudden cardiac 
death 
971 3.6 1,280 4.8 
Unstable angina 875 3.3 910 3.4 
Abdominal aortic aneurysm  435 1.6 1,007 3.8 
Non-ST elevation myocardial infarction 329 1.2 450 1.7 
ST elevation myocardial infarction 160 0.6 333 1.2 
All CVD presentations 26,653 -- 25,928 -- 
Deaths from other causes 15,369 -- 11,221 -- 
      * Presentations ordered in descending order of frequency in women 
 
5.3. Testing model assumptions – proportional hazards of current and 
ex smoking compared to non-smoking 
The proportion hazard assumption was tested using the log-log graph method for both 
current smokers and for ex-smokers compared to non-smokers. These graphs are shown 
in Appendix G.  The proportional hazard assumption for both smokers and ex-smokers 
compared to non-smokers appears to be violated for the following endpoints only: AAA, 
AMI, stroke and unstable angina. However, given the size of the current cohort any test of 
proportional hazard is likely to be violated and the hazard lines are broadly parallel for all 
endpoints, I decided that using the Cox proportional hazard model would be a reasonable 
approach to modelling the association with smoking.  
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5.4. Association of smoking status with initial presentation of stroke, 
acute MI and unheralded coronary death, peripheral artery disease 
and abdominal aortic aneurysm 
The association of current smoking differed markedly across the cerebral, coronary, 
peripheral and abdominal endpoints, as shown in Figure 18.   The effects were weakest 
for AMI and unheralded coronary death (UCD), moderate for stroke and PAD and 
strongest for AAA. For all patients, the association of smoking with different endpoints 
was decisively heterogeneous (I2= 99.5%), with a variance between HRs as measured by 
Τ2 of 0.1951. The inclusion of additional variables in the multivariable Cox proportional 
hazard model had almost no effect on the size of the HR or measures of heterogeneity. 
(See Figure 19.)  Inclusion of a random effect variable for GP practice in the model also 
had minimal impact on the effect estimates. (See Figure 20.) 
 
Compared to men, women had a modestly increased hazard associated with being a 
current smoker, for AMI and UCD, but a markedly increased hazard for AAA.  There was 
no gender difference in hazard ratio for stroke and minimal for PAD.  In both men and 
women, the association of smoking with these endpoints was heterogeneous, with similar 
variance in association between endpoints (men I2= 99.1%, Τ2= 0.2210; women I2= 
98.9%, Τ2= 0.2006).  
 
Although being an ex-smoker was associated with increased hazard for most of the 
cardiovascular presentations compared to non-smokers, the effect size was considerably 
smaller than for current smokers. For AMI and UCD, PAD and AAA, the hazard was less 
than half of the hazard for being a current smoker.  (Figure 18.) Also, the variance in the 
association of being an ex-smoker with these presentations was negligible, although still 
significant (overall: I2= 97.9%, Τ2= 0.0593; men:  I2= 97.1%, Τ2= 0.0771; women:  I2= 
92.8%, Τ2= 0.0387).  Again, the inclusion of additional variables or the frailty term had 
almost no effect on the strength of the association. (Figure 19 and Figure 20 below.)  The 
gender difference in HR for AAA present for smokers was absent for ex-smokers.  
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Figure 18: Age-adjusted hazard ratios for initial presentations of cardiovascular disease associated with being current smoker or ex-smoker 
compared to non-smokers, overall and in women and men 
 
Hazard ratios for current smokers or ex-smokers compared to non-smokers, adjusted for age at baseline for men and women, and additionally for sex for all 
patients, in complete cases. N= 897,892. MI indicates myocardial infarction; CI, confidence interval; HR, hazard ratio. 
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Figure 19: Multivariable adjusted hazard ratios for initial presentations of cardiovascular disease associated with being current smoker or ex-
smoker compared to non-smokers, overall and in women and men 
 
Hazard ratios adjusted for age at baseline, sex, deprivation (index of multiple deprivation quintile), smoking status (current smoker, ex-smoker, non-smoker), 
diabetes mellitus (yes/no), mean systolic blood pressure at baseline, blood pressure medication (yes/no) and statin use at baseline (yes/no), in complete cases. 
N= 897,892. MI indicates myocardial infarction; CI, confidence interval; HR, hazard ratio.
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Figure 20: Multivariable adjusted hazard ratios (with random effects for GP practice) for initial presentations of cardiovascular disease 
associated with being current smoker or ex-smoker compared to non-smokers, overall and in women and men 
 
Hazard ratios adjusted for age at baseline, sex, deprivation (index of multiple deprivation quintile), smoking status (current smoker, ex-smoker, non-smoker), 
diabetes mellitus (yes/no), mean systolic blood pressure at baseline, blood pressure medication (yes/no) and statin use at baseline (yes/no), with frailty term 
to take account of clustering at practice level, in complete cases. N= 897,892. MI indicates myocardial infarction; CI, confidence interval; HR, hazard ratio. 
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5.5. Association of smoking with cardiac disease  
As with cardiovascular endpoints across all four arterial beds, I found considerable 
variation in the association with being a current smoker at baseline and the specific 
cardiac endpoints. There were much stronger associations with myocardial infarction and 
unheralded coronary death than with the other more chronic presentations such as stable 
angina, unstable angina, coronary heart disease not otherwise specified (CHD NOS) and 
heart failure and no increased hazard of ventricular arrhythmias, cardiac arrest and SCD.  
(Figure 21) This pattern was unchanged when additional variables were added in the 
multivariable model (Figure 22) or the frailty model (Figure 23). The variance in 
association of current smoking with these endpoints was lower than the variance in 
association found across all the arterial beds (Overall: I2= 98.9%, Τ2= 0.1101) 
 
Smoking posed a similar hazard for men and women for all cardiac endpoints except 
acute MI and possibly unheralded coronary death, with women were at greater risk. 
Again, the variance in association between endpoints was similar in men and women 
(men:  I2= 97.4%, Τ2= 0.0951; women:  I2= 97.8%, Τ2= 0.1339). 
 
The association of being an ex-smoker with the cardiac endpoints was smaller across all 
endpoints than the association of being a current smoker.  (See Figure 21.) However, the 
extent of the difference was much greater with the more acute presentations, with the 
hazard of acute MI and unheralded coronary death less than half that of current smokers.  
The variance in the association between the cardiac endpoints is negligible (Overall: I2= 
68.3%, Τ2= 0.0028).  The addition of other variables or a frailty term into the model made 
little difference to the effect estimates (Figure 22 and Figure 23). There were no gender 
differences in the association of being an ex-smoker with these endpoints.  
 
I also investigated the association of smoking with initial presentation of AMI subtypes, 
with the age-adjusted estimates, multivariable-adjusted estimates, and multivariable-
adjusted with random effect for GP all shown in Appendix G.  Overall, current smoking 
had the strongest association with STEMI, followed by MI NOS, followed by NSTEMI, but 
with overlapping confidence intervals. These analyses were repeated on a subset of the 
cohort with initial presentations after January 2003 (n= 847,415), with similar effect sizes 
and gender differences. Smoking posed the greatest hazard for STEMI (HR in women: 3.09 
(CI 2.15-4.44; HR in men: 2.63 (2.04-3.38)), followed by MI not otherwise specified 
(women: 2.46 (2.23-2.72); men: 2.09 (1.92-2.27)) and nSTEMI (women: 2.57 (1.97-3.34); 
men: 1.83 (1.47-2.29)).  
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Figure 21: Age-adjusted hazard ratios for initial presentations of cardiac disease associated with being current smoker or ex-smoker compared 
to non-smokers, overall and in women and men 
 
 
 
Hazard ratios adjusted for age at 
baseline for men and women, and 
additionally for sex for all patients, 
in complete cases. N= 897,892. MI 
indicates myocardial infarction; CI, 
confidence interval; NOS, not 
otherwise specified.
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Figure 22: Multivariable adjusted hazard ratios for initial presentations of cardiac disease associated with being current smoker or ex-smoker 
compared to non-smokers, overall and in women and men 
 
 
 
Hazard ratios adjusted for age at 
baseline, sex, deprivation (index of 
multiple deprivation quintile), 
smoking status (current smoker, 
ex-smoker, non-smoker), diabetes 
mellitus (yes/no), mean systolic 
blood pressure at baseline, blood 
pressure medication (yes/no) and 
statin use at baseline (yes/no), in 
complete cases. N= 897,892. MI 
indicates myocardial infarction; CI, 
confidence interval; NOS, not 
otherwise specified.
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Figure 23: Multivariable adjusted hazard ratios (with random effects for GP practice) for initial presentations of cardiac disease associated 
with being current smoker or ex-smoker compared to non-smokers, overall and in women and men 
 
 
 
Hazard ratios adjusted for age at 
baseline, sex, deprivation (index of 
multiple deprivation quintile), 
smoking status (current smoker, ex-
smoker, non-smoker), diabetes 
mellitus (yes/no), mean systolic 
blood pressure at baseline, blood 
pressure medication (yes/no) and 
statin use at baseline (yes/no), with 
frailty term to take account of 
clustering at practice level, in 
complete cases. N= 897,892. MI 
indicates myocardial infarction; CI, 
confidence interval; NOS, not 
otherwise specified. 
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While the likelihood ratio tests comparing all three models showed that the fully adjusted 
model with shared frailty was the best fit to the data for all endpoints, the change in effect 
size for the hazard of smoking from the model simply adjusted for age was minimal. I 
therefore reran the analyses for all cohort participants, including those with missing data, 
to determine whether similar effect sizes would be seen with all patients, given the 
potential bias in analysing only patients with complete data. The pattern of association 
and size of effect with cardiac endpoints remained virtually unchanged in the expanded 
cohort. There was no association with ventricular arrhythmias, small associations with 
the more chronic presentations and stronger association with the acute presentations of 
MI and unheralded coronary death. Women had a stronger association than men for the 
latter two endpoints. These findings have been shown in Figure 24 and Figure 25 below.   
 
In my subgroup analysis of the effect of quitting smoking, I had 232,416 participants with 
second smoking status record and a further two years of observation time after the start 
of endpoint follow-up. Of these, 45,320 women and 27,267 men continued to smoke and 
2,814 women (5.84% of female smokers) and 1,691 men (5.84% of male smokers) quit. 
When modelling the effect of quitting, we found reduced risks with quitting for most 
endpoints, but with wide confidence intervals, particularly in women, due to the limited 
number of patients. The largest differences between quitters and continuers were for 
AMI, unstable angina and unheralded coronary death for both men and women. The 
hazard ratios for the cardiac presentations for patients who continued to smoke and 
patients who quit compared to non-smokers are shown in Figure 26 and Figure 27. 
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Figure 24: Age-adjusted hazard ratios for initial presentations of cardiovascular disease associated with being current smoker or ex-smoker 
compared to non-smokers, overall and in women and men, in all patients with smoking record 
 
Hazard ratios for current smokers or ex-smokers compared to non-smokers, adjusted for age at baseline for men and women, and additionally for sex for all 
patients, in all patients with smoking record. N=1,453,635. MI indicates myocardial infarction; CI, confidence interval.
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Figure 25: Age-adjusted hazard ratios for initial presentations of cardiac disease associated with being current smoker or ex-smoker compared 
to non-smokers, overall and in women and men, in all patients with smoking record 
 
 
 
Hazard ratios adjusted for age at 
baseline for men and women, and 
additionally for sex for all patients, in 
complete cases. N= N=1,453,635. MI 
indicates myocardial infarction; CI, 
confidence interval; NOS, not 
otherwise specified. 
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Figure 26: Age-adjusted hazard ratios for initial presentations of cardiac disease associated with continuing to smoke or quitting compared to 
non-smokers, overall and in women and men 
 
 
Hazard ratios adjusted for age 
at baseline for men and 
women, and additionally for 
sex for all patients, in patients 
with two years of observation 
after study entry and 2nd 
smoking status recorded. N=. 
MI indicates myocardial 
infarction; CI, confidence 
interval; NOS, not otherwise 
specified.
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Figure 27: Multivariable-adjusted hazard ratios for initial presentations of cardiac disease associated with continuing to smoker or quitting 
compared to non-smokers, overall and in women and men 
 
 
 
Hazard ratios adjusted for age at 
baseline, sex, deprivation (index 
of multiple deprivation quintiles), 
smoking status (current smoker, 
ex-smoker, non-smoker), diabetes 
mellitus (yes/no), mean systolic 
blood pressure at baseline, blood 
pressure medication (yes/no) and 
statin use at baseline (yes/no), in 
patients with two years of 
observation after study entry and 
2nd smoking status recorded. N=.  
MI indicates myocardial 
infarction; CI, confidence 
interval; NOS, not otherwise 
specified.
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6. Discussion 
I found in a cohort of almost 900,000 people with more than 56,000 endpoints of 12 
different types that current smoking has heterogeneous effects on the initial presentation 
of cardiovascular diseases.  There have been no other prospective cohorts in which such a 
range of initial presentations of cardiovascular disease has been assessed.    A novel 
feature of my analysis was to study initial presentations with non-fatal or fatal endpoints.   
Most cohort studies do not do this; an ‘incident’ acute myocardial infraction includes 
patients who have previously manifested another symptomatic cardiovascular disease.  
This matters because the causes of onset and causes of progression may differ. The 
considerable heterogeneity in association with different initial presentations empirically 
demonstrates the importance of making this distinction. 
 
In each section below, I summarise my findings for each objective. I then describe the 
strengths and limitations of this set of analyses. The implications for clinical care, public 
health practice, and research of my findings from these and my other analyses are 
discussed in Chapter 8 – Conclusions and Recommendations.  
6.1. Summary of existing literature (Objective 1) 
There are a dearth of studies investigating the association between smoking and the onset 
of CVD across multiple presentations, with only five studies identified in which at least 
two endpoints were compared, only one of which included women. None of the studies 
identified included ventricular arrhythmias, cardiac arrest, sudden cardiac death, heart 
failure, AAA, or PAD as endpoints.  These studies found smoking to be more strongly 
associated with coronary heart disease than stroke and women to be at greater risk than 
men of CHD, but not stroke, only amongst the heaviest smokers. 
6.2. Association of smoking with onset of symptomatic cardiovascular 
disease across a wide range of disease presentations (Objective 2)  
In general, the associations of smoking with specific presentations which I found fit into a 
pattern of both acute and chronic effects of smoking, as would be expected from the 
physiological effects of smoking. However, for the first time the size of these effects on 
clinical presentations of cardiovascular disease were estimated within a single study, 
allowing direct comparison between presentations.  I found the strongest association in 
both men and women between smoking and PAD and AAA, as well as the acute coronary 
presentations of AMI and UCD, suggesting an acute triggering effect of smoking such as 
thrombus formation. I found much lower associations between smoking and the more 
chronic forms of coronary disease such as stable angina and heart failure, indicating a 
more limited chronic effect possibly through effects on lipid levels and platelet formation. 
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I found no additional risk for ventricular arrhythmias (including cardiac arrest and 
sudden cardiac death).  The effect size for ex-smokers for the acute presentations was 
similar to that for chronic presentations, and the heterogeneity between effect sizes also 
became negligible, again supporting the more limited chronic (and apparently 
irreversible) effect of having previously been a smoker, when compared to the much 
larger effects of being a current smoker.  These findings are robust, remaining essentially 
unchanged with  adjustment for additional risk factors and clustering at GP practice level, 
as well as being replicated in a much larger cohort of patients for whom gender, age and 
smoking status only were recorded.  
 
My findings are consistent with previous literature for initial presentations of 
CVD.(222,225,270,274) Small, retrospective case-control studies comparing only two or 
three morbidities have suggested that smoking is more strongly associated STEMI than 
nSTEMI;(275) with acute myocardial infarction (AMI) than unstable angina;(276) with  
AMI than stable angina;(14,277–279)and with unstable versus stable angina,(280) all 
findings consistent with the dual impact of chronic and acute effects. The heterogeneity of 
association is  also consistent with findings from a recent large study of the association of 
smoking with a range of different causes of mortality in healthy women.(269)  
6.3. Gender differences in the association of smoking with initial CVD 
presentations (Objective 3)  
I found limited evidence of gender differences in the effect of smoking for most 
presentations with the association of being a current smoker being somewhat stronger in 
women for an initial presentation of AMI and considerably stronger in women for AAA.   
While the AMI finding is consistent with existing studies(2,272),  my findings do not apply 
generally to coronary heart disease; by using composite endpoints, previous studies may 
disguise the differences between more specific endpoints and may exaggerate the extent 
of gender differences in effect of smoking. The strong association between AAA and 
smoking, particularly in women, is consistent with the finding of both a recent individual 
participant meta-analysis of rupture rates of screening-identified AAA(236) and a recent 
large study of the association between smoking and cause-specific mortality in women, 
(269) as well as a study of AAA clinically significant events in a women-only cohort.(241) 
6.4. Association of smoking cessation compared to continuing to 
smoke on initial CVD presentations (Objective 4) 
In the subgroup of patients for whom quitting or continuing to smoke could be 
ascertained, quitters had lower hazard of onset of symptomatic CVD across most 
endpoints, particularly the acute coronary presentations compared to those patients who 
continued to smoke. However, the number of quitters was only 5% of this subgroup, so 
   
 
 
167 
the confidence intervals around these estimates are large. Although the lack of precision 
is disappointing, these findings are in keeping with existing literature on the impact of 
quitting on risk of cardiovascular disease.(272,281,282) 
6.5. Strengths 
The strengths of these analyses, like much of my thesis, lie in the size of the cohort which 
enables me to investigate individual cardiovascular phenotypes, as well as the 
prospective nature of the data allowing me to identify initial presentations. For this 
chapter’s analyses, I was also able to assess my measurement of current smoking and ex-
smoking with lung cancer, providing face validity to my exposure measurement.  
6.6. Limitations 
The first limitation of the current study is that level of missing data, leading to greater 
exclusion of men from the study than women. However, my analyses with all patients who 
had a smoking status recorded regardless of other missing data also found similar 
associations to my complete case analyses, indicating that the complete case analysis did 
not introduce serious bias.  Second, as with all electronic health record research, the data 
was not collected according to protocol so GPs may differ in their coding practices as well 
as diagnostic approaches. Although my models incorporating shared frailty at practice 
level were a better fit to the data, the effect estimates did not differ materially suggesting 
that any differences in coding which may exist do not substantially affect my findings. The 
third limitation is the lack of greater detail on smoking status, either in terms of amount 
smoked or duration of smoking. The fourth limitation is the potential for misclassification 
of my endpoints; of concern here is CHD NOS which is likely to be a mixture of patients 
with coronary artery disease, stable angina and acute coronary syndromes. Although I 
could not accurately allocate these patients to a more specific category, the inclusion of 
CHD NOS as an endpoint allows an estimation of the size of risk attributable to this rather 
nebulous endpoint.  I found that the strength of association of smoking with CHD NOS to 
be between that of stable and unstable angina; while this known misclassification may 
affect the size of the effect estimates, it is unlikely to affect the relative effect size between 
these endpoints. Fifth, it is possible that I missed some presentations, particularly deaths 
abroad as these are not included in ONS data, but the number of these is likely to be small.  
 
The implications of these finding for research, clinical and public health practice are 
discussed in Chapter 8.  
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7. Summary of Findings 
 Little is known from previous studies about heterogeneity in the association of  
smoking status with the onset of symptomatic CVD across a wide range of 
presentations 
 The association of being a current smoker (compared to being a non-smoker) with 
the initial presentations of CVD varied considerably across all presentations, 
ranging from no association with the ventricular arrhythmias to a strong 
association with AAA.  
 The association of being an ex-smoker (compared to being a non-smoker) was 
considerably smaller and less variable across the range of CVD presentations than 
those found for current smokers.  
 Women who smoked had moderately increased risk of AMI compared to men, but 
markedly increased risk of AAA. No other significant gender differences were 
identified.  
 Weak evidence was found for the benefit of quitting compared to continuing to 
smoke, particularly for the more acute coronary presentations (unstable angina, 
AMI, and unheralded coronary death).  
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Differential effects of systolic and diastolic blood pressure on 
initial presentations of cardiovascular diseases in women and 
men 
1. Abstract 
Background: It is unknown whether blood pressure is differentially associated with the 
onset of cardiovascular disease (CVD) across a wide range of presentations, covering the 
cerebral, coronary, abdominal and peripheral arterial circulations. 
Objectives: To determine whether systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) differ in their associations with a wide range of initial CVD presentations 
and whether those associations are modified by gender or age. 
Design: Cohort study using data from the CALIBER research platform linking four data 
sources (primary care, disease registry, hospitalisation and mortality records) for 
961,350 patients free from symptomatic CVD, with a BP measurement recorded in the 
two years before endpoint follow-up. 
Main outcome measures: Initial presentation of CVD with stable angina, unstable 
angina, myocardial infarction (MI), heart failure, ventricular arrhythmias, coronary death, 
stroke, abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). 
Results:  There were a total of 52,581 CVD events in the 4,742,025 years of follow-up. The 
association of SBP with most CVD endpoints was modest, ranging from HR 1.19 (1.16-
1.22) per standard deviation (SD) for heart failure to 1.28 (1.24-1.31) for PAD. The 
exception was AAA where no association with raised SBP was found (1.00, 0.95-1.06). The 
association of DBP with all endpoints was slightly lower across all endpoints than that 
found for SBP, with the exception of stronger association with AAA (1.26, 1.19-1.34) and 
none with PAD (1.02, 0.99-1.05).  The increased hazard of most initial presentations was 
seen at the lowest blood pressure categories. SBP and DBP had a stronger association 
with stroke in men than in women (men HR 1.27 (1.22-1.32); women 1.17 (1.14-1.20)) 
while women were at greater risk of arrhythmia than men with higher SBP and DBP 
(women 1.35 (1.26-1.44); men 1.12 (1.06-1.20)).  The association of SBP and DBP 
decreased with age up to 70-79 years across all endpoints, with the strongest effect 
modification by age for onset of CVD with heart failure and unheralded coronary death at 
younger ages.  
Conclusions:  For most initial presentations, the effects of SBP and DBP were broadly 
homogeneous and modest, with exception of no association of SBP with AAA and of DBP 
with PAD. Age was an important effect modifier across all presentations but gender was 
not.  
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2. Introduction 
The previous two chapters covered the association of gender and smoking with the initial 
presentations of cardiovascular disease. In this set of analyses, I investigate whether 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) are differentially 
associated with the onset of CVD across a wide range of presentations, covering the 
cerebral, coronary, abdominal and peripheral arterial circulations.  
 
The role of raised blood pressure (BP) as a risk factor for cardiovascular death is well-
documented. The Prospective Studies Collaboration found increased risk of mortality 
from stroke, ischaemic heart disease (IHD) and other vascular causes, even at lower levels 
of SBP and DBP, across all ages.(283)  These findings are supported by other smaller 
studies of both blood pressure(284,285) and hypertension(286,287) in IHD and stroke 
deaths.  Most studies have also found broadly homogeneous associations between blood 
pressure and the different causes of death.(283–285) However, by focussing on the 
association between baseline blood pressure and mortality, these studies conflate the 
association between development of the different cardiovascular disease (CVD) 
phenotypes, disease progression and mortality from cardiovascular causes.  
 
A better understanding of the association between blood pressure and the way in which 
cardiovascular disease first presents, across a range of different cardiovascular disease 
phenotypes, will help to illuminate the aetiological mechanisms underlying that 
association. In particular, potentially differing associations with more finely-grained 
diseases than the composite cardiovascular disease (CVD) endpoints commonly used in 
mortality studies could indicate differing mechanisms for onset and disease progression. 
There is considerable debate about which elements of blood pressure best capture the 
increases in risk associated with cardiovascular disease,(283,288–290) so, in addition to 
investigating the independent association of SBP and DBP the range of different initial 
presentations, I will investigate any differences between these two measures of blood 
pressure for each presentation. 
 
Not only do the levels of blood pressure change with age,(291,292) but the level of risk 
associated with blood pressure appears to increase with age, at least for some 
presentations. For example, SBP has been found to be the chief contributor to age-related 
excess in coronary heart disease (CHD) mortality.(207,293) There is also conflicting 
evidence whether the risk associated with SBP,  DBP and other blood pressure measures, 
such as pulse pressure, change relative to each other with age.(284,294) I will therefore 
investigate whether the association between the initial presentation of a range of 
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cardiovascular diseases and SBP and DBP is modified by age, both independently and 
compared to each other.  
 
Many studies have found no gender differences in the risk of cardiovascular disease 
attributable to blood pressure(283,295) or in the response to treatment(296), while 
others have identified increases in blood pressure, usually SBP, as posing a greater risk to 
women.(1,297,298) The modification of any association between SBP and DBP and the 
initial presentations of cardiovascular diseases by gender will therefore be investigated.  
 
The objectives of this chapter are to:  
1. Summarise the existing literature on the association of blood pressure with the 
initial presentation of CVD across a wide range of presentations;  
2. Investigate whether SBP and DBP differ in their individual associations with the 
onset of CVD across a wide range of  disease presentations;  
3. Investigate whether the association with specific initial presentations differs 
between SBP and DBP; 
4.  Investigate whether these associations are modified by either gender or age. 
3. Literature review 
3.1. Search Strategy 
The aim of my literature review was to find cohort studies on the initial presentation of 
symptomatic CVD with specific diseases in populations without clinically manifest 
cardiovascular disease. To be included, any study had to include at least two endpoints 
and report the gender-specific association of systolic or diastolic blood pressure or 
hypertension with those endpoints.  Studies which investigated only men or women were 
included.  I used both a specific strategy focussing on the association of blood pressure 
with initial CVD presentation for different specific presentations and a sensitive search 
focussing on observational studies on the association of blood pressure with 
cardiovascular disease in general, when my specific search found few papers. The search 
terms I used are reproduced in Table 22 below. I limited both searches to papers in 
English with the full text available, published since 1992, using PubMed as my principal 
index. For the specific search, I searched on pairs of specific endpoint groups in turn to 
make the process of sifting through papers manageable. I supplemented the studies found 
through the formal search strategy by searching reference lists of relevant papers, using 
forward citation searches of earlier relevant papers and asking other researchers for the 
details of any papers of which they were aware.  Where I found relevant studies published 
before 1992, I included those in the Table. 
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Table 22: Search strategy used to identify studies on association of blood pressure 
with initial presentation of CVD 
Concepts Boolean 
operator 
Terms used 
Specific search 
Blood pressure  “diastolic blood pressure” OR “systolic blood pressure” OR 
“hypertens*” 
Endpoints AND "myocardial infarction" OR STEMI OR nSTEMI OR "acute 
coronary syndrome"  OR “angina” OR “coronary insufficiency” 
or “acute coronary syndrome” OR “heart attack” 
 AND “abdominal aortic aneurysm” OR “peripheral arterial disease” 
OR “peripheral vascular disease” OR PAD OR “intermittent 
claudication” OR “peripheral ischaemia”  
 AND Stroke OR “cerebrovascular disease” OR “cerebrovascular 
accident” 
 AND (ventricu* AND arrhythm*) OR “cardiac arrest” OR “sudden 
cardiac death” OR “sudden death”  
 AND “heart failure” 
Gender AND “sex factor”[MESH] OR (gender OR sex) OR (women AND 
men) OR (male AND female) 
Initial presentation  ((first OR initial) AND (presentation OR manifestation) ) OR 
(onset) 
Sensitive search 
Blood pressure  “diastolic blood pressure” OR “systolic blood pressure” OR 
“hypertens*” 
Endpoints AND “coronary disease” OR “CHD” OR “IHD”  OR  ((“ischemic” OR 
“ischaemic”) AND “heart disease”) OR “cerebrovascular 
disease” OR “peripheral arterial disease” OR “cardiovascular 
disease” OR “CVD”  
Gender AND “sex factor”[MESH] OR (gender OR sex) OR (women OR men) 
OR (male OR female) 
Cohort  AND “observational study” OR “cohort studies”[MESH] 
 
3.2. Findings of Literature Review 
I found seven studies(222,223,264,299–301) which reported the association between a 
measure of blood pressure and initial presentation of CVD in at least two endpoints, only 
two of which included both women and men in the study,(300,301) neither of which 
reported sex-specific results. The most common endpoints compared are either stable 
angina versus acute myocardial infarction (AMI)(222,225,299) or AMI versus 
stroke,(223,300) although one study compared AMI to heart failure(301) and another 
AMI to sudden cardiac death.(264) No studies which included ventricular arrhythmias or 
abdominal aortic aneurysm were found. Methods used by these studies included bespoke 
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cohorts, use of electronic health records (EHRs), and systemic review with individual 
participant meta-analysis. The studies are summarised in Table 23 below. 
 
Some studies found possibly heterogeneous associations with different 
presentations,(225,286,299) while most did not. Given the limited number of papers I 
found on initial presentation, I have included in the table papers which report results in 
combined men and women, as well as papers on first presentation or mortality endpoints 
where these met my criteria of publishing sex-specific associations of blood pressure on 
more than one endpoint.  
 
 These studies have a number of limitations; specifically, they: 
a) are restricted to a few endpoints;(222,223,225,264,299,300,302) 
b) have investigated combined systolic and diastolic hypertension 
only;(286,287,299,303) 
c) are too small to estimate modification by age or gender(300,302) or are limited to 
one sex (222,223,225,226,304) 
The additional studies investigated first presentation or mortality within a specific 
cardiovascular disease subtype (e.g. first stroke even if preceded by an MI) rather than 
first of any cardiovascular presentation.(226,283–287,303,304) 
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Table 23: Summary of studies investigating the strength of association of systolic blood pressure, diastolic blood pressure or hypertension with specific 
cardiovascular disease presentations (initial, first within presentation, and mortality) 
Study Details Adjusted for 
B
P
 m
e
as
u
re
m
e
n
t Groups 
Cardiovascular Disease Presentations 
HR or RR (95%CI) per 1 standard deviation unless otherwise noted 
First 
Author & 
publ. year 
C
o
h
o
rt
 s
iz
e
 
C
V
D
 E
ve
n
ts
 
A
ge
 
Sm
o
ki
n
g 
Li
p
id
s 
O
b
e
si
ty
 
D
ia
b
e
te
s 
A
lc
o
h
o
l 
G
e
n
d
e
r 
A
ge
  a
t 
e
n
tr
y 
Stable Angina Acute MI 
Unheralded 
Coronary 
Death 
Sudden 
Cardiac 
Death 
Heart 
Failure 
Stroke 
Peripheral 
Arterial 
Disease 
Studies of overall onset of  cardiovascular disease with specific presentations 
Canoui-
Poitrine 
2009(222)
 
9,758 292       SBP M 
50-
59 
1.3 (1.1-1.5) 1.3 (1.2-1.5)
a
      
         DBP   1.0 (0.9-1.3) 1.3 (1.2-1.5)
a
      
Conen, 
2007(299)
 37,787 930    HT W 45+ 1.1 (0.9-1.3)
b
 1.0 (0.8-1.4)    1.6 (1.2-2.1)  
Glynn 
2005(223)
c
 
18,662 2,250  HT M 
40-
84 
 1.7 (1.6-2.0)   1.9 (1.7-2.2)  
Mattace-
Raso,  
2004(300) 
4,234 342  SBP
60% 
W 
55+  1.2 (1.1-1.5)    1.6 (1.4-1.9)  
         DBP    1.1 (0.9, 1.3)    1.3 (1.1, 1.5)  
Vaccarino, 
2000(302) 
2,153 552    SBP 
61% 
W 
65+  1.1 (1.0-1.2)   1.1 (1.0-1.2)   
         DBP    1.0 (0.9-1.2)   1.0 (0.9-1.2)   
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Study Details Adjusted for 
B
P
 m
e
as
u
re
m
e
n
t Groups 
Cardiovascular Disease Presentations 
HR or RR (95%CI) per 1 standard deviation unless otherwise noted 
First 
Author & 
publ. year 
C
o
h
o
rt
 s
iz
e
 
C
V
D
 E
ve
n
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ge
 
Sm
o
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s 
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ty
 
D
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s 
A
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o
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o
l 
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A
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  a
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Stable Angina Acute MI 
Unheralded 
Coronary 
Death 
Sudden 
Cardiac 
Death 
Heart 
Failure 
Stroke 
Peripheral 
Arterial 
Disease 
Dagenais 
1990(225)
f 
 
4,576 603       
SBP 
125-132 
M 
35-
64  
0.9(0.6-1.3)
a
 1.0 (0.6-1.7)
g 
0.8 (0.3-2.1)     
 
        
SBP 
133-140 
  1.0(0.7-1.5)
a
 0.8 (0.5-1.4)
g 
2.1 (0.9-4.7)     
 
        
SBP 
141- 152 
  1.3(0.9-1.9)
a
 1.3 (0.9-2.1)
g 
2.4 (1.1-5.2)     
 
        
SBP 
>152 
  1.4(1.0-2.1)
a
 1.6 (1.0-2.5)
g 
3.1 (1.5-6.5)     
 
        
DBP 
78-82 
  1.0 (0.7-1.4)
a
 1.2 (0.7-1.9)
g
 1.1 (0.6-2.3)     
 
        
DBP 
83-87 
  1.1 (0.7-1.6)
a
 1.1 (0.7-1.8)
g
 1.1 (0.5-2.3)     
 
        
DBP 
88-92 
  1.2 (0.8-1.7)
a
 1.3 (0.8-2.1)
g
 1.7 (0.9-3.2)     
 
        
DBP 
>92 
  1.6 (1.1-2.2)
a
 2.3 (1.5-3.5)
g
 2.5 (1.3-4.5)     
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Stable Angina Acute MI 
Unheralded 
Coronary 
Death 
Sudden 
Cardiac 
Death 
Heart 
Failure 
Stroke 
Peripheral 
Arterial 
Disease 
First presentation 
Gu, 
2009(286)
 
158,666 1,371    HT h 
53% 
W 
 
40+  1.8 (1.6-2.1)    3.1 (2.8-3.3)  
Silven- 
toinen 
2008(226)
 
1,145758 65,611      SBP M 
16-
25 
 1.2 (1.2-1.2)    1.1 (1.0-1.1)  
         DBP    1.2 (1.2-1.2)    1.1 (1.1-1.2)  
O’Donnell 
1997(304) 
18,682 1,562    HT M 
40-
84 
 1.8 (1.5-2.1)    2.2 (1.8-2.7)  
Mortality 
Sauvaget, 
2010(285) 
167,331 4,007    SBPh W 
35-
90 
 1.7  (1.3-2.2)   1.9 (1.4-2.7)  
          M   1.5  (1.3-1.8)   2.2 (1.6-2.9)  
         DBPh W   1.0  (0.8-1.2)   1.2 (1.0-1.5)  
          M   1.1  (0.9-1.2)   1.3 (1.0-1.6)  
Gu, 
2009(286)
h
 158,666 1,310    HT
h
 
53% 
W 
40+  1.9 (1.6-2.3)   3.0 (2.6-3.3)  
Jouven, 
1999(264)
 7,746 310  SBP M 
43-
52 
 1.5 (1.2-1.8)
d
  1.2 (1.0-1.5)    
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Stable Angina Acute MI 
Unheralded 
Coronary 
Death 
Sudden 
Cardiac 
Death 
Heart 
Failure 
Stroke 
Peripheral 
Arterial 
Disease 
                  
Lawes 
2003(284) 
94,147 3,491    SBP W <50  2.4 (1.9-3.1)   1.9 (1.6-2.4)  
          M   1.5 (1.3-1.7)   2.0 (1.7-2.3)  
         DBP W <50  2.4 (1.7-3.5)   1.8 (1.4-2.4)  
          M   1.5 (1.3-1.8)   2.5 (2.1-3.0)  
         SBP W 
50-
59 
 1.5 (1.3-1.7)   1.7 (1.4-1.9)  
          M   1.4 (1.2-1.6)   2.0 (1.8-2.2)  
 
        DBP W 
50-
59 
 1.6 (1.4-1.9)   1.6 (1.4-2.0)  
          M   1.4 (1.2-1.6)   1.9 (1.7-2.2)  
 
        SBP W 
60-
69 
 1.5 (1.4-1.7)   1.5 (1.3-1.7)  
          M   1.3 (1.2-1.4)   1.5 (1.3-1.7)  
 
        DBP W 
60-
69 
 1.5 (1.3-1.7)   1.5 (1.3-1.7)  
          M   1.1 (1.0-1.2)   1.4 (1.3-1.6)  
         SBP W 70+  1.2 (1.1-1.5)   1.3 (1.1-1.4)  
          M   1.1 (1.0-1.3)   1.4 (1.2-1.6)  
         DBP W 70+  1.2 (1.0-1.4)   1.2 (1.0-1.3)  
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Stable Angina Acute MI 
Unheralded 
Coronary 
Death 
Sudden 
Cardiac 
Death 
Heart 
Failure 
Stroke 
Peripheral 
Arterial 
Disease 
          M   1.1 (0.9-1.3)   1.1 (0.9-1.3)  
Lida, 
2003(303) 
9,633 446       HTh W 30+  1.2 (0.6-2.6)   3.5 (1.3-9.3)  
          M   7.7 (1.1-55.2)   2.3 (0.6-8.6)  
Lewington, 
2002(283) 
1,000,0
00 
56,137       SBP j n/s 
40-
49 
 0.5 (0.5-0.5)   0.4 (0.3-0.4) 0.4 (0.4-0.5) 
 
          
50-
59 
 0.5 (0.5-0.5)   0.4 (0.4-0.4) 0.5 (0.5-0.5) 
 
          
60-
69 
 0.5 (0.5-0.6)   0.4 (0.4-0.5) 0.5 (0.5-0.6) 
 
          
70-
79 
 0.6 (0.6-0.6)   0.5 (0.5-0.5) 0.6 (0.6-0.7) 
 
          
80-
89 
 0.7 (0.6-0.7)   0.7 (0.6-0.7) 0.7 (0.7-0.8) 
 
        DBP j n/s 
40-
49 
 0.5 (0.4-0.5)   0.4 (0.3-0.4) 0.4 (0.4-0.5) 
 
          
50-
59 
 0.5 (0.5-0.6)   0.3 (0.3-0.4) 0.5 (0.4-0.5) 
 
          
60-
69 
 0.6 (0.5-0.6)   0.4 (0.4-0.4) 0.5 (0.5-0.5) 
 
          
70-
79 
 0.6 (0.6-0.6)   0.5 (0.5-0.5) 0.6 (0.6-0.7) 
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Stable Angina Acute MI 
Unheralded 
Coronary 
Death 
Sudden 
Cardiac 
Death 
Heart 
Failure 
Stroke 
Peripheral 
Arterial 
Disease 
 
          
80-
89 
 0.7 (0.7-0.7)   0.6 (0.6-0.7) 0.7 (0.6-0.8) 
Antikainen, 
1998(287)
 21,493 2,295   HT
h
 W 
45-
64 
 2.3 (1.6-3.4)   4.4 (2.3-8.4)  
          M   1.9 (1.6-2.3)   3.3 (1.9-5.8)  
HR/RR in merged cells indicates combined endpoint; SBP and DBP per standard deviation unless otherwise specified. Studies adjusted for additional co-variates included social 
factors (Conen, Dagenais, Gu, Sauvegnet), family history of CVD (Canoui-Poitrine, Jouven, O’Donnell), BP medication (Canoui-Poitrine, Gu).HR indicates hazard ratio; RR, relative 
risk; CI, confidence interval; CVD, cardiovascular disease; BP, blood pressure; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure; HT, 
hypertension; M,  men; W, women; ns – not specified in paper; 
a
 Includes unstable angina; 
b
 SA here coronary revascularisation only; 
c Venous thromboembolism included as a 
competing risk; 
d
 AMI here fatal AMI only;  
f 
HR per quintile -  reference category <125 mmHg SBP and <78 mmHg DBP; 
g
 AMI here non-fatal AMI only;  
h
 Stage 1 hypertension 
(140-159 mmHg SBP and 90-99 mmHg DBP,  other hypertension categories also given in paper;  
j
 HR for reduction of 20 mm Hg SBP and of 10 mm Hg DBP. 
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4. Methods 
The data sources, population, risk factor and endpoint definitions, as well as composition 
of the cohort, are described in detail in Chapters 3 and 4. These are, however, briefly 
summarised here for ease of reference. Any methodological details specific to the set of 
analyses in this chapter are also noted.  
4.1. Data sources 
The data sources are described more fully in Chapter 3. In brief, the Cardiovascular 
disease research using Linked Bespoke studies and Electronic Records (CALIBER) e-
health research platform links NHS primary care data from the General Practice Research 
Database (GPRD),(76) to data for acute coronary syndrome (ACS) admissions from the 
Myocardial Ischaemia National Audit Project registry (MINAP),(98) NHS hospital 
admissions data from Hospital Episodes Statistics (HES),(230) and mortality and social 
deprivation data from the Office of National Statistics (ONS).(113,123) Records were 
primarily linked using a pre-defined deterministic linkage algorithm based on NHS 
number, with a small minority linked using a probabilistic method using DOB and 
postcode.(77) A web-based portal documenting the creation of all CALIBER data items, 
from these multiple data sources, is available at www.caliberresearch.org and further 
details on the creation of the CALIBER research platform have been publish 
elsewhere.(231) 
4.2.  Population 
The identification of the general cohort is described in detail in Chapter 3. For the analysis 
in this chapter, the cohort was restricted to those patients who had at least one blood 
pressure measurement in the two years prior to endpoint follow-up. In the overall cohort 
for this PhD, I found 45.3% of adult patients had no such blood pressure measurement. 
Further information on patients excluded due to missing blood pressure data are given in 
Chapter 4. 
4.3. Blood pressure measurements 
Blood pressure used in the present study was measured in general practice as part of 
routine clinical care. Since April 2004, UK general practitioners have received 
performance-related pay, worth approximately 25% of a practice’s income,(81) for 
measuring and recording a number of health indicators, including annual blood pressure 
measurements of anyone over 45 or with hypertension, coronary heart disease, chronic 
kidney disease or diabetes.  Consequently, recording of key indicators increased 
substantially,(85) with over 80% of adults on average having blood pressure 
recorded.(305) Among the patients in this thesis cohort with at least one blood pressure 
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measurement, patients had a median of 3 blood pressure measurements (interquartile 
range:  1-10). I calculated mean systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) recording from the two years prior to endpoint follow-up as my baseline 
measurements.  
4.4. Other risk factors 
More detailed information on the definition of other risk factors is given in Chapter 3. To 
recapitulate briefly, I defined the other risk factors as follows.  Except for ethnic group, all 
these risk factors were taken from GPRD data. Gender was defined as the gender recorded 
in the GPRD patient data file. Age at entry was defined as the age in years in January of the 
year of study entry. Social deprivation was measured by the index of multiple deprivation 
(IMD) 2007,(123) dividing IMD into quintiles.  Ethnic group was categorised as White, 
Black, South Asian or Other, using self-reported ethnic group recorded in GPRD and HES, 
with unresolvable code conflicts between the two data sources recorded as missing. 
Smoking status was defined as the GPRD record of smoking status with the last possible 
date before study entry and categorised as non-smoker, ex-smoker, or current smoker. If 
non-smokers had a previous record indicating smoking in their history, they were 
counted as an ex-smoker. For all remaining risk factors, I used the most recent record 
from GPRD in the two years before study entry. Total cholesterol level was taken from 
laboratory results from plasma or serum samples, recorded mmol/L units. Lipid-lowering 
medication at baseline was derived from one or more prescriptions for a statin.  Diabetes 
mellitus was defined as a diagnosis of Type 1, Type 2 or unspecified diabetes or at least 
one prescription for insulin or oral hypoglycaemic agent.  Body mass index (BMI) was 
defined as weight in kilograms over height in metres squared. The number of different 
blood pressure-lowering medication classes prescribed was based on prescriptions for 
thiazides, potassium-sparing diuretics, beta-blockers, ace inhibitors and other less 
common medications. A complete list of drug classes and specific preparations is available 
in Appendix D.  
4.5. Outcomes:  Initial symptomatic presentations of cardiovascular 
disease 
The definition of my primary endpoints are described in more detail in Chapter 3, with 
additional information on the contribution of the different data sources to each endpoint 
described in Chapter 4.  To summarise briefly, my primary endpoints were fatal and non-
fatal presentations of a range of cardiovascular disease phenotypes encompassing 
coronary heart disease (stable angina, unstable angina, coronary heart disease not 
otherwise specified (CHD NOS), ST-elevation myocardial infarction (STEMI), non-ST-
elevation myocardial infarction (NSTEMI), myocardial infarction not otherwise specified 
(MI NOS), and coronary death unheralded by prior symptomatic disease (UCD)), stroke, 
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peripheral arterial disease, abdominal aortic aneurysm (AAA), heart failure and 
ventricular arrhythmias including cardiac arrest and sudden cardiac death (SCD).  Given 
the limited number of myocardial infarctions specified as STEMI or NSTEMI, the main 
analyses used a composite endpoint of all acute myocardial infarctions (AMI) as an 
endpoint. Secondary analyses with specific myocardial infarction types have also been 
presented.  For ease of comparison with previous studies, a composite endpoint of AMI 
and unheralded coronary death has also been included.  Diagnoses were identified using 
codes from the International Classification of Diseases 10th Revision (ICD 10)(232) for the 
hospital data (HES) and mortality data (ONS), from Read Codes(78) for primary care data 
(GPRD) and bespoke variables in the ACS registry (MINAP).   
4.6. Statistical analysis 
The principal analysis assessed the relationship between SBP and DBP separately, as 
linear continuous variables, with the initial presentation of all of the cardiovascular 
presentations. I developed a stratified Cox proportional hazard model  for competing 
risks, using data augmentation,(184) to estimate the hazard ratios and 95% confidence 
intervals  for one standard deviation difference in SBP and DBP  for each presentation.   
The SBP and DBP measurements were scaled using the standard deviation estimated 
from the entire cohort, with the same standard deviation used in all analyses.  Although 
there are cogent arguments against using standardised regression coefficients as the 
measure of effect, not least because such a practice does not allow comparison between 
studies,(306) I took this approach here to allow direct comparison between SBP and DBP 
within the current study. Without this standardisation, these two measures of blood 
pressure could not be compared to each because they are measured on different 
scales.(284,300) The cohort-wide standard deviation for SBP at baseline in the cohort 
was 18.9 mmHg, and for DBP, 10.0 mmHg, similar to 20 mmHg SBP and 10 mmHg used to 
report BP in the Prospective Studies Collaboration study of  blood pressure.(283) 
I produced three models for each measure of blood pressure, the first adjusted for gender, 
age and age-squared, the second also adjusted for deprivation, smoking, use of statins, 
and diabetes, and the third also including a shared frailty term to take account of patients 
clustered at general practice level. Given the level of missingness in ethnic group, lipids 
and BMI, these variables were not included in the principal analyses. I explicitly tested for 
interaction between gender and SBP and DBP and age and SBP and DBP.  Subsequently, 
models stratified for gender and for age were estimated to test whether these modified 
the association of SBP and DBP with the range of endpoints. All analyses were conducted 
on complete cases.  I used the Efron method to deal with tied failure times (except for the 
model for stroke in women where Breslow method had to be used for the model to 
converge). (190)   
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Multiple imputation for missing data was not undertaken, as there is some evidence that, 
at least for some risk factors, data recorded in these kind of primary care data are not 
missing at random.(180,273)The existence of heterogeneity in the hazard ratios (HRs) 
was formally tested using the I-squared (I2) test for heterogeneity, while the extent of the 
heterogeneity across CVD phenotypes was estimated using Tau-squared (Τ2).(189)  
 
Given the digit preference for recording blood pressure measurements in multiples of ten 
evident from the data (See Figure 28 below), I  also investigated whether modelling the 
association of BP with my endpoints using categories of blood pressure centred around 
the preferred digits produced similar results to those using continuous BP variables. For 
SBP,  I used the following categories <124, 125-134, 135-144, 145-154, 155-164, 165+ 
mmHG  and for  DBP, <75, 75-84, 85-94, 95-104, 105+ mmHg).   I tested the proportional 
hazards assumption for SBP and DBP visually using log-log plots on these categorical SBP 
and DBP variables. I also tested whether the standard deviation of SBP and DBP was 
substantially influenced by the digit preference evident in the data. If all values that were 
multiples of 10 were dropped from the dataset, the standard deviation was similar to that 
derived from all measurements, leading to the conclusion that the standard deviation was 
not influenced by GPs’ digit preference. 
 
Continuous variables are shown as the mean (standard deviation) and categorical 
variables shown as frequencies (percentage). All analyses were performed using STATA 
version 12 (StataCorp, 4905 Lakeway Drive, College Station, TX 77845, United States). 
 
I have first presented the association between SBP and DBP with presentations in the 
cerebral, coronary, abdominal and peripheral arterial circulations (Stroke, AMI plus UCD 
presentations, AAA, and PAD) and then with the specific cardiac presentations (stable 
angina, unstable angina, CHD NOS, AMI, ventricular arrhythmias/cardiac arrest/sudden 
cardiac death combined, heart failure and UCD).  Finally, the specific myocardial 
infarction subtypes (STEMI, NSTEMI, and MI NOS) have been presented in Appendix H. 
5. Results 
797,234 patients, from the overall healthy cohort of 1,758,584, did not have a BP 
measurement recorded at baseline. Therefore a total of 961,350 patients (581,580 
women and 379,770 men) met the inclusion criteria for this set of analyses. (Further 
information on difference between patients with missing data and those with complete 
data is given in Chapter 4.) Women had a follow-up time from study entry of 2,952,608 
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person years and men, 1,792,417 person years, with a median of 4.94 person years (1.92-
9.09) for women and 4.25 (1.73 -8.20) for men.   
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Figure 28: Distribution of systolic and diastolic blood pressure before study entry showing digit preference in recording 
 
BP indicates blood pressure.  
   
186 
 
5.1. Baseline characteristics 
The baseline characteristics of the cohort y are shown in Table 24 and Table 25 below, 
stratified by 10 mmHg bands of SBP and DBP. As expected, the mean age increased with 
each increase in BP category, for both SBP and DBP.  Women formed a greater proportion 
of the lower blood pressure categories, as did those from Black and South Asian ethnic 
groups, though it should be noted that ethnic group is missing for 32% of the cohort. The 
proportion of ex-smokers increased with SBP and DBP levels, as did the proportion of 
patients on statins. The proportion of patients with a diabetes diagnosis increased with 
SBP but not DBP.   The mean BMI did not vary appreciably across the levels of SBP but did 
increase with levels of DBP.
   
187 
 
Table 24: Characteristics of cohort stratified by systolic blood pressure levels  
Systolic Blood pressure <120 120-129 130-139 140-149 150-159  160 
Number 258,907 204,238 183,364 147,367 88,442 79,032 
Age at cohort entry in years, mean (95% CI) 39.6 (10.1) 43.7 (12.5) 49.0 (14.3) 55.4 (14.8) 61.0 (14.1) 66.4 (13.5) 
Female, % 197,612 (76.3) 121,861 (59.7) 93,738 (51.1) 73,804 (50.1) 47,793 (54) 46,772 (59.2) 
Ethnic group:    White 128,634 (83.6) 100,286 (87.8) 91,704 (89.6) 78,468 (92.2) 49,703 (94) 46,921 (95.2) 
                               Black 6,523 (4.2) 4,392 (3.8) 3,617 (3.5) 2,460 (2.9) 1,275 (2.4) 1,026 (2.1) 
                               South Asian 8,394 (5.5) 4,238 (3.7) 3,160 (3.1) 1,910 (2.2) 932 (1.8) 587 (1.2) 
Deprivation:      Least deprived quintile 53,894 (20.9) 41,440 (20.4) 36,659 (20.1) 29,494 (20.1) 17,403 (19.7) 14,337 (18.2) 
                              Most deprived quintile 53,001 (20.6) 40,732 (20.0) 35,519 (19.5) 27,759 (18.9) 16,827 (19.1) 15,590 (19.8) 
Smoking status:  Ex-smoker 39,112 (15.9) 33,117 (17.1) 31,993 (18.5) 27,936 (20.4) 17,360 (21.3) 14,881 (21) 
                              Current smoker 66,939 (27.2) 52,732 (27.3) 43,586 (25.2) 31,125 (22.7) 16,688 (20.5) 14,093 (19.9) 
Total cholesterol in mmol/L, mean (sd) 5.2 (1.1) 5.3 (1.2) 5.4 (1.1) 5.5 (1.1) 5.6 (1.1) 5.7 (1.1) 
On statins  2,869 (1.1) 5,461 (2.7) 9,029 (4.9) 10,111 (6.9) 6,654 (7.5) 5,240 (6.6) 
Diabetes mellitus 4,209 (1.6) 6,237 (3.1) 9,017 (4.9) 9,262 (6.3) 6,508 (7.4) 5,844 (7.4) 
BMI in kg/m2, mean (sd) 24.5 (4.5) 26.3 (5) 27.4 (5.3) 28.1 (5.5) 28.4 (5.6) 28.4 (5.8) 
Classes of BP lowering medication:                 0 251,640 (97.2) 191,017 (93.5) 155,880 (85) 106,247 (72.1) 50,933 (57.6) 36,779 (46.5) 
                                               1  6,218 (2.4) 9,968 (4.9) 19,348 (10.6) 28,433 (19.3) 26,429 (29.9) 29,825 (37.7) 
                                                                       2    831 (0.3) 2,560 (1.3) 6,389 (3.5) 9,927 (6.7) 8,565 (9.7) 9,554 (12.1) 
                                                                       3+ 218 (0.1) 693 (0.3) 1,747 (1) 2,760 (1.9) 2,515 (2.8) 2,874 (3.6) 
Values are n (%) unless otherwise specified. CI indicates confidence interval; sd, standard deviation; BMI, body mass index; BP, blood pressure. Data presented 
for subset of patients for ethnic group (n=557,615 (58.0%)), deprivation status (n=957,382 (99.6%)), smoking status (n=901,629 (93.8%)), total cholesterol 
(n=185,223 (19.3%)), BMI (n=627,175 (65.2%)). 
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Table 25: Characteristics of cohort stratified by diastolic blood pressure levels 
Diastolic Blood pressure <70 70-79 80-89 90-99  100 
Number of patients 133,837 315,352 362,809 126,425 22,927 
Age at cohort entry in years, mean (sd) 41.2 (13.5) 46.1 (15.2) 51.9 (15.4) 54.5 (14.2) 53.6 (13.6) 
Female, % 101,897 (76.1) 207,461 (65.8) 200,817 (55.4) 61,929 (49) 9,476 (41.3) 
Ethnic group:     White 68,863 (84.6) 160,954 (87.8) 188,143 (90.6) 66,284 (91.3) 11,478 (89.7) 
                               Black 3,276 (4) 6,533 (3.6) 6,320 (3) 2,527 (3.5) 637 (5) 
                               South Asian 4,104 (5) 6,968 (3.8) 6,097 (2.9) 1,757 (2.4) 295 (2.3) 
Deprivation:        Least deprived quintile 28,438 (21.3) 64,008 (20.4) 72,663 (20.1) 24,088 (19.1) 4,030 (17.6) 
                              Most deprived quintile 27,458 (20.6) 62,230 (19.8) 69,541 (19.2) 25,054 (19.9) 5,145 (22.5) 
Smoking status:  Ex-smoker 21,402 (16.9) 52,966 (17.7) 63,338 (18.7) 22,863 (19.6) 3,830 (18.5) 
                              Current smoker 34,450 (27.1) 77,150 (25.8) 81,066 (23.9) 26,986 (23.1) 5,511 (26.7) 
Total cholesterol in mmol/L, mean (sd) 5.1 (1.1) 5.3 (1.1) 5.5 (1.1) 5.6 (1.1) 5.7 (1.1) 
On statins  2,403 (1.8) 11,373 (3.6) 17,529 (4.8) 6,896 (5.5) 1,163 (5.1) 
Diabetes mellitus 3,217 (2.4) 13,681 (4.3) 17,576 (4.8) 5,709 (4.5) 894 (3.9) 
BMI in kg/m2, mean (sd) 24.0 (4.1) 25.7 (4.8) 27.4 (5.3) 29.1 (5.8) 30.1 (6.2) 
Classes of BP lowering medication:   0 127,562 (95.3) 282,991 (89.7) 287,042 (79.1) 81,377 (64.4) 13,524 (59) 
                                                                       1 4,538 (3.4) 22,089 (7) 52,813 (14.6) 33,481 (26.5) 7,300 (31.8) 
                                                                       2 1,208 (0.9) 7,627 (2.4) 18,148 (5) 9,224 (7.3) 1,619 (7.1) 
                                                                       3+ 529 (0.4) 2,645 (0.8) 4,806 (1.3) 2,343 (1.9) 484 (2.1) 
Values are n (%) unless otherwise specified. CI indicates confidence interval; sd, standard deviation; BMI, body mass index; BP, blood pressure. Data presented 
for subset of patients for ethnic group (n=557,615 (58.0%)), deprivation status (n=957,382 (99.6%)), smoking status (n=901,629 (93.8%)), total cholesterol 
(n=185,223 (19.3%)), BMI (n=627,175 (65.2%)). 
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5.2. Events 
Amongst patients with complete data for this chapter’s analyses, there were a total of 
52,581 CVD endpoints with a further 26,590 deaths from other causes. The number of 
specific CVD presentations for women and men are shown in Table 21 above, in 
descending order of frequency of CVD presentation in women. 
Table 26: Number of specific initial presentations for women and men 
 Women Men 
Presentation n % CVD n % CVD 
Stable angina 6,495 24.4 5,686 21.3 
Stroke 5,039 18.9 3,448 12.9 
Heart Failure 4,026 15.1 2,933 11.0 
Peripheral arterial disease 2,810 10.5 2,828 10.6 
Acute myocardial infarction (all) 2,747 10.3 3,943 15.2 
     Myocardial infarction NOS 2,258 8.5 3,160 11.9 
     Non-ST elevation myocardial infarction 329 1.2 450 1.7 
     ST elevation myocardial infarction 160 0.6 333 1.2 
Coronary heart disease NOS 2,141 8.0 2,520 9.5 
Unheralded coronary death 1,114 4.2 2,933 11.0 
Vent arrhythmias, cardiac arrest & sudden cardiac 
death 
971 3.6 1,280 4.8 
Unstable angina 875 3.3 910 3.4 
Abdominal aortic aneurysm  435 1.6 1,007 3.8 
All cardiovascular disease presentations 26,653 -- 25,928 -- 
Deaths from other causes 15,369 -- 11,221 -- 
Presentations listed in order of frequency in women. CVD indicates cardiovascular disease; 
NOS, not otherwise specified.  
 
5.3. Testing Model Assumptions 
The proportion hazard assumption, tested using the log-log graphs using the categorical 
variables for SBP and DBP, was broadly met for most endpoints although there was some 
overlap between the hazard lines. The presentations where the hazards were less 
proportional were AAA, unstable angina, and ventricular arrhythmias for both SBP and 
DBP and for unheralded coronary death for SBP only. However, given the size of the 
current cohort any test of proportional hazard is likely to be violated.  I therefore decided 
that using the Cox proportional hazard model would be a reasonable approach to 
modelling the association between initial presentations and blood pressure. These graphs 
are shown in Appendix H.   
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5.4. Association of blood pressure with initial presentation of stroke, 
acute MI and unheralded coronary death, peripheral artery disease 
and abdominal aortic aneurysm 
5.4.1. Overall 
For all patients in the age-adjusted model, one SD increase in SBP was associated with a 
moderate increased risk (25%) of an initial presentation of CVD with stroke, acute MI/ 
coronary death and PAD, but not AAA.  Ignoring AAA, the lowest HR for an increase in SBP 
was associated with stroke and highest with PAD. Heterogeneity between the HRs was 
minimal, with a variance between the HRs, as measured by Τ2, of 0.0107. In contrast, one 
SD increase in DBP was associated with a moderate risk of an initial presentation with 
stroke, acute MI/ coronary death and AAA, but not PAD.    Ignoring PAD, the lowest HR for 
an increase in DBP was acute MI/coronary death and the highest with AAA. Again, 
heterogeneity between the HRs for DBP presentations was limited (Τ2= 0.0060).  These 
results are shown in Figure 29.  
 
The inclusion of additional variables in the multivariable Cox proportional hazard model 
had minimal effect on the size of the HR except for HR for DBP and PAD, where the HR 
and 95% CI increased above 1 (Figure 30).  Adding a random effect variable for GP 
practice into the model also had minimal impact on the effect estimates (Figure 31). 
 
Given the sizeable differences in effect estimates of the association with peripheral 
arterial disease between SBP and DBP, in a post-hoc analysis I examined whether this 
finding could be the result of outlying values by estimating a model with measurements 
below the 5th centile and above the 95th centile. Although the effect size was slightly 
reduced, the effect estimate for DBP remained substantially lower than that for SBP.  
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Figure 29: Age-adjusted hazard ratios for initial presentations of cardiovascular disease associated with 1 standard deviation increase in 
systolic and diastolic blood pressure overall and in women and men 
 
Hazard ratios for mean systolic or diastolic blood pressure at baseline (per 1 standard deviation (sd)), adjusted for age at baseline in men and women, and 
additionally for sex in all patients, in complete cases. N= 897,892. For SBP, 1 sd = 18.9 mmHg; for DBP, 1 sd=10 mmHg. Endpoints ordered by size of HR in all 
patients. MI indicates myocardial infarction; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; SBP, systolic blood pressure. *Sex-BP 
interaction not included in model used to estimate HR for figure. 
   
192 
 
Figure 30: Multivariate adjusted hazard ratios for initial presentations of cardiovascular disease associated with 1 standard deviation increase 
in systolic and diastolic blood pressure overall and in women and men 
 
Hazard ratios for mean systolic or diastolic blood pressure at baseline (per 1 standard deviation (sd)), adjusted for age at baseline, sex, deprivation (index of 
multiple deprivation quintile), smoking status (current smoker, ex-smoker, non-smoker), diabetes mellitus (yes/no) and statin use at baseline (yes/no) , in 
complete cases. N= 897,892. For SBP, 1 sd = 18.9 mmHg; for DBP, 1 sd=10 mmHg. MI indicates myocardial infarction; CI, confidence interval; DBP, diastolic 
blood pressure; HR, hazard ratio; SBP, systolic blood pressure. *Sex-BP interaction not included in model used to estimate HR for figure. 
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Figure 31: Multivariate adjusted hazard ratios (with random effects for GP practice) for initial presentations of cardiovascular disease 
associated with 1 standard deviation increase in systolic and diastolic blood pressure overall and in women and men 
 
 
Hazard ratios for mean systolic or diastolic blood pressure at baseline (per 1 standard deviation (sd)), adjusted for age at baseline, sex, deprivation (index of 
multiple deprivation quintile), smoking status (current smoker, ex-smoker, non-smoker), diabetes mellitus (yes/no) and statin use at baseline (yes/no), , with 
frailty term to take account of clustering at practice level, in complete cases. N= 897,892. For SBP, 1 sd = 18.9 mmHg; for DBP, 1 sd=10 mmHg. MI indicates 
myocardial infarction; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; SBP, systolic blood pressure. *Sex-BP interaction not included in 
model used to estimate HR for figure. 
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5.4.2. Modification of effect of SBP and DBP by gender 
As can be seen from Figure 29 to Figure 31 above, there were no gender differences in the 
association of SBP with the initial presentations of acute MI/coronary death and PAD, but 
men were at somewhat greater risk of stroke from increases in SBP than women.  
Increases in SBP appear to have a protective effect in women for AAA, but not in men; 
however, given the limited number of AAA events in women these results should be 
treated with caution.  In both men and women, the association of SBP with these 
endpoints was heterogeneous, but with minimal variance in the association between SBP 
and the endpoints (men I2= 97.7%, Τ2= 0.0105; women I2=98.0%, Τ2=0.0111). Men were 
also at greater risk of stroke from increases in DBP compared to women, but the gender 
differences were smaller. There were no other gender differences in the association of 
DBP with the other endpoints. The extent of heterogeneity in the association of DBP with 
the endpoints was minimal in both men and women (men I2= 96.7%, Τ2= 0.0073; women 
I2=94.4%, Τ2=0.0045). 
 
I explicitly tested for interaction between blood pressure and gender, across these 
endpoints. The hazard ratios for the interaction terms, with 95% confidence interval and 
p-value are shown in Appendix H, along with the results of the likelihood ratio test 
comparing the model with the interaction term to the model without.  Stroke was the only 
endpoint where the interaction term was significant showing a smaller effect of increase 
in both systolic and diastolic blood pressure on the hazard of stroke in women compared 
to men. The inclusion of the interaction term marginally improved the fit of the model.   
5.4.3. Categorical SBP and DBP variables 
Similar results were found when the associations of SBP and DBP with these endpoints 
were modelled using categorical blood pressure measures, with categories centred on the 
ten-digit numbers, rather than continuous measures of SBP and DBP. There was an 
increasing trend with each increase in BP category across the endpoints where the 
continuous variable showed an increased hazard (i.e. for stroke and AMI/coronary death 
with SBP and DBP, for PAD with SBP and for AAA with DBP) and no increasing trend 
where there was no positive association with the continuous BP variable and endpoint. 
The hazard between the lowest and the highest categories of SBP doubled for stroke, 
acute MI/coronary death and PAD.  The hazard of AAA and stroke tripled from lowest to 
highest category of DBP and doubled for acute MI/coronary death. Additionally, there was 
an increased hazard for all endpoints for the highest categories of both SBP and DBP 
(Figure 32). As with the continuous SBP and DBP variables, there was little change to the 
estimates with the inclusion of additional variables into the model (Figure 33).  
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The gender difference identified with continuous blood pressure measure was replicated 
in these analyses, but the excess hazard for stroke in men was restricted to the highest BP 
categories (165+ mmHG SBP and 105+ mmHg DBP).  
 
Given the linear trend evident in these categorical analyses, no attempt was made to 
improve the fit to the data with inclusion of quadratic terms for SBP and DBP.  
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Figure 32: Age-sex adjusted hazard ratios for initial presentations of cardiovascular disease by baseline systolic and diastolic blood pressure 
categories 
Hazard ratios for blood pressure 
category compared to lowest 
category (SBP: <125 mmHg; DBP: 
<75 mmHg), adjusted for age at 
baseline and gender, in complete 
cases. N= 897,892. MI indicates 
myocardial infarction; CI, 
confidence interval; DBP, diastolic 
blood pressure; SBP, systolic 
blood pressure.
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Figure 33: Multivariable adjusted hazard ratios for initial presentations of cardiovascular disease for baseline systolic and diastolic blood 
pressure categories 
 
Hazard ratios for blood pressure 
category compared to lowest 
category (SBP: <125 mmHg; 
DBP: <75 mmHg), adjusted for 
age at baseline, gender, 
deprivation (index of multiple 
deprivation quintile), smoking 
status (current smoker, ex-
smoker, non-smoker), diabetes 
mellitus (yes/no) and statin use 
at baseline (yes/no) , in complete 
cases. N= 897,892. MI indicates 
myocardial infarction; CI, 
confidence interval; DBP, 
diastolic blood pressure; SBP, 
systolic blood pressure.
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5.5. Association of blood pressure with cardiac diseases 
5.5.1. Overall 
As with cardiovascular endpoints across all four arterial beds, there was a modest 
increased risk (20-25%) with each standard deviation increase in SBP in the age-adjusted 
model. For most presentations, there was a slightly smaller increased hazard for DBP 
(~15%) with the exception of unstable angina and CHD NOS where the hazard was the 
same between SBP and DBP.  However, all these differences were small (Figure 34). There 
was also little heterogeneity in the association between blood pressure (both systolic and 
diastolic) and the different cardiac endpoints for patients overall, reflected in the low Tau-
squared for both SBP and DBP (SBP: I2= 98.9%, Τ2= 0.0138; DBP: I2= 97.9%, Τ2= 0.0079).   
 
As with stroke, AAA, PAD and the composite CHD endpoint, the multivariable adjusted 
model slightly attenuated the effect estimates across all endpoints (Figure 35). Inclusion 
of a random effect variable for GP practice in the model had minimal impact on the effect 
estimates (Figure 36below).  
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Figure 34: Age-adjusted hazard ratios for initial presentations of cardiac disease associated with 1 standard deviation increase in systolic and 
diastolic blood pressure overall and in women and men  
 
Hazard ratios for mean systolic or 
diastolic blood pressure at baseline 
(per 1 standard deviation (sd)), 
adjusted for age at baseline and 
gender, in complete cases. N= 
897,892. For SBP, 1 sd = 18.9 
mmHg; for DBP, 1 sd=10 mmHg.  
CI indicates confidence interval; 
DBP, diastolic blood pressure; NOS, 
not otherwise specified; SBP, 
systolic blood pressure; Vent 
arrhyth, ventricular arrhythmias.
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Figure 35: Multivariable adjusted hazard ratios for initial presentations of cardiac disease associated with 1 standard deviation increase in 
systolic and diastolic blood pressure overall and in women and men 
 
Hazard ratios for mean systolic or 
diastolic blood pressure at baseline 
(per 1 standard deviation (sd)), 
adjusted for age at baseline, sex, 
deprivation (index of multiple 
deprivation quintile), smoking 
status (current smoker, ex-smoker, 
non-smoker), diabetes mellitus 
(yes/no) and statin use at baseline 
(yes/no), in complete cases. N= 
897,892. For SBP, 1 sd = 18.9 
mmHg; for DBP, 1 sd=10 mmHg. MI 
indicates myocardial infarction; CI, 
confidence interval; DBP, diastolic 
blood pressure; SBP, systolic blood 
pressure. *Sex-BP interaction not 
included in model used to estimate 
HR for figure.
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Figure 36: Multivariable adjusted hazard ratios (with random effects for GP practice) for initial presentations of cardiac disease associated 
with 1 standard deviation increase in systolic and diastolic blood pressure overall and in women and men 
 
Hazard ratios for mean systolic 
or diastolic blood pressure at 
baseline (per 1 standard 
deviation (sd)), adjusted for 
age at baseline, sex, deprivation 
(index of multiple deprivation 
quintile), smoking status 
(current smoker, ex-smoker, 
non-smoker), diabetes mellitus 
(yes/no) and statin use at 
baseline (yes/no) with frailty 
term for general practice, in 
complete cases. N= 897,892. 
For SBP, 1 sd = 18.9 mmHg; for 
DBP, 1 sd=10 mmHg. CI 
indicates confidence interval; 
DBP, diastolic blood pressure; 
SBP, systolic blood pressure; 
NOS, not otherwise specified. 
*Sex-BP interaction not 
included in model used to 
estimate HR for figure.
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5.5.2. Modification of effect of SBP and DBP by gender 
The effect of SBP and DBP on the ventricular arrhythmias was clearly modified by gender, 
with a substantially increased hazard for women compared to men from increases in both 
SBP and DBP.  Other gender differences were less clear, although men appeared to have a 
greater hazard than women of unheralded coronary death from increases in SBP and DBP 
and of unstable angina from increases in DBP only.  Women appeared to have a greater 
hazard than men of acute MI and CHD NOS from increases in SBP only.  
 
In my modelling of association of SBP and DBP with the specific cardiac endpoints, the 
interaction term with gender and BP was only significant for the arrhythmias, showing 
increased risk for women compared to men with each standard deviation change in SBP, 
and to a lesser extent for DBP.  See Appendix H for the HR for the interaction term and the 
likelihood ratio (LR) test values and p values for the model fit comparing the model with 
the interaction term and without.  
5.5.3. Categorical SBP and DBP variables 
The hazard of SBP increased twofold from a SBP below <125 mmHg to a SBP 165+ mmHg 
across most presentations, with a broadly linear progression for each 10 mmHg increase. 
The increase in hazard from lowest to highest SBP was smallest for unstable angina 
(67%) and highest for CHD NOS (227%).  With the stable angina and CHD NOS endpoints, 
the rate of increased appeared to slow above 154 mmHg.  For DBP, the hazard also 
doubled from the lowest (<75 mmHg) to the highest (105+) category, again with a 
broadly linear progression for each 10 mmHg increase. The smallest increase was for 
stable angina (60%) and the largest was for heart failure (240%). (See Figure 37.)  
 
There was little change in these effects with the addition of other variables to the model. 
(Figure 38)  These results are similar to those found when the association of SBP and DBP 
with the cardiac endpoints was modelled using continuous variables. As with the 
continuous SBP variables, SBP had greater association with arrhythmias in women than 
in men, although only at SBP of 145 mmHg or greater. There were no gender differences 
in the association of DBP with cardiac endpoints.  
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Figure 37: Age-sex adjusted hazard ratios for initial presentations of cardiac 
disease associated with categorical increase in  baseline systolic  blood pressure 
(A) and diastolic blood pressure (B) 
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Hazard ratios for blood pressure category compared to lowest category (SBP: <125 mmHg; 
DBP: <75 mmHg), adjusted for age at baseline and gender, in complete cases. N= 897,892. CI 
indicates confidence interval; DBP, diastolic blood pressure; NOS, not otherwise specified; 
SBP, systolic blood pressure; Vent arrhyth, ventricular arrhythmias. 
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Figure 38: Multivariable adjusted hazard ratios for initial presentations of cardiac 
disease associated with categorical increased in  baseline systolic  blood pressure 
(A) and diastolic blood pressure (B) 
 
 
   
206 
 
 
Hazard ratios for blood pressure category compared to lowest category (SBP: <125 mmHg; 
DBP: <75 mmHg), adjusted for age at baseline, sex, deprivation (index of multiple 
deprivation quintile), smoking status (current smoker, ex-smoker, non-smoker), diabetes 
mellitus (yes/no) and statin use at baseline (yes/no) , in complete cases. N= 897,892. CI 
indicates confidence interval; DBP, diastolic blood pressure; NOS, not otherwise specified; 
SBP, systolic blood pressure; Vent arrhyth, ventricular arrhythmias. 
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5.6. Association of blood pressure with specific AMI subtypes 
When acute myocardial infarction is divided into the constituent endpoints of STEMI, 
nSTEMI and MI NOS, the pattern of homogeneity of effect among endpoints, no gender 
interaction and similar effect size between diastolic and systolic seen with acute MI 
overall remains unchanged.  (See Appendix H for figures.) No interaction effects between 
gender and either systolic or diastolic blood pressure were significant. (See Appendix H 
for table with interaction effects) 
 
5.7. Modification of Association by Age 
The strength of association with increases in both SBP and DBP and the initial CVD 
presentations of stroke, AMI and UCD, and peripheral arterial disease declined with each 
additional decade of age up to age 70-79; thereafter there was a slight increase in the 
strength of association, particularly with DBP.  The modification by age of the association 
between SBP and DBP with AAA was less clear, but is potentially also consistent with a 
linear decrease up to age 70-79. (See Figure 41 below.) Age modified the effect of SBP and 
DBP on stroke to the greatest extent and on peripheral arterial disease to the least extent, 
but these differences were small. The impact of age on the association of SBP and DBP 
with these endpoints remained unchanged in the multivariable model, although the effect 
estimates were attenuated, particularly for peripheral arterial disease. (See Figure 42 
below.)   
 
Among most of the cardiac presentations, there was again a linear decreasing association 
between SBP and DBP and all the endpoints with each decade of age up to age 70-79, with 
slight increase in the association above age 80, particularly for DBP. The exceptions to this 
pattern were unstable angina and unheralded coronary death where the association 
continued to decline above age 70-79. There was greater heterogeneity in the 
modification of SBP and DBP by age among the cardiac presentations than among the 
other CVD presentations, with more marked effects of an increase in blood pressure on 
unheralded coronary death and heart failure in younger age groups, compared to the 
other presentations. Estimates were slightly attenuated in the multivariable model, but 
otherwise the patterns of associations remained unchanged.  
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Figure 39: Sex adjusted hazard ratios for initial presentations of cardiovascular disease associated with 1 standard deviation increase in 
systolic and diastolic blood pressure, stratified by age group 
 
 
 
 
Hazard ratios for mean systolic 
or diastolic blood pressure at 
baseline (per 1 standard 
deviation (sd)), adjusted for 
age at baseline and gender, in 
complete cases, stratified by 
age group. HRs for <40 and 90+ 
years not shown.  N= 897,892. 
For SBP, 1 sd = 18.9 mmHg; for 
DBP, 1 sd=10 mmHg. MI 
indicates myocardial 
infarction; CI, confidence 
interval; DBP, diastolic blood 
pressure; SBP, systolic blood 
pressure.
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Figure 40: Multivariable adjusted hazard ratios for initial presentations of cardiovascular disease associated with 1 standard deviation 
increase in systolic and diastolic blood pressure, stratified by age group  
 
 
 
 
Hazard ratios for mean systolic or 
diastolic blood pressure at baseline 
(per 1 standard deviation (sd)),  
adjusted for gender, deprivation 
(index of multiple deprivation 
quintile), smoking status (current 
smoker, ex-smoker, non-smoker), 
diabetes mellitus (yes/no) and statin 
use at baseline (yes/no), in complete 
cases, stratified by age group. HRs for 
<40 and 90+ years not shown.  N= 
897,892. For SBP, 1 sd = 18.9 mmHg; 
for DBP, 1 sd=10 mmHg. MI indicates 
myocardial infarction; CI, confidence 
interval; DBP, diastolic blood pressure; 
SBP, systolic blood pressure. 
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Figure 41: Hazard ratios, adjusted by gender, for initial presentations of cardiac 
phenotypes associated with 1 standard deviation increase in systolic blood 
pressure (A) and diastolic blood pressure (B), stratified by age group 
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Hazard ratios for mean systolic or diastolic blood pressure at baseline (per 1 standard 
deviation (sd)),adjusted for age at baseline and gender, in complete cases, stratified by age 
group. HRs for <40 and 90+ years not shown. . N= 897,892. For SBP, 1 sd = 18.9 mmHg; for 
DBP, 1 sd=10 mmHg. CI indicates confidence interval; DBP, diastolic blood pressure; NOS, 
not otherwise specified; SBP, systolic blood pressure; Vent arrhyth, ventricular arrhythmias. 
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Figure 42: Multivariable adjusted hazard ratios for initial presentations of cardiac 
phenotypes associated with 1 standard deviation increase in systolic blood 
pressure (A) and diastolic blood pressure (B), stratified by age group  
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Hazard ratios for mean systolic or diastolic blood pressure at baseline (per 1 standard 
deviation (sd)), adjusted for age at baseline, sex, deprivation (index of multiple deprivation 
quintile), smoking status (current smoker, ex-smoker, non-smoker), diabetes mellitus 
(yes/no) and statin use at baseline (yes/no), in complete cases, stratified by age group. HRs 
for <40 and 90+ years not shown.  N= 897,892. For SBP, 1 sd = 18.9 mmHg; for DBP, 1 sd=10 
mmHg. CI indicates confidence interval; DBP, diastolic blood pressure; NOS, not otherwise 
specified; SBP, systolic blood pressure; Vent arrhyth, ventricular arrhythmias.
 
6. Discussion 
I found in a cohort of almost 900,000 with more than 56,000 endpoints of 12 different 
types that SBP and DBP have broadly homogenous effects on most initial presentations of 
cardiovascular disease, with the exception of AAA and PAD.  The increased hazard 
associated with increases in SBP and DBP were evident even at the lowest blood pressure 
categories. While the effect of one standard deviation increase in SBP and DBP was 
moderate, the increase in hazard between patients with the lowest BP compared to those 
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with highest were doubled for SBP and, for some presentations, tripled for DBP.   There 
have been no other prospective cohorts in which such a range of initial presentations 
(both fatal and non-fatal) of cardiovascular disease have been assessed. Most cohorts do 
not take this approach; an ‘incident’ myocardial infarction, for example includes patients 
who have previously manifested other symptomatic cardiovascular disease. 
Understanding differences in the causes of onset versus the causes of progression of 
cardiovascular disease cannot be unpicked unless the onset of symptomatic 
cardiovascular disease is recognised across a range of potential presentations. The 
homogeneity in association with a wide range of initial presentations suggests a common 
physiological mechanism for the role of blood pressure in the onset of cardiovascular 
disease, regardless of initial presentation, with the exception of AAA and PAD.  
 
In each section below, I summarise my findings for each objective. I then describe the 
strengths and limitations of this set of analyses. The implications for clinical care, public 
health practice, and research of my findings from these and my other analyses are 
discussed in Chapter 8 – Conclusions and Recommendations.  
6.1. Summary of existing literature (Objective 1) 
The limited evidence on the association between blood pressure and the initial 
presentation of CVD suggest a possible increased risk of unheralded coronary death and 
stroke compared to acute MI, with no difference in risk between cardiac diseases. 
However, the available literature is limited by inclusion of few endpoints, small number of 
participants, the use of hypertension as the only measure of blood pressure and a lack of 
sex-specific estimates of risk in both men and women. One limitation of the search 
strategy was the omission of epidemiological studies using data from clinical trials; 
inclusion of such studies in the initial search might have yielded additional studies for 
inclusion in the review.  
6.2. Association of SBP and DBP with onset of symptomatic 
cardiovascular disease across a wide range of disease presentations 
(Objective 2)  
SBP and DBP are both positively associated with the initial presentation of CVD across all 
endpoints with the exception of SBP and AAA, where no effect of increasing SBP on onset 
of AAA was shown. With the exception of AAA, there is little heterogeneity in the size of 
the effect estimates, which range from an age-adjusted HR for one sd increase in SBP of 
1.19 (95% CI 1.16-1.22) for heart failure to 1.28 (1.24-1.31) for peripheral arterial 
disease. This relatively low effect estimate of the association of increases in BP with heart 
failure is surprising, given the generally strong association of two to three times the risk 
of heart failure with hypertension commonly  found in the general literature.(307) The 
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increased hazard associated raised SBP and DBP was evident with even the lowest blood 
pressure categories. While the increase in hazard is modest for one standard deviation, 
the differences in hazard between patients with the lowest and the highest categories of 
blood pressure are substantial: twofold for SBP and triple for DBP for some presentations.  
 
In addition to assessing the effect of blood pressure across such a wide range of 
presentations, examining the independent effects of SBP and DBP adds to the debate 
about which measures of blood pressure are the most accurate measure of risk. My 
findings indicate that for most presentations there is no difference between SBP and DBP, 
although SBP poses a slightly higher risk.  
 
The size of the effect estimates are consistent with some of previous studies which 
specifically examined initial presentation of CVD using more chronic CVD endpoints, such 
as stable angina and heart failure(222,301) but not all.(225) Previous studies which were 
restricted to acute forms of CVD (MI and stroke) found stronger associations with stroke 
than found in the current analyses, for both initial presentation(223,299,300) and first 
presentation within phenotype(286,304).  This discrepancy in findings indicates that not 
including a wider range of endpoints in any analysis of initial presentation may over-
estimate the effect of BP on onset of CVD with stroke but also suggests the importance of 
blood pressure in the development of stroke after onset of CVD with other presentations. 
When they become available, the findings of studies using the REACH registry, which is 
investigating subsequent events in patients with atherosclerotic disease, may provide 
further information on this point.(308)  
 
6.3. Differences in association of SBP and DBP with initial 
presentations of CVD (Objective 3) 
As mentioned above, the effect estimates for SBP are slightly higher than the estimates for 
DBP for all endpoints. The exceptions are a) PAD where the estimate for DBP was 
considerably lower than that for SBP and b) AAA where the effect estimate for DBP was 
significantly higher than that for SBP.  Unlike the current analyses, previous studies which 
have investigated the differences in different blood pressure measures have tended to 
focus on one or two individual presentations,(300) global CVD risk,(289) or 
mortality.(283) 
 
The lack of effect of increases in SBP on AAA is potentially inconsistent with previous 
studies which consistently show an effect of hypertension of AAA, (235,242) but most 
previous studies have used hypertension as the only blood pressure measure rather than 
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looking at the individual elements. One possible explanation for the lack of association of 
SBP with AAA is that patients also have dilation of thoracic aorta, causing lower resistance 
to the heart pumping and therefore lower SBP. 
 
6.4. Modification by gender and age (Objective 4)  
Men and women do not differ in the association of SBP and DBP with initial presentation 
of CVD endpoints, with the exception of stroke and the ventricular arrhythmias. Men have 
a greater hazard of SBP and DBP for initial presentation of stroke compared to women; 
the analysis of categorical measures of SBP and DBP indicates this difference is principally 
due to an effect at the highest SBP / DBP categories.  Women had a markedly higher 
hazard from increases in SBP/ DBP than men for ventricular arrhythmia, cardiac arrest 
and sudden cardiac death. 
 
No studies with multiple endpoints of initial presentation of CVD or first presentation 
within phenotype produced gender-specific effect estimates for SBP or DBP for 
comparison.  The existing literature on risks associated with increases in blood pressure 
which have looked at gender-specific effects have not found consistent associations. 
Sauvaget found a higher risk from SBP of mortality from stroke in men compared to 
women in a South Asian population,(285) but Lida found a higher risk from SBP in 
women in a Japanese population.(303) Hypertension has been found to be a major risk 
factor for sudden cardiac death in a woman-only study(309) but has been found to pose a 
lower risk to women than men in an earlier Framingham study.(310)  Results from a 
study on new onset hypertension in  participants in the Framingham cohort found a 
higher proportion of  men presenting with stable angina, PAD (intermittent claudication) 
and AMI, while a higher proportion of women presented with stroke when compared to 
controls who experienced non-CVD death.(311) 
 
A clear reduction in the hazard posed by increases in BP with age was found across all 
endpoints, with the strongest modification of the effect of age in unheralded coronary 
death and heart failure.  Indeed, increases in blood pressure doubled the association with 
heart failure in patients below the age of 50 compared to the oldest age group. This age 
effect may reflect different aetiological causes of heart failure at different ages, with poor 
left ventricular function, i.e. subclinical heart failure, causing low SBP  in the older age 
groups, while the presentations in the youngest groups caused  exclusively by 
hypertension.  
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These findings are consistent with mortality studies of the effect of increases in blood 
pressure which show a decline in effect with age for acute myocardial infarction, stroke 
and vascular disease.(283,284) However, the size of effect estimates in the current 
analyses are somewhat smaller, which is consistent with increased blood pressure not 
only being associated with onset but also conferring additional risk for progression to 
subsequent CVD events or CVD mortality.   Unlike the current analyses, Franklin et al. 
found DBP to be more strongly associated with CVD in patients under 50 while SBP and 
pulse pressure assumed greater importance in older people.(294) 
6.5. Strengths 
The general strengths of data from the CALIBER research platform have been rehearsed 
elsewhere in this thesis, but include the large cohort size, the ability to identify with some 
degree of certainty the initial presentation of CVD, and the detailed risk factor and 
prescribing data available. With specific reference to this set of analyses, one key strength 
is the availability of continuous measures of both systolic and diastolic blood pressure, 
allowing comparison of the effects of each measure. 
6.6. Limitations 
A key limitation of cohort studies using EHR is missing data and the biases introduced by 
losing patients without complete data.  A detailed discussion of this issue can be found in 
Chapters 4, but of concern for this set of analysis is that younger patients were more 
likely to be excluded from the cohort because of missing blood pressure data. My finding 
of stronger association of raised blood pressure at younger ages may be due to recording 
bias, with GPs recording blood pressure in younger people about whom they had 
concerns for other reasons such as obesity.     A further limitation of EHRs is the quality of 
recording of blood pressure. Figure 28 above showed that GPs have a clear preference for 
recording data in multiples of 10 (and to a lesser extent 5).  However, additional 
modelling of the association of blood pressure using categorical variables for SBP and 
DBP found the same effects as models using blood pressure as a continuous variable.  
There is concern within the epidemiological literature about the use of standardised 
regression coefficients, such as used in the present analyses, because such 
standardisation has the potential to confound aspects of study design which drive the 
variance of the standardised measure with effect of interest, as well as militating against 
valid comparisons between studies.(306)  However, the first concern does not apply in 
the current situation where the same standard deviation is used across the whole study, 
and the same covariates are used in models for SBP and DBP. (312) The value of being 
able to make a direct comparison between SBP and DBP in the current study was thought 
to outweigh the potential for lack of comparability with future studies.(313) 
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The current analyses did not use repeated measures of blood pressure, so there was the 
potential for regression dilution.(314) However, with a mean follow-up time of 
approximately 5 years, the extent of the dilution would be considerably less than in some 
of the longer term cohort studies.  Only linear effects for both SBP and DBP were 
modelled; a possible j-shaped association, particularly with DBP, which has been found in 
the previous literature,(315) was not assessed. Although the relationship looks broadly 
linear in the categorical analysis, the lowest DBP category is higher than in some other 
studies. The lower effect estimate for DBP across most endpoints could be due to 
increased risk at the lowest levels of DBP.  The proportional hazard assumptions 
appeared to be violated with the specific presentation, AAA, which appears to differ from 
the other presentations in lack of effect of SBP. It is possible that alternative approaches 
to modelling the association with SBP and AAA would better capture the relationship. 
This may also hold true for the ventricular arrhythmias, the only presentation where 
there were clear gender differences in effect.  
 
Although data on blood pressure-lowering medication was available in this dataset, it was 
not included in the model estimating the effect of increases in blood pressure on initial 
presentation of CVD because medication would be in the causal pathway between 
exposure and outcome. However, patients on medication whose blood pressure is not 
controlled may have additional risk not simply related to their blood pressure level. This 
complexity would not be adequately captured in the model used. Also, there is good 
evidence that calcium-channel blockers have a greater preventative effect on stroke than 
other blood-pressure lowering medications, so that medication has an effect on likelihood 
of different initial presentations.(316) 
 
7. Summary of Findings 
 Little is known from previous studies about heterogeneity in the association of 
SBP and DBP with the initial presentation of CVD across a range of presentations. 
 One standard deviation increase in SBP and DBP was associated with increased 
hazard of initial presentation across all presentations, with the exception of AAA 
(SBP only) and PAD (DBP only). 
 Some heterogeneity in the strength of association of SBP and DBP with a range of 
CVD endpoints was found, but was limited compared to heterogeneity of effects 
found with smoking. 
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 The increased hazard associated with higher SBP and DBP were evident even with 
the lowest blood pressure categories. 
 The association of increases in BP with initial presentation is modified by gender 
only for stroke, with increased hazard in men, and for ventricular arrhythmias, 
with increased hazard in women. 
 The association of SBP and DBP with most endpoints decreases with age up to 70-
79 years.  This effect modification is particularly notable for heart failure where 
one standard deviation increase in SBP had double the hazard for patients under 
50 as for those over 80.  
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Overall Conclusions and Implications for Public Health, Clinical 
Practice and Research 
1. Introduction 
In this thesis, I have described briefly the field of electronic health record (EHR) research and 
the specific research platform, CALIBER, used for my research (Chapter 2). I then went on to 
describe my general methods (Chapter 3) and report on results applicable to all the analyses 
in this thesis (Chapter 4). In chapters 5 to 7, I discussed the results of my investigation of the 
association between gender, smoking and blood pressure on the onset of cardiovascular 
diseases (CVD) across a range of initial presentations. Here, I pull together the threads of the 
thesis and discuss some of the wider implications of my findings.  I begin with a summary of 
my methodological approach and main findings, discuss the overall strengths and limitations 
of the cohort and my analyses, followed by my views on the implications of this research for 
clinical and public health practice and recommendations for research.  
2. Overall approach and main findings 
The cornerstone of my thesis has been the development, with colleagues, of the CALIBER 
research platform.(167) CALIBER incorporates linked electronic health records data from 
four data sources, a common data model  and transparency through analytic protocols 
registered in the public domain. CALIBER was used to implement the current research study 
but provides the tools for building programmes of epidemiological research such those 
currently being undertaken by the Clinical Epidemiology Group at University College London 
(UCL), the London School of Hygiene and others. Using CALIBER, I developed a large cohort of 
1,758,584 patients free from symptomatic CVD with which to investigate the association of 
gender, smoking and blood pressure with the onset of cardiovascular disease with a wide 
range of initial presentations.  
 
My principal findings were: 
 69% of initial presentations (N=95,267) of CVD were neither acute myocardial infarction 
(AMI) nor stroke 
  Men had higher rates of all presentations, with age-adjusted gender rate ratios from 1.23 
(95% confidence interval 1.19-1.27)) for stroke to 4.27 (3.92-4.65) for AAA.  
 The association of current smoking (compared to non-smoking) varied from an age-
adjusted hazard ratio (HR) of 1.01 (0.90-1.13) for arrhythmia to 4.71 (4.15-5.35) for AAA. 
 Gender differences were found only for MI (women: 2.59 (2.37-2.83); men: 2.20 (2.05-
2.37)) and AAA (women: 7.00 (5.64-8.70); men: 3.88 (3.33-4.53)).  
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 The association of systolic blood pressure was similar across all CVD presentations, 
excepting AAA, ranging from age-adjusted HR of 1.19 (1.16-1.22) per standard deviation 
(SD) for heart failure to 1.28 (1.24-1.31) for PAD, with minimal gender differences.   
3. Overall strengths 
This thesis provides a demonstration of the value of linked electronic health records for 
programmes of cohort research. By linking the longitudinal record from primary care data to 
the episodic records provided by secondary care and clinical registry data with final outcome 
data from mortality data, a detailed picture of the patient journey over time can be seen. The 
current work has focussed on initial presentation of cardiovascular disease, using the 
primary record to exclude patients with prior history, provide detailed baseline risk factor 
information and, along with the secondary care, clinical registry and mortality data, to 
provide endpoint data.  
 
The results from the thesis combine replicating results from previous studies, which provides 
reassurance about the accuracy of the findings overall, with novel results which extend 
knowledge.  The association I found in the linked EHR  between smoking and lung cancer is 
consistent with results of a meta-analysis of the studies based on investigator led bespoke 
studies used in the International Agency for  Research on Cancer (IARC) review of smoking 
and lung cancer,(317) but I also showed the relationship between smoking and onset of CVD 
across a wide range of CVD endpoints for the first time.  The association I found between 
being an ex-smoker and multiple CVD endpoints is consistent with findings of the Million 
Women study,(269) but shows the relationship with the overall onset of CVD rather than 
with the  first occurrence of CVD endpoints, regardless of previous disease. The pattern of the 
relationship between raised blood pressure and cardiovascular endpoints, as modified by 
age, replicates the findings of the Prospective Studies Collaboration(283) but extends both 
the range of endpoints investigated and focusses on onset of CVD rather than CVD mortality.  
 
Other novel insights provided by the approach of focussing on initial presentation of CVD 
across a broad range of specific presentations include the frequency with which CVD first 
presents with diseases other than MI and stroke – almost 70% of endpoints are other 
presentations. Most previous investigator-led studies have relied on so-called hard endpoints 
such as MI and stroke. The presentations of stable angina and peripheral arterial disease 
which I found to be more common have better initial prognosis and more chronic 
presentations than either MI or stroke, allowing greater opportunities for intervention.  I also 
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identified the heterogeneity of association of gender and smoking with multiple CVD 
endpoints in contrast to the relative homogeneity of association of blood pressure with these 
endpoints.  
4. Overall limitations  
There are four key limitations to the dataset and the research presented in the thesis which 
are discussed here. Future research, either currently planned or potential, to address these 
limitations is described in 6.1 Implications for research methods. 
4.1. Selection of cohort patients 
The patients included in the overall cohort were those who met the age and observation time 
criteria and had no prior history of cardiovascular disease. However, for the specific analyses 
on gender, smoking and blood pressure, patients were excluded if risk factor data were 
missing. Approximately a fifth of patients who met the general inclusion and exclusion 
criteria were excluded for the analyses in Chapter 6 and half of all possible patients for 
Chapter 7. (See Chapter 4 for more detailed analysis of missing data). The majority of those 
excluded were younger men, who are less likely to attend general practice even if registered. 
This potential selection bias does raise concerns, but which are common to cohort studies 
using this sort of data, particularly those investigating aetiological questions. One approach to 
addressing this concern has been to investigate the possibilities for imputation, which are 
further discussed in 6.1 below. Another approach to dealing with missingness, which I favour, 
is to investigate the informativeness of missing data, also discussed below.  
 
One question worth asking is whether this selection bias I have identified is in fact worse or 
simply more explicit than other studies. With electronic health records research, it is easier to 
identify and characterise those not included in a cohort compared to investigator-led cohorts. 
Such studies may not be able to describe potentially eligible participants who were excluded 
because they did not volunteer to participate, which could be seen as the equivalent of 
registered population excluded because of missing data. Only individual participant meta-
analyses are currently able to compete with EHR studies on the size of cohort, but these are a 
collection of multiple different individual studies, all with different approaches to patient 
recruitment and retention. For example, in the Prospective Studies Collaboration study on the 
association of blood pressure with  cardiovascular mortality,(42) it is not clear how many 
potential participants have been excluded due to missing data because the overall figure 
across the 61 studies has not been reported. Further discussion on methods of comparison 
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between EHR studies, investigator-led cohort studies and individual participant meta-
analyses would be helpful so that biases introduced by each could be fairly adjudicated.  
4.2. Determination of endpoints 
In conventional bespoke cohorts, the determination of endpoints is commonly accomplished 
by an adjudication panel, often using multiple sources of information to arrive at a conclusion 
about each specific endpoint. There is a large literature describing these processes, if not 
evaluating them, for a wide variety of studies and endpoints. For electronic health record 
studies the determination of endpoints is conventionally an assessment of the sensitivity, 
specificity or positive and negative predictive value (PPV) of specific codes or coding 
algorithms, determined by comparing codes against a gold standard such as medical records. 
Those validation studies which relate to the endpoints in this thesis have been described in 
Chapter 2. It is not clear whether a similar approach is even theoretically possible with linked 
datasets, such as CALIBER, because there is no obvious gold standard. One approach to 
addressing this issue has been to assess the extent of overlap between multiple EHR data 
sources, the most recent of which examined the overlap in myocardial infarction cases 
between the constituent datasets within CALIBER.(101) This study found that each individual 
data source missed a substantial number of cases (between 25-50%), substantiating the 
importance of using multiple sources of information, as has been done in this thesis.   
 
In order to provide sound determination of endpoints, the CALIBER research collaboration 
implemented a rigorous, documented and auditable approach to:  
a) Defining reusable algorithms to identify relevant codes – agreed by at least two 
clinicians, including a practising GP, and recorded as STATA do-files which can be 
rerun and updated 
b) Defining base variables – specifying the algorithm used to create data variables from 
a single data source and identifying multiple response categories which can be 
combined or excluded depending on the purpose of individual researchers 
c) Defining risk factors and endpoints – combining base variables from multiple data 
sources in specified and documented ways to arrive at endpoint and risk factor 
definitions 
d) Recording metadata – all variables include meta-data which includes a plain English 
definition, specification of minimum and maximum values if appropriate, response 
categories, data sources, and version control information.(167)  
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The determination of some endpoints in CALIBER, specifically the acute coronary ones, is 
likely to be more accurate than others because of the linkage with the acute coronary 
syndrome registry, MINAP. At present, there are no other equivalent registries for the other 
endpoints although there are some promising developments. The only national clinically 
collected data source for stroke is a bi-annual sentinel survey of two months of stroke 
admissions.(318) There is a relatively new registry for heart failure, curated by the National 
Institute for Cardiovascular Outcomes Research, who curate MINAP, but the proportion of 
cases in this four-year-old audit remains relatively low with 58% of heart failure admissions 
submitted to the audit.(319) The National Cardiac Arrest Registry (NCAR) which aims to 
capture all  in-hospital cardiac arrests involving a resuscitation team,(320) has not yet begun 
to collect data. From the evidence on comparison of data sources for acute myocardial 
infarction, (101) addition of any of these data sources could increase the number of 
endpoints over inclusion of HES and could improve the quality of clinical information about 
stroke, heart failure or cardiac arrest. The possibility of linkage with these sources of data 
should be considered for future development of CALIBER.   
4.3. Missing data for adjustment 
The section above highlights the issue of patients excluded from the cohort because of 
missing information.  Data on other key risk factors such as lipid levels, ethnic group, alcohol 
consumption and body mass index were also missing to such an extent (Chapter 4) that they 
were not included in the adjusted models. Future work on electronic health record data 
needs to address this issue of missingness. Possible approaches to addressing this 
methodological issue are described in 6.1 Implications for research methods below.   
4.4. Measurement of risk factors  
The measurement of the risk factors used in this research were completed in real-world 
settings and are likely to have greater errors of measurement than those collected under 
research conditions, particularly the blood pressure measurements. I have already shown 
GP’s preference for recording blood pressure in  multiples of 5 or 10, providing evidence of 
systematic under or over-estimation of actual blood pressure (Chapter 7).  The possibility of 
measurement by indication is likely; patients with greater risk factor profile or higher 
baseline blood pressure maybe more likely to have their blood pressure recorded in 
subsequent periods.  Additionally, there is the possibility of changes in risk factors over time, 
with smokers quitting or ex-smokers resuming and blood pressure increasing with age, 
raising the possibility of regression dilution.  
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These short-comings in the quality of the data could explain, for instance, differences in the 
size of association of blood pressure found in the current analyses compared with those 
found in the Prospective Studies Collaboration (PSC) study on blood pressure.(283) I did not 
adjust for regression dilution, while the PSC did. However, the maximum period of follow-up 
for the current cohort is 10 years, with a median of 5, which Clarke, Shipley, Lewington et al. 
estimate would under-estimate the risk by approximately one third in the first decade,(314) 
bringing my estimates more in line with those of the PSC. The studies which contributed data 
to the PSC measured blood pressure under research conditions, again another explanation of 
possible different effects.  However, the obvious small errors in measurements in the current 
data due to digit preference did not appear to have a substantial impact of the findings from 
the current analyses, with similar results from both continuous and categorical 
measurements of blood pressure (Chapter 7). Differences in findings with Prospective 
Studies Collaboration could also be due to the endpoints investigated – onset of CVD versus 
CVD mortality.  
4.5. Use of relative measure of risk  
Throughout this thesis, relative measures of risk have been used to investigate the 
hetereogeneity of association between the risk factors and the endpoints:- rate ratios for the 
association of gender and hazard ratios for the association of smoking and blood pressure on 
the initial presentations of CVD.  The appropriateness of relative measures of risk has been 
extensively debated within the epidemiological literature, particularly in the assessment of 
interactions or effect modification.(321)  Weed and Trock(322) have suggested that content 
of these debates can be divided into three sorts of questions: 
1. What is the definition of effect modification? These ontological questions have been 
addressed for example in Rothman, Greenland and Lash,(323) Siemiatycki and 
Thomas,(324) and  Weinburg.(325) 
2. How should we measure or infer the existence of effect modification? These 
epistemiologial or methodological questions have been addressed for example in Walter 
and Holdford,(326) and Pearce(327); and  
3. What action should we take as a consequence of such identification? These ethical or 
public health/clinical questions have been addressed for example in Weed and 
Trock(322) and Spiegelhalter.(328)  
Rothman, Greenland and Walker proposed a similar taxonomy of questions, dividing 
implications for action into those at population level and individual level. (329)  
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Conversion of relative measures of risk derived from time-to-event analyses into measures of 
risk difference in order to assess effect modification or determine appropriate individual or 
population-level action are not as straight-forward as with other regression analyses, 
although approaches have been suggested.(330,331) Time-to-event analyses with competing 
risks provide an additional complication in seeking to assess differences in risk but 
differences in cumulative incidence which take account of cause-specific hazard ratios have 
been proposed.(332) Such a measure has the virtue providing a measure of the absolute risk 
difference between groups which takes into account both frequency of events in such groups 
and relative hazards.(183) In order to assess the impact of potential risk reduction measures, 
for populations, such absolute measures of risk are needed in order to estimate the effect on 
incidence of specific presentations in the presence of competing risks.(333) For individuals to 
determine their own risk reduction with changes in behaviour or treatment, the same 
absolute measures are required. The current analyses are therefore not sufficient to 
determine individual or public health action but have the potential to indicate areas where, 
with further modelling, fruitful approaches may be determined.   For example, in a 
development of the approach used in this thesis, differences in absolute (lifetime) risks for 
different CVD disease presentations between men and women identified similar male excess 
for myocardial infarction and abdominal aortic aneurysm as indicated by the current relative 
measures of risk.(334) Further work to develop calculations of absolute measures of risk 
difference to assess the impact of smoking and blood pressure are currently underway. 
 
5. Implications of findings for public health & clinical practice  
5.1. Development and use of risk scores 
The choice of endpoints included in the risk scores in common use in the UK or 
recommended by National Institute for Health and Care Excellence (NICE) guidance (Table 
27) varies widely.(335)  Few risk scores include peripheral arterial disease or heart failure in 
the endpoints assessed.(336) This situation prevails despite NICE guidance recommending 
inclusion of all symptomatic atherosclerotic vascular disease, including revascularisation and 
PAD, as endpoints in the risk equations used for formal risk assessment. My research 
demonstrates the extent to which the range of endpoints selected for inclusion in the 
calculation of risk scores matters. I have shown that the onset of symptomatic CVD is with 
presentations other than MI and stroke in approximately 70% of cases.  Many of these other 
presentations are more chronic and potentially treatable diseases than either of these so-
called hard endpoints (Chapter 4).  From the perspective of specific risk factors, smoking is 
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used in all widely used risk prediction models for CVD onset.  However, I found that the most 
common initial presentation, stable angina, is only weakly associated with smoking (Chapter 
6). Clinicians may be underestimating the risk of chronic presentations of CVD and therefore 
missing opportunities for targeting primary prevention therapy for patients at risk of 
developing CVD.  
 
The latest Framingham risk score(41) does include the widest range of CVD endpoints, but 
given findings on the importance of ethnicity(337) and social deprivation(338) in the UK 
context, there is an urgent need to create – and use - a UK risk score for onset of CVD which 
includes both a broader range of endpoints and risk factors than any of the risk equations 
currently in use.  The importance of this recommendation is reinforced by evidence about the 
seriousness of onset of CVD with any presentation.  For example, the rate of progression from 
less acute presentation of CVD with PAD to more acute presentations of CVD or death is high: 
20-40% of patients with PAD have subsequent acute MI or stroke and 50% die within 6 
years.(339,340) 
 
The finding of heterogeneity in the gender rate-ratios suggests that disease-specific gender 
coefficients, as well as gender-specific baseline survival, would lead to a risk prediction 
model with better discrimination than one which does not distinguish between a range of 
endpoints.  However, the interaction between smoking and gender in the risk of onset with 
acute MI and AAA also suggests that gender-specific risk scores may better capture the risk of 
onset, if indeed there is modification of the effect of gender by smoking.  Simply including a 
coefficient term for gender, even ones which are disease-specific may not adequately capture 
differences in risk for men or women across the range of endpoints. Further work is indicated 
to assess the discrimination of risk prediction models which use disease-specific sex 
coefficients or separate sex-specific risk prediction models. The latest Framingham risk score 
for use in primary care, which uses the sex-specific approach, suggests adding a calibration 
factor to the overall CVD risk score to predict disease-specific risks, (41) making it an ideal 
benchmark against which to measure the performance of the approaches mooted above.  
The range in the strength of association between the risk factors studied in this thesis and the 
specific diseases with which CVD initially presents also raises the question of whether 
primary prevention treatment might be tailored to the individual elements which contribute 
to a risk score, where that specific risk element has a greater association with particular 
presentations. For example, a systematic review of blood pressure lowering medication 
found that although different regimens reduced overall cardiovascular risk, their effect on 
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cause-specific risk varied.(341) The endpoints studied in this review did not include PAD, but 
on the basis of my findings in Chapter 7, a blood-pressure-lowering regimen which reduced 
the risk of PAD the most, for example, might be preferred to one which acted more effectively 
on prevention of other endpoints.  
 
Risk scores could also potentially be personalised to take account of individual priorities. 
Patients may have specific CVD diseases which they are more motivated to avoid; for 
example, my father, a life-long academic, is most fearful of suffering a stroke and losing his 
intellectual capacities than suffering other CVD presentations. Other patients may have seen 
family members die from specific diseases and wish to avoid their fate.  A range of risk 
prediction scores which cover specific endpoints could be used to tailor specific prevention 
strategies to patient priorities, which in turn could enhance compliance.  
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Table 27: Cardiovascular Risk Scores commonly used in England and Wales  
Endpoints included FRS - Original 
Total CVD 
(1991) (342) 
FRS - CHD 
Total CHD 
(1998) (259) 
FRS - ATP-III 
Hard CHD  
(2001) (343)  
FRS - Updated 
Total CVD 
(2008) (41) 
QRisk – 1 
CVD 
(2007) 
(169) 
QRisk – 2 
Total CVD 
(2008) (344) 
Score 
Fatal CVD 
(2003) 
(345) 
Assign 
CVD 
(2007) (338) 
 
Endpoints included         
   Ischaemic stroke X   X X X X X 
   Haemorrhagic stroke X   X X X X X 
   Transient ischaemic attack X   X X X X X 
   Angina Pectoris X X  X  X X X 
   Unstable angina X X  X  X X X 
   Myocardial infarction X X X X X X X X 
   Sudden CHD death X X X X X X X X 
   Revascularisation procedure        X 
   Congestive heart failure X   X  X X  
   Peripheral arterial disease X   X  X X  
   Abdominal aortic aneurysm       X  
Proportion of women in cohort 53.5% 53.4% 53.4% (assumed) 53.3% 50.4% 50.4% 42.9% 49.2% 
Adapted from information in Systematic review of cardiovascular disease risk assessment tools(346) 
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5.2. Gender and cardiovascular disease 
The association of gender with onset of a wide range of cardiovascular presentations 
clearly varies. As has been previously documented, acute MI and coronary death are more 
common in men at a younger age than in women (Chapter 5). However, similar effect 
modification with age did not hold for other disease presentations. These findings point to 
the importance both of more finely specified endpoints in understanding cardiovascular 
risk, but also the importance of adequately powering studies so that effects in men and 
women can be studied separately. Furthermore, it raises concerns about the 
generalisation of earlier CHD risk in men being extended to all CVD, as can be found, for 
example on popular website such as the British Heart Foundation 
(http://www.bhf.org.uk/heart-health/conditions/cardiovascular-disease.aspx). If such 
conflation of risk is a view also held by primary or secondary care doctors, it could lead to 
the under-estimation of risk in women for presentations other than coronary heart 
disease at younger ages.  
 
Although the gains for public health made in reducing the rate of onset of both AMI and 
unheralded coronary death (UCD) in men, the apparent lack of similar progress in women 
is of grave concern, particularly given that coronary heart disease remains the most 
common cause of death in women and therefore reducing onset must remain a priority. 
Although the reasons for the lack of change in the rate ratio over the 10 years of this study 
are still unclear, clinicians should ensure that women with similar risk factor profile to 
men are offered the same primary prevention interventions.   
5.3. Smoking 
5.3.1. Better smoking data should be recorded 
The lack of detail recorded in general practice on patients who smoke, i.e. number of 
cigarettes per day, pack years or age of taking up smoking, is of grave concern. Being a 
current smoker has a strong association with onset of CVD across a wide range of 
presentations, but little detail is recorded which would enable a better understanding and 
management of this risk. GPs would not consider using a blood pressure machine which 
simply records hypertension or not, so one must ask why are they are prepared to record 
a binary measure for smoking, when smoking is a risk factor which poses such an acute 
risk for some CVD presentations and is at least as serious a risk factor as blood pressure 
for overall risk? Under the Quality and Outcomes Framework, which provides financial 
incentives for general practitioners to record risk factor information about their patients, 
more detailed information than simply smoking status could be required. For example, 
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GPs are required to measure HbA1c for diabetic patients and cholesterol levels for 
patients with CHD. Recording the number of cigarettes smoked per day or pack years for 
smokers would be both feasible and appropriate.  
5.3.2. Importance of quitting  
My findings on the variation in the strength of association between smoking status and 
different endpoints support both an acute and a chronic effect of smoking on the onset of 
CVD.  The large heterogeneity between different endpoints for current smoking and the 
much more limited heterogeneity and weaker associations for ex-smokers demonstrates 
the large gain to be made from quitting but also that some damage caused by having 
smoked cannot be undone.  These conclusions are similar to those reached in the Million 
Women study based on a narrow set of endpoints.(269) 
  
The large risk of smoking with acute MI and unheralded coronary death, which is 
physiologically consistent with smoking playing a role in platelet aggregation and 
thrombus formation, poses the question of whether primary prevention should be 
tailored to reduce thrombus formation in smokers. Clearly quitting smoking would have 
the largest impact on risk of such an event, but a harm-reduction strategy, such as the 
prescription of antiplatelet drugs for smokers who cannot or will not quit should be 
explored. Indeed, the UK National Institute for Health and Care Excellence has recently 
published guidance on harm reduction with tobacco use.(347) 
5.3.3. Risks of smoking in women 
I found smoking was much more strongly associated with onset of CVD presenting with 
AAA in women than in men.  Currently in the UK, women are not screened for AAA for 
cost-effectiveness reasons, because AAA is a rare event in women.(243) My findings raise 
the question of whether a  two-stage screening process for AAA should be explored, 
starting with assessment of current and past smoking behaviour and then proceeding 
with abdominal ultrasound screening in smokers or ex-smokers, but not in non-smokers.  
If such an approach were shown to be effective, the case finding in the second stage of 
screening, and therefore the cost-effectiveness of the AAA screening programme as a 
whole, could be improved. The conclusion of an individual-participant meta-analysis of 
screen-detected AAA suggested the importance of earlier intervention in women and 
smokers,(236) both conclusions of which would be supported by my current findings. 
 
Evidence indicates  increasing prevalence of AAA in women(242) with these increases 
potentially accelerating as the effect of the wide uptake of smoking in women in the 
1950s, 60s, and 70s plays out.  Coupled with my findings on the greater relative risk of 
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smoking in women than in men, these changes in epidemiology should be considered in 
the next review of the National Screening Committee’s (NSC) policy on AAA screening. 
Given the current Cochrane review of AAA screening which informs the NSC policy was 
last updated in 2007 and includes only one study which included women,(243) there is 
also a need to undertake further research on investigate the potentially changing risk of 
AAA in women.  
 
5.4. Blood pressure 
5.4.1. Increased risk of raised blood pressure at all levels 
The most important finding from my analyses of the association of blood pressure with 
the onset of cardiovascular disease is that the risk of onset of CVD across virtually all 
presentations is increased even at the lowest levels of systolic and diastolic blood 
pressure. This finding supports the view that blood pressure should be addressed at a 
population level. Individual treatment with medication across such a large population is 
neither feasible nor desirable.  Although NICE has clinical standards on hypertension, 
reducing blood pressure at a population level does not feature in the list of topics for 
which NICE are developing public health standards. Interventions to reduce blood 
pressure tend to be scattered throughout guidance on other topics such as increasing 
physical activity and reducing alcohol consumption. Action on reducing salt intake does 
not yet have the consensus and impetus behind it that tobacco control policies do, but has 
the potential to have significant effects on blood pressure levels at population level. The 
latest Health Survey for England identified that mean SBP and DBP fell “marginally but 
significantly” between 2003 and 2011, which the survey suggests equates to a reduction 
in ischaemic heart disease deaths of 9% in men and 12% in women and a greater 
reduction in stroke deaths (men:13%, women 18%).(37) 
5.4.2. AAA and blood pressure 
I found that SBP was not associated with initial presentation of CVD with AAA, while DBP 
was.  Some studies have previously identified raised DBP as a risk factor for 
AAA.(348,349)but much of the literature focuses on hypertension, rather than SBP or DBP 
as individual risk factors. One systematic review and meta-analysis of screen-detected 
AAA found a modest effect of hypertension,(350) while other studies have found no 
effect(351) or only in women(352).  None of the previous studies have the scale of the 
current study, although previous studies have the benefit of being able to distinguish 
between screen-detected AAA and AAA events, unlike the current study.  Greater clinical 
attention should be paid to raised DBP, particularly in current or ex-smokers, who may be 
at greater risk of AAA. 
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5.4.3. Blood pressure in people under 50 years 
The strongest association of increases in SBP and DBP were seen with heart failure and 
unheralded coronary death in people under 50 (Chapter 7), although it must be 
emphasized that this is a relative measure.  These findings support the recent revisions to 
National Institute of Clinical Excellence guidance on hypertension which recommended 
further investigation of hypertension in people aged under 40 whose 10 year risk might 
be under-estimated by standard risk scores.(353) Further research would be required to 
determine whether the most appropriate public health target group for blood pressure 
reduction would be the few younger people at greater relative risk or the more numerous 
older people at lower relative risk. Measures of absolute risk would, no doubt, favour 
interventions with older people given the frequency of presentations in this group, but 
measurement of the years of life lost or reduction in disease-free years should also be 
considered, given the estimated association of higher blood pressure with presentations 
which have such poor prognosis. Broad public health measures to reduce blood pressure, 
such as reducing the population average intake of salt(354), have the potential to address 
a broad range of age groups 
6. Implications for research methods and areas for research 
6.1. Implications for research methods 
The success of this thesis in identifying novel findings on the initial presentation of CVD 
raises the possibility of linked electronic health records replacing investigator-led 
registries. To take an example from prognosis research, the REACH registry is the largest 
current international cohort seeking to understand the nature and frequency of 
subsequent CVD events in patients with stable atherosclerotic disease. (23) It aims to 
recruit a total of 60,000 patients, and is in the early stages of endpoint follow-up.  My 
cohort from the current analyses has data on over 80,000 patients with CVD endpoints 
which they survived for at least one day with up to 10 years of follow-up time.  This 
simple comparison shows the potential for research similar to that of the REACH registry 
using EHR records at a fraction of the cost and with the potential for quicker publication 
of results.  
 
Missingness continues to be an issue with EH-based research. As discussed in Chapter 3, 
researchers are investigating approaches to imputation with longitudinal primary care 
data similar to GPRD, which may lead to a better understanding of the suitability of 
imputation in these datasets, where missingness is likely not to be completely at 
random.(180)  The breadth of additional variables available to use for imputation and the 
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large number of patients may make these approaches feasible, although imputation with 
such large datasets is computationally intensive.  Repeating the analyses in this thesis 
with a multiple imputation dataset is planned and the results of the comparison with the 
complete case analysis presented here will be informative.   
 
Another approach to handling missingness, particularly where data is not missing at 
random, is to treat missing data as informative. For example, in a preliminary analysis not 
presented in this thesis, I found that having no smoking status recorded was as strongly 
associated with unheralded coronary death as was being a current smoker, at least in 
men. Further work should be undertaken to investigate whether risk scores or 
stratification based on missing information, although not intuitive for clinicians, could be 
valid approach to dealing with missing data in electronic health records. 
 
To date, CALIBER has not included more complex algorithms to verify endpoints, as has 
been done in other EHR research. Some have sought confirmation of diagnoses, such as 
myocardial infarction, by requiring evidence of hospital admission, raised enzymes or 
subsequent appropriate treatment.(150,355,356) However, evidence from Herrett et al. 
indicates that such complex approaches may not be necessary, with the PPV  of 92.2% 
(95% confidence interval 91.6-92.8%) for a record of acute AMI in GPRD and 91.5% 
(90.8-92.1%) for a record in HES.(101) Planned further research by UK Biobank will 
identify the PPV of different algorithms and combinations of linked electronic health 
record sources against manual review of the full, locally held, case notes for stroke, 
diabetes and coronary disease as part of the endpoint ascertainment, validation and 
phenotyping project.  It is possible that the results of the UK Biobank and other related 
initiatives may lead to refinement in the algorithms used to define variables in CALIBER.   
Research to create codes from free text fields, which often include confirmatory 
information,(357,358) as well as a pilot project to make data from ECG readings machine 
interpretable for epidemiological research, will, in time, improve the specificity of 
endpoints from EHR data.  
 
Heterogeneity in smoking effects has been observed in observational and clinical trials 
with composite endpoints. My study suggests that the specific composition of those 
composite endpoints may itself to be the source of the heterogeneity, rather than 
necessarily differences in actual effect of the exposure, indicating the need for greater 
specificity of CVD endpoints in studies of smoking. As efforts to understand the interplay 
between genes and environmental factors such as behaviour increase, my findings 
underscore the importance of specifying the phenotypes under study. This was 
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demonstrated by recent study identifying variant related to smoking and well-defined 
endpoint of PAD. (265)  
 
6.2. Areas for future research 
With such a wide-reaching thesis, there are a number of different areas where my 
findings suggests areas for possible future research. Here, I first indicate research 
questions around gender, smoking and blood pressure and then more far-reaching ideas.  
 
Given the heterogeneity of association between gender and the initial presentations of 
cardiovascular disease, it would be useful to evaluate patients’ and doctors’ views of CVD 
risk, as affected by age and gender, and the ways in which those views affect care-seeking 
or provision of care. Given the indications I found of changes over time in the rate ratios 
for a number of different presentations, mainly driven by reductions in men, further 
research to identify trends in gender differences in primary prevention linked to changes 
in onset of disease is both feasible and desirable. This seems particularly important given 
that I also found that women were more likely to present with fatal presentations than 
men.  
 
A better understanding of the age-period-cohort effect of smoking behaviour in men and 
women as related to cardiovascular disease prevalence would add to the understanding 
of changes in gender differences in risk over time.  This could be particularly useful in 
understanding the apparent gender modification of the risk of smoking for AAA, as well as 
trends in AAA identified elsewhere. Where there appears to be a decline in men in the 
incidence of AAA(251) which may be linked to decline in men’s smoking in previous 
decades, the pattern in women is less clear. An increase in the incidence in AAA in women 
might be expected, because the smoking prevalence in women did not peak until after the 
1960s, two decades after the peak in men.(359) Further research to model the effect of 
smoking on expected AAA incidence rates to inform decisions about screening for AAA in 
women would be important. 
 
With a median of eight blood pressure measurements in men and 10 in women, this EHR 
cohort could be used to study regression dilution in a real world cohort, to compare to the 
findings using the Whitehall II cohort, used to identify regression dilution.(314)  In 
addition to the academic interest such a comparison would hold, information from EHR 
cohort could be useful in assessing risk in patients where recent measurements may be 
lacking.  Planned future research of the Clinical Epidemiology Group will look at the 
changing profile of risk factors over time and its relationship to prognosis, initially 
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focussing on blood pressure. The present findings do suggest further work to 
disaggregate the elements of raised blood pressure which are associated with initial 
presentation with AAA would be worthwhile, particularly given the conflicting evidence 
from previous studies. Further research could help to determine the causes of raised 
blood pressure in the young, whether this be obesity, salt intake or lack of exercise, which 
would indicate the most appropriate interventions to contribute to primary prevention of 
CVD. Discrepancies between the findings of the current analyses on the strength of 
association between raised blood pressure and initial presentation of CVD and published 
studies on first presentation show the importance of further research which follows the 
course of the disease from initial presentation to subsequent presentations to mortality. 
By segmenting each stage, important insights can be gained which can be used to improve 
health outcomes.   
 
There are a number of different directions in which the current research could be 
extended. The present analyses have been limited to three factors associated with onset 
of cardiovascular disease: gender, smoking and blood pressure; future analyses planned 
for the Clinical Epidemiology Group include extending this research to investigate the 
association of diabetes, lipids, obesity and alcohol with a wide range of CVD 
presentations. Fatal and non-fatal presentations have been combined in these analyses. 
Distinguishing between the two would allow comparability with a wider range of 
published studies.  Investigation of the progression after onset of CVD to subsequent 
events, and the potentially changing role of risk factors in that progression in individuals, 
poses an interesting and worthwhile challenge. Trends in mortality of CVD are changing 
rapidly so modelling the impact of changes in the prevalence of risk factors over time, 
particularly the age period cohort effects of smoking, would add to a more nuanced 
understanding of the nature of cardiovascular disease.  
 
6.3. Conclusions 
In summary, I built with my colleagues in CALIBER some of the tools necessary to use 
linked EHRs for this specific project, but also for building programmes of research. In my 
substantive analyses, I demonstrated heterogeneous associations between gender, 
smoking and, to a lesser extent, blood pressure across a wide range of initial CVD 
presentations. Such heterogeneity indicates the importance of investigation of the 
association of risk factors with more granular endpoints in understanding the aetiology of 
cardiovascular disease, as well as the importance of studying onset of the disease, rather 
than mortality. My findings have important implications for risk assessment, screening, 
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quality of care and public health interventions to reduce risk in several disease areas, as 
well as indicating promising areas for future research.  
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7. Summary of recommendations for public health and clinical 
practice 
 There is an urgent need to create – and use - a UK risk score for onset of CVD 
which includes both a broader range of endpoints and risk factors than any of the 
risk equations currently in use. 
 The possibility of personalising primary prevention treatment, to take account of 
the weight of risk factors for specific endpoint or patient preference, should be 
considered. 
 Doctors should recognise that the substantially increased risk in men compared to 
women at younger ages is restricted to myocardial infarction and coronary death 
and not discount the possibility of other CVD presentations in younger women. 
 Where women present with increased risks, those risk factors should be treated 
as aggressively as they would be in men. 
 GPs should record more detailed information on smoking behaviour, so that more 
accurate assessments of risk can be made. Changes to incentives such as QoF 
should be considered. 
 Quitting smoking should be encouraged as much as possible, but where 
individuals cannot or will not quite, harm reduction treatment to additionally 
reduce their risk of myocardial infarction should be considered. 
 Further research should be undertaken to determine whether  including women 
who are current or ex-smokers in the AAA screening programme is warranted. 
  
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8. Summary of recommendations for research 
 The possibility of linked EHR research to replace investigator-led cohorts should 
continue to be explored. 
 Approaches to address missingness in EHRs should continue to be explored, 
including treating missing data as informative, for example in risk stratification.  
 The accuracy of algorithms using multiple EHR sources to identify multiple 
endpoints should be investigated.  
 The views of patients and doctors on CVD risk, as affected by gender and age, and 
the ways in which those views affect care-seeking / giving should be investigated.  
 Further research to model the effect of age-period-cohort effects of smoking on 
expected AAA incidence rates to inform decisions about screening for AAA in both 
women and men should be undertaken.  
 The changing profile of risk from changes in blood pressure should be 
investigated, to improve understanding of prognosis from this risk factor and to 
provide a comparison to regression dilution identified in investigator lead cohort.    
 Further research to distinguish between fatal and non-fatal presentations of 
cardiovascular disease should be undertaken. 
 Additional risk factors, including lipids, BMI, diabetes and alcohol and their 
association with initial presentations of CVD should be undertaken.  
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Appendix A: Acronyms 
Acronym Full Text 
AAA abdominal aortic aneurysm 
ACE Angiotensin-converting enzyme  
ACEI Angiotensin-converting enzyme inhibitor 
ACS Acute coronary syndrome 
AHA American Heart Association 
AMI Acute myocardial infarction 
ARB Angiotensin receptor blocker 
BMI Body mass index 
BP Blood pressure 
CA Calcium 
CABG Coronary artery bypass graft 
CALIBER CArdiovascular disease research using LIinked Bespoke studies and 
Electronic health Records 
CCAD Central Cardiac Audit Database 
CHD Coronary heart disease 
CI Confidence interval 
CPRD Clinical Practice Research Datalink 
CT Computed tomography 
CVA Cerebrovascular accident 
CVD Cardiovascular disease 
DBP Diastolic blood pressure 
DC Death certificate 
ECG Electrocardiogram 
EHR Electronic health record 
Gb Gigabyte 
GHZ Gigahertz 
GPRD General Practice Research Database 
HDL High-density lipoprotein 
HES Hospital Episode Statistics 
HF Heart failure 
HR Hazard ratio 
ICD International of the Classification of Diseases 
ICD-10 International of the Classification of Diseases, Version 10 
ICD-9 International of the Classification of Diseases, Version 9 
ICVD Ischaemic cerebrovascular disease 
IHD Ischemic heart disease 
IMD Index of multiple deprivation  
IQR Inter-quartile range 
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Acronym Full Text 
kg kilograms 
L litre 
LDL Low-density lipoprotein 
LSHTM London School of Hygiene and Tropical Medicine 
LVA Left ventricular arrhythmia 
m metre 
MI Myocardial infarction 
MINAP Myocardial Ischaemia National Audit Project 
mm Hg Millimetre of mercury 
mmol Micromole 
MRI Magnetic resonance imaging 
NICE National Institute for Health and Clinical Excellence 
NOS Not otherwise specified 
NRT Nicotine replacement therapy 
nSTEMI Non-ST-elevation myocardial infarction 
ONS Office for National Statistics 
OPCS Office of Population Censuses and Surveys 
PAD Peripheral arterial disease 
PbR Payment by results 
PCI Percutaneous coronary intervention 
PEDW Patient Episode Database for Wales 
PPV Positive predictive value 
QoF Quality and Outcomes Framework 
RAM Rapid access memory 
RR Rate Ratio 
SA Stable angina 
SAIL Secure anonymised information linkage 
SBP Systolic blood pressure 
SCD Sudden cardiac death 
sd standard deviation 
SHIP Scottish Health Informatics Programme 
STEMI ST-elevation myocardial infarction 
THIN The Health Improvement Network 
TIA Transient ischaemic attack 
UA Unstable angina 
UCD Unheralded coronary death 
UCL University College London 
UCOD Underlying cause of death 
UTS Up to standard 
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Appendix B: Literature Review of Studies Validating Death Certificates 
Death Certificate Studies: Coronary Heart Disease 
Study Data 
Years 
Country ICD  Rate of 
Autopsy 
(where 
given) 
ICD 
Code 
on DC 
Patient details Cases 
reviewed 
Certified 
as IHD 
True 
positives 
Measure of 
Accuracy 
Significant 
gender 
differences? 
Type 1 Studies: Death Certificates compared to autopsy results 
Modelmog, 
1992(360) 
1986-
1987 
Germany 9 97% 390-
459 
 1023 511 229 Sensitivity: 83% 
Specificity: 69% 
lower sensitivity 
and specificity for 
specific ICD codes 
Not assessed 
Type 2 Studies: Death Certificates compared to conclusions of adjudication panel 
Alperovitch, 
2009(361) 
1999-
2004 
France 10 -- I00-
I99 
Male and female 
(45%), 65+ 
625 203 129 Kappa for CVD = 
0.46 
No 
Coady, 
2001(362) 
1987-
1995 
USA 9 7% to 
25%8 
410-
414, 
429.2 
Male,35-74,  
IH deaths 
1712 -- 36.4% Sensitivity:  77% 
PPV: 85% 
No 
      Male, 35-74, 
OOH deaths 
2331 -- 56.0% Sensitivity:  88% 
PPV: 64% 
No 
      Female,35-74,  
IH deaths 
1204 -- 30.1% Sensitivity:  71% 
PPV: 79% 
No 
      Female, 35-74, 
OOH deaths 
1069 -- 43.9% Sensitivity:  81% 
PPV: 52% 
No 
de Henauw, 
1998(363) 
1983-
1991 
Belgium 9 -- 410-
414 
Male and female, 
25-69, IH and OOH 
deaths 
15559 1987 1135 Sensitivity: 53% 
Specificity: 99% 
PPV: 91% 
Not assessed 
Folsom, 
1987(364) 
1979      USA 9 24% 410-
414, 
427 
Male and female 
(31%), 30-74, 
OOH deaths 
328 237 223 Sensitivity: 90% 
Specificity: 83% 
PPV: 94% 
Yes, greater 
sensitivity in 
men 
                                                             
8 Proportion of deaths autopsied varied by county. 
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Study Data 
Years 
Country ICD  Rate of 
Autopsy 
(where 
given) 
ICD 
Code 
on DC 
Patient details Cases 
reviewed 
Certified 
as IHD 
True 
positives 
Measure of 
Accuracy 
Significant 
gender 
differences? 
Goraya, 
2000(119) 
1981-
1994 
USA 9 38% 410-
414 
Male and female, 
age range not 
given, OOH deaths 
174 131 126 Sensitivity: 91% 
Specificity: 86% 
PPV: 96% 
Not assessed 
Ives, 
2009(365) 
1989-
2004 
USA 9 -- 410-
411, 
413-
414, 
428, 
429 
(CHD 
& HF) 
Male and female, 
65+  
3194 877 612 Sensitivity: 74% 
Specificity: 89% 
PPV: 70% 
kappa=0.61 (0.58-
0.64) 
Not assessed 
Lahti, 
2001(366) 
1995 Finland 9 34% 390-
459 
Male and female 
(7.4%), no age 
restriction, death 
certificates 
requiring further 
adjudication by 
panel 
3478 926 739 False –ve rate: 
23% 
False +ve rate: 
20% 
Yes. 4% more 
cases in 
women 
referred to 
panel than 
expected  
     410-
414 
  216 155 False –ve rate: 
37% 
False +ve rate: 8% 
Yes. 4% more 
cases in 
women 
referred to 
panel than 
expected  
Lloyd-Jones, 
1998(367) 
1948-
1988 
USA 9 12% 410-
414, 
427 
Male and female, 
45+ 
2683 942 635 Sensitivity: 84% 
Specificity: 84% 
PPV: 67% 
 
Yes, PPV 
lower in 
women 
because 
fewer deaths 
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Study Data 
Years 
Country ICD  Rate of 
Autopsy 
(where 
given) 
ICD 
Code 
on DC 
Patient details Cases 
reviewed 
Certified 
as IHD 
True 
positives 
Measure of 
Accuracy 
Significant 
gender 
differences? 
Pajunen, 
2005(118) 
1998-
2002 
Finland 10 -- I20-25, 
I46, 
R96, 
R98 
Male, 35-74  -- 1281 -- Sensitivity: 92% 
PPV:92% 
No 
      Female, 35-74  -- 490 -- Sensitivity: 92% 
PPV:91% 
No 
      Male, 75+ -- 1054 -- Sensitivity: 89% 
PPV: 93% 
Slight 
difference 
      Female, 75+ -- 1984 -- Sensitivity: 90% 
PPV: 89% 
Slight 
difference 
Rapola, 
1997(368) 
1985-
1993 
Finland 8/ 
9 
-- 410-
414 
Male and female, 
age range not 
given 
191 191 181 PPV: 95% Not assessed 
Type 3: Death Certificates compared to contemporaneous prior hospitalisations 
Goldacre, 
1993(114) 
1979-
1986 
England 9 -- 410-4, 
427-9 
Male and female, 
age range not 
given, dying within 
4 weeks of 
hospitalisation 
55318 10635 8271 86% of people 
with admission for 
circulatory disease 
had circulatory 
disease certified as 
underlying cause 
of death. 
Not assessed 
Goldacre, 
2003(369) 
1979-
1998 
England 9 -- 410 Male and female, 
age range not 
given 
69333 -- -- Ratio of 
mentioned to 
underlying is 
1.088 
No 
Goldacre, 
2004(116) 
1979-
1998 
England 9 -- 410-4 Male and female, 
35-74, dying 
within 1 year of 
hospitalisation 
7964 -- -- 90% of deaths 
occurring within 
30 days of 
admission for MI 
coded IHD on DC 
Not assessed 
   
245 
 
Study Data 
Years 
Country ICD  Rate of 
Autopsy 
(where 
given) 
ICD 
Code 
on DC 
Patient details Cases 
reviewed 
Certified 
as IHD 
True 
positives 
Measure of 
Accuracy 
Significant 
gender 
differences? 
Johansson, 
2009(370) 
1995 Sweden 9 26% 410-
414 
Male and female, 
age range not 
given, death 
within 1 year of 
hospitalisation 
1094 115 -- 87% of patients 
admitted for IHD 
had same cause on 
DC 
No 
Johansson, 
2002(371) 
1995 Sweden 9 -- 390-
459 
Male, age range 
not given, death 
within 1 year of 
hospitalisation 
35,836 16370 5868 32.3% (3395) had 
diagnosis 
incompatible with 
original 
underlying cause 
of death-- 
Not assessed 
      Female, age range 
not given, death 
within 1 year of 
hospitalisation 
33,982 15989 5458 37.0% (3897) had 
diagnosis 
incompatible with 
original 
underlying cause 
of death. 
Not assessed 
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Death Certificate Studies: Sudden Cardiac Death 
Study Data Years Country ICD  Rate of 
Autopsy 
(where 
given) 
ICD 
Code on 
DC 
Patient details Cases 
reviewed 
Certified 
as SCD 
True 
positives 
Measure of 
Accuracy 
Significant 
gender 
differences? 
Type 2 Studies: Death Certificates compared to conclusions of adjudication panel 
Chugh, 
2004(202)  
2002-
2003 
USA 10 12% I00-I09, 
I11, I20-
I51, 
Q20-
Q24, 
R95-R99 
Male and female 
(43%), cases of 
sudden cardiac 
death based on 
WHO definition 
1007 325 193 Sensitivity: 
59% 
Specificity: 
86% 
PPV: 19% 
Not assessed 
Fox, 2005(120) 1948-
1999 
USA 9 -- 410-414, 
429.2 
Male and female 
(45%), 28-62 (at 
study enrolment), 
OOH death 
1797 592 187 Sensitivity: 
46% 
Specificity: 
71% 
PPV: 32% 
Yes, twofold 
overestimation 
in women 
 1948-
1999 
USA 9 -- 410-414, 
429.2 
Male, 28-62 (at 
study enrolment), 
OOH death 
960 324 141 Sensitivity: 
48% 
Specificity: 
73% 
PPV: 44% 
Yes 
 1948-
1999 
USA 9 -- 410-414, 
429.2 
Female, 28-62 (at 
study enrolment), 
OOH death 
837 268 46 Sensitivity: 
41% 
Specificity: 
69% 
PPV: 17% 
Yes 
Goraya, 
2000(119) 
1981-
1994 
USA 9 38% 410-414 Male and female, 
age range not 
given, OOH 
deaths 
174 131 113 Sensitivity: 
89% 
Specificity: 
51% 
PPV: 77% 
Not assessed 
Iribarren, 
1998(121) 
1985-
1990 
USA 9 19% 410-414 Male and female, 
30-74, OOH 
2035 835 222 Sensitivity: 
87% 
Not assessed 
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Study Data Years Country ICD  Rate of 
Autopsy 
(where 
given) 
ICD 
Code on 
DC 
Patient details Cases 
reviewed 
Certified 
as SCD 
True 
positives 
Measure of 
Accuracy 
Significant 
gender 
differences? 
deaths Specificity: 
66% 
PPV: 27% 
     427.5   322 60 Sensitivity: 
23% 
Specificity: 
85% 
PPV: 19% 
Not assessed 
Traven, 
1996(372) 
1984-
1989 
USA 9 56% 410-414, 
429.2 
Male and female, 
black and white, 
aged 35-44 years 
-- -- -- 52% of 
sudden deaths 
validated as 
caused by CHD 
Presented but 
not assessed 
WOSCOPS, 
1995(168) 
1989-
1991 
Scotland 9 -- all codes Male, aged 45-64 58 --  56% 
agreement 
between cause 
of death from 
patient follow-
up and linked 
computerised 
records 
Not assessed 
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Appendix C: CALIBER Data Portal and Developmental Tools 
A key feature of the CALIBER research platform is the algorithms for research-ready data 
which incorporate data definitions, including meta-data, and the code lists required to 
produce research-ready datasets. These algorithms are now accessed electronically via 
the CALIBER web data portal at https://www.caliberresearch.org/portal. The data 
definitions are open-source, but accessing the code lists requires researchers to register 
and login. A time-limited account (Login: JG_Thesis, Password: AMxtsoqv4) has been 
created to provide access to this information.  For further information, email Spiros 
Denaxas at s.denaxas@ucl.ac.uk . 
 
To ensure consistency in approaches to allocating response categories across multiple 
variables, principles for response category allocation for types of Read codes were agreed. 
These principles are shown in Table 28 below. The coding programs which provide the 
auditable algorithms used to generate the coding lists employed by the CALIBER research 
platform are not currently uploaded routinely on the data portal.  An exemplar STATA do-
file is shown in Table 28 below.  As part of the process for ensuring accurate variable 
algorithms and code lists, we produced entity code reports, which identified which entity 
codes were used with specific coding lists. An exemplar entity code report is shown in 
Table 30. We also conducted reverse entity reports, which cross-referenced coding lists 
used with specific entity codes (Table 31). 
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Table 28: Principles for Allocation of Response Categories  
Codes about … Phrase Example Rule Rationale Exceptions 
Patient treatment / 
measurement 
 [condition] 
[medication] 
contraindicated 
66U6. – HRT 
contraindicated 
Definite diagnosis (if 
treatment indicates 
diagnosis)  
Indicates GP’s intention to treat 
which in turn indicates patient 
has relevant condition 
 
 not [condition] 
[medication] 
tolerated 
8I71.00 – Warfarin not 
tolerated 
Definite diagnosis (if 
treatment indicates 
diagnosis)  
Indicates GP’s intention to treat 
which in turn indicates patient 
has relevant condition  
 
  adverse reaction to 
[condition] 
[medication] 
TJC7. – adverse reaction to 
other antihypertensives 
Definite diagnosis (if 
treatment indicates 
diagnosis)  
Indicates patient has received 
treatment which in turn 
indicates that patient has 
relevant condition 
adverse reaction to 
anti-depressants, as 
can be used for 
anxiety – coded as 
possible.  
 [condition] 
[medication] 
poisoning 
SL234 – insulin poisoning Exclude, except 
where the medication 
is hard to obtain (e.g. 
streptokinase) 
Not known whether drug taken 
by person for whom it was 
prescribed, so no conclusions 
can be drawn 
SL44200 – 
Streptokinase 
poisoning 
 [condition] 
[medication]  not 
indicated 
8I68. – calcium channel 
blocker not indicated 
Decide on case by 
case basis 
depends on condition and 
treatment so must be decided 
on case by case basis 
 
 [condition] treatment 
stopped 
667A.00 – epilepsy 
treatment stopped 
Decide on case by 
case basis 
depends on condition and 
treatment so must be decided 
on case by case basis 
 
 target 
[measurement]... 
246K.00 - target systolic 
blood pressure 
Not used to indicate 
specific 
measurement.  For 
diagnosis decide on a 
case by case basis. 
depends on condition and 
measurement so must be 
decided on case by case basis 
 
Patient behaviour 
relating to healthcare 
… [condition] 
[treatment] refused 
8I3X. – diabetic 
retinopathy screening 
refused  
Definite diagnosis (if 
treatment indicates 
diagnosis)  
Indicates GP’s intention to treat 
which in turn indicates patient 
has relevant condition 
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Codes about … Phrase Example Rule Rationale Exceptions 
Patient education / 
advice 
Education score -  
[condition] 
3881. Education score -
diabetes 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Attends … [condition]  
education 
9OLB. Attended diabetes 
structured education 
programme 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Referred/ Referral  to 
…  [condition] 
education 
8Hj4. Referral to 
DESMOND diabetes 
structured education 
programme 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Did not attend / did 
not complete …  
[condition] education 
9NiD. Did not attend 
DESMOND diabetes 
structured education 
programme 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Advice … [condition] 67I9. Advice about weight Decide on case by 
case basis 
Don’t know nature of advice 
and whether predicated in 
prevention or treatment 
 
 Leaflet ... [condition] 8CE1.00 – Alcohol leaflet 
given 
Decide on case by 
case basis 
Don’t know why given leaflet 
and whether predicated in 
prevention or treatment 
 
 Health education -  
[condition] 
679L. Health education - 
diabetes 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
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Codes about … Phrase Example Rule Rationale Exceptions 
 [condition] education  
… completed  
9OLJ. DAFNE diabetes 
structured education 
programme completed 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 member of 
[condition] society 
13Y5.00 Epilepsy society 
member 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
Referral or care Seen in … [condition] 
clinic 
9N1Q. Seen in diabetic 
clinic 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 [condition] D.V. done 8Hl4.00 Cardiology D.V. 
done 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Seen by [condition] 
clinician 
9N2k. Seen by smoking 
cessation advisor 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Referred to 
[condition] clinician 
8H4C. Referred to chest 
physician 
Exclude do not know reason for referral referral to diabetic 
foot clinic – count 
as possible diabetes 
 [condition] D.V. 
requested 
8HKE.00 Diabetology D.V. 
requested 
Exclude do not know reason for 
referral.  
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Codes about … Phrase Example Rule Rationale Exceptions 
 Under care of 
[condition] clinician 
ZL183 Under care of 
cardiologist 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Discharged from 
[condition] care …  
8Hg4. Discharged from 
care of diabetes specialist 
nurse 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Waiting / awaited  5531. - Angiocardiography 
awaited 
Exclude  Waiting for test or admission 
does not indicate [condition] 
diagnosis 
 
 DNA ... [condition] 
clinic 
 Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if the only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
Chronic disease 
identification & 
management 
... [condition] 
monitoring/ 
monitoring admin 
662.. – hypertension 
monitoring 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
662o.00 – 
Haemorrhagic 
stroke monitoring – 
code as history of ... 
 ...[condition] 
review/annual 
review 
66AS.00 – Diabetic annual 
review 
OR 
662e.00 Stroke/CVA 
annual review 
 
Definite diagnosis 
 
OR 
 history of 
Regular review of chronic 
condition (definite) OR review 
following acute event (history 
of) 
 
 ... [condition] register 8HHy. – Referral to 
diabetic register 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
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Codes about … Phrase Example Rule Rationale Exceptions 
 ... deleted/removed 
from [condition] 
register  
9HA1.00 – Removed from 
depression register 
Exclude   
 ... [condition] initial 
assessment 
66U1. Menopause initial 
assessment 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 Screening for 
[condition] 
68X.. Screening for 
cardiovascular system 
disease 
Exclude Screening does not indicate 
[condition], unless screening is 
for complication of [condition] 
68A7.00 – Diabetic 
retinopathy 
 Follow-up [condition] 
assessment 
66A2. follow-up diabetic 
assessment 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 ... [condition] 
monitoring not 
required 
hypertension monitoring 
not required 
Exclude No conclusions can be drawn 
from these codes 
 
 ... [condition] 
resolved 
hypertension resolved history of ... diagnosis Indicates had [condition] in the 
past  
 
 ... [condition] 
monitoring deleted 
9OI9.00 -  hypertens. 
monitor deleted 
history of ... diagnosis Indicates had [condition] in the 
past  
 
 exception reporting: 
[condition]... 
9h3..00 - Exception 
reporting: hypertension 
quality indicators 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 excepted from 
[condition] quality 
indicators ... 
9h31.00 
Excepted from 
hypertension qual 
indicators: Patient unsuit 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
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Codes about … Phrase Example Rule Rationale Exceptions 
 refuses ... [condition] 
monitoring 
9Ob1.00 – Refuses 
coronary heart disease 
monitoring 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
 [condition] care plan 8CS0.00 – Diabetes care 
plan agreed 
Possible diagnosis of 
[condition] 
Indicates possibility of 
diagnosis but if only code in 
patient record definite 
diagnosis of [condition] 
inappropriate 
 
Neonatal/infant/child neonatal/infant/child 
[condition] 
Q492.00 – neonatal 
hypertension 
case by case CALIBER only includes adults, 
so if code include indicates a 
history of [condition] 
 
 
Date created: 15.3.2011 
Agreed: 8.4.2011 
Amended: 12.4.2011 
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Table 29: STATA do-file to create code-list for Stable Angina (GPRD) 
clear all 
macro drop _all 
set linesize 100 
version 10.0 
// Program:  do file to create coding list for diagnosis of stable angina 
//  NB excludes ischaemia chest pain which is included in chest pain code list 
// Name: stable_angina.do 
// Authors: Julie George, harry Hemingway, UCL; Liam Smeeth & Emily Herrett, 
LSHTM 
// Date created: 13.3.2011, amended 24.3.2011, 25.3.2011, 1.4.2011, 11.4.2011 
 
// STEP 1: DEFINE SEARCH TERMS 
loc interm " "*angina*" "*stenocard*" "*coronary*artery*spasm*" "*spasm*cor*artery*"  " 
loc interm "`interm' "*card*syndrome*x*" "*cor*syndrome*x*"  " 
 
/// STEP 2: WORD SEARCH OF GPRD MEDICAL CODE DICTIONARY 
** GPRD Gold Medical Browser, Version 1.3.0 
** using Read information 27th November 2009 
** Read code chapters relating to occupation (Chapter 0) have been removed 
use "C:\Users\JulieG\Dropbox\Coding_lists\_GPRD Pegasus 
dictionary\medical_with_counts.dta", clear 
 
*** update the marker where read term matches search terms 
foreach word in `interm'  { 
 replace marker = marker |strmatch(lc_readterm, "`word'") 
 } 
* 
// STEP 3: CODE SEARCH OF GPRD MEDICAL CODE DICTIONARY 
*** search for specific terms not found by word search using read codes 
 ** G33z200 Syncope anginosa 
 ** G34y000 chronic coronary insufficiency 
foreach word in "G33z200" "G34y000"{ 
  replace marker = marker | strpos(readcode,"`word'") 
} 
* 
// STEP 4: DROP ALL TERMS NOT CAPTURED BY SEARCH TERMS 
keep if marker 
 
// STEP 5: EXCLUDE TERMS TO MAKE SEARCH MORE SPECIFIC 
*** remove terms that rated by clinician as not relevant 
  ** %%% 
loc exterm " "fh*" "no fh*" "*score*" "vincent*" "strepto*" "herp*" "*unstable*" "*at rest*"" 
loc exterm "`exterm'"*worsening*" "*abdominal*" "*ludwig*" " 
foreach word in `exterm' { 
 drop if strmatch(lc_readterm,"`word'")  
 } 
* 
// STEP 6: EXCLUDE ANY REMAINING UNWANTED CODES 
*** remove codes that rated by clinician as not relevant 
**388E.00 Canadian Cardiovascular Society classification of angina 
**G311.11 Crescendo angina 
**G311300 Refractory angina 
**ZR37.00 Canadian Cardiovascular Society classification of angina 
local excode ""388E.00"  "G311.11" "G311300" "ZR37.00"" 
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foreach word in `excode' { 
 drop if strmatch(readcode, "`word'") 
} 
* 
//STEP 7: ALLOCATE CODES TO SPECIFIC CATEGORIES 
gen int sa_cat = 4 
lab var sa_cat "Category" 
lab def sa_cat 0 "0.Not diagnosed" 1 "1.History of" 2 "2. Vasospastic" 3 "3. Cardiac 
syndrome X" /// 
4 "4.Stable angina", modify 
lab val sa_cat sa_cat 
 
** History of codes 
loc interm " "*h/o*" " 
foreach word in `interm'  { 
 replace sa_cat = 1 if strmatch(lc_readterm, "`word'") 
 } 
* 
local incode ""%%%" " 
foreach word in `incode' { 
 replace sa_cat = 1 if strmatch(readcode, "`word'") 
} 
* 
** Vasospastic codes 
loc interm " "*prinzmetal*" "*variant*" "*spasm*" " 
foreach word in `interm'  { 
 replace sa_cat = 2 if strmatch(lc_readterm, "`word'") 
 } 
* 
local incode ""%%%" " 
foreach word in `incode' { 
 replace sa_cat = 2 if strmatch(readcode, "`word'") 
} 
*** Cardiac syndrome x codes 
loc interm " "*syndrome x*"" 
foreach word in `interm'  { 
 replace sa_cat = 3 if strmatch(lc_readterm, "`word'") 
 } 
local incode ""%%%" " 
foreach word in `incode' { 
 replace sa_cat = 3 if strmatch(readcode, "`word'") 
} 
* 
//STEP 7: SAVE LIST OF CODES 
*** drop redundant variables 
drop marker lc_readterm immun_events db_date 
order medcode readcode readterm sa_cat 
sort sa_cat readcode 
*** save to STATA file and text file 
save "stable_angina_codes.dta", replace 
outsheet using "stable_angina_codes.txt", replace 
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Table 30: Entity Code report for HDL/LDL ratio and Total: HDL ratio 
GPRD variable report: HDL LDL ratio 
Generated on: Fri May  6 11:18:26 BST 2011 
 
*** Test 
Total records: 107058 
 
Readcode breakdown: 
     14369 - HDL : LDL ratio - 95022 records 
     19853 - Serum LDL/HDL ratio - 7537 records 
     49695 - Plasma LDL/HDL ratio - 4499 records 
 
Entity type breakdown: 
 
Entity: 338 - HDL/LDL ratio - 106976 
data1 - Operator 
        3 - '=' - 106802 records 
        0 - 'Data Not Entered' - 172 records 
        1 - '<' - 2 records 
data3 - Unit of measure 
        151 - 'ratio' - 71691 records 
        0 - 'No Data Entered' - 23925 records 
        96 - 'mmol/L' - 10423 records 
        161 - '1/1' - 649 records 
        1 - '%' - 238 records 
        104 - 'ng' - 26 records 
        26 - '1' - 15 records 
        156 - 'mmol' - 3 records 
        124 - 's' - 1 records 
        185 - 'L/L' - 1 records 
        97 - 'mmol/mol' - 1 records 
        122 - 'rad' - 1 records 
        99 - 'mol/L' - 1 records 
        126 - 'u' - 1 records 
data4 - Qualifier 
        0 - 'Data Not Entered' - 90269 records 
        9 - 'Normal' - 7263 records 
        41 - 'High' - 4609 records 
        8 - 'High' - 3978 records 
        10 - 'Low' - 651 records 
        40 - 'Low' - 95 records 
        7 - 'Very High' - 74 records 
        12 - 'Abnormal' - 32 records 
        13 - 'Potential Abnormal' - 4 records 
        11 - 'Very Low' - 1 records 
data7 - Normal range basis 
        0 - 'Data Not Entered' - 106921 records 
        5 - 'Generic normal range' - 53 records 
        4 - 'Gestational age based' - 2 records 
 
------------------------------------------------------------ 
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Entity: 288 - Other laboratory tests - 82 
data1 - Operator 
        0 - 'Data Not Entered' - 78 records 
        3 - '=' - 4 records 
data3 - Unit of measure 
        0 - 'No Data Entered' - 82 records 
data4 - Qualifier 
        0 - 'Data Not Entered' - 82 records 
data7 - Normal range basis 
        0 - 'Data Not Entered' - 82 records 
------------------------------------------------------------ 
 
 
*** Referral 
Total records: 80 
 
Readcode breakdown: 
     14369 - HDL : LDL ratio - 80 records 
     19853 - Serum LDL/HDL ratio - 0 records 
     49695 - Plasma LDL/HDL ratio - 0 records 
 
*** Clinical 
 
Total records: 18 
Total records with data: 
 
Readcode breakdown: 
     14369 - HDL : LDL ratio - 17 records 
     19853 - Serum LDL/HDL ratio - 1 records 
     49695 - Plasma LDL/HDL ratio - 0 records 
 
GPRD variable report: Total HDL ratio 
Generated on: Fri May  6 11:13:04 BST 2011 
 
*** Test 
 
Total records: 1993866 
 
Readcode breakdown: 
     14105 - Cholesterol/HDL ratio - 16312 records 
     14108 - HDL : total cholesterol ratio - 321582 records 
     14371 - Serum cholesterol/HDL ratio - 888987 records 
     14372 - Total cholesterol:HDL ratio - 736790 records 
     40935 - Plasma cholesterol/HDL ratio - 30195 records 
 
Entity type breakdown: 
 
Entity: 163 - Serum cholesterol - 600 
data1 - Operator 
        3 - '=' - 600 records 
data3 - Unit of measure 
        0 - 'No Data Entered' - 356 records 
        96 - 'mmol/L' - 179 records 
        1 - '%' - 48 records 
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        26 - '1' - 12 records 
        151 - 'ratio' - 5 records 
data4 - Qualifier 
        0 - 'Data Not Entered' - 577 records 
        9 - 'Normal' - 12 records 
        8 - 'High' - 11 records 
data7 - Normal range basis 
        0 - 'Data Not Entered' - 600 records 
 
------------------------------------------------------------ 
 
Entity: 265 - Sinus x-ray - 1 
data1 - Qualifier 
        0 - 'Data Not Entered' - 1 records 
 
------------------------------------------------------------ 
 
Entity: 214 - Blood lipids - 93 
data1 - Qualifier 
        0 - 'Data Not Entered' - 93 records 
 
------------------------------------------------------------ 
 
Entity: 338 - HDL/LDL ratio - 1969029 
data1 - Operator 
        3 - '=' - 1968679 records 
        0 - 'Data Not Entered' - 339 records 
        4 - '>' - 6 records 
        2 - '<=' - 3 records 
        1 - '<' - 1 records 
        5 - '>=' - 1 records 
 
data3 - Unit of measure 
        0 - 'No Data Entered' - 1737307 records 
        151 - 'ratio' - 150422 records 
        161 - '1/1' - 63005 records 
        1 - '%' - 14930 records 
        26 - '1' - 3147 records 
        96 - 'mmol/L' - 129 records 
        104 - 'ng' - 59 records 
        126 - 'u' - 4 records 
        146 - 'us' - 4 records 
        156 - 'mmol' - 3 records 
        187 - 'mmol/mmol' - 3 records 
        124 - 's' - 2 records 
        21 - '/mL' - 2 records 
        41 - 'd' - 2 records 
        45 - 'feet' - 2 records 
        142 - 'umol/L' - 1 records 
        125 - 'stone' - 1 records 
        110 - 'nmol/L' - 1 records 
        82 - 'mg/dL' - 1 records 
        27 - '1(tot)' - 1 records 
        185 - 'L/L' - 1 records 
        61 - 'iu/L' - 1 records 
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        86 - 'mg/mmol' - 1 records 
 
data4 - Qualifier 
        0 - 'Data Not Entered' - 1856216 records 
        41 - 'High' - 96733 records 
        9 - 'Normal' - 6737 records 
        8 - 'High' - 4924 records 
        44 - 'Abnormal' - 1874 records 
        12 - 'Abnormal' - 1184 records 
        7 - 'Very High' - 634 records 
        40 - 'Low' - 194 records 
        38 - 'Potentially abnormal' - 183 records 
        10 - 'Low' - 133 records 
        43 - 'Significantly High' - 124 records 
        13 - 'Potential Abnormal' - 87 records 
        11 - 'Very Low' - 3 records 
        14 - 'Outside ref range' - 3 records 
 
data7 - Normal range basis 
        0 - 'Data Not Entered' - 1969016 records 
        5 - 'Generic normal range' - 13 records 
 
------------------------------------------------------------ 
 
Entity: 288 - Other laboratory tests - 12965 
data1 - Operator 
        3 - '=' - 12785 records 
        0 - 'Data Not Entered' - 180 records 
data3 - Unit of measure 
        0 - 'No Data Entered' - 11949 records 
        1 - '%' - 611 records 
        151 - 'ratio' - 246 records 
        161 - '1/1' - 155 records 
        96 - 'mmol/L' - 2 records 
        123 - 'rem' - 1 records 
        26 - '1' - 1 records 
data4 - Qualifier 
        0 - 'Data Not Entered' - 12829 records 
        25 - 'Normal' - 106 records 
        26 - 'Abnormal' - 30 records 
data7 - Normal range basis 
        0 - 'Data Not Entered' - 12965 records 
 
------------------------------------------------------------ 
 
Entity: 438 - Other biochemistry test - 11178 
data1 - Operator 
        3 - '=' - 11175 records 
        0 - 'Data Not Entered' - 2 records 
        4 - '>' - 1 records 
data3 - Unit of measure 
        151 - 'ratio' - 6150 records 
        96 - 'mmol/L' - 2484 records 
        0 - 'No Data Entered' - 2234 records 
        161 - '1/1' - 222 records 
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        1 - '%' - 72 records 
        123 - 'rem' - 12 records 
        185 - 'L/L' - 1 records 
        122 - 'rad' - 1 records 
        187 - 'mmol/mmol' - 1 records 
        100 - 'mol/s' - 1 records 
 
data4 - Qualifier 
        0 - 'Data Not Entered' - 9964 records 
        41 - 'High' - 926 records 
        8 - 'High' - 171 records 
        9 - 'Normal' - 99 records 
        7 - 'Very High' - 6 records 
        10 - 'Low' - 6 records 
        13 - 'Potential Abnormal' - 5 records 
        12 - 'Abnormal' - 1 records 
 
data7 - Normal range basis 
        0 - 'Data Not Entered' - 11178 records 
 
------------------------------------------------------------ 
 
*** Referral 
 
Total records: 195 
 
Readcode breakdown: 
     14105 - Cholesterol/HDL ratio - 31 records 
     14108 - HDL : total cholesterol ratio - 7 records 
     14371 - Serum cholesterol/HDL ratio - 13 records 
     14372 - Total cholesterol:HDL ratio - 144 records 
     40935 - Plasma cholesterol/HDL ratio - 0 records 
 
*** Clinical 
 
Total records: 809 
 
Readcode breakdown: 
     14105 - Cholesterol/HDL ratio - 329 records 
     14108 - HDL : total cholesterol ratio - 215 records 
     14371 - Serum cholesterol/HDL ratio - 20 records 
     14372 - Total cholesterol:HDL ratio - 245 records 
     40935 - Plasma cholesterol/HDL ratio - 0 records 
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Table 31: Reverse Entity Code Report for 217 Electrocardiogram: Read codes, and 
their frequency, used with entity code  
Read code Read Term Frequency in CALIBER 
32...12 ECG 292000 
3212.00 Standard ECG 204872 
32...00 Electrocardiography 91476 
3216.00 ECG normal 33647 
32M..00 24 Hour ECG 23698 
321B.00 12 lead ECG 17536 
3272.00 ECG: atrial fibrillation 16746 
32...11 Cardiography - ECG 16582 
3217.00 ECG abnormal 10886 
321..00 ECG - general 10196 
3211.00 ECG requested 3712 
324..00 ECG:left ventricle hypertrophy 1645 
3242.00 ECG: shows LVH 1186 
329A.00 ECG: left bundle branch block 1130 
3299.00 ECG: right bundle branch block 1031 
32Z..00 Electrocardiography NOS 955 
3241.00 ECG: no LVH 897 
3213.00 Exercise ECG 822 
322..00 ECG: myocardial ischaemia 781 
3214.00 Ambulatory ECG 778 
321C.00 ECG sinus rhythm 740 
3273.00 ECG: atrial flutter 733 
3219.00 ECG equivocal 478 
321A.00 ECG - no new changes 439 
3213000 Exercise ECG normal 366 
329..00 ECG: heart block 353 
321Z.00 ECG - general - NOS 324 
3282.00 ECG: ventricular tachycardia 235 
3263.00 ECG: ventricular ectopics 203 
3274.00 ECG: paroxysmal atrial tachy. 172 
32F4.00 ECG: T wave inverted 157 
323..00 ECG: myocardial infarction 154 
32J5.00 Left axis deviation 147 
327..00 ECG: supraventricular arrhythmia 141 
3214000 Ambulatory ECG normal 135 
3232.00 ECG: old myocardial infarction 133 
3264.00 ECG: atrial ectopics 126 
32E2.00 ECG: S-T interval abnormal 113 
3222.00 ECG:shows myocardial ischaemia 105 
328..00 ECG: ventricular arrhythmia 103 
329Z.00 ECG: heart block NOS 98 
3213100 Exercise ECG abnormal 96 
326..00 ECG: ectopic beats 90 
327Z.00 ECG: supraventric. arryth. NOS 88 
3215.00 ECG not done 87 
3262.00 ECG: extrasystole 85 
32L..00 ECG: left ventricular strain 74 
32...13 EKG 69 
32F2.00 ECG: T wave abnormal 65 
3294.00 ECG:partial A-V block-long P-R 62 
32E4.00 ECG: S-T depression 57 
3233.00 ECG: antero-septal infarct. 52 
3214100 Ambulatory ECG abnormal 51 
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Read code Read Term Frequency in CALIBER 
32J1.00 ECG: QRS complex normal 49 
32E3.00 ECG: S-T elevation 46 
324Z.00 ECG: LVH NOS 46 
32J2.00 ECG: QRS complex abnormal 45 
3297.00 ECG: Wenckebach phenomenon 36 
3234.00 ECG:posterior/inferior infarct 35 
32F3.00 ECG: T wave flattened 32 
3298.00 ECG: complete A-V block 27 
3213011 Negative exercise ECG test 27 
32K3.00 ECG: Q-T interval prolonged 25 
325..00 ECG:right ventricle hypertrop. 25 
R143100 [D]Electrocardiogram (ECG) abnormal 24 
3221.00 ECG: no myocardial ischaemia 21 
328Z.00 ECG: ventricular arrhythmia NOS 21 
32B2.00 ECG: Q wave abnormal 20 
32B..00 ECG: Q wave 20 
32F..00 ECG: T wave 19 
326Z.00 ECG: ectopic beats NOS 19 
33B9100 Exercise tolerance test done 18 
32I3.00 ECG: P-R interval prolonged 15 
32C2.00 ECG: R wave abnormal 14 
32J6.00 Right axis deviation 14 
323Z.00 ECG: myocardial infarct NOS 14 
3271.00 ECG: no supraventric. arryth. 12 
3231.00 ECG: no myocardial infarction 12 
32FZ.00 ECG: T wave NOS 11 
3293.00 ECG:complete sinu-atrial block 10 
3218.00 ECG - improved 9 
3283.00 ECG: ventricular fibrillation 9 
32A2.00 ECG: P wave abnormal 9 
3213111 Positive exercise ECG test 8 
3292.00 ECG: partial sinu-atrial block 8 
3236.00 ECG: lateral infarction 7 
322Z.00 ECG: myocardial ischaemia NOS 7 
3295.00 ECG: partial A-V block - 2:1 6 
32C..00 ECG: R wave 6 
32I4.00 ECG: P-R interval shortened 6 
3291.00 ECG: no heart block 6 
32JZ.00 ECG: QRS complex NOS 5 
32E1.00 ECG: S-T interval normal 5 
3251.00 ECG: no RVH 5 
3261.00 ECG: no ectopic beats 5 
32KZ.00 ECG: Q-T interval NOS 5 
32C1.00 ECG: R wave normal 5 
8HR1.00 Refer for ECG recording 4 
32IZ.00 ECG: P-R interval NOS 4 
32C3.00 ECG: R wave tall 4 
32I1.00 ECG: P-R interval normal 4 
32A..00 ECG: P wave 4 
32BZ.00 ECG: Q wave NOS 4 
32AZ.00 ECG: P wave NOS 4 
32B3.00 ECG: Q wave pathological 4 
32B1.00 ECG: Q wave normal 3 
32A3.00 ECG: P mitrale 3 
32m..00  3 
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Read code Read Term Frequency in CALIBER 
32A4.00 ECG: P pulmonale 3 
3252.00 ECG: shows RVH 3 
G20..00 Essential hypertension 2 
32I..00 ECG: P-R interval 2 
32K1.00 ECG: Q-T interval normal 2 
32EZ.00 ECG: S-T interval NOS 2 
32F1.00 ECG: T wave normal 2 
325Z.00 ECG: RVH NOS 2 
32K..00 ECG: Q-T interval 2 
662P.00 Hypertension monitoring 2 
662..12 Hypertension monitoring 2 
32E..00 ECG: S-T interval 2 
3235.00 ECG: subendocardial infarct 2 
32A1.00 ECG: P wave normal 2 
32I2.00 ECG: P-R interval abnormal 2 
G2...00 Hypertensive disease 2 
32D1.00 ECG: S wave normal 1 
3281.00 ECG: no ventricular arrhythmia 1 
56F..00 Diagnostic procedure declined 1 
4145.00 Blood sample -> Lab NOS 1 
G580.00 Congestive heart failure 1 
8A52.11 ECG monitoring 1 
32K4.00 ECG: Q-T interval shortened 1 
32K2.00 ECG: Q-T interval abnormal 1 
32D3.00 ECG: S wave deep 1 
32J..00 ECG: QRS complex 1 
J10y400 Oesopheal reflux without mention of oesophagitis 1 
G65..00 Transient cerebral ischaemia 1 
32J3.00 ECG: QRS complex prolonged 1 
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Appendix D: Medications 
Table 32: Nitrates and specific anti-anginal medications 
BNF 
chapter 
Drug category Specific drugs 
2.6.1 Nitrates Glyceryl trinitrate, isosorbide dinitrate, 
isosorbide mononitrate 
2.6.3 Other antianginal drugs Ivabradine, nicorandil, ranolazine 
 
Table 33: Blood-pressure -lowering medication  
BNF 
chapter 
Drug category Specific drugs 
2.2.1 Thiazides & related diuretics bendroflumethiazide, chlortalidone, 
cyclopenthiazide, indapamide, metolazone, 
xipamide 
2.2.3 Potassium-sparing diuretics 
and aldosterone antagonists 
Amiloride hydrochloride, triamterene, 
aldosterone antagonists (eplerenone, 
spironolactone) 
2.2.4 Potassium-sparing diuretics 
with other diuretics 
Co-amilofruse, co-amilozide, triamterene 
with furosemide, amiloride with 
cyclopenthiazide, amiloride with 
bumatanide, triamterene with thiazides, 
spironolactone with thiazides, 
spironolactone with loop diuretics 
2.4 Beta-adrenoceptor blocking 
drugs 
Propranolol hydrochloride, acebutolol, 
atenolol, bisoprolol fumarate, carvedilol, 
celiprolol hydrochloride, co-tenidone, 
esmolol hydrochloride labetalol 
hydrochloride, metoprolol tartrate, nadolol, 
nebivolol, oxprenolol hydrochloride, 
pindolol, sotalol hydrochloride. (Not timolol 
maleate eye drops) 
2.5 Hypertension and heart failure (All sections listed below) 
2.5.1 Vasodilator antihypertensive 
drugs 
Hydralazine hydrochloride, minoxidil. (Not 
sildenafil, sodium nitroprusside, tadalafil 
Ambrisentan, bosentan, diazoxide, iloprost) 
2.5.2 Centrally acting 
antihypertensive drugs 
Moxonidine, methyldopa (not clonidine) 
2.5.4 Alpha-adrenoceptor blocking 
drugs 
Doxazosin, indoramin, prazosin, terazosin 
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2.5.5 Drugs affecting the renin-
angiotensin system 
(All sections listed below) 
2.5.5.1 Angiotensin-converting enzyme 
inhibitors (ACE inhibitors) 
Captopril, cilazapril, enalapril maleate, 
fosinopril sodium imidapril hydrochloride, 
lisinopril, moexipril hydrochloride, 
perindopril erbumine, perindopril arginine, 
quinapril, ramipril, ramipril with felodipine, 
trandolapril 
2.5.5.2 Angiotensin-II receptor 
antagonists 
Candesartan cilexetil, eprosartan, irbesartan, 
losartan potassium, olmesartan medoxomil, 
telmisartan, valsartan 
2.5.5.3 Renin inhibitors aliskiren 
2.6.2 Calcium-channel blockers Amlodipine, diltiazem hydrochloride, 
felodipine, isradipine, lacidipine, 
lercanidipine hydrochloride, nicardipine 
hydrochloride, nifedipine, nimodipine, 
verapamil hydrochloride 
Excluded drugs: 
 Timolol eye drops (BNF 2.4 Beta-adrenoceptor blocking drugs) 
 Sildenafil, sodium nitroprusside, tadalafil, bosentan, diazoxide, ambrisentan, iloprost (BNF 
2.5.1 Vasodilator antihypertensive drugs) 
 Clonidine (BNF 2.5.2 Centrally acting antihypertensive drugs) 
 Guanethidine monosulphate (BNF 2.5.3 Adrenergic neurone blocking drugs) 
 
Table 34: Statins 
BNF 
chapter 
Drug category Specific drugs 
2.12.1 Statins Atorvastatin, fluvastatin, pravastatin sodium, 
rosuvastatin, simvastatin 
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Appendix E: Hierarchy of diagnoses used to select initial 
presentation 
 
category variable event_code order 
End of study  400 0.5 
Left practice tod_date 401 0.5 
Last practice download lcd_date 402 0.5 
Specified other deaths ons_mortality 500 0.8 
CHD death ons_mortality 501 0.8 
Sudden cardiac death ons_mortality 502 0.8 
Cardiac arrest death ons_mortality 503 0.8 
Heart failure death ons_mortality 504 0.8 
Cerebrovascular death (Stroke) ons_mortality 505 0.8 
Peripheral arterial disease death ons_mortality 506 0.8 
Abn cerebro test cerebro_test_gprd 88 1 
Ischaem Stroke ischaem_stroke_gprd 69 2 
ischaemic stroke (HES) ishc_stroke_hes 141 3 
Stroke NOS stroke_nos_gprd 72 4 
Stroke NOS (HES) stroke_nos_hes 146 5 
isch cerebro disease NEC cerebro_NEC_gprd 74 6 
ischaemic cvd (HES) ischaem_cvd_hes 151 7 
Cerebrovascular ops cerebro_ops_gprd 75 8 
cerebrovascular ops (OPCS) cerebro_procs_opcs 215 9 
PAD test abnormal pad_test_gprd 99 10 
AAA aaa_gprd 77 11 
AAA  (HES) aaa_hes 156 12 
AAA ops aaa_ops_gprd 79 13 
AAA ops (OPCS) aaa_procs_opcs 221 14 
PAD pad_gprd 78 15 
PAD (HES) pad_hes 158 16 
PAD ops pad_ops_gprd 80 17 
PAD ops (OPCS) pad_procs_opcs 225 18 
CHD NOS (HES) chd_nos_hes 120 19 
CHD NOS chd_nos_gprd 56 20 
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category variable event_code order 
abnormal itests_gprd 22 21 
abnormal atest_gprd 27 22 
beginning of at least two nitrate_meds_gprd 30 23 
Stable angina diagnosis SA_diagnosis 13 24 
CABG CABG_gprd 16 25 
CABG revision CABG_gprd 17 26 
PCI pci_gprd 19 27 
PCI during admission (MINAP) coronary_intervention 331 28 
CABG done cabg_opcs 200 29 
CABG revision cabg_opcs 201 30 
PCI done pci_opcs 202 31 
Acute coronary syndrome acs_gprd 58 32 
Acute IHD (HES) acute_ihd_hes 125 33 
unstable angina UA_gprd 35 34 
angina pectoris (HES) angina_hes 105 35 
Unstable angina (HES) uangina_hes 115 36 
UA MI_phenotype 322 37 
transluminal coronary thrombolysis lysis_gprd 50 38 
coronary thrombolysis, mode 
unspecified lysis_gprd 51 
39 
transluminal coronary thrombolysis lysis_opcs 204 40 
Troponin abnormal gprd_troponins_cat 95 41 
Cardiac markers abnormal gprd_cardiac_markers_cat 97 42 
CKMB abnormal gprd_ckmb_cat 98 43 
MI, timing uncertain (HES) mi_hes 112 44 
MI NOS mi_nos_gprd 45 45 
Definite MI (HES) mi_hes 111 46 
nSTEMI nstemi_gprd 41 47 
nSTEMI MI_phenotype 321 48 
STEMI stemi_gprd 38 49 
STEMI (MINAP) MI_phenotype 320 50 
Ventricular tachycardia arrest_gprd 63 51 
Ventricular fibrillation arrest_gprd 64 52 
Implanted cardiac defibrillation device arrest_gprd 65 53 
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category variable event_code order 
Asystole/EMD/cardiac arrest/resusc arrest_gprd 66 54 
ventricular tachycardia (HES) arrest_hes 133 55 
V Fib (HES) arrest_hes 134 56 
ICD (HES) arrest_hes 135 57 
asystole/EMD/cardiac arrest/resusc 
(HES) arrest_hes 136 
58 
ventricular arryhthmia (HES) arrest_hes 137 59 
ICD device (OPCS) arrest_opcs 206 60 
asystole/EMD/cardiac arrest/resusc arrest_opcs 207 61 
HF NOS hf_gprd 85 62 
HF, specified other cause hf_gprd 86 63 
Echo abnormal: LVD echo 87 64 
HF NOS (HES) hf_hes 167 65 
HF: hypertension cause hf_gprd 84 66 
HF hypertension cause (HES) hf_hes 166 67 
Sudden cardiac death sudden_death_gprd 92 68 
sudden cardiac death (HES) sudden_death_hes 172 69 
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Appendix F: Additional Tables and Figures for Chapter 5 
Gender and the Initial Presentation of a Wide Range of 
Cardiovascular Diseases 
 
Figure 43: Incidence rate ratios (men compared to women) for initial presentation 
of myocardial infarction types, stratified by age group 
 
N=1,758,584.  NOS indicates not otherwise specified; MI, myocardial infarction 
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Figure 44: Incidence rate ratios (men compared to women) for initial presentation of specific myocardial infarction phenotypes, stratified by 
smoking status 
 
 
N=1,453,635.  NOS indicates not otherwise specified; MI, myocardial infarction 
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Figure 45: Incidence rate ratios (men compared to women) for initial presentation of myocardial infarction types, stratified by diabetes status 
 
 
N=1,758,584.  NOS indicates not otherwise specified; MI, myocardial infarction
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Appendix G: Additional Tables and Figures for Chapter 6 - Association of smoking with initial presentation of 
cardiovascular disease across a wide range of presentations  
 
Figure 46: Proportional hazard of smoking compared to not smoking for range of initial presentations of CVD (in alphabetical order) 
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Log log graph of current smokers compared to non-smokers, adjusted for age at entry. Ln indicates log. 
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Figure 47: Proportional hazard of ex-smoking compared to not smoking for range of initial presentations of CVD (in alphabetical order) 
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Log log graph of current smokers compared to non-smokers, adjusted for age at entry. Ln indicates log.  
   
277 
 
Figure 48: Age-adjusted hazard ratios for initial presentations of acute myocardial infarction overall and for AMI subtypes associated with 
being current smoker or ex-smoker compared to non-smokers, overall and in women and men 
 
 
Hazard ratios adjusted for age at baseline for men and women, and additionally for sex for all patients, in complete cases. N= 897,892. MI indicates myocardial infarction; CI, 
confidence interval; HR, hazard ratio.
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Figure 49: Multivariable adjusted hazard ratios for initial presentations of cardiac disease associated with being current smoker or ex-smoker 
compared to non-smokers, overall and in women and men 
 
Hazard ratios adjusted for age at baseline, sex, deprivation (index of multiple deprivation quintile), smoking status (current smoker, ex-smoker, non-smoker), diabetes mellitus 
(yes/no), mean systolic blood pressure at baseline, blood pressure medication (yes/no) and statin use at baseline (yes/no) , in complete cases. N= 897,892. MI indicates 
myocardial infarction; CI, confidence interval; HR, hazard ratio.
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Figure 50: Multivariable adjusted hazard ratios (with random effects for GP practice) for initial presentations of cardiac disease associated 
with being current smoker or ex-smoker compared to non-smokers, overall and in women and men 
 
Hazard ratios adjusted for age at baseline, sex, deprivation (index of multiple deprivation quintile), smoking status (current smoker, ex-smoker, non-smoker), diabetes mellitus 
(yes/no), mean systolic blood pressure at baseline, blood pressure medication (yes/no) and statin use at baseline (yes/no), with frailty term to take account of clustering at 
practice level, in complete cases. N= 897,892. MI indicates myocardial infarction; CI, confidence interval; HR, hazard ratio. 
   
280 
 
Appendix H: Additional Tables and Figures for Chapter 7 - Association of blood pressure with initial 
presentation of cardiovascular disease across a wide range of presentations  
 
Figure 51: Proportional hazards of SBP categories (10mmHg)  for range of initial presentations of CVD (in alphabetical order) 
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Log log graph of categorical SBP variable, adjusted for age at entry. Ln indicates log.  
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Figure 52: Proportional hazard of DBP categories (10mmHg)  for range of initial presentations of CVD (in alphabetical order) 
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Log log graphs of categorical DBP variable, adjusted for age 
at entry. Ln indicates log. 
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Table 35: Hazard ratio for gender-BP interaction for AAA, Acute MI / Coronary 
death, PAD and Stroke 
 HR* p LR chi2(1) Prob > chi2 
SBP     
AMI + UCD 1.01 (0.98, 1.04) 0.617 0.25 0.6167 
Stroke 0.95 (0.92, 0.98) 0.000 12.82 0.0003 
AAA 0.95 (0.88, 1.02) 0.181 1.78 0.1824 
PAD 0.98 (0.94, 1.01) 0.220 1.50 0.2202 
DBP     
AMI + UCD 0.99 (0.94, 1.03) 0.565 0.33 0.5649 
Stroke 0.93 (0.88, 0.97) 0.001 11.51 0.0007 
AAA 0.97 (0.86, 1.10) 0.652 0.20 0.6519 
PAD 0.98 (0.93, 1.04) 0.543 0.37 0.5425 
*Interaction HR in model adjusted for age, age2, gender, age-gender interaction, deprivation, 
diabetes, statin use, BP, and interaction between BP and gender for specific CVD endpoints.  
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Table 36: Hazard ratios for gender-BP interaction for cardiac endpoints 
 HR* p LR test P 
SBP     
Stable angina 1.00 (0.97, 1.04) 0.830 0.05 0.8289 
Unstable angina 1.02 (0.92, 1.13) 0.720 0.13 0.7190 
CHD NOS 1.04 (0.98, 1.11) 0.238 1.39 0.2377 
AMI 1.04 (0.99, 1.10) 0.121 2.40 0.1215 
Heart failure 1.01 (0.96, 1.06) 0.715 0.13 0.7146 
Ventricular arrhythmias 1.19 (1.08, 1.30) 0.000 13.44 0.0002 
Unheralded coronary death 0.92 (0.84, 1.00) 0.040 4.22 0.0398 
DBP     
Stable angina 1.02 (0.98, 1.07) 0.233 1.42 0.2329 
Unstable angina 0.96 (0.87, 1.06) 0.435 0.61 0.4348 
CHD NOS 1.01 (0.95, 1.08) 0.684 0.17 0.6837 
AMI 1.00 (0.95, 1.06) 0.930 0.01 0.9303 
Heart failure 0.97 (0.92, 1.03) 0.324 0.97 0.3241 
Ventricular arrhythmia 1.10 (1.00, 1.21) 0.039 4.24 0.0395 
Unheralded coronary death 0.94 (0.86, 1.02) 0.145 2.13 0.1448 
*Interaction HR in model adjusted for age, age2, gender, age-gender interaction, deprivation, 
diabetes, statin use, BP, and interaction between BP and gender.  
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Figure 53: Age-adjusted hazard ratios for initial presentations of  ST elevation myocardial infarction, non ST elevation myocardial infarction 
and myocardial infarction not otherwise specified associated with 1 standard deviation increase in systolic and diastolic blood pressure 
overall and in women and men 
 
Hazard ratios for mean systolic or diastolic blood pressure at baseline (per 1 standard deviation (sd)), adjusted for age at baseline, and sex in complete cases. N= 897,892. For 
SBP, 1 sd = 18.9 mmHg; for DBP, 1 sd=10 mmHg. MI indicates myocardial infarction; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; SBP, systolic 
blood pressure.
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Figure 54: Multivariable adjusted hazard ratios for initial presentations of  ST-
elevation myocardial infarction, non ST-elevation myocardial infarction and 
myocardial infarction not otherwise specified associated with 1 standard deviation 
increase in systolic and diastolic blood pressure overall and in women and men  
 
 
Hazard ratios for mean systolic or diastolic blood pressure at baseline (per 1 standard deviation (sd)), 
adjusted for age at baseline, sex, deprivation (index of multiple deprivation quintile), smoking status 
(current smoker, ex-smoker, non-smoker), diabetes mellitus (yes/no) and statin use at baseline 
(yes/no), in complete cases. N= 897,892. For SBP, 1 sd = 18.9 mmHg; for DBP, 1 sd=10 mmHg. MI 
indicates myocardial infarction; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard 
ratio; SBP, systolic blood pressure. 
 
Table 37: Hazard ratios for gender-BP interaction for specific myocardial infarction 
endpoints 
 HR* p LR test P 
SBP     
STEMI 0.93 (0.76, 1.14) 0.484 0.49 0.4838 
NSTEMI 1.00 (0.86, 1.17) 0.986 0.00 0.9864 
MI NOS 1.06 (1.00, 1.12) 0.060 3.53 0.0604 
DBP     
STEMI 1.01 (0.95, 1.07) 0.643 0.21 0.6432 
NSTEMI 0.93 (0.79, 1.08) 0.340 0.91 0.3398 
MI NOS 1.05 (0.85, 1.29) 0.776 0.08 0.7765 
*Interaction HR in model adjusted for age, age2, gender, age-gender interaction, deprivation, 
diabetes, statin use, BP, and interaction between BP and gender.  
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